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Zusammenfassung 
 
Um ein breites Verständnis der Lipopeptid-Biosynthese in Myxobakterien zu erhalten, 
wurden im Rahmen dieser Arbeit neue Lipopeptid-Biosynthesewege unter Einsatz eines 
umfangreichen Screenings myxobakterieller Genome identifiziert und charakterisiert. Auf 
diesem Weg konnten vier bisher unbekannte Lipopeptid-Gerüste vorhergesagt und im 
weiteren Verlauf durch Strukturaufklärung bestätigt werden. Daneben konnten anhand 
detaillierter Sequenzanalysen der beteiligten Biosynthesewege die strukturellen Unterschiede 
der Lipopeptid-Gerüste auf genetischer Ebene erklärt werden. Diese Untersuchungen haben 
ebenfalls zur Aufklärung der genetischen Mechanismen beigetragen, welche zur Evolution 
dieser Biosynthesewege geführt haben. 
 
Darüber hinaus wurden die identifizierten Lipopeptid-Biosynthesewege als Modellsysteme 
zur Etablierung synthetischer Expressionsplattformen herangezogen. Im Rahmen dieser 
Arbeit konnte eine flexible Assemblierungsstrategie zur Konstruktion artifizieller Lipopeptid-
Gencluster entwickelt und eine Genbibliothek generiert werden, auf deren Basis nicht 
natürliche Lipopeptid-Biosynthesewege mittels kombinatorischer Biosynthese erzeugt und 
heterolog exprimiert werden konnten. Diese Studien führten zur Produktion von fünf 
neuartigen Lipopeptid-Gerüsten und demonstrieren eindrucksvoll die Vorteile synthetisch-
biologischer Methoden gegenüber klassischen Ansätzen. Die beschriebene Strategie erlaubt 
darüber hinaus die schnelle Modifikation der artifiziellen Biosynthesewege. 
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Abstract 
 
To gain a deep understanding of the lipopeptide biosynthesis in myxobacteria, a 
comprehensive screening of myxobacterial genomes was initially carried out in the course of 
this thesis leading to the identification and characterization of novel lipopeptide biosynthetic 
pathways. By following this strategy, four yet unknown lipopeptide cores were predicted and 
further structurally characterized to ultimately prove the predicted structures. On the basis of 
detailed sequence analyses of the underlying biosynthetic pathways, the structural differences 
of the lipopeptide cores could be rationalized on a genetic basis. These studies also 
contributed to the elucidation of the genetic mechanisms, by which the different biosynthetic 
pathways have evolved. 
 
Furthermore, the identified lipopeptide biosynthetic pathways were used as model systems to 
establish synthetic expression platforms. In the course of this thesis, a versatile assembly 
strategy for the construction of artificial lipopeptide gene clusters was developed, which 
allowed the generation and heterologous expression of unnatural lipopeptide biosynthetic 
pathways based on an established gene library via combinatorial biosynthesis. These studies 
led to the production of five novel lipopeptide scaffolds and impressively demonstrate the 
huge potential of synthetic biology techniques compared to classical approaches. Moreover, 
the described strategy allows the rapid modification of the artificial biosynthetic pathways. 
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1     Introduction 
 
1 Introduction 
1.1 Lipopeptides – A Distinguished Class of Natural Products 
Natural products are defined as chemical compounds that are produced by a biological 
source,1 e.g. microorganisms such as bacteria and fungi, but also by higher organisms like 
plants and animals, and often exhibit interesting biological and pharmacological activities.2  
These compounds are usually referred to as secondary metabolites since they are not essential 
for the producer organisms’ life cycle. However, microbial secondary metabolites often have 
important functions in the biology of the producer organisms, e.g. as protective agents against 
pathogens or predators in defense mechanisms, as signaling molecules in cell development, 
differentiation, inter- and intraspecies communication and induction of sporulation, as 
motility factors, and as siderophores for efficient metal uptake.3–6 In many cases, the functions 
of natural products in their native context are not known. A distinguished class of microbial 
natural products that attracted attention over the past decades are the lipopeptides (LPs), 
which are composed of a fatty acid moiety linked to a peptide core that can either be linear or 
cyclic,7,8 and can further include several nonproteinogenic or unusual amino acids such as 
chemically modified (O-methylated, N-methylated, β-hydroxylated, halogenated amino 
acids), D-configured or β-amino acids. In conjunction with the occurrence of various lipid 
chains given by differences in the length, the oxidation state and the degree of branching of 
the acyl chain, microbial LPs constitute a structurally diverse compound class occupying an 
enormous chemical space (Figure 1).6,8–10 Among the different LP classes, the cyclic 
lipopeptides (CLPs) are most abundant and are produced by various bacteria such as soil-
dwelling Pseudomonas spp.,6 Bacillus spp.,6 Streptomyces spp.,11 Actinomyces spp.,12 as well 
as cyanobacterial Microcystis spp. found in marine habitats.13 In addition, fungal species such 
as Aspergillus spp. and Candida spp. are capable of producing a vast array of CLPs amongst 
others.14,15 Due to their potent medicinally relevant activities and their distinct amphiphilic 
properties, CLPs came recently into the focus of pharmaceutical companies and other 
industries.16,17 The cyclic lipopeptide antibiotic daptomycin (Figure 1A), which is produced 
by Streptomyces roseoporous,18,19 is the first approved member of the CLP family for the 
treatment of systemic infections caused by Gram-positive and often multi-resistant bacteria 
such as methicillin-resistant Staphylococcus aureus (MRSA).20 Beside the bactericidal 
activities,18,21,22 CLPs have also been found to exhibit promising antifungal,23–26 antiviral,27,28 
anticancer,29,30 immunosuppressant,31 immunomodulating,32 and hemolytic properties.33,34 
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Figure 1. Prominent cyclic lipopeptides of microbial origin. A: Structure of the antimicrobial compound 
daptomycin produced by Streptomyces roseoporous. B: Structure of surfactin A from Bacillus subtilis exhibiting 
multiple pharmacological activities. C: Structure of the immunosuppressive agent cyclosporine A from 
Tolypocladium inflatum. D: Structure of the antifungal compound friulimicin B produced by Actinoplanes 
friuliensis. 
D 
A 
B C 
N
H
O
NH
O
H
N
CONH2
O
H
N
O
O
NH
H
N
HN
NH
HN
HN
N
H
NH
N
H
COOH
O
O
H2N
O
O
O
O
O
O
O
O
O
HO
NH2
HOOC
COOH
COOH
O O
NH
O
NH
O
H
N
O
H
N
COOH
NH
O
O
HN
O
N
H
O
HOOC
H
N
H
O
H
N
H
N
O
O
H
N
N
H
HN
HN
NH
N
H
NH
O
H
N
O
N
O
O
O
COOH
O
O
COOH
O
COOH
NH2
H
H
O
CONH2
3     Introduction 
 
Interestingly, many CLPs have been recognized as effective biosurfactants,35 which find 
commercial application in environmental industries for the treatment of soil and water due to 
their ability to enhance biodegradation and bioavailability by improving the solubility of 
poorly water-soluble pollutants.36 In addition, CLPs are widely used in other fields such as 
crop protection,7 and as ingredients of cosmetic formulations.37,38 However, CLPs also fulfill 
a wide range of functions in their producer strains or in their natural environment. Recent 
studies on the versatile functions of microbial CLPs from Pseudomonas spp. and Bacillus spp. 
revealed their roles in the protection against predatory microbes, active cell movement on 
surfaces and the formation of complex biofilms, thereby enabling the microorganisms to 
colonize novel habitats.6 Furthermore, functions as signaling molecules for coordinated cell 
growth and differentiation, in the biodegradation of xenobiotics and as metal chelators have 
been recently reported for CLPs.6 The latter ability can also essentially contribute to the 
pharmacological activity of CLPs as recently described for the calcium-dependent compounds 
daptomycin and friulimicin (Figure 1D).39–41 The intriguing structural diversity of CLPs 
together with their remarkable potential in the application as highly effective surfactants, 
biological pesticides, cosmeceuticals and in particular as drugs exhibiting novel modes of 
action, underscore the importance of searching new LP scaffolds in the yet underexplored 
microbial species. 
 
1.2 Myxobacteria – An Underexplored Source of Microbial Natural Products 
Historically, initiatives in natural product discovery from microbial resources particularly 
focused on well-studied microbes such as actinomycetes, in particular streptomycetes, and 
fungi.42 Unsurprisingly, the majority of bioactive compounds found over the past decades 
originated from these proficient producers of secondary metabolites and rapidly changed into 
stagnation as more and more known compounds have been reisolated from related species. 
The emerging resistance of high-risk pathogens against these formerly useful antibiotics 
called for the exploitation of yet untapped microbial habitats and ecological niches in order to 
isolate novel microbes and their corresponding secondary metabolites. Among the 
underexplored microbial sources for bioactive natural products, the myxobacteria represent a 
promising resource as proficient producers of pharmacologically interesting natural products. 
Myxobacteria are Gram-negative, rod-shaped, slime bacteria belonging to the group of δ-
proteobacteria (order Myxococcales). They can be ubiquitary found around the globe and 
occupy diverse habitats such as soil, dung and marine habitats.43 Myxobacteria exhibit unique 
and characteristic features making them outstanding prokaryotes, which is also reflected by 
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their exceptional genomic capacities. The myxobacterium Songarium cellulosum So0157-2 
possesses the largest bacterial genome discovered so far (14.8 Mbp),44 and average genome 
sizes of 9-15 Mbp with a high GC content of about 70% are usually common for 
myxobacterial strains.45,46 The enormous genetic information used by these bacteria especially 
attributes to their complex cellular developmental cycle (Figure 2), which is adapted to 
various environmental conditions, their distinct social behavior, their ability to cooperatively 
glide on surfaces, their ability to prey on other microbes and their potential to produce a 
plethora of bioactive secondary metabolites.47,48 
Most myxobacteria are chemoorganotrophic microorganisms,49 which means that they are 
reliant on insoluble organic substances to maintain their cellular processes. In order to find 
nutrients in their habitat, myxobacteria are able to move in swarms in a chemotaxis-like 
manner, although they do not possess flagella or similar structures for directed movement like 
other bacteria.50 In contrast, flagella-independent swarming motility in myxobacteria is 
mediated by two different motility systems, which are referred to as social (S-) and 
adventurous (A-) motility.51 S-motility plays a crucial role in multicellular swarms (Figure 
2A) for both predation and fruiting body formation,52–54 another feature which was originally 
thought to be a characteristic of eukaryotic fungi. S-motility is triggered by different 
extracellular components including exopolysaccharide (EPS) containing fibrils, 
lipopolysaccharide and retractile type IV pili, which provide direct cell-cell contact.55,56 
During the swarming process the pili, which are located at the leading pole of the cell, are 
attached to the EPS of adjacent cells, thereby coordinating swarm movement by multiple 
cycles of extension and retraction.57 If necessary, this machinery can be reassembled at the 
opposite pole of the cell to change the direction. In contrast, A-motility describes the 
movement of single cells at the edge of a swarm to explore new habitats, thereby leaving 
behind an extracellular matrix, that ‘paves the way’ for the following companions.51 Although 
a large set of genes was identified to be involved in the A-motility system over the past 
decades,58,59 the precise mechanisms are still not understood in detail. Two main hypotheses 
have been proposed, which try to explain the movement of A-motile cells both suggesting the 
involvement of a proton motive force, which drives different protein motors.58,60 There is 
consensus in both models, that the traits of extracellular slime produced by the gliding 
bacteria plays a crucial role in bacterial A-motility and in facilitating cell adhesion to the 
surface they move on. In addition, it has been proposed that the deposited slime also 
contributes to the social capabilities in myxobacteria.61 Interestingly, previous studies 
demonstrated the effect of LPs on motility in various bacterial producer strains.6 LP-deficient 
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mutant strains lost their ability to glide on solid surfaces suggesting the biological function of 
LPs to help the bacteria to translocate to nutrient-rich habitats, amongst others.  
 
 
Figure 2. Developmental stages of Myxococcus xanthus on solid agar (pictures taken by Ronald Garcia). A: 
Swarming colony showing flare edges. B: Vegetative cells. C: Developing fruiting bodies on agar. D: Slide 
mount of myxospores. A/C: stereo photomicrographs, B/D: phase contrast photomicrographs. 
 
Besides their unique swarming motility, myxobacteria are distinguished by a complex life 
cycle, which largely relies on the supply of nutrients in their habitat. Myxobacteria are 
capable of coordinated predation by making use of the described motility systems in 
conjunction with segregation of lytic enzymes in order to degrade suitable biopolymers or to 
prey on other bacteria or fungi by the action of additionally secreted antibiotics.62–64 When the 
continuous nutrient supply becomes limited, myxobacteria enter several developmental 
stages, which are characterized by the formation of multicellular fruiting bodies from 
thousands of vegetative cells (Figures 2B/C). Prerequisites for the development of fruiting 
bodies are a critical cell density, which requires motility on solid surfaces, recognition of the 
limited nutrient supply as well as a complex interplay of inter- and intracellular signaling 
pathways.48 In M. xanthus, it was shown that a reduced cell movement supports cell 
aggregation to form fruiting bodies.65 In the course of this process, vegetative cells undergo 
significant morphological changes including the formation of spherical cells, which are 
enveloped by several lipid layers. Under constant starvation conditions, more and more cells 
aggregate to form the fruiting bodies, in which approximately 10% of the cells develop into 
viable myxospores (Figure 2D).66 Myxospores are highly resistant to heat, desiccation, pH 
value, UV radiation and the continued absence of nutrients,67 which displays an efficient 
D 
A B 
C 
200 µm 5 µm 
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strategy to survive under extreme environmental conditions. Most of the cells become lysed 
during fruiting body development,68 thereby providing essential nutrients for the sporulation 
process and the differentiation of myxospores. When nutrient supply is restored, myxospores 
germinate and rearrange to vegetative cells, which are again able to glide in cooperative 
swarms, thereby restarting the myxobacterial growth cycle.66 In analogy to the motility 
systems described above, microbial LPs seem to have biological functions linked to the 
producer’s ability to form fruiting bodies and other biofilms. In a recent study, fruiting body 
development in a M. xanthus mutant strain exhibiting accelerated production levels of the 
lipohexapeptide myxochromide A was dramatically downregulated.69 In Bacillus sp. and 
Pseudomonas sp. LPs were shown to likely play essential roles as inducers of multicellularity 
by stimulating morphological rearrangements.6 
Taxonomically, myxobacteria display a coherent group comprising three suborders 
(Cystobacterineae, Nannocystineae and Sorangiineae), 11 families and 29 genera, which were 
validated at the time of writing this thesis,70 but the aforementioned numbers continue to 
increase due to innovative biodiversity mining. Traditionally, classification of novel isolates 
was realized by investigation of the unique phenotypic and morphological features.71 It turned 
out soon that this strategy alone is not sufficient to certainly assign the novel strains to the 
existing families and genera as many strains were misclassified in the past, which needed to 
be carefully revisited. Today, a combination of physiological, phenotypic and genetic 
features, especially the use of 16S rRNA genes, complemented by instrumental techniques 
such as GC-MS analysis of specific fatty acids contributes to the clarification of the 
phylogenetic position of novel taxa.72–74 In addition, analysis of 16S DNA sequences as well 
as coding DNA sequences or protein sequences allows for the in silico reconstruction of 
phylogenetic trees to illuminate strain phylogenies. Phylogenetic studies can also be applied 
to the underlying natural product pathways, which direct the production of certain secondary 
metabolites, by in silico analysis of DNA sequences coding for the corresponding pathways. 
In this way, it is possible to directly link strain phylogeny to pathway phylogeny in order to 
investigate the evolutionary origins, relationships and histories of these secondary metabolite 
pathways and the respective producer strains. 
Over the past decades, myxobacteria have been recognized as proficient producers of such 
secondary metabolites, mainly polyketides and peptides, exhibiting an intriguing diversity 
concerning their chemical structures and bioactivities ranging from antifungal, antibacterial, 
antiviral and antimalarial to cytotoxic, immunosuppressive and antioxidative properties.75 
This is in fact expressed by their aforementioned huge genetic capacities pointing up their 
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biosynthetic potential. Around 10% of a myxobacterial genome encode for natural product 
biosynthetic pathways resulting in a number of usually 10 to more than 20 biosynthetic 
pathways per genome.45,76 Until today, more than 100 distinct natural product core structures 
harboring partly unusual structural elements and about 600 derivatives have been isolated and 
characterized.47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structures of selected secondary metabolites produced by the model strain Myxococcus xanthus 
DK1622. A: myxoprincomide. B: myxalamid A. C: myxovirescin A. D: DKxanthen-534. E: myxochelin A. 
 
Most myxobacterial natural products were isolated from Sorangium, Myxococcus, and 
Chondromyces strains, as compound screening particularly focused on these genera in the 
past.77 The model strain M. xanthus DK1622 is e.g. capable of producing a vast array of 
diverse secondary metabolites such as myxoprincomide,78 myxovirescin A,79 myxalamides,80 
DKxanthenes,81,82 and myxochelin A (Figure 3),83 exhibiting various natural functions or 
antibiotic activities. Lipopeptides were found in myxobacteria as well but compared to the 
extensively studied LP producers Pseudomonas spp. and Bacillus spp., LP biosynthesis in 
myxobacteria is currently underexplored. The best studied myxobacterial LP pathways direct 
the biosynthesis of myxochromides A from M. xanthus DK1622,84 and myxochromides S 
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produced by Stigmatella aurantiaca DW4/3-1.85 Additionally, the structure of another 
member of this LP family, myxochromide B3 from an unclassified Myxococcus sp. strain, was 
previously elucidated.86 Cystomanamides A-D produced by Cystobacter fuscus MCy9118 
display a novel class of myxobacterial linear LPs, which was recently structurally 
characterized.87 Both LP families do not exhibit any biological activity under the applied 
conditions in standard bioactivity screenings, but one has to consider that LPs often exhibit 
highly specific functions or bioactivities, which are frequently not detected in these screens. 
Another type of mxyobacterial lipopeptides are the lipothiazoles, which have been detected in 
extracts of Sorangium cellulosum GT47.88 However, the most prominent myxobacterial 
secondary metabolite, which was approved by the FDA in 2007 as an agent against advanced 
breast cancer,89 is the macrolide epothilone produced by various Sorangium strains.90 In 
addition, five compound classes from myxobacteria targeting different medical indications are 
currently assessed in preclinical studies and 14 different scaffolds are extensively under 
investigation concerning their mechanisms of action, thereby being promising candidates for 
future drug development programs.47 Considering the relatively small number of 
myxobacterial strains screened so far, these examples illustrate the potential of myxobacteria 
as a still rich source of bioactive natural products, which is far from being exhausted. 
 
1.3 Natural Product Biosynthesis by Multimodular Enzyme Complexes 
Nature developed intriguing concepts for the formation of bioactive substances during billions 
of years, which led to diverse groups of natural products. Many of these concepts include the 
supply of simple precursor molecules, which can be subsequently transformed into rather 
complex metabolites either by a subset of single enzymes or by multienzyme complexes. For 
instance, plant polyphenolic compounds like flavonoids or stilbenes usually derive from 
simple phenylpropanoids using the Shikimate pathway,91 whilst terpenes are made of isoprene 
or its activated forms,92 respectively, in multistep enzymatic conversions. In myxobacteria, 
most of the secondary metabolites characterized so far belong to the class of polyketides and 
nonribosomal peptides, many of them were shown to exhibit antibiotic and/or cytotoxic 
activities.47 Such polyketides and nonribosomal peptides also consist of simple building 
blocks that can be assembled to form a vast number of structurally diverse compounds. 
Condensation of these precursors is mediated by polyketide synthases (PKS) and 
nonribosomal peptide synthetases (NRPS), giant multimodular enzyme complexes, which act 
as molecular assembly lines in natural product formation.93,94 The genes encoding these 
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assembly lines are usually clustered, thereby simplifying the identification and analysis of 
gene clusters that are associated with natural product biosynthesis. 
1.3.1 Biochemistry of PKS Machineries 
Polyketide synthases (PKS) are evolutionary linked to and derived from fatty acid synthases 
(FAS).95 FASs have been intensively studied since their discovery, and it was quickly 
recognized that these systems can appear either as a set of distinct enzymes or as multienzyme 
complexes, which convert simple carboxylic acid monomers into saturated fatty acids using 
an iterative assembly strategy.96,97 In general, fatty acids are biosynthesized via successive, 
decarboxylative Claisen-like condensations of the short-chain carboxylic acids acetyl-CoA 
and malonyl-CoA.98 The dimeric FAS machinery involves seven catalytic functionalities to 
specifically select the precursor molecules and to further process the growing acyl chains.99 
Malonyl/acyl transferase (MAT) is responsible for transferring the starter unit acetyl-CoA and 
the extender units malonyl-CoA onto the acyl carrier protein (ACP). ACPs are four-helix 
bundles consisting of 80-100 amino acid residues. The substrates are covalently linked to a 
conserved serine residue of the ACP as a thioester using a phosphopantetheinyl (ppant) linker, 
which is derived from CoA.100 The ppant moiety acts as a flexible arm and can subsequently 
guide the substrates and intermediates to other catalytic functionalities for further processing, 
thereby providing an efficient biosynthetic system, which is not dependent on and limited to 
diffusion control as it is the case for isolated enzymes. Phosphopantetheinyl transferases 
(PPTases) catalyze the posttranslational transfer of the CoA-derived linker molecule onto the 
ACP.101,102 After loading of the starter and extender units, β-ketoacylsynthase (KS) catalyzes 
C-C bond formations by employing decarboxylative condensations between KS-bound acetyl-
CoA starter units or biosynthetic intermediates and extender units, which are bound to the 
ACP.103 The repetitive extension of the growing ACP-bound acyl chain with C2 carboxylic 
acid monomers results in poly-β-oxo compounds, which are further processed by a set of 
reductive enzymes to build up fully reduced fatty acids. This set of reductive domains of 
FASs consists of three catalytically active enzymes: a ketoreductase (KR), a dehydratase 
(DH) and an enoylreductase (ER). Stepwise processing of the introduced extender units first 
leads to the conversion of the β-ketoacyl functionality to β-hydroxy compounds by 
NAD(P)H-dependent KR catalysis. DHs subsequently catalyze water elimination, thereby 
forming a C=C double bond, which is finally being reduced to a saturated C-C bond by ERs 
(Figure 4).96 The final product of the FAS is being cleaved off the ACP by a thioesterase 
(TE). The product spectrum, an iterative FAS is able to produce, is quite limited. Only acetyl-
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CoA and malonyl-CoA are being used as starter and extender units usually providing 
saturated fatty acids with chain lengths of C14-C18.99 
 
 
 
 
Figure 4. Reaction scheme illustrating the stepwise formation of products derived from FAS and PKS 
machineries (adapted from Smith and Tsai)96. A: FAS pathway leading to the formation of fully reduced fatty 
acids. Condensation of an acetyl-CoA starter unit with the first extender unit malonyl-CoA yields a β-oxo 
diketide, which is successively reduced by a set of reductive domains consisting of the KR, DH and ER domains 
prior to the following round of chain elongation. B: PKS pathway leading to the formation of various compound 
species. The β-oxo diketide produced in the first chain extension can undergo several reaction scenarios leading 
either to the formation of poly-β-oxo compounds or to the biosynthesis of partially or fully reduced polyketide 
structures depending on whether the reductive domains are present/active or not present/inactive in the 
corresponding module. 
 
Studies about FASs essentially contributed to the still expanding knowledge in the field of 
PKS research,94,104 and since sophisticated genomics, proteomics and structural 
methodologies have become routinely applicable, it was possible to gain detailed insights into 
how such giant megasynthase complexes are capable of producing structurally diverse and 
complex polyketides. In contrast to FASs, most bacterial PKSs are composed of so-called 
modules, which contain catalytically active domains fulfilling the tasks described above for 
FASs and which are arranged as a kind of molecular assembly line.105 A minimal PKS 
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module is composed of at least an acyltransferase (AT) domain, a KS domain and an ACP. In 
such multimodular PKSs, every module is thus responsible for one round of chain elongation 
during biosynthesis. Consequently, the number of functional modules in the PKS system 
usually correlates with the number of incorporated building blocks, which is known as the co-
linearity rule.106 Although FASs and PKSs share basically closely related catalytic 
mechanisms, there are significant differences between both systems concerning building 
block selection, different degrees of reduction after each elongation step, the use of additional 
modifying domains/enzymes as well as chain termination mechanisms, thereby leading to an 
unique structural diversity of polyketides.96 
Unlike in FASs, where the MAT domain exhibits dual-specificity for acetyl-CoA and 
malonyl-CoA for both substrate loading and chain extension, the AT domains present in 
modular PKSs usually have distinct specificities either for malonyl- or methylmalonyl-
CoA.107 In addition to the standard building blocks described, the structural diversity of 
polyketides can be dramatically increased by selection of various unusual starter and extender 
units. Besides acetyl-CoA, possible starter units are e.g. isovaleryl-CoA, benzoyl-CoA, 
cyclohexanyl-CoA, cinnamoyl-CoA and many more.108 Diversification by using alternative 
extender units is less common but there are some examples known, e.g. methoxymalonyl-
CoA, ethylmalonyl-CoA, hydroxylmalonyl-CoA and aminomalonyl-CoA.109–111 
The sequential use of the reductive domains (KR, DH, ER) increases the structural diversity 
of polyketides as well. The poly-β-oxo compounds produced by multiple rounds of chain 
extension can either form complex polyphenolic compounds by undergoing orchestrated 
cyclizations or can be fully or partially reduced by KR, DH and ER domains (Figure 4). 
While the reductive domains are necessarily required in iterative FASs for fatty acid 
biosynthesis, it is merely optional in PKS machineries.94 
In addition, polyketides can be further structurally diversified by the action of unusual 
domains, enzymatic mechanisms and assembly line organizations.94 Several optional domains 
integrated into PKS assembly lines can be found such as methyltransferases (MT) that 
catalyze SAM-dependent C- or O-methylation.112 In addition, tailoring enzymes that act in 
trans transform the often pharmacologically inactive precursor polyketides into potent 
bioactive natural products. The most common tailoring enzymes are glycosyltransferases that 
attach sugars – predominantly hexoses, which can also be highly modified – to hydroxyl 
groups of the polyketide scaffold, thereby increasing the hydrophilicity, oxygenases that 
introduce hydroxyl or epoxide functionalities and halogenases that catalyze chlorination or 
bromination, which is often found in polyketides from marine origin.113 Modifications that are 
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catalyzed by these dedicated tailoring enzymes usually affect biological activity, metabolic 
stability and/or solubility. Apart from that, there are several unusual mechanisms, which 
deviate from the standard ‘textbook’ enzymology of PKS systems, thereby violating the co-
linearity rule.114 In some biosynthesis pathways, modules appear to be skipped during chain 
assembly. Based on a study of an engineered PKS system, module skipping is most likely 
facilitated by ACP-to-ACP transfer of the nascent intermediate, while the ACP of the skipped 
module carries over the acyl chain to the downstream extension module.115 In opposite cases, 
PKS assembly lines contain fewer modules than should be present according to the number of 
incorporated building blocks in a certain polyketide. This phenomenon, which is called 
‘stuttering’, implies the back transfer of the growing polyketide chain from the ACP to the KS 
domain of the same module, repeated loading of the free ACP domain followed by 
condensation.114 The affected polyketides are often by-products, while the major product 
conforms to the co-linearity rule. However, ‘stuttering’ is more appropriately referred to as 
‘programmed iteration’, since this process seems to play an important role in the biosynthesis 
of the major polyketides as well.114 
The chain termination also contributes to the intriguing structural diversity of polyketides. 
Whilst TE domains from FAS systems only hydrolyze the fatty acid-CoA thioester releasing 
linear products, the TE domains in PKSs often catalyze intramolecular cyclizations to form 
complex macrolides.116 
Furthermore, PKSs can interact with another class of multimodular enzyme complexes, which 
includes the incorporation of a vast array of amino acids into the acyl chain. The observed 
structural diversity accounts for numerous functions polyketides have in Nature, which are 
largely linked to secondary metabolism, thereby discriminating them from fatty acids 
produced by FASs, which are involved in primary metabolism. The seemingly endless options 
to combine different domains, modules and subunits in conjunction with the possibility to 
interact with different classes of molecular assembly lines give rise to an unprecedented 
structural diversity of polyketides exhibiting diverse biological activities. 
 
1.3.2 Biochemistry of NRPS Machineries 
Scientific reports about the biosynthesis of biopolymers that consist of amino acid monomers 
have traditionally their roots in the field of ribosome research. Protein synthesis is thereby 
mediated by a huge protein/RNA complex that coordinates a rather complicated interplay 
between various catalytic centers and enzymes finally facilitating the translation of the 
information encoded in the mRNA into a polypeptide chain.117 Furthermore, the ribosome is 
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also able to produce small genome-encoded precursor peptides found in some 
microorganisms, so-called RiPPs (ribosomally synthesized and posttranslationally modified 
peptides), which are usually being highly posttranslationally modified to become biologically 
active.118 In contrast, many bacteria and fungi make use of another biosynthetic machinery to 
produce structurally diverse peptides. The multimodular nonribosomal peptide synthetases 
(NRPS) employ a highly similar biosynthetic strategy as already described for PKSs using 
peptidyl carrier proteins (PCP) as a substrate shuttling platform and canonical as well as non-
canonical amino acids as building blocks for the biosynthesis of nonribosomal peptides 
discriminating them from their counterparts synthesized by the ribosome.93 In analogy to PKS 
modules, every NRPS module consists of several catalytically active domains, which are 
responsible for building block activation (A, adenylation domain), substrate transfer (PCP) 
and condensation/chain elongation of usually L-configured amino acids (LCL, condensation 
domain). Similar to PKS machineries, most NRPS assembly lines contain a loading or 
initiation module, which often harbors only an A domain as well as a PCP domain in order to 
start the biosynthesis. In addition, termination modules contain TE domains to release the 
final linear product by hydrolysis. In many cases, the TE domains are also able to catalyze 
macrocyclizations, which lead to complex macrolactames, macrolactones and related 
compounds.119,120 Similar to short-chain carboxylic acids in PKS biosynthesis, the amino 
acids used as building blocks in NRPS systems need to be presented in an activated form. 
Unlike the related AT domains in PKS modules, A domains select the corresponding amino 
acid and catalyze the formation of an aminoacyl-adenylate (AMP-ester) using adenosine-
triphosphate (ATP) and magnesium ions as cofactors.121 When two adjacent NRPS modules 
are loaded with amino acids, the downstream C domain catalyzes peptide bond formation, 
which yields a peptide intermediate that is bound to the PCP of the second downstream 
module. During this reaction, the upstream PCP-bound donor amino acid is attacked by the 
nucleophilic amino group of the downstream PCP-bound acceptor amino acid (Figure 5).122 In 
general, A domains specifically recognize amino acids depending on the cavity in their active 
sites, which is largely determined by a certain set of amino acid residues. 
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Figure 5. Mechanism of peptide bond formation in NRPSs. Active domains are highlighted in orange. A: 
Adenylation domains catalyze amino acid activation via formation of an aminoacyl-adenylate and subsequent 
transfer to the adjacent peptidyl carrier protein, thereby consuming ATP. B: Condensation of two amino acids 
attached to neighboring NRPS modules catalyzed by the downstream condensation domain. 
 
This amino acid specificity-conferring code has been intensively investigated by Stachelhaus 
et al. and other research groups and provides an useful tool for the in silico prediction of 
amino acids selected by distinct A domains.123,124 However, substrate specificities of A 
domains are very often not stringent allowing the activation of more than one amino acid by 
an A domain. A domains of NRPS assembly lines are not only capable of activating and 
incorporating proteinogenic amino acids but also of an almost uncountable number of non-
proteinogenic amino acid precursors. These precursors are usually being synthesized in trans 
by a set of dedicated enzymes and often originate from proteinogenic amino acids or other 
primary metabolites and can subsequently be loaded onto PCP domains.125 Prominent 
examples are 2,3-diaminopropionate (DAP), which is made from L-serine and the amino 
group donor L-ornithine,126 as well as L-p-hydroxyphenylglycine, which is biosynthesized in a 
transamination-like conversion, in which the amino functionality of L-tyrosine is transferred 
to the acceptor p-hydroxybenzoylformate.127 The β-hydroxylation of amino acids is another 
possibility to further extend the scope of precursor molecules that can be incorporated by 
NRPS systems during assembly of the NRPS-derived peptide. Oxidative enzymes that 
catalyze β-hydroxylation of amino acids are usually cytochrome P450 monooxygenases 
(CYPs), di-iron monooxygenases or iron/α-ketoglutarate-dependent dioxygenases and can act 
either on free amino acids or on PCP-bound amino acids of external A-PCP didomains.128–131 
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β-hydroxylation has been reported for the proteinogenic amino acids L-phenylalanine, L-
tyrosine, L-leucine and L-valine, amongst others, as well as for the non-proteinogenic 
counterpart L-p-aminophenylalanine.131–133 Furthermore, non-proteinogenic amino acids 
derived from the primary metabolism can be directly introduced into NRPs, e.g. L-ornithine.18 
Similar to PKS enzymology, there are additional catalytic domains that can be integrated into 
the assembly line in order to modify single building blocks or the mature peptide. For 
instance, D-configured amino acids can be found in many NRPS products. Since D-
configured amino acids usually do not occur in the primary metabolism, they are directly 
converted from L-amino acids by epimerization domains (E), which are located downstream a 
PCP domain in NRPS modules.134,135 In those cases, the C domain of the following module 
exhibits an altered stereospecificity (DCL). Additionally, typical modification reactions 
comprise N- or C-methylations catalyzed by methyltransferases (MT), glycosylations 
catalyzed by glycosyltransferases (GT), hydroxylations and oxidative cross-coupling reactions 
mainly mediated by CYPs, transaminations (AMT, aminotransferase domain) and 
heterocyclizations (HC, heterocyclization domain or Cy, cyclisation domain), rarely also 
cyclopropanations (Cyp, cyclopropanase domain).136–138 Heterocyclizations in NRPS systems 
frequently involve serine, threonine and cysteine residues, which can be converted into 5-
membered oxazoline or thiazoline rings, respectively. Oxidase domains (Ox), which often 
appear to be present together with HC domains are able to catalyze dehydrogenation of the 
oxazoline or thiazoline yielding the respective oxazole or thiazole.139 In addition, reduction by 
dedicated reductases (Re) leads to the formation of oxazolidine or thiazolidine rings.140 
Moreover, Re domains are found to be involved in reductive product release mechanisms, 
which facilitates the formation of carboxylic acid and aldehyde moieties, amongst others.141 
Module skipping, as already described for PKS biosynthesis, can also occur during NRP 
formation and contributes to the expansion of secondary metabolites, which can be made by a 
single assembly line.84 Since the PKS and NRPS biosynthetic logic and assembly line 
organizations share many striking similarities following modular biosynthetic principles, it is 
not surprising that PKS/NRPS hybrid assembly lines evolved over time and greatly contribute 
to the incredibly versatile pool of microbial natural products. 
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1.3.3 PKS/NRPS Hybrid Megasynthetases 
In principle, modular PKS and NRPS megaenzymes share the same biosynthetic strategies, 
which comprise building block selection, priming of a carrier protein and condensation with a 
downstream extender unit. ACPs and PCPs with their flexible ppant linkers therefore guide 
the substrates or biosynthetic intermediates along the assembly line by providing them in the 
active site of the downstream domain that catalyzes condensation of the ACP/PCP-bound 
templates (C or KS). Since the functions of domains or even modules of PKS and NRPS 
systems and their arrangement are highly similar, the discovery of hybrid PKS/NRPS 
assembly lines was the logical consequence.142 This concept further diversifies microbial 
natural products that are made either of PKS or NRPS assembly lines and combines enzyme 
functions and features of both production routes. An example of a prominent PKS/NRPS 
hybrid system is the heptamodular tubulysin assembly line from the myxobacterium 
Angiococcus disciformis, which directs the biosynthesis of the potent cytotoxic peptides 
tubulysins exhibiting antimitotic activity (Figure 6).143 
 
Figure 6. Assembly line architecture and proposed biosynthetic pathway of the tubulysins. The PKS/NRPS 
hybrid machinery consists of seven modules, two PKS (illustrated in gray) and five NRPS (colored) modules and 
facilitates the incorporation of acyl units plus a set of proteinogenic, unusual and modified amino acids. The 
coloring of the catalytic domains corresponds to the biosynthetic intermediate and product structures. 
Abbreviations of catalytic domains are explained in the main text; S = spacer. 
module 6
C PCPMT C PCPA AC PCPMT KS AT
KR
PCP Ox KSHC
S
AA
DH
ER
ACP AT
MT
KR
DH
ER
ACP TE
module 1
module 2 module 3 module 4 module 5 module 7
C PCPA
tailoring
modifications 
Tubulysins
TubB TubC TubD TubE TubF
17     Introduction 
 
The tubulysin biosynthetic machinery involves five NRPS and two PKS modules distributed 
over five protein subunits (TubB-F), which catalyze successive elongation of the growing 
peptide chain and an additional enzyme, which supplies the starter amino acid (TubZ). 
Several deviations from ‘textbook’ NRPS enzymology, which were discussed above, lead to 
the production of a highly unusual natural product. The initiation module starts biosynthesis 
with the incorporation of the unusual amino acid pipecolic acid, which derives from lysine. 
Pipecolic acid is generated in situ by the action of lysine cyclodeaminase TubZ, which is also 
encoded in the tubulysin biosynthetic gene cluster. The amino acids isoleucine and valine are 
installed in the peptide chain by two subsequent NRPS modules. Both the first and the third 
module contain a MT domain integrated into the respective A domains. Accordingly, the 
corresponding amino acids were found to be methylated.143 The most fascinating aspect of 
PKS/NRPS hybrid systems is how they manage the translocation of the nascent product chain 
at the interfaces between PKS and NRPS subunits. Transition from module 3 to module 4 
constitutes the first NRPS/PKS interface in the assembly line and requires a KS domain to be 
able to accept the peptidyl donor from module 3 and catalyzes C-C bond formation with a 
malonyl-CoA extender unit selected by module 4, which contains a fully active reductive 
loop. In analogy, the downstream HC domain is capable of catalyzing the condensation of the 
acyl/peptidyl chain with cysteine, thereby forming the thiazoline moiety, which is 
subsequently oxidized to the thiazole ring by the Ox domain. The minimal NRPS module 6 
incorporates an aromatic amino acid residue (either phenylalanine or tyrosine) followed by 
the condensation of the resulting intermediate with the second malonyl-CoA extender unit, 
which is fully reduced and methylated at the α-carbon atom via action of the reductive loop 
and the integrated MT domain. Product release is facilitated by the TE domain, which 
hydrolyzes the linear PK/NRP hybrid product to form a mature peptide that is subjected to 
further rare tailoring modifications.143 
Although many PKS/NRPS hybrid machineries like the tubulysin assembly line have been 
characterized over the past years, there is still a lack of mechanistic insights into how PKS 
and NRPS subunits or modules can interact with each other. Several attempts to reprogram 
these biosynthetic megaenzymes to produce ‘unnatural’ scaffolds failed in most cases, which 
suggests that intersubunit or intermodule communication is mediated by rather sensitive and 
fine-tuned protein interactions.144 Previous studies revealed that the specific intersubunit 
recognition processes are mediated by so-called docking domains in PKSs and 
communication-mediating (COM) domains in NRPS systems, which are located at the N- and 
C-termini of the respective protein subunits.145,146 It likely seems to be that a similar 
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quaternary structure of both the PKS and NRPS subunits is crucial for their correct interaction 
and orientation in the operative assembly line. Several studies suggested that PKS as well as 
the cognate FAS subunits occur as homodimeric, ‘double-helical’ proteins,147 whereas 
investigations about quaternary structures of NRPS systems are rather inconsistent.148,149 
Monomeric as well as dimeric structures have been found using sophisticated analytical 
techniques and it is assumed that NRPS subunits are able to switch between both states 
depending on whether they interact with other NRPS subunits (monomeric) or PKS subunits 
(dimeric) in hybrid megasynthetases.148 By now, several families of docking or COM 
domains have been identified and many hybrid pathways have been intensively 
characterized.144 However, detailed insights into enzymatic mechanisms and particularly into 
the dynamics and protein-protein interaction networks of PKS and NRPS systems and their 
hybrids remain largely to be deciphered. State-of-the-art structural techniques like protein 
NMR, X-ray crystallography and cryo electron microscopy are currently used to study 
multienzyme architectures as well as domain and module contact regions, interaction surfaces 
and dynamic mechanisms of precursor processing/product formation. The output of those 
studies is assumed to have a significant impact on the rational design of PKS, NRPS and 
PKS/NRPS hybrid assembly lines in order to produce novel metabolites, which would 
otherwise not be synthesized in Nature, by combinatorial biosynthesis. 
 
1.3.4 Bioinformatics Tools to Identify and Characterize Biosynthetic Gene Clusters 
Recent advances in high-throughput shotgun genome sequencing techniques such as Illumina, 
PacBio, IonTorrent and 454 pyrosequencing essentially contributed to the exploding number 
of microbial genome sequence data over the past years.150 The progress achieved so far made 
the sequence-based analysis of these genomes and, in particular, of biosynthetic gene clusters 
a routine approach in natural product research as the costs of whole genome sequencing 
dramatically dropped, while the sequences can be provided in unforeseen short time frames 
and accuracy. The approach that attempts to translate the underlying molecular genetics into 
isolated natural products by analyzing pathway-specific sequence motifs is known as 
‘genome-mining’ and is widely used in the identification process of biosynthetic gene clusters 
and their corresponding secondary metabolites.151 The genome-mining process can be 
generally subdivided into three stages: 1) NGS data acquisition from natural sources, e.g. 
genome sequencing of microbial producers, 2) Identification of biosynthetic gene clusters and 
prediction of corresponding product structures using bioinformatics tools and 3) 
Identification, isolation and structure elucidation of the predicted secondary metabolites. 
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Genome-mining also allows to back correlate identified product structures to the respective 
biosynthetic gene clusters to gain deep insights into the enzymology of the biosynthetic 
processes. The modular architecture and mechanistic similarities of both PKS and NRPS 
biosynthetic machineries in conjunction with high sequence similarities of PKS and NRPS 
domains, especially on the protein level, allows for the rapid identification and comparative 
analysis of microbial biosynthetic gene clusters based on the genome sequence of a certain 
producer strain. Many in silico tools have been developed and refined in the PKS/NRPS field 
over the past decade to assist genome-mining initiatives. The most prominent tool among 
those is certainly antiSMASH, which provides a comprehensive platform for the analysis of 
microbial biosynthetic gene clusters.152 This tool requires an input DNA sequence and offers 
the automated genome-wide analysis and annotation of biosynthetic gene clusters based on 
sequence similarity compared to deposited sequences as well as specific sequence motifs, 
which are characteristic features of PKS and NRPS domains. These sequence motifs are 
referred to as core motifs, which are highly or even strictly conserved regions on the protein 
level of a certain domain and were previously found in obligatory core domains of both PKS 
and NRPS systems.119,153 The antiSMASH tool enables a fast assessment of the biosynthetic 
potential of a given producer strain, thereby enabling the possibility to further focus on 
interesting and unusual assembly line organizations. The annotated sequence data can be used 
in the following to postulate a biosynthesis model for the assembly of a certain secondary 
metabolite prior to experimental verification, e.g. by gene inactivation or heterologous 
expression, and provides a basis for the prediction of the secondary metabolite core structure 
by implementing additional tools covering the substrate specificities of the PKS/NRPS 
domains such as NRPSpredictor2.154 This tool relies on different approaches for the analysis 
of the A domain substrate specificities, which are determined by a set of distinct amino acid 
residues of A domains. These amino acids have been previously identified by Stachelhaus et 
al., and Challis et al. based on an A domain crystal structure and are widely known as the 
Stachelhaus code,124,155 which was recently further extended to an overall set of 34 amino 
acids lining the active site of the A domain in a distance of 8 Å around the bound substrate.123 
In addition, several other approaches have been developed to predict A domain specificities, 
which complement the current tool box.106 In a similar way, AT domain specificities in PKS 
modules can be predicted using computational tools considering amino acid residues within 
the AT domain active sites, which e.g. discriminate between malonyl-CoA and 
methylmalonyl-CoA.156 Bioinformatics tools allow not only the in silico prediction of the 
building blocks that are incorporated into the assembled product but also the prediction of the 
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stereochemical course during PKS/NRPS biosynthesis. In NRPS assembly lines, C domains 
can be usually classified as DCL, LCL and starter C domains depending on the observed 
substrate specificities. DCL domains catalyze the condensation between a D-configured donor 
peptide intermediate and an L-configured acceptor substrate, whilst LCL domains facilitate 
peptide bond formation between donor and acceptor building blocks, which show both L-
configuration. In contrast, starter C domains can be e.g. found in initiation modules of 
lipopeptide assembly lines, where they catalyze the covalent linkage of the acyl side chain 
with the first amino acid precursor, a process known as lipoinitiation.157 The different types of 
C domains significantly differ at several positions in their core motifs, which allow 
assignment of uncharacterized C domains by means of in silico predictions.158 In PKS 
biosynthesis, stereochemical preferences can be predicted for KR domains, which produce 
either an (R)-3-OH or an (S)-3-OH acyl intermediate during catalysis. There are two different 
types of KR domains, A-type and B-type KR domains, which differ in a highly conserved 
core motif, thereby making stereopreferences predictable based on sequence analysis.159 The 
ACPs and PCPs, which are responsible for the translocation of biosynthetic intermediates in 
the respective megasynthetases, share a common core motif (GGH(D)SL) harboring the 
active site serine residue. In NRPSs, a second class of PCPs was detected, that exhibits a 
slightly modified but absolutely conserved signature motif (GGDSI). These PCPE domains are 
specifically found in modules, in which the PCP domain directly interacts with a downstream 
E domain.134 Based on comparative sequence alignments, the two PCP types can be easily 
differentiated. 
The presented sequence-based analysis tool box has become indispensable for the discovery 
of novel natural products and uncommon enzymatic activities. However, the approaches 
described here are depending on the sequences of all available biosynthetic gene clusters and 
domain crystal structures, which serve as references in the existing databases as well as on 
algorithms developed for in silico predictions, which implies that the current models cannot 
provide the full picture. Thus, in silico predictions always need to be critically examined as 
many predictions and assignments turned out to be wrong in the past. Deviations from 
‘textbook’ biosynthetic logic, violation of the co-linearity rule as well as unexpected inactivity 
of catalytic domains, which cannot be explained by sequence analysis so far significantly 
attribute to this issue. In addition, genes that encode tailoring enzymes and stand-alone 
domains or modules are sometimes not present in the corresponding biosynthetic gene cluster, 
but are located somewhere else in the genome, which makes it difficult to correlate such 
genes to the gene cluster of interest. As more and more gene cluster sequences will be 
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deciphered and provided to the scientific community, the developed models will be further 
refined to improve the accuracy of such predictions.  
 
1.4 Synthetic Biotechnology Approaches in Natural Products Research 
The discovery and in-depth analysis of novel natural products and the corresponding 
biosynthetic pathways from natural sources usually involved a low-throughput, time-
consuming and expensive workflow over the past decades. This especially holds true for the 
investigation of natural product biosynthesis in myxobacteria as most of the candidate 
producer strains exhibit low growth rates or even cannot readily be cultivated under standard 
laboratory conditions, and are often not susceptible to genetic manipulations, e.g. to alter the 
complex product structures or to improve production yields, which are often found to be 
homeopathic, thereby hampering the discovery process. In addition, and despite of the 
impressive advances made in the field of microbial genomics, which revealed a by far 
underestimated biosynthetic capacity of microbes,160 many microbial biosynthetic gene 
clusters appear to be inactive under standard cultivation conditions.161 These limitations have 
been addressed (amongst other approaches) by transferring the gene cluster of interest into a 
well-studied heterologous host that is, often in contrast to the native producer, amenable to 
further strain improvement by genetic engineering. Heterologous expression of biosynthetic 
pathways has been successfully used to modify the natural products produced by the encoded 
pathways, to essentially increase production titers and to unleash secondary metabolite 
production by activating silent gene clusters.162 However, heterologous production of natural 
products is by no means trivial as the chosen host strain needs to meet several key 
requirements, which critically influence the outcome of such experiments. The foreign 
biosynthetic gene cluster must be stably and functionally expressed in the surrogate host, 
which requires suitable genetic elements such as promoters and terminators, as well as vector 
systems that allow stable transfer and maintenance.162,163 Regarding PKS and NRPS 
pathways, the heterologous host needs to bear the genetic capacity for posttranslational 
activation of the encoded megasynthetases, e.g. PPTases,102 and for the supply of simple 
precursor molecules, which is particularly important if these precursors derive from building 
blocks of the primary metabolism and are produced in situ.  Otherwise, the host strain has to 
be equipped with essential genes via genetic engineering.164 In addition, toxic effects of the 
secondary metabolites produced need to be avoided to protect the heterologous host, which 
can be realized via expression of additional genes that confer self-resistance.165 Another factor 
that seems to have a great impact on the efficient heterologous expression of biosynthetic 
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gene clusters is the codon usage of the host strain. PKS and NRPS genes found in 
myxobacterial genomes usually exhibit a high GC content, which requires an appropriate 
codon usage bias of the selected surrogate host.166 Taking these requirements into account, the 
lateral transfer of a target biosynthetic gene cluster into a closely related host strain developed 
for heterologous secondary metabolite production might be obviously the most convenient 
way to establish heterologous production platforms. 
Once a biosynthetic gene cluster of interest has been selected for heterologous expression, the 
respective DNA needs to be captured from the native producer strain. Conventionally, the 
target genes are mobilized from the genomic DNA of the producer strain via library 
preparation using cosmids, fosmids or bacterial artificial chromosomes. As the screening for 
correct constructs harboring the target gene cluster or parts thereof is very laborious, recent 
developments focused on direct cloning methods, which allow recombination-based capture 
of the target gene cluster and provide possibilities for subsequent downstream engineering. 
The most widely used cloning techniques encompass the transformation associated 
recombination (TAR) protocol in yeast,167,168 as well as Red/ET recombineering.169,170 The 
latter technology is directly applicable to further vector backbone modifications, e.g. to insert 
suitable promoters for controlled gene expression, selection markers or transfer cassettes as 
well as to modify the biosynthesis genes. The large recombinant DNA constructs are 
subsequently transferred into the host strain, e.g. via electroporation or conjugation, and are 
either be integrated into the host chromosome via homologous recombination, phage 
attachment sites or transposon-based approaches, or can be expressed as replicative 
plasmids.165 However, heterologous expression of biosynthetic gene clusters often lead to 
reduced or even abolished secondary metabolite production, since the manifold demands that 
need to be met are not sufficiently tackled as many factors associated with efficient 
expression in the host cell remain unknown. 
Alternatively, target biosynthetic gene clusters can now be manufactured via DNA synthesis, 
which provides custom-specific DNA sequences within steadily shorter delivery times and at 
decreasing costs without being dependent on physically existing DNA.171 The sole input 
required for de novo gene synthesis is a DNA sequence acquired from DNA sequencing, 
which can be almost arbitrarily redesigned according to specific constructional and functional 
sequence requirements. The first totally synthesized natural product pathway, that was 
successfully assembled via conventional cloning and subsequently expressed, was the 
erythromycin biosynthetic gene cluster reported by Kodumal et al.172 As the synthesis of large 
genes or even entire gene clusters is still rather challenging, DNA synthesis is often combined 
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with state-of-the-art DNA assembly strategies that enable construction of the entire gene 
cluster construct from pre-defined DNA fragments. Most prominent among the recent 
developments in high-throughput DNA assembly technologies are the recombination-based 
technologies such as TAR, Gibson assembly and sequence and ligation independent cloning 
(SLIC).173–175 In addition, several restriction/ligation-based methods have been developed 
such as the Golden Gate cloning method and the ligase cycling reaction (LCR).176,177 
The high-throughput synthesis of arbitrary DNA sequences opens up versatile possibilities in 
the field of ‘Synthetic Biology’ enabling e.g. the translation of biological systems into 
interchangeable modular building blocks in a ‘bio brick’ manner based on engineering 
principles for the redesign of metabolic pathways and the creation of designer 
microorganisms that serve as tailor-made production factories. One approach in natural 
product research is to reduce the complexity of a natural system, e.g. a given producer 
organism, and to build up a ‘minimal’ chassis, in which non-essential parts are completely 
removed and physiological bottlenecks are eliminated. The gene cluster sequence to be 
heterologously expressed can be modulated towards optimized codon usage in the host strain 
and non-essential genes and regulatory elements are being removed to bring the artificial 
system under the control of synthetic regulators that govern transcription and translation.178 In 
this context, constructional sequence requirements notably cover the necessary changes to be 
introduced to allow for efficient construction of the synthetic gene cluster from smaller DNA 
segments and for downstream engineering. To be not reliant on naturally occurring restriction 
sites in the native gene cluster sequence, restriction sites engineering can be performed by 
applying silent mutations to remove disturbing restriction sites or to introduce restriction sites 
used for pathway assembly and modification, thereby conserving the native protein sequence. 
Additionally, homology arms can be introduced into the synthetic gene cluster to facilitate 
integration into the host’s chromosome via homologous recombination. Functional sequence 
requirements encompass selection of suitable regulatory elements and vector systems, which 
are known to be functional in the chosen heterologous host, as well as sequence optimization 
regarding GC content and codon usage, respectively. This approach is referred to as 
‘refactoring’ and holds great potential for the future engineering of artificial production 
platforms. Refactoring of natural product pathways has already been applied to several 
biosynthetic gene clusters to establish production platforms for combinatorial biosynthesis, to 
activate orphan gene clusters and to study the effects of codon adaption on the productivity of 
the underlying pathway. For instance, the erythromycin gene cluster was one of the first 
pathways, which was shown to be redesigned including restriction sites engineering to 
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facilitate exchange of domains or modules as well as codon optimization, which essentially 
boosted production levels in E. coli.179 The spectinabilin biosynthetic gene cluster was 
refactored via exchange of every native promoter for well-known promoters, which are 
functional in the heterologous host Streptomyces lividans. Decoupling of pathway expression 
from the native regulation machinery resulted in detectable amounts of spectinabilin, which 
was not identified in the native producer before.180 The same research group recently 
managed to activate another biosynthetic gene cluster in S. lividans using a highly similar 
strategy, thereby resulting in the production of novel polycyclic tetramate macrolactams. In 
addition, the synthetic expression platform was also used to characterize the underlying 
biosynthetic pathway via a set of gene deletions.181 The first artificial PKS/NRPS hybrid 
pathway from a myxobacterium was established initially in E. coli and later on in M. xanthus. 
Oßwald et al. reconstructed the large 58 kb epothilone pathway from S. cellulosum using a 
flexible modular assembly strategy and analyzed the codon optimized gene cluster variant in 
M. xanthus using a multiplasmid approach.182 However, production titers were found to be 
very low, which underpins that codon adaption alone does not necessarily lead to improved 
secondary metabolite production, if the complete regulatory networks in the heterologous host 
are not fully understood or if there are additional limiting factors. 
In conclusion, the tool box that is currently available allows the synthetic biologist to 
redesign, construct and optimize a gene cluster of interest in multifaceted ways and in a high-
throughput manner. DNA synthesis and assembly of redesigned sequences enables 
experimental set-ups, in which many different sequence designs can be analyzed in parallel. 
Dissection of the biosynthetic pathways into modular parts and the generation of synthetic 
libraries consisting of standardized building blocks for swapping genetic elements and the 
fine-tuned control of gene expression in appropriate heterologous hosts will essentially 
accelerate the development of microbial cell factories for manufacturing natural products. 
  
1.5 Myxochromide Pathways as Model Systems – Current State of Research and Outline 
of the Presented Work 
Synthetic biology has a great potential to overcome the described limitations, which are 
associated with conventional heterologous expression platforms based on native biosynthetic 
gene clusters. Due to the impressive development of chemical DNA synthesis, it is possible to 
design and to synthesize optimized gene fragments, which need to be subsequently assembled 
to the entire biosynthetic gene cluster using state-of-the-art cloning techniques. The native 
DNA sequences are adapted to the constructional and functional requirements of the 
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biosynthetic pathway and particularly of the host organism that was chosen for heterologous 
secondary metabolite production.182 However, the optimal sequence design of genes as well 
as the use of not well-established host organisms, such as myxobacteria, still remains a 
challenge. Therefore, the BMBF-funded ‘SynBioDesign’ project (Synthetic Biology to 
Design Production Platforms for Complex Natural Products) aimed at a comprehensive 
understanding of all factors, which are relevant for natural product formation in a 
heterologous host starting from artificial DNA over the levels of transcription and translation 
to the point of natural product biosynthesis from simple precursor molecules to systematically 
optimize artificial production platforms. By combining advanced high-throughput analytical 
techniques covering transcriptomics and proteomics approaches, it might be possible to 
illuminate unknown but often limiting factors regarding secondary metabolite production such 
as the stability of messenger RNA (mRNA), the available pools of aminoacyl-transfer RNAs 
(aminoacyl-tRNA), and proper co-translational folding of the expressed megasynthetases. 
Detailed knowledge on these basic cellular features would allow to directly link the gained 
experimental qualitative and quantitative data to the sequence design, thereby facilitating the 
optimization process during multiple rounds of adapted sequence design, assembly and 
heterologous expression of modified gene cluster versions, acquisition of analytical data and 
eventually data interpretation. In conjunction with modern analytical equipment, this 
approach would also require a fast and efficient DNA assembly strategy for the construction 
of many different synthetic gene clusters, which can subsequently be tested in parallel in a 
high-throughput manner and might lead to significant advances towards yield improvement of 
synthetic production platforms. In addition, the resulting generic production platforms can 
also be used for the rational engineering of the underlying pathways to generate chemical 
diversity. To address these aims, the choice of a suitable biosynthetic pathway that serves as a 
model system as well as an already well-studied myxobacterial heterologous host is essential. 
Due to several reasons discussed below, the biosynthesis of the myxobacterial lipopeptides 
myxchromides appeared to be the ideal model systems in the ‘SynBioDesign’ project to 
establish synthetic DNA platforms for the fundamental understanding of pathway design and 
optimization. At the beginning of the project, three myxochromides have been described in 
the literature, which differ in the number, order, composition and configuration of the amino 
acids in the peptide core and in the acyl side chains, which can vary in length: the 
lipohexapeptides myxochromides A2-4 from Myxococcus xanthus,84 the lipopentapeptides 
myxochromides S1-3 from Stigmatella aurantiaca,85 and the lipoheptapeptide myxochromide 
B3 from an unclassified Myxococcus sp. (Figure 7C).86  
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Figure 7. Overwiev on different myxochromide pathways. The coloring of the catalytic domains corresponds to 
the biosynthesis products shown in Figure 7C. The PKS/NRPS hybrid machineries (A- and S-type) consist of an 
iterative PKS module and six NRPSs modules and facilitates myxochromide biosynthesis. Abbreviations of 
catalytic domains are explained in the main text. A: Organization of the myxochromide A biosynthetic gene 
cluster and model for the biosynthesis of myxochromides A. B: Comparison of the A-, S- and the proposed B-
type myxochromide pathways. C: Structures of different myxochromides. 
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The biosynthetic machineries of the myxochromide A and S pathways are encoded in 
relatively small biosynthetic gene clusters (~30 kb) comprising one single operon that consists 
of three biosynthetic genes mchA-C. These genes contain the blueprint of ~1MDa PKS/NRPS 
hybrid megasynthetases, which combine the biosynthesis of the polyene side chains with the 
formation of the peptide core. The mchA gene encodes for an iterative ‘unimodular’ PKS, 
which is mainly found in eukaryotic fungi, whereas the mchB and mchC genes are translated 
into a hexamodular NRPS system.84,85 In myxochromide A biosynthesis, the PKS subunit that 
contains a full set of reductive domains (KR, ER, DH) starts the biosynthesis with the 
formation of the lipid chains, which have been found to be fully unsaturated. It is assumed 
that the ER domain, which might be responsible for the reduction of the enoyl moiety to the 
saturated lipids is inactive.85 Various lengths of the polyene side chain have been detected 
depending on the number of iterative elongation cycles and the selected starter unit (acetate or 
propionate). The lipid chains are transferred to the first NRPS subunit (MchB), where N-
acylation of the first amino acid L-threonine is catalyzed by the initial C domain in module 1. 
The MT domain integrated into the downstream A domain is responsible for N-methylation of 
L-threonine and the first biosynthetic intermediate is subsequently translocated to the second 
module by the PCP. Module 2 also contains a ‘non-standard’ domain (E domain) and 
catalyzes elongation with the second amino acid (L-alanine) along with epimerization to form 
a racemic mixture of the dipeptide intermediate (D/L-Ala-N-Me-L-Thr), whereas only the D-
configured intermediate is further processed by the second NRPS subunit (MchC). MchC 
contains four standard ‘C-A-PCP’ modules responsible for selection, activation and 
incorporation of the amino acids L-leucine, L-proline, L-alanine and L-glutamine. The 
additional TE domain of the termination module catalyzes cyclization between the hydroxyl 
group of the N-Me-L-Thr side chain and the carboxylic acid of L-Gln of the linear 
hexapeptide intermediate to form the cyclic lipohexapeptide products (Figure 7A). Although 
both myxochromide A and S assembly lines appear to be organized in an identical 
arrangement of catalytic domains (Figure 7B), studies on the biosyntheses of both types of 
myxochromides revealed striking differences between the underlying pathways leading to 
structural diversity.84 Most intriguing is an unique ‘module-skipping’ process in the 
myxochromide S pathway, which results in skipping of module 4 in the MchC NRPS subunit, 
and which has been known only for PKS systems before. Consequently, the L-Pro residue that 
might be activated by this module, is missing in the final lipopentapeptide products 
myxochomides S, thereby violating the co-linearity rule. It has been shown that a Ser  Pro 
loss-of-function mutation of the conserved serine residue in the PCP of module 4 might be 
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responsible for ‘module-skipping’, as the PCP domain cannot be posttranslationally primed 
with the CoA-derived phosphopantetheinyl arm. In addition, the A domain of this module has 
been shown to be still active in in vitro studies with expressed A domains.84 Another 
difference is the observed switch in substrate specificities of modules 2 and 3, which was 
previously explained by point mutations in the corresponding A domains of the S-type 
myxochromide pathway, thereby probably changing the binding pockets. Interestingly, the L-
Leu residue that is incorporated by module 2 in the myxochromide S assembly line is not 
epimerized, although the E domain is present in this module as well. Protein sequence 
alignments did not reveal any mutations in critical positions of the E domain. It is still not 
known if the E domain may be inactive or if the more bulky L-Leu residue is not properly 
used as a substrate by the E domain in the myxochromide S pathway.84,85 In addition to 
myxochromides A and S, a third myxochromide type from a Myxococcus sp. was isolated and 
structurally characterized by Ohlendorf et al.86 Myxochromide B3 has been found to be the 
only representative of this new family and no further derivatives exhibiting different acyl 
chain lengths have been detected. Myxochromide B3 is a lipoheptapeptide and shares the same 
peptide core as observed for myxochromides A with an additional leucine residue located 
adjacent to the leucine residue that is incorporated by module 3 in myxochromide A 
biosynthesis. Since the corresponding B-type pathway was not identified and further 
characterized, it was not clear if a module duplication event or the iterative use of only one 
Leu-incorporating module is responsible for this observation (Figure 7B).86 Some isolated 
myxochromide derivatives have been tested for their antimicrobial and cytotoxic activities, 
but have been shown to exhibit no interesting pharmacological properties.84–86 
Choosing the myxochromide pathways as model systems for the ‘SynBioDesign’ project has 
several significant advantages: 1) The myxochromide biosynthetic gene clusters are relatively 
small and encode both PKS and NRPS subunits, 2) heterologous expression of native 
myxochromide gene clusters has already been successfully demonstrated in various host 
organisms such as myxobacteria, pseudomonads and burkholderia strains in high yields up to 
500 mg/L,183–186 3) the myxochromide pathways do not require any unusual precursor 
molecules, 4) myxochromides did not show any toxicity to the heterologous hosts tested and 
5) different myxochromide families are known and widely distributed among myxobacteria, 
which provides promising opportunities for combinatorial approaches to generate hybrid 
natural products. The choice of a suitable heterologous host is as much as important as the 
selection of a model pathway to be designed. In the ‘SynBioDesign’ project, M. xanthus is 
used as surrogate host for several reasons. M. xanthus is one of the best-studied myxobacteria 
29     Introduction 
 
and is amenable to genetic manipulation. Several genetic and regulatory elements have been 
characterized and complement the tool box for host strain engineering. Furthermore, M. 
xanthus exhibits short doubling times (~ 5 hours) compared to other myxobacteria, bears the 
biosynthetic capacities to produce polyketides as well as nonribosomal peptides and is able to 
posttranslationally activate the corresponding megasynthetases by using two broad spectrum 
PPTases, which were previously identified.187 Additionally, M. xanthus has already been 
demonstrated to be a suitable host for heterologous production of natural products, including 
myxochromides S from S. aurantiaca in high production yields.186 Since all myxochromide 
gene clusters originate from myxobacterial producers, it is very likely that foreign 
myxochromide pathways are efficiently expressed in the related M. xanthus host due to their 
similar codon usage. 
By combination of synthetic genes of different myxochromide pathways or of differentially 
optimized gene versions, it might be possible to identify gene cluster features/regions, which 
have a positive or negative influence on myxochromide biosynthesis and thus on the 
production yields in case the optimization of the culture conditions ensures that the gene 
design is the limiting factor. High production yields have already been achieved with the 
native gene clusters, so that the multifactorial optimization of precursor supply is not further 
necessary to hold the system manageable. Following, structural genes can be directly 
modified. In conclusion, acquisition, analysis and implementation of sequence data of 
different myxochromide pathways and subsequent establishment of synthetic DNA platforms 
for the production of myxochromides in M. xanthus in this context might build the basis for 
the deduction of conceptional guidelines for designing complex natural product pathways and 
for the future creation of predictable microbial cell factories. 
 
1.5.1 Outline I: Genome-Mining to Find New Lipopeptide Scaffolds in Myxobacteria 
In the course of the ‘SynBioDesign’ project, the initial aim of this work was to exploit 
myxochromide diversity in myxobacteria in order to achieve a comprehensive understanding 
of the PKS/NRPS-mediated myxochromide biosynthesis as a broad basis for the sequence 
design and the creation of flexible synthetic DNA platforms. This part is covered by chapter 2 
of this thesis. Sequence data acquisition should be performed by genome sequencing of 
myxobacterial strains as well as screening of available genome data followed by detailed in 
silico sequence analysis to identify new putative myxochromide biosynthetic gene clusters. 
By applying the genome-mining approach, identified myxobacterial producer strains should 
be cultivated and the corresponding myxochromide families, which were predicted, should be 
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detected, isolated and structurally characterized. This approach was expected to provide first 
insights into the biosynthesis of the previously described myxochromides B, as the 
corresponding biosynthetic pathway has not been deciphered yet.86 In addition, genome-
mining was intended to be used to directly link structural differences of different 
myxochromide families to the acquired genetic information, complemented by in-depth 
computational analysis of the evolutionary relationships of different myxochromide 
biosynthetic gene clusters. Furthermore, selected representatives of different myxochromide 
families should be analyzed for their natural functions as myxochromides do not exhibit any 
pharmacological activities in the available test panels so far. These studies are expected to 
provide an ideal starting point towards the development of synthetic DNA platforms and the 
rational engineering of the model pathways to generate novel lipopeptides. 
 
1.5.2 Outline II: Synthetic Biotechnology to Produce Novel Hybrid Myxochromides 
Based on the valuable insights gained from the genome-mining approach in conjunction with 
evolutionary aspects of myxobacterial pathway diversification, chapter 3 of this thesis 
addresses the constructional and functional redesign of the identified myxochromide 
pathways. Specific sequence requirements should be predefined in order to allow assembly of 
synthetic expression constructs harboring artificial myxochromide gene clusters and their 
heterologous expression in the selected host strain M. xanthus. In the course of the 
‘SynBioDesign’ project, the establishment of a fast and efficient strategy for the assembly of 
large synthetic gene cluster constructs from synthetic building blocks was a major goal to 
generate various artificial gene cluster variants in parallel, which is a key prerequisite for the 
pursued high-throughput workflow. Simultaneously, the assembly strategy should be highly 
flexible to facilitate engineering efforts to alter myxochromide structures and to generate 
entirely new lipopeptide scaffolds. Chapter 3 covers the development of such an assembly 
strategy based on a dedicated gene library that contains synthetic myxochromide biosynthesis 
genes originating from different myxochromide pathways. The cloning approach should 
involve the generation of the gene library by using modern restriction/ligation-based 
techniques followed by the in vitro reconstitution of the entire pathways based on the Golden 
Gate cloning method,177 both covered by the constructional sequence design. The described 
strategy should also exhibit broad applicability regarding possible combinations with different 
cloning techniques and the possibility for specific exchanges on the subunit, module and 
domain level. Exemplarily, the established assembly strategy should be demonstrated in a 
structural engineering approach to produce ‘unnatural’ myxochromides. The effects of 
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artificial gene combinations on the functionality and productivity of the engineered 
PKS/NRPS assembly lines should be analyzed, which would provide first insights into how 
complex natural product pathways should be designed, thereby serving as versatile platforms 
for the ‘SynBioDesign’ project. 
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2 Genomics-Guided Exploitation of Lipopeptide Diversity in Myxobacteria 
 
2.1 Abstract 
Analysis of 122 myxobacterial genome sequences suggested 16 strains as producers of the 
myxochromide lipopeptide family. Detailed sequence comparison of the respective mch 
biosynthetic gene clusters informed a genome-mining approach, ultimately leading to the 
discovery and chemical characterization of four novel myxochromide core types. The 
myxochromide megasynthetase is subject to evolutionary diversification, resulting in 
considerable structural diversity of biosynthesis products. The observed differences are due to 
the number, type, sequence, and configuration of the incorporated amino acids. The analysis 
revealed molecular details on how point mutations and recombination events led to structural 
diversity. It also gave insights into the evolutionary scenarios that have led to the emergence 
of mch clusters in different strains and genera of myxobacteria. 
 
2.2 Introduction 
Lipopeptides (LPs) constitute a distinguished class of microbial secondary metabolites with 
multifaceted biological functions. These include, for example, surfactant, antimicrobial, or 
cytotoxic activities attracting interest in diverse industrial fields.1,2 Bacterial LPs are generally 
synthesized in a ribosome-independent manner by large multimodular enzymes called 
nonribosomal peptide synthetases (NRPS).3 Often, they are produced as mixtures of 
components varying in their lipid tail and/or amino acid composition.4,5 Whereas various LP 
biosynthetic pathways from Bacillus, Pseudomonas, Streptomyces, and other microbes have 
been intensively studied over the past decades,6 LP biosynthesis in myxobacteria is currently 
underexplored. Most prominent among the very few products characterized so far are the 
myxochromides, for which three different types have been described: myxochromides A (1) 
from Myxococcus xanthus,7 myxochromides B (2) from an unclassified Myxococcus sp.,8 and 
myxochromides S (3) from Stigmatella aurantiaca.9 The cyclic peptide structures are 
composed of five to seven amino acids and are linked to a polyunsaturated acyl chain, which 
can vary in length (Figure 1). Biosynthetic studies on myxochromides A (lipohexapeptides) 
and myxochromides S (lipopentapeptides) revealed that an iterative polyketide synthase 
(PKS) generates the lipid chains, thereby initiating the assembly of the peptidyl backbone 
catalyzed by a hexamodular NRPS system.7,9 Specifically, it was shown how point mutations 
switch substrate specificity in NRPS modules and cause an unusual “module-skipping” 
process during biosynthesis of the myxochromide S pentapeptide core.7 However, the 
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assembly line for production of myxochromides B (lipoheptapeptides) was not deciphered 
yet. Driven by the progress in bacterial genome-mining in general,10 as well as myxobacterial 
genomics,11 and secondary metabolomics,12 we aimed to achieve a comprehensive 
understanding of the biosynthesis of this versatile LP family and thereby intended to further 
exploit myxochromide chemical diversity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structures of myxochromides. 
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2.3 Results and Discussion 
2.3.1 Discovery of Novel Types of Myxochromide Megasynthetases 
Initially, we targeted to establish a molecular comprehension of how the myxochromide B 
pathway evolved from the known A- and S-type pathways. The putative B-type biosynthetic 
gene cluster harbors large sequence repeats and could thus only be deciphered using shotgun 
genome data of the producer Myxococcus sp. 171 in conjunction with significant additional 
sequencing efforts based on the generation of a cosmid library (Supporting Information 
Figure S1). 
 
Table1: Myxochromide producers and their biosynthetic gene clusters (mch clusters) analyzed in this study. 
Strain Strain abbrev. Cluster 
GenBank  
Accession[a] 
Myxococcus fulvus HW-1 Mf1 A-type KX622592 
Myxococcus xanthus DK1622 Mx1 A-type [b] KX622595 
Myxococcus xanthus DK897 Mx2 A-type KX622596 
Myxococcus xanthus A47 Mx3 A-type KX622597 
Myxococcus xanthus Mx48 Mx4 A-type KX622598 
Myxococcus sp. 171 [c] M1 B-type KX622591 
Myxococcus virescens ST200611 Mv1 C-type KX622594 
Myxococcus hansupus mixupus Mh1 C-type KX622593 
Cystobacterineae sp. CcG34 [d] Cy1 D-subtype 2 KX622587 
Hyalangium minutum DSM14724 Hm1 D-subtype 1 KX622588 
Hyalangium minutum Hym-3 Hm2 D-subtype 1 KX622589 
Hyalangium minutum NOCb10 Hm3 D-subtype 1 KX622590 
Stigmatella erecta Pde77 Se1 D-subtype 1 KX622602 
Stigmatella aurantiaca DW4/3-1 Sa1 S-type [e,f] KX622599 
Stigmatella aurantiaca Sga15 Sa2 S-type [f] KX622600 
Stigmatella aurantiaca Sga32 Sa3 S-type [f] KX622601 
[a] Annotated cluster files were additionally deposited in the MiBIG database (BGC0001417-BGC0001432)14; 
[b] Characterized in previous study.7 [c] Unclassified strain belonging to the genus Myxococcus. [d] Unclassified 
species belonging to the suborder Cystobacterineae (16S analysis indicates that this species might belong to the 
genus Hyalangium). [e] Characterized in previous study.9 [f] S-type gene clusters were shown to also produce 
myxochromides S-Abu and S-diAbu. 
 
Sequence analysis of the encoded assembly line revealed an additional leucine-specific NRPS 
module in comparison to the hexamodular A-type megasynthetase, indicating that the B-type 
pathway emerged from a module duplication event. To obtain deeper insights into 
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myxochromide pathway evolution, we screened genome data from 122 myxobacterial strains 
subjected to automated annotation13 and identified numerous additional putative 
myxochromide biosynthetic gene clusters (mch clusters) exclusively from species belonging 
to the suborder Cystobacterineae (Table 1). 
Among those, four other A-type pathways (from strains Mf1, Mx2, Mx3, and Mx4) and two 
other S-type pathways (from strains Sa2 and Sa3) were retrieved. Intriguingly, some of the 
detected putative mch clusters (from strains Mv1, Mh1, Cy1, Hm1, Hm2, Hm3 and Se1) 
appeared to encode novel types of myxochromide megasynthetases differing in their domain 
arrangement and functionality from the previously characterized A- and S-types7,9 as well as 
the newly discovered putative B-type megasynthetase. The new mch cluster types were 
designated as C-type and D-type pathways predicted to direct the biosynthesis of two novel 
pentapeptide cores (see Supporting Information). 
 
2.3.2 Genome-Mining for Novel Myxochromide Lipopeptide Cores 
To connect this genetic information with the actual biosynthesis products, the putative 
producer strains listed in Table 1 (with exception of strain Mh1) were cultivated and analyzed 
for myxochromide production by HPLC-MS (Supporting Information Figure S3). Indeed, 
novel myxochromide derivatives exhibiting MS data consistent with the expected 
myxochromide C and D derivatives could be detected in extracts of the respective strains. The 
genome-mining approach was pursued by isolation of a representative of the two novel 
myxochromide types, later designated as myxochromide C3 from strain Mv1 and 
myxochromide D1 from strain Se1. Structure elucidation including assignment of the absolute 
stereochemistry unambiguously confirmed consistency with the in silico predicted structures 
featuring novel pentapeptide cores (Figure 1). Besides myxochromides C and D, additional 
putative novel myxochromide types, designated as myxochromides S-Abu and S-diAbu, were 
detected as minor products from myxochromide S producing S. aurantiaca strains. A 
representative of each myxochromide type was isolated from a previously described high titer 
myxochromide S heterologous production strain.15 Structure elucidation revealed that the 
minor products indeed represent novel lipopentapeptides that differ from myxochromide S by 
replacement of L-alanine with L-α-aminobutyric acid (Abu) in one or two positions (Figure 
1). Putative novel Abu-containing myxochromide derivatives were later on also detected from 
A-, B-, C- and D-type producer strains after supplementing the cultures with L-Abu 
(Supporting Information Figure S5). In summary, a combined myxobacterial 
genomics/secondary metabolomics approach led to the discovery of four novel 
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myxochromide types (myxochromides C, D, S-Abu, and S-diAbu; Figure 1). Although there 
is no direct experimental evidence for the correlation of the newly identified “putative” mch 
clusters to myxochromide production (e.g., via gene inactivation or heterologous expression), 
sequence comparison with described mch clusters from Mx1 and Sa1 and myxochromide 
production analysis (Supporting Information Figure S3) strongly supports the classification of 
mch pathways as shown in Table 1. In the following discussion regarding the mch pathway 
comparison, the term “putative” is avoided for better readability. 
 
2.3.3 Comparative Analysis of Myxochromide Megasynthetases 
We next analyzed all respective biosynthetic gene clusters aiming at a deeper understanding 
of the biochemical and genetic basis for the observed structural diversity. Figure 2 illustrates 
the different types of myxochromide megasynthetases, which consist of three subunits: an 
iterative PKS (MchA) and two NRPSs (MchB, MchC). 
 
 
Figure 2. Different types of myxochromide megasynthetases from myxobacteria (for host strains see Table 1). 
The coloring of the catalytic domains corresponds to the biosynthesis products shown in Figure 1 (for 
phylogenetic analysis, see Supporting Information Figure S23). As verified for S-type pathways, there are 
indications for alternative incorporation of α-aminobutyric acid (Abu) by alanine (Ala)-specific modules of A-, 
B-, C-, and D-type megasynthetases (see Supporting Information Figure S5). Catalytic domain abbreviations: 
KS, ketosynthase; AT, acyltransferase; DH, dehydratase; ER, enoylreductase; KR, ketoreductase; CP, acyl 
carrier protein (in MchA) or peptidyl carrier protein (in MchB/C); C, condensation domain; A, adenylation 
domain; MT, methyltransferase; E, epimerization domain; TE, thioesterase. Domains marked with an asterisk are 
supposed to be inactive. 
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Whereas all MchA homologues as well as all MchB homologues show identical arrangements 
of catalytic domains, respectively (MchA: KS-AT-DH-ER*-KR-CP and MchB: C1-A1-MT1-
CP1-C2-A2-CP2-E2; Figure 2), MchC subunits differ significantly. Compared to the A-type 
assembly line, the B-type megasynthetase features an additional leucine-incorporating module 
consistent with the biosynthesis of its lipoheptapeptide products (2a−2c). On the contrary, the 
C-type megasynthetase lacks a complete module, resulting in the production of novel 
lipopentapeptides (6a−6c), which do not contain L-alanine as predicted from in silico analysis 
and confirmed by genome-mining. Phylogenetic analysis of NRPS condensation (C), 
adenylation (A), and carrier protein (CP) domains (Supporting Information Figure S23) from 
all 16 myxochromide megasynthetases indicated that “A-CP-C units” instead of dedicated “C-
A-CP modules” are duplicated (A3-CP3-C4 in B-type) or deleted (A5-CP5-C6 in C-type). 
Detailed sequence analysis of the MchC subunits from Myxococcus strains even revealed the 
corresponding recombination sites, which are located at the 5′ end of the A domain or 3′ end 
of C domain encoding regions, respectively (Supporting Information Figures S20 and S21). 
Another recombination event led to partial module deletion in the D-subtype 2 assembly line, 
which lacks the A4-CP4 domains (Supporting Information Figure S22). However, as module 4 
in the related D-subtype 1 megasynthetase is already inactive due to the mutated CP4 core 
motif (Supporting Information Figure S18), the same myxochromide structures were actually 
expected and found to be produced by the two different D-type assembly lines. In accordance 
with the in silico analysis, the biosynthesis products represent novel lipopentapeptides 
(7a−7d) lacking L-proline as compared to myxochromides A (1). A similar scenario (inactive 
module 4) causing so-called “module-skipping”16 was already observed for the 
myxochromide S megasynthetase,7 which also differs from all other myxochromide assembly 
lines in terms of module 2 and 3 biochemistry (L-Leu/L-Ala instead of D-Ala/L-Leu). Here, 
sequence-based structure prognosis did not allow prediction of accurate stereochemistry and 
substrate specificity (see Supporting Information). However, the in silico analysis suggests 
that point mutations rather than intragenic A domain swapping17 cause the observed reversed 
amino acid order in myxochromides S (3). Overall, the diversity of detected assembly line 
variations (Figure 2) shows that the myxochromide biosynthetic pathway is subject to 
significant evolutionary diversification (compare, e.g., cyanobacterial toxin pathways18 and 
other expamples19–22). Sequence analysis of mch genes revealed that adaptation in local 
synonymous codon usage is reduced in module 3 and 4 regions. Especially the A domain 
regions show lower adaptation compared to other modules, which may indicate recent 
mutational activity and diversification or more recent acquisition (see Supporting 
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Information).23 Even further reduced is the codon adaptation of inactive A4- CP4 domains 
from Stigmatella producers and also the region encoding the inactive PKS ER* domain in all 
mch pathways (Supporting Information Figure S25). 
 
2.3.4 Evolutionary Relationship and Distribution of mch Clusters in Myxobacteria 
According to the analyzed myxobacterial genome data, mch clusters only occur in strains 
belonging to the Cystobacterineae suborder, more precisely to the Cystobacteraceae and 
Myxococcaceae families. Comparative phylogenetic analysis of the 16 mch clusters with 
selected house-keeping genes of their hosts revealed an overall congruence between strain and 
cluster phylogeny with one exception: The D-type pathway from S. erecta Pde77 (Se1), which 
was likely obtained via horizontal gene transfer from Hyalangium species (Figure 3). 
 
 
 
Figure 3. Comparison of myxochromide producer strain and mch cluster phylogeny (for details, see Supporting 
Information). The three megasynthetase coding sequences (CDS) (mchA, mchB, mchC) are shown as disks, 
colored according to their adaptation of synonymous codon usage to the highly expressed gene sets of their hosts 
(see Supporting Information Table S12). Common cluster genome environments are indicated (Locus A−F; see 
Supporting Information Figure S2). 
 
In addition, it can be assumed that Stigmatella S-type pathways derive from D-subtype 1 
clusters and diversify via additional mutations switching substrate specificities of NRPS 
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modules 2 and 3 (Figure 2). Within the Myxococcaceae, three different pathway types (A, B 
and C) occur, which deviate in the MchC subunit due to module duplication/deletion events 
resulting in heptamodular/pentamodular NRPS assembly lines. However, the hexamodular A-
type pathway represents the most common variant in this analysis occurring in all M. xanthus 
species and in M. fulvus (Table 1; Figure 3). In fact, a study on secondary metabolomes from 
98 different M. xanthus strains determined myxochromides A as ubiquitous metabolites from 
this species.24 Overall, our phylogenetic analysis strongly suggests that myxochromide 
biosynthetic pathways have evolved from a common ancestor, which based on all available 
data seems to be the A-type cluster. Codon adaptation analysis revealed that mch clusters 
found in Cystobacteraceae are much less adjusted to their hosts than clusters from 
Myxococcaceae, which thus seem to have resided in their hosts for a longer time period 
(Figure 3). The best average adaptation value was obtained for the cluster from strain Mf1 
supporting the proposed ancestral role of the A-type pathway. It is likely that the also well 
adapted C-type cluster of Mv1 evolved in the same genomic context (Supporting Information 
Figure S2). The less adapted A-type clusters were then distributed to other M. xanthus strains, 
from which the even younger and less adapted B-type cluster of M1 originated. The original 
C-type cluster was transferred to Mh1. All of these clusters are currently found in the same 
genomic context. Several independent integration events led, in the sequence suggested by the 
codon adaptation level, to the origin of the D-subtype 2 cluster of Cy1; the three D-subtype 1 
clusters of Hm1, Hm2, and Hm3; the two S-type clusters from Sa1 and Sa3; and lately to the 
quite little adapted S-type cluster of Sa3. Most recently, the D-subtype 1 cluster was 
integrated into Se1, where it shows the least adaptation. 
 
2.3.5 Potential Biological Function of Myxochromides 
The widespread occurrence of myxochromides among different myxobacterial species 
suggests a relevant biological function for the producer strain as known from other bacterial 
LPs.25 As myxochromides did not exhibit significant antimicrobial or cytotoxic activities,8,9 
they might play a role in the developmental life cycle of myxobacteria. This was analyzed in 
established assays with the myxochromide producer M. xanthus DK1622 and respective 
myxochromide overproduction and knockout mutants (Supporting Information Figures 
S26−27). It could be demonstrated that myxochromide overproduction has a negative effect 
on fruiting body development, which correlates with observations from previous studies.26 
This finding may be explained by myxochromide surfactant properties, which probably 
increase cell motility and hamper cell aggregation. As no difference between the mch cluster 
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knockout mutant and the wildtype strain could be observed, myxochromides do not seem to 
be essential for fruiting body formation and swarming of M. xanthus. However, specific 
biological functions of myxochromides, possibly even different functions for structural 
variants, can currently not be excluded. 
2.4 Significance 
In conclusion, we demonstrate how myxobacterial genome-mining can provide a broad 
picture regarding the distribution, genetic basis, and evolution of secondary metabolite 
pathways. Additionally, our approach enabled the discovery and isolation of novel derivatives 
of the selected lipopeptide compound class by prioritizing potential producer strains for 
chemical analysis. Detailed biosynthetic pathway comparison revealed an impressive 
diversification of the involved megasynthetases among various producer strains and allowed 
rationalization of the observed structural differences of the corresponding products. Our 
comprehensive study thus provides a broad picture on the interrelationship of genetic changes 
as causative agents for chemical diversification of lipopeptides from a whole taxon of 
microorganisms. The described genetic changes leading to natural product pathway evolution 
(recombination sites, point mutations, codon adaptation) represent valuable information for 
the future engineering of microbial NRPS pathways via synthetic biology approaches.27,28  
 
2.5 Experimental Procedures 
2.5.1 Identification and Decipherment of the Myxochromide B Biosynthetic Gene 
Cluster from Myxococcus sp. 171. 
Shotgun genome sequence data of strain Myxococcus sp. 171 (M1) were generated by 
employing Illumina sequencing technology, and the putative myxochromide B biosynthetic 
gene cluster was identified by comparative sequence analysis using the published 
myxochromide A gene cluster from M. xanthus DK1622 as reference (Genbank accession 
number CP000113). The identified myxochromide B gene cluster region contained several 
sequence gaps. For the decipherment of the entire gene cluster sequence, a cosmid library of 
strain M1 comprising 3072 clones was constructed on the basis of the SuperCos 1 cosmid 
vector (Agilent Technologies). In a PCR-based approach, the library was screened for 
cosmids harboring the myxochromide B gene cluster or parts thereof. Two of the identified 
cosmids (Cos8F11 and Cos1P19) were used as starting constructs to subclone fragments 
covering the unresolved gene cluster region (see Supporting Information Figure S1). The 
inserts from four of the generated plasmids (pASK_mchB6, pBCSK_mchB5, 
pBCSK_mchB4, and pBCSK_mchB3) were completely sequenced, which allowed for 
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decipherment of the repetitive myxochromide B gene cluster regions. For additional details, 
see Supporting Information Chapter 2.7.1. 
 
2.5.2 Screening of Myxobacterial Genome Data for Additional Myxochromide 
Biosynthetic Gene Clusters and Verification via Production Analysis 
Genome data from 122 myxobacterial species including representatives of the three suborders 
Cystobacterineae (68 strains), Sorangiineae (43 strains), and Nannocystineae (11 strains) 
were screened for putative myxochromide biosynthetic gene clusters by using the antiSMASH 
3.0.4 tool;13 all strains are listed in Supporting Information Chapter 2.7.2. In total, 16 
myxochromide biosynthetic gene clusters (mch clusters) were identified in strains belonging 
to the suborder Cystobacterineae. The genomic context of the mch cluster was analyzed in 
each host strain, revealing six different chromosomal loci (A−F; see Figure 3 and Supporting 
Information Figure S2). The automatic annotation of the mch gene clusters from the 
antiSMASH 3.0.4 analysis13 was manually revised based on reported core motifs and 
structural data of other PKS/NRPS megasynthetases. The gene cluster data were submitted to 
GenBank (accession numbers are listed in Table 1) and deposited in the MiBIG database.14 
The domain organization of the encoded megasynthetases was compared and revealed novel 
types of putative myxochromide biosynthetic pathways (C- and D-type clusters; Table 1 and 
Figure 2), for which putative pathway products were predicted based on the in silico data. 
Myxochromide production analysis of the identified strains listed in Table 1 (except Mh1) 
was carried out on a 50 mL scale under routine cultivation conditions. Crude extracts were 
prepared and subjected to HPLC-MS analysis including FT-ICR-MS2 measurements to 
characterize the myxochromide production profiles (Supporting Information Figures S3 and 
S4). Selected producer strains (Mx1, M1, Mv1, Se1, and Sa1) were additionally grown in 
media supplemented with L-α-aminobutyric acid (L-Abu), and the effect on myxochromide 
production profiles was analyzed by HPLC-MS (Supporting Information Figure S5). For 
additional details, see Supporting Information Chapter 2.7.2.3. 
 
2.5.3 Isolation and Structure Elucidation of Novel Myxochromides 
Representatives of four novel myxochromide types (C-type, D-type, S-Abu-type, and S-diAbu 
type) were isolated from culture extracts of selected producer strains via a combination of size 
exclusion chromatography and reversed-phase HPLC. The planar structures were elucidated 
based on 1D (1H) and 2D (1H−1H COSY, HSQC, HMBC, and ROESY) NMR spectroscopy 
as well as HR-ESI-MS data. The absolute configuration of the amino acid residues was 
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determined by HPLC-MS analysis of the L- and D-FDLA (1-fluoro-2,4- dinitrophenyl-5-L-
/D-leucinamide) derivatives of the acid hydrolysate of myxochromides in comparison with 
corresponding derivatives of L-configured amino acid standards (Marfey’s method29). The 
following myxochromide derivatives were purified and structurally characterized. 
Myxochromide C3 (6b). A total of 2.3 mg of 6b was isolated from a 20 L culture of 
Myxococcus virescens ST200611 (Mv1). The molecular formula was established to be 
C42H58N6O8 (m/z 775.43921 [M + H]+). NMR spectra and selected correlations are illustrated 
in Supporting Information Figures S6 and S7, and HPLC-MS analysis of L- and D-FDLA 
derivatives from the 6b hydrolysate is shown in Supporting Information Figure S8. For 
details, see Supporting Information Chapter 2.7.3. 
Myxochromide D1 (7a). A total of 2.7 mg of 7a was isolated from a 20 L culture of 
Stigmatella erecta Pde77 (Se1). The molecular formula was established to be C38H54N6O8 
(m/z 723.40748 [M + H]+). NMR spectra and selected correlations are illustrated in 
Supporting Information Figures S9 and S10, and HPLC-MS analysis of L- and D-FDLA 
derivatives from the 7a hydrolysate is shown in Supporting Information Figure S11. For 
details, see Supporting Information Chapter 2.7.4. 
Myxochromide S2-Abu (4b). A total of 5.3 mg of 4b was isolated from a 9 L culture of the 
heterologous production strain M. xanthus DK1622::pTpS-mchS.15 The molecular formula 
was established to be C40H58N6O8 (m/z 751.43940 [M + H]+). NMR spectra and selected 
correlations are illustrated in Supporting Information Figures S12 and S13, and HPLC-MS 
analysis of L- and D-FDLA derivatives from the 4b hydrolysate is shown in Supporting 
Information Figure S14. For details, see Supporting Information Chapter 2.7.5. 
Myxochromide S2-diAbu (5b). A total of 6.4 mg of 5b was isolated from a 4.5 L culture of 
the heterologous production strain M. xanthus DK1622::pTpS-mchS.15 The molecular formula 
was established to be C41H60N6O8 (m/z 765.45520 [M + H]+). NMR spectra and selected 
correlations are illustrated in Supporting Information Figures S15 and S16, and HPLC-MS 
analysis of L- and D-FDLA derivatives from the 5b hydrolysate is shown in Supporting 
Information Figure S17. For details, see Supporting Information Chapter 2.7.6. 
 
2.5.4 Detailed in Silico Analysis of the 16 mch Clusters 
The mch clusters listed in Table 1 were analyzed according to different aspects using 
established bioinformatics tools. Protein sequence alignments of selected catalytic domains 
were performed using the Geneious alignment tool integrated into Geneious software version 
9.1.2.30 As shown in Supporting Information Figure S18, these include alignments of C 
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domains from modules 2 and 3 (C2 and C3) and E domains from module 2 (E2) as well as PCP 
domains from modules 2, 3, and 4 (PCP2, PCP3, and PCP4). The reported C, E, and PCP 
domain core motifs31,32 and additional residues to distinguish LCL and DCL domain subtypes33 
were analyzed. In addition, substrate specificities of all A domains from the 16 
myxochromide megasynthetases (in total 94 A domains) were analyzed using the antiSMASH 
3.013 and NRPSpredictor2 analysis tools.34 The substrate predictions together with the A 
domain 8 Å signatures and Stachelhaus codes35,36 are shown in Supporting Information Figure 
S19. In order to identify recombination sites from domain duplication and deletion events, 
alignments with selected regions of mchC genes were performed using the Geneious 
alignment tool integrated into Geneious software version 9.1.2.30 The outcome of this analysis 
is illustrated in Supporting Information Figure S20 for the “module duplication” 
(myxochromide B pathway), Supporting Information Figure S21 for the “module deletion” 
(myxochromide C pathway), and Supporting Information Figure S22 for the “partial module 
deletion” (myxochromide D-subtype 2 pathway). The analysis of the recombination events 
was supported by findings from phylogenetic analysis of myxochromide megasynthetase 
NRPS domains. Phylogenetic trees for A, C, and PCP domains, which were performed based 
on DNA sequences, are shown in Supporting Information Figure S23. In addition, 
phylogenetic relationships of all myxochromide megasynthetase subunits were analyzed 
based on DNA and protein sequences (mchA/MchA, mchB/MchB, and mchC/MchC; see 
Supporting Information Figure S24). Phylogenetic reconstitutions were carried out by 
applying the distance-based neighbor-joining method using the modules “neighbor” and 
“dnadist” or “protdist” of the PHYLIP package.37 The sequences were aligned using the 
GUIDANCE2 Server38 by applying the MAFFT algorithm or using ClustalX.39 For the 
comparison of strain and mch cluster phylogenies illustrated in Figure 3, the mchA, mchB, and 
mchC nucleotide sequences of the myxochromide megasynthetase encoding genes were 
concatenated (cluster phylogeny), and the nucleotide sequences of the 16S rRNA gene were 
concatenated with nucleotide sequences of 15 selected genes encoding highly conserved 
proteins (strain phylogeny). The phylogenetic analysis was complemented by codon 
adaptation index (CAI40 analysis, which was performed based on a set of selected high 
expression genes from the analyzed myxochromide producer strains (“hxp2 gene sets”, each 
harboring 343−405 genes). On the basis of these gene sets, codon usage tables were 
calculated by the EMBOSS program cusp.41 The respective sequence-specific CAI for the 
mch cluster genes was calculated by a Perl program as described by Sharp and Li40 and is 
illustrated for mchA, mchB, and mchC in Figure 3 (for CAI values see Supporting Information 
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Table S12, Chapter 2.7.7.4). In addition, local CAI values along the CDS of mchA, mchB, and 
mchC were calculated for overlapping CDS regions of 101 codons using a Perl program and 
were visualized as plotted color-shaded vertical lines along the CDS. For comparison of the 
local CAI distribution in the mchA, mchB, and mchC gene sets from the 16 analyzed 
myxochromide producers, codons were aligned to orthologous positions based on protein 
sequence alignments performed with ClustalX.39 Alignments of mchC were modified 
according to the identified recombination sites. The local CAI values along the mchA, mchB, 
and mchC CDS sequences of the 16 analyzed myxochromide pathways are illustrated in 
Supporting Information Figure S25. For additional details, see Supporting Information 
Chapter 2.7.7.4. 
 
2.5.5 Fruiting Body Formation and Swarm Expansion Assays 
The myxobacterial model strain and myxochromide A producer M. xanthus DK1622 wild 
type (Mx1) was analyzed in established developmental assays in comparison to three mutants. 
These include M. xanthus DK1622::pMch22a,7 which is deficient in myxochromide A 
production, M. xanthus DK1622::pMch70a (Wenzel et al., unpublished), which produces 
about 10-fold higher amounts of myxochromides A compared to the wildtype, and M. xanthus 
DK1622::pTpsmchS,15 which produces myxochromides S in around 50-fold higher amounts 
in addition to wildtype levels of myxochromides A. The results from the comparative fruiting 
body formation assays are illustrated in Supporting Information Figure S26. The outcome of 
the comparative swarm expansion assays, which were performed according to the procedure 
described by Kaiser et al.42 is shown in Supporting Information Figure S27. For additional 
details, see Supporting Information Chapter 2.7.8. 
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2.7 Supporting Information 
2.7.1 Identification and Decipherment of the Myxochromide B Biosynthetic Gene 
Cluster from Myxococcus sp. 171 
2.7.1.1 Shotgun Genome Sequencing of Myxococcus sp. 171 and Identification of the 
Myxochromide B Biosynthetic Gene Cluster 
Draft genome sequence of the myxochromide B producer Myxococcus sp. 171 was 
determined by employing Illumina sequencing technology at Seq-It GmbH (Kaiserslautern, 
Germany). Paired-end sequencing library was prepared from the strain's total DNA. This 
library was then sequenced to a mean genome coverage of 357x; mean read length was 251 
bp; mean distance between reads (fragment size) was 378 bp. Raw sequencing data were then 
assembled by Abyss-pe software 1.3.6 to yield 61 contigs in 47 scaffolds. The estimated 
genome size of Myxococcus sp. 171 was 9,603,576 bp. The putative myxochromide B 
biosynthetic gene cluster was identified by comparative sequence analysis using the 
myxochromide A biosynthetic gene cluster from Myxococcus xanthus DK1622 (Genbank 
accession number CP000113) as a reference.43 However, due to repetitive sequence elements, 
the sequence of the mchC gene was not completely resolved (see Figure S1). 
2.7.1.2 Construction and Screening of a Cosmid Library from Myxococcus sp. 171 
To elucidate the entire gene cluster sequence, a cosmid library of the producer strain was 
constructed to enable subcloning and sequencing of unsolved gene cluster fragments. 
Chromosomal DNA from Myxococcus sp. 171 was prepared by standard 
phenol/chloroform/isoamylalcohol extraction.44 Isolated genomic DNA was subsequently 
used for the construction of a cosmid library according to the SuperCos 1 Cosmid Vector Kit 
protocol (Agilent Technologies). Cosmid packaging reactions were carried out using the 
Gigapack III Packaging Extract Kit (Agilent Technologies) according to the manufacturer’s 
protocol. The resulting cosmid library consists of 3072 clones (8×384 microtiter plates, 
MTPs), which were subsequently screened for cosmids harboring the putative myxochromide 
B biosynthetic gene cluster or fragments thereof. A PCR-based screening approach was 
applied using three oligonucleotide pairs specific for both ends of the gene cluster as well as 
for an internal region around the mchB/mchC interface (see Figure S1). PCRs were performed 
with Taq polymerase (Fermentas) using different cosmid DNA pools or DNA from single 
cosmids as templates and the following primer pairs (expected PCR product sizes are 
indicated):  
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Oligonucleotide  Sequence  Amplicon size  
P1 
 
P2 
5’TGCGAGGATGATTCTGGGC-3’ 
 
5’-TGTCAACAGTTCCCAGAGG-3’ 
 
 
 
P3 
 
P4 
5’-AGACCCTCGAGCGGCTGAAC-3’ 
 
5’-TCCCACAGAAAGGCCGAACG-3’ 
 
               
 
P5 
 
P6 
5’-ATGGGCGTGGGGGTGGTGTAG-3’ 
 
5’-GTTGATTTCACGCGACTTCTGG-3’ 
 
 
 
     
Initially, the 3072 library clones were pooled and inoculated as 16 sets, each representing 192 
cosmid clones from a half MTP. The combined clones were grown in 1.5 mL LB medium 
(tryptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L) amended with kanamycin (50 µg/mL) at 37 
°C overnight to isolate the respective cosmid DNA mixtures via standard alkaline lysis.44 
Cosmid sets revealing PCR products with primer pairs P1/P2 as well as P5/P6 were further 
screened by at first preparing 8 subsets of 24 clones, from which in the next step (in case of 
positive PCR results) the individual cosmid clones were analyzed. However, as this strategy 
did not lead to the identification of cosmids harboring the entire putative myxochromide B 
biosynthetic gene cluster, which would result in PCR products with the P1/P2 as well as 
P5/P6 primer set, the screening approach was altered to detect cosmid inserts covering one 
half of the gene cluster including the unsolved region of mchC. A number of cosmids yielding 
PCR products with P3/P4 and either P1/P2 or P5/P6 were identified and further analyzed by 
end-sequencing of the inserts using primers T3 (5’-ATTAACCCTCACTAAAGGGA-3’) and 
T7 (5’-TAATACGACTCACTATAGGG-3’). Based on the obtained data, cosmids Cos1P19 
and Cos8F11, both harboring the unsolved mchC region and combined harboring the entire 
gene cluster, were selected for subsequent subcloning approaches. 
 
2.7.1.3 Subcloning and Sequencing of Myxochromide B Biosynthetic Gene Cluster 
Fragments 
To decipher the sequence of the unsolved mchC region, detailed restriction analysis of 
cosmids Cos1P19 and Cos8F11 was performed. As illustrated in Figure S1B, seven plasmids 
harboring smaller gene cluster fragments including (part of) the gap region, were constructed 
by using standard cloning methods. First of all, a 8.9 kb NotI fragment was subcloned from 
340 bp 
411 bp 
299 bp 
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cosmid Cos8F11 to reveal plasmids pBCSK_mchB1-R1 and pBCSK_mchB1-R2 (harboring 
the insert in different directions). Based on these constructs, three smaller gene cluster 
fragments were subcloned and completely sequenced from the following three plasmids: 
pBCSK_mchB3 (4.3 kb SpeI/PvuII fragment from pBCSK_mchB1-R1 ligated into pBC 
SK(+) linearized with SpeI/EcoRV), pBCSK_mchB4 (1.5 kb PvuII fragment from 
pBCSK_mchB1-R1 ligated into pBC SK(+) linearized with EcoRV) and pBCSK_mchB5 (3.1 
kb SpeI/PvuII fragment from pBCSK_mchB1-R2 ligated into pBC SK(+) linearized with 
SpeI/EcoRV). In parallel, a 9.0 kb EcoRI/HindIII fragment from cosmid Cos1P19 was 
subcloned into pASK-IBA6 (Iba Life Sciences) to reveal plasmid pASK_mchB2. Based on 
this construct, a 2.7 kb StuI/HindIII fragment was subcloned into pASK-IBA6 and completely 
sequenced from plasmid pASK_mchB6. 
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Figure S1. Illustration of repetitive regions within the mchC gene and subcloning strategy to decipher the 
complete putative myxochromide B biosynthetic gene cluster sequence. A: Dotplot of the mchABCD operon of 
the myxochromide B pathway performed with the Geneious 9.1.2 software45 based on the EMBOSS 6.5.7 tool 
dottup.41 Large sequence repeats can be detected within the mchC gene, a region which could not completely 
deciphered based on shotgun genome sequence data. B: Subcloning approach based on two cosmids, which were 
identified by PCR-based screening of a cosmid library using three primer sets (P1/P2, P3/P4, P5/P6, highlighted 
in green). Seven plasmids harboring smaller gene cluster fragments were constructed (for details see chapter 
2.7.1.3). Fragments shown in black were completely sequenced to reconstitute the repetitive region of mchC. 
B 
A 
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2.7.2 Screening of Myxobacterial Genome Data for Additional Myxochromide 
Biosynthetic Gene Clusters and Verification via Production Analysis  
2.7.2.1 Identification and Annotation of Additional Myxochromide Biosynthetic Gene 
Clusters 
For the identification of additional putative myxochromide biosynthetic gene clusters (mch 
clusters), 122 myxobacterial genome sequences were screened by using the antiSMASH 3.0.4 
tool.13 The analyzed species include 68 representatives of the suborder Cystobacterineae, 43 
representatives of the suborder Sorangiineae and 11 representatives of the suborder 
Nannocystineae (Table S1). In addition to the previously described A-type mch cluster from 
M. xanthus DK1622,7 the S-type mch cluster from S. aurantiaca DW4/3-1,9 and the B-type 
mch cluster from Myxococcus sp.  171 (see chapter 2.7.1), 13 putative mch clusters were 
identified, from which 7 represent a new type of mch gene cluster (B-type, C-type, D-subtype 
1, D-subtype 2; see Table 1 in the manuscript). The 16 identified mch clusters were 
exclusively found in myxobacterial strains, which belong to the suborder Cystobacterineae. 
The mch clusters are organized in a four-gene operon (mchA-mchD) encoding an iterative 
type I polyketide synthase (MchA), two nonribosomal peptide synthetases (MchB and MchC) 
as well as a conserved hypothetical protein with unkown function (MchD), which was not 
reported as part of the myxochromide pathway in previous studies.7,9 Based on in-silico 
protein sequence analysis using the Pfam database,46 the hypothetical protein MchD was 
predicted to be an integral membrane protein, since it contains the conserved DUF2269 
domain. The MchD protein could potentially act as a transmembane anchor for the 
myxochromide assembly lines. Association of a polyketide megasynthetase with the bacterial 
cell membrane was previously described for the myxovirescin biosynthetic machinery.47 
Analysis of the genomic context of the 16 mch gene clusters revealed their loci in the 
genomes of the respective producer strains (see Figure S2). The A-type, B-type  and C-type 
mch operons of the analyzed Myxococcus species (Mf1, Mx1, Mx2, Mx3, Mx4, M1, Mh1, 
Mv1) share basically the same set of genes surrounding the mch gene clusters with only little 
differences (see Figure S2A). In contrast, the mch gene cluster loci from Stigmatella (Sa1, 
Sa2, Sa3, Se1) and Hyalangium strains (Hm1, Hm2, Hm3) as well as from the unclassified 
strain (Cy1) significantly differ from the loci, which were observed for Myxococcus species. 
Interestingly, the mch cluster loci from Stigmatella sp. and Hyalangium sp. also partly differ 
within the same family from each other, except the S-type mch gene clusters from Sa1 and 
Sa3, which are integrated in the same genomic locus.  
To prepare the mch gene cluster sequences for detailed in-silico analyses, manual gap closing 
for the mch gene clusters from Mx2, Mx3 and Mv1 was performed by amplifying and 
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sequencing respective PCR products covering the sequence gap (not shown). Based on the 
automatic annotation of the mch gene clusters from the antiSMASH 3.0.4 analysis,13 the 
borders of catalytic domains from the polyketide synthase MchA and the two multimodular 
nonribosomal peptide synthetases MchB and MchC were manually revised and core motifs, 
which characterize these  domains, were annotated as well.31,32 The considerably increased 
sequence information of mch gene clusters, in addition to the novel identified putative types 
of mch gene clusters (B-type, C-type, D-subtype1, D-subtype2) allowed for detailed 
characterization of the different pathways in order to explain the structural diversity of the 
myxochromide family on a genetic basis (see chapter 2.7.7). 
 
 
Table S1. Myxobacterial genomes screened for mch gene clusters. Strains, which harbor a mch gene cluster, are 
highlighted in boldface. 
 
No. Strain Suborder Family Genus 
1 Anaeromyxobacter dehalogenans 2CP-1 Cystobacterineae Cystobacteraceae Anaeromyxobacter 
2 Anaeromyxobacter dehalogenans 2CP-C Cystobacterineae Cystobacteraceae Anaeromyxobacter 
3 Anaeromyxobacter sp. Fw109-5 Cystobacterineae Cystobacteraceae Anaeromyxobacter 
4 Anaeromyxobacter sp. K Cystobacterineae Cystobacteraceae Anaeromyxobacter 
5 Anaeromyxobacter sp. PSR-1 Cystobacterineae Cystobacteraceae Anaeromyxobacter 
6 Angiococcus disciformis AngGT8 Cystobacterineae Cystobacteraceae Angiococcus 
7 Archangium gephyra Ar8082 Cystobacterineae Cystobacteraceae Archangium 
8 Archangium gephyra DSM 2261 Cystobacterineae Cystobacteraceae Archangium 
9 Archangium sp. Ar3548 Cystobacterineae Cystobacteraceae Archangium 
10 Cystobacter armeniaca Cba6 Cystobacterineae Cystobacteraceae Cystobacter 
11 Cystobacter ferrugineus Cbfe23 Cystobacterineae Cystobacteraceae Cystobacter 
12 Cystobacter fuscus DSM 2262 Cystobacterineae Cystobacteraceae Cystobacter 
13 Cystobacter fuscus SBCb021 Cystobacterineae Cystobacteraceae Cystobacter 
14 Cystobacter sp. MCy9104 Cystobacterineae Cystobacteraceae Cystobacter 
15 Cystobacter sp. SBCb004 Cystobacterineae Cystobacteraceae Cystobacter 
16 Cystobacter velatus Cbv34 Cystobacterineae Cystobacteraceae Cystobacter 
17 Cystobacter violaceus Cb vi76 Cystobacterineae Cystobacteraceae Cystobacter 
18 Cystobacter violaceus Cbvi35 Cystobacterineae Cystobacteraceae Cystobacter 
19 Cystobacterineae sp. SBAr0011) Cystobacterineae - - 
20 Cystobacterineae sp. SBCy0081) Cystobacterineae - - 
21 Cystobacterineae sp. SBCy0121) Cystobacterineae - - 
22 Cystobacterineae sp. SBCy0161) Cystobacterineae - - 
23 Cystobacterineae sp. SBCy0171) Cystobacterineae - - 
24 Cystobacterineae sp. SBCy0181) Cystobacterineae - - 
25 Cystobacterineae sp. SBCy0271) Cystobacterineae - - 
26 Cystobacterineae sp. SBCy0301) Cystobacterineae - - 
27 Cystobacterineae sp. SBCy0481) Cystobacterineae - - 
28 Cystobacterineae sp. SBCy0501) Cystobacterineae - - 
29 Hyalangium minutum DSM 14724 (Hm1) Cystobacterineae Cystobacteraceae Hyalangium 
30 Hyalangium minutum Hym3 (Hm2) Cystobacterineae Cystobacteraceae Hyalangium 
31 Hyalangium minutum NOCb10 (Hm3) Cystobacterineae Cystobacteraceae Hyalangium 
32 Melittangium boletus Meb2 Cystobacterineae Cystobacteraceae Melittangium 
33 Melittangium lichenicola Mel 24 Cystobacterineae Cystobacteraceae Melittangium 
34 Stigmatella aurantiaca DW4/3-1 (Sa1) Cystobacterineae Cystobacteraceae Stigmatella 
35 Stigmatella aurantiaca Sga15 (Sa2) Cystobacterineae Cystobacteraceae Stigmatella 
36 Stigmatella aurantiaca Sga32 (Sa3) Cystobacterineae Cystobacteraceae Stigmatella 
37 Stigmatella erecta Pde77(Se1) Cystobacterineae Cystobacteraceae Stigmatella 
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38 Vulgatibacter incomptus DSM 27710 Cystobacterineae Vulgatibacteraceae Vulgatibacter 
39 Aggregicoccus edoensis MCy10622 Cystobacterineae Myxococcaceae Aggregicoccus 
40 Corallococcus coralloides Ccc1071 Cystobacterineae Myxococcaceae Corallococcus 
41 Corallococcus coralloides DSM 2259 Cystobacterineae Myxococcaceae Corallococcus 
42 Corallococcus coralloides ST201330 Cystobacterineae Myxococcaceae Corallococcus 
43 Corallococcus sp. Ccc127 Cystobacterineae Myxococcaceae Corallococcus 
44 Corallococcus sp. MCy10984 Cystobacterineae Myxococcaceae Corallococcus 
45 Myxococcus fulvus 124B02 Cystobacterineae Myxococcaceae Myxococcus 
46 Myxococcus fulvus HW-1 (Mf1) Cystobacterineae Myxococcaceae Myxococcus 
47 Myxococcus fulvus Mxf50 Cystobacterineae Myxococcaceae Myxococcus 
48 Myxococcus fulvus Mxf65 Cystobacterineae Myxococcaceae Myxococcus 
49 Myxococcus fulvus SBMx122 Cystobacterineae Myxococcaceae Myxococcus 
50 Myxococcus fulvus SBMx132 Cystobacterineae Myxococcaceae Myxococcus 
51 Myxococcus hansupus mixupus (Mh1) Cystobacterineae Myxococcaceae Myxococcus 
52 Myxococcus sp. 171 (M1) Cystobacterineae Myxococcaceae Myxococcus 
53 Myxococcus sp. MCy10608 Cystobacterineae Myxococcaceae Myxococcus 
54 Myxococcus stipitatus DSM 14675 Cystobacterineae Myxococcaceae Myxococcus 
55 Myxococcus virescens ST200611 (Mv1) Cystobacterineae Myxococcaceae Myxococcus 
56 Myxococcus xanthus DK 1622 (Mx1) Cystobacterineae Myxococcaceae Myxococcus 
57 Myxococcus xanthus DK897 (Mx2) Cystobacterineae Myxococcaceae Myxococcus 
58 Myxococcus xanthus DZ2 Cystobacterineae Myxococcaceae Myxococcus 
59 Myxococcus xanthus DZF1 Cystobacterineae Myxococcaceae Myxococcus 
60 Myxococcus xanthus MxA47 (Mx3) Cystobacterineae Myxococcaceae Myxococcus 
61 Myxococcus xanthus Mxx48 (Mx4) Cystobacterineae Myxococcaceae Myxococcus 
62 Pyxidicoccus fallax And48 Cystobacterineae Myxococcaceae Pyxidicoccus 
63 Pyxidicoccus sp. SBCy002 Cystobacterineae Myxococcaceae Pyxidicoccus 
64 Unclassified sp. And301) Cystobacterineae - - 
65 Unclassified sp. Ang9831) Cystobacterineae - - 
66 Unclassified sp. CcG341) (Cy1) Cystobacterineae - - 
67 Unclassified sp. SBCy0061) Cystobacterineae - - 
68 Unclassified sp. SBMx1521) Cystobacterineae - - 
69 Aetherobacter fasciculatus SBSr002 Sorangiineae Polyangiaceae Aetherobacter 
70 Aetherobacter rufus SBSr003 Sorangiineae Polyangiaceae Aetherobacter 
71 Aetherobacter sp. SBSr001 Sorangiineae Polyangiaceae Aetherobacter 
72 Aetherobacter sp. SBSr008 Sorangiineae Polyangiaceae Aetherobacter 
73 Byssovorax cruenta Byc1 Sorangiineae Polyangiaceae Byssovorax 
74 Chondromyces apiculatus DSM 436 Sorangiineae Polyangiaceae Chondromyces 
75 Chondromyces catenulatus SBCm007 Sorangiineae Polyangiaceae Chondromyces 
76 Chondromyces crocatus Cm c5 Sorangiineae Polyangiaceae Chondromyces 
77 Chondromyces pediculatus Cmp5 Sorangiineae Polyangiaceae Chondromyces 
78 Jahnella sp. SBSr007 Sorangiineae Polyangiaceae Jahnella 
79 Polyangium spumosum Plsm9 Sorangiineae Polyangiaceae Polyangium 
80 Sorangiineae sp. SBSr022 Sorangiineae Polyangiaceae Sorangium 
81 Sorangium cellulosum SBSo026 Sorangiineae Polyangiaceae Sorangium 
82 Sorangium cellulosum So ce56 Sorangiineae Polyangiaceae Sorangium 
83 Sorangium cellulosum So0157-2 Sorangiineae Polyangiaceae Sorangium 
84 Sorangium cellulosum Soce10 Sorangiineae Polyangiaceae Sorangium 
85 Sorangium cellulosum Soce1128 Sorangiineae Polyangiaceae Sorangium 
86 Sorangium cellulosum Soce1525 Sorangiineae Polyangiaceae Sorangium 
87 Sorangium cellulosum Soce1875 Sorangiineae Polyangiaceae Sorangium 
88 Sorangium cellulosum Soce26 Sorangiineae Polyangiaceae Sorangium 
89 Sorangium cellulosum Soce307 Sorangiineae Polyangiaceae Sorangium 
90 Sorangium cellulosum Soce340 Sorangiineae Polyangiaceae Sorangium 
91 Sorangium cellulosum Soce377 Sorangiineae Polyangiaceae Sorangium 
92 Sorangium cellulosum Soce38 Sorangiineae Polyangiaceae Sorangium 
93 Sorangium cellulosum Soce439 Sorangiineae Polyangiaceae Sorangium 
94 Sorangium cellulosum Soce690 Sorangiineae Polyangiaceae Sorangium 
95 Sorangium cellulosum Soce836 Sorangiineae Polyangiaceae Sorangium 
96 Sorangium cellulosum Soce960 Sorangiineae Polyangiaceae Sorangium 
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97 Sorangium cellulosum Soce969 Sorangiineae Polyangiaceae Sorangium 
98 Sorangium cellulosum SoceGT47 Sorangiineae Polyangiaceae Sorangium 
99 Sorangium nigrum Soce487 Sorangiineae Polyangiaceae Sorangium 
100 Sandaracinus amylolyticus DSM 53668 Sorangiineae Sandaracinaceae Sandaracinus 
101 Sandaracinus sp. SBSa001 Sorangiineae Sandaracinaceae Sandaracinus 
102 Labilithrix luteola strain DSM 27648 Sorangiineae Labilitrichaceae Labilithrix 
103 Minicystis sp. SBNa008 Sorangiineae - - 
104 Unclassified sp. MSr106812) Sorangiineae - - 
105 Unclassified sp. MSr31392) Sorangiineae - - 
106 Unclassified sp. NOSO-31) Sorangiineae - - 
107 Unclassified sp. SBSr0152) Sorangiineae - - 
108 Unclassified sp. SBSr0172) Sorangiineae - - 
109 Unclassified sp. SBSr0442) Sorangiineae - - 
110 Unclassified sp. SBSr0602) Sorangiineae - - 
111 Unclassified sp. SBSr0712) Sorangiineae - - 
112 Nannocystineae sp. SBNc001 Nannocystineae Nannocystaceae  
113 Nannocystis exedens Nae485 Nannocystineae Nannocystaceae Nannocystis 
114 Nannocystis exedens Nae487 Nannocystineae Nannocystaceae Nannocystis 
115 Enhygromyxa salina DSM 15201 Nannocystineae Nannocystaceae Enhygromyxa 
116 Enhygromyxa salina SBCm009 Nannocystineae Nannocystaceae Enhygromyxa 
117 Haliangium ochraceum DSM 14365 Nannocystineae Haliangiaceae Haliangium 
118 Haliangium ochraceum GS1 Nannocystineae Haliangiaceae Haliangium 
119 Kofleria flava Plvt1 Nannocystineae Kofleriaceae Kofleria 
120 Plesiocystis pacifica SIR-1 Nannocystineae Nannocystaceae Plesiocystis 
121 Unclassified sp. Nc0053) Nannocystineae - - 
122 Unclassified sp. Nc0183) Nannocystineae - - 
1) unclassified species belonging to the suborder Cystobacterineae 
2) unclassified species belonging to the suborder Sorangiineae 
3) unclassified species belonging to the suborder Nannocystineae 
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Figure S2. Myxochromide biosynthetic gene cluster loci from the 16 analyzed myxobacterial producer strains. 
The (putative) mch gene clusters (highlighted by a dashed rectangle) represent four-gene operons (mchA-D) 
encoding an iterative polyketide synthase (MchA), two multimodular nonribosomal peptide synthetases (MchB 
and MchC) and a conserved hypothetical protein (MchD). A: A-type mch gene clusters from Myxococcus fulvus 
HW-1 (Mf1_A), M. xanthus DK1622 (Mx1_A7, M. xanthus DK897 (Mx2_A), M. xanthus A47 (Mx3_A) and M. 
xanthus Mx48 (Mx4_A), B-type mch gene cluster from Myxococcus sp. 171 (M1_B) and C-type mch gene 
cluster from M. hansupus mixupus (Mh1_C) and M. virescens ST200611 (Mv1_C). Minor differences in the 
flanking chromosomal regions can be observed (4b, 5, 7), which encode: glycosyl hydrolase (1), multidrug ABC 
transporter ATP-binding protein (2), membrane protein (3), uncharacterized protein (4/4b), AraC family 
transcriptional regulator (5), ATP-dependent RNA helicase RhlE (6), elongation factor G (7), cyclic nucleotide-
binding protein (8), peptidyl-prolyl cis-trans isomerase (9) and metallophosphatase (10). B: D-type mch gene 
cluster from Cystobacterineae sp. CcG34 (Cy1_D). Flanking regions encode: two-component sensor histidine 
kinase (1), membrane protein (2), uncharacterized protein (3), uncharacterized protein (4), uncharacterized 
protein (5), aldo/keto reductase (6), uncharacterized protein (7) and uncharacterized protein (8). C: D-type mch 
gene clusters from Hyalangium minutum DSM14724 (Hm1_D), H. minutum Hym-3 (Hm2_D), H. minutum 
NoCb10 (Hm3_D). Flanking regions encode: uncharacterized protein (1), uncharacterized protein (2), pilus 
assembly protein PilZ (3), amino acid dehydrogenase (4), tRNA-Thr (5), uncharacterized protein (6), ABC 
transporter ATP-binding protein (7), ABC transporter permease (8), uncharacterized protein (9), benzoate-CoA 
ligase family protein (10), 8-amino-7-oxononanoate synthase (11), phosphopantetheine-binding protein (12), 
acyl-CoA dehydrogenase (13) and acyl-CoA synthetase (14). The downstream region 6-9 identified in 
Hm1_D/Hm2_D plus additional ~20 kb are missing from cluster downstream DNA in Hm3_D. D: D-type mch 
gene cluster from Stigmatella erecta Pde77 (Se1_D). Flanking regions encode putative homologous of the 
dawenol (Daw) and myxalamid (Mxa) biosynthetic pathways,48,49 polyketide synthases homologous to Daw3 (1), 
Daw2 (2) and MxaF (3). E: S-type mch gene clusters from S. aurantiaca DW4/3-1 (Sa1_S9) and S. aurantiaca 
Sga32 (Sa3_S). Flanking regions encode: cation/H(+) antiporter (1), hydrolase (2), ABC transporter permease 
(3), ABC transporter ATP-binding protein (4), alpha/beta hydrolase (5), uncharacterized protein (6), 
coproporphyrinogen III oxidase (7) and uncharacterized protein (8). F: S-type mch gene cluster from 
S. aurantiaca Sga15 (Sa2_S). Flanking regions encode: uncharacterized protein (1), TetR family transcriptional 
regulator (2), 3-oxoadipate enol-lactonase (3), PHB depolymerase esterase (4), glutathione S-transferase (5), 
uncharacterized protein (6), protein kinase (7) and protein kinase (8). 
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2.7.2.2 In-silico Predicition of Products of the C-type and D-type Megasynthetases 
In the course of the genome mining approach described in chapter 2.7.2.1, 7 putative mch 
gene clusters covering 4 novel types (B-type, C-type, D-subtype1, D-subtype2) were 
identified, which deviate from the previously described myxochromide A and S pathways in 
terms of the modular organization of the respective assembly lines.7,9 
In the putative C-type mch gene clusters from Mh1 and Mv1, the (compared to the A-type 
mch gene cluster) corresponding A5-PCP5-C6 unit is deleted, which led to recombination of 
the ‘hybrid’ C5-A6-PCP6-TE6 module. In-silico prediciton of the substrate specifities of all 
adenylation domains present in the putative C-type mch gene clusters (see chapter 2.7.7) 
revealed the same amino acid specificities as already predicted and experimentally verified 
for myxochromides A.7 As a result, it was expected that myxochromides C might have the 
same peptide core structure as myxochromides A but lack the alanine residue between the 
proline and glutamine residues. Since there are only minor differences in the protein 
sequences of the epimerization domains of module 2 from A-type and putative C-type mch 
gene clusters, it was assumed that the alanine residue, that might be introduced by module 2, 
has D configuration in the final product, which was already shown for myxochromides A.7 
Theoretical masses of proposed myxochromides C1-C4 were predicted, for which extracts of 
Mv1 (strain Mh1 was not availbale) were screened by HPLC-MS analysis (see chapter 
2.7.2.3). 
Sequence analysis of the putative D-type mch gene clusters (subtype 1) from Hm1, Hm2, 
Hm3 and Se1 revealed the same critical mutation within the core motif of the peptidyl carrier 
protein of module 4, which was already described for myxochromide S biosynthesis (see 
chapter 2.7.7).7 Here, this loss of function mutation led to ‘module-skipping’ resulting in the 
production of a pentapeptide core. The same scenario was now postulated for the putative D-
subtype 1 pathways, which were predicted to generate pentapeptide cores lacking the proline 
residue compared to myxochromides A. Similar products were expected from the putative D-
subtype 2 pathway from Cy1, which actually lacks two catalytic domains (A4-PCP4) 
obviously also resulting in a non-functional module 4. Specificity predictions of the 
adenylation domains from both subtypes indicate that both putative myxochromide D 
assembly lines might recruit and incorporate the same amino acid residues as previously 
described for the myxochromide A biosynthetic machinery (see chapter 2.7.7).7 In 
comparison to myxochromides S, the amino acid specificities of modules 2 and 3 might be 
interchanged (see chapter 2.7.7) leading to the production of a novel pentapeptide. Based on 
the high protein sequence similarity between the epimerization domains from A-type and 
putative D-type pathways, the absolute configuration of myxochromides D might be the same 
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as described for myxochromides A with one alanine residue (incorporated by module 2) 
showing D configuration. Theoretical masses of proposed myxochromides D1-D4 were 
predicted, for which extracts of Hm1, Hm2, Hm3, Se1 and Cy1 were screened by HPLC-MS 
analysis (see chapter 2.7.2.3). 
2.7.2.3 Analysis of Myxochromide Production Spectra  
To verify myxochromide production in the (putative) producer strains identified in the 
genome-based screening (Table S1), the strains (except strain Mh1, which was not available) 
were routinely grown in 50 mL liquid medium (300 mL shaking flasks) including 2% of 
amberlite XAD-16 adsorber resin at 30 °C and 180 rpm for up to 7 days. The strains Mf1, 
Mx1, Mx2, Mx3 and Mx4 were grown in CTT medium (casitone 1%, Tris-HCl [pH 8.0] 10 
mM, K2HPO4/KH2PO4 buffer [pH 7.6] 1 mM, MgSO4 × 7 H2O 8 mM, pH adjusted to 7.6), 
strains Sa1, Sa2 and Sa3 were grown in tryptone medium (tryptone 1%, MgSO4 × 7 H2O 
0.2%, pH adjusted to 7.2), strains Hm1, Hm2 and Hm3 were grown in MD1G medium 
(casitone 0.3%, CaCl2 × 2 H2O 0.05%, MgSO4 × 7 H2O 0.1%, glucose 0.35%, HEPES 0.11%, 
pH adjusted to 7.0), strain Se1 was grown in VY/2 medium (Baker’s yeast 0.5%, CaCl2 × 2 
H2O, HEPES 0.11%, vitamin B12 0.5 µg/mL, pH adjusted to 7.0), strain Cy1 was grown in H 
medium (soy flour 0.2%, yeast extract 0.2%, glucose 0.2%, starch 0.8%, CaCl2 × 2 H2O 
0.1%, MgSO4 × 7 H2O 0.1%, HEPES 0.11%, pH adjusted to 7.4), strain Mv1 was grown in 
CY medium (casitone 0.3%, yeast extract 0.1%, CaCl2 × 2 H2O 0.1%, MgSO4 × 7 H2O 0.2%, 
vitamin B12 0.5 µg/mL, pH adjusted to 7.4) and strain M1 was grown in a peptone medium 
(casitone 0.3%, yeast extract 0.3%, CaCl2 × 2 H2O 0.07%, MgSO4 × 7 H2O 0.2%, glucose 
0.1%, starch  1%, pH adjusted to 7.2).  
Cells and XAD-16 were harvested by centrifugation at 8,000 rpm and 4 °C for 10 min and 
subsequently extracted twice with 50 mL of a mixture of methanol and acetone (1:1). The 
extracts were evaporated to dryness, dissolved in methanol and subjected to HPLC-MS 
analysis using a Dionex Ultimate 3000 RSLC system coupled to a Bruker maXis 4G TOF 
mass spectrometer. Separation was performed using a Waters BEH C18, 100 × 2.1 mm, 1.7 
µm dp column. At a flow rate of 0.6 mL/min, the following gradient was applied (A: 
deionized water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid): 0-0.5 min 5% B, 
0.5-18.5 min 5-95% B, 18.5-20.5 min 95% B. Full scan mass spectra were acquired in 
positive ESI mode in a range from 150-2500 m/z. All MS2 experiments of target masses were 
performed on a Bruker solariX XR FT-ICR (7T) mass spectrometer. Initially, precursors were 
isolated in the quadrupole with an isolation width of 5 Da and subsequently fragmented in the 
collision cell by applying an energy of 20eV. Occurred fragments were then transferred to the 
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ICR cell and detected in a mass range from 100-1600 m/z by acquiring a 490 ms transient. 
The chromatograms and selected MS2 fragment spectra obtained from the HPLC-MS analysis 
are illustrated in Figures S3/S4.  A peak list, in which identified MS2 fragments are 
summarized, is shown in Table S2. Myxochromides with different polyunsaturated acyl side 
chains can be distinguished by MS2 fragmentation yielding a highly characteristic N-Me-
threonine-acyl chain fragment as most prominent ion (Figure S4).7,9  
All 15 analyzed (putative) producer strains were shown to produce specific types of 
myxochromides as illustrated in Figure S3 and summarized below.  
Myxochromides A  
The previously described lipohexapeptides myxochromides A2, A3 and A4 (1a-c7; for MS2 
spectra see Figure S4A) were detected in extracts of Myxococcus strains Mf1, Mx1, Mx2, 
Mx3 and Mx4. The most prominent derivative was in most cases 1b, in case of strain Mx2 1a 
under the applied cultivation conditions (Figure S3). Thus, all M. xanthus species analyzed in 
this study were verified as A-type producers, which correlates with a previous secondary 
metabolome analysis of 98 M. xanthus strains revealing myxochromides A to be ubiquitous 
metabolites in this species.24  
Myxochromides B 
The lipoheptapeptides myxochromides B2, B3 and B4 (2a-c; for MS2 spectra see Figure S4B) 
were detected in extracts of strain M1. Whereas production and structure elucidation of the 
most prominent derivative 2b was previously reported,8 two additional minor derivatives 2a 
and 2c were identified in this study (Figure S3). Based on the analytical HPLC-MS data 
including high-resolution MS2 spectra, 2a and 2c were assigned as myxochromides B2 and B4.  
Myxochromides C – novel lipopentapeptides 
From the putative myxochromide C producers assigned based on genomic data (Mv1 and 
Mh1, Table 1), only strain Mv1 was available for production analysis. As discussed in chapter 
2.7.2.2, sequence analysis of the encoded putative myxochromide megasynthetase allowed for 
structure prediction of potential biosynthesis products designated as myxochromides C. 
Respective myxochromide derivatives with [M+H]+ masses and MS2 spectra corresponding 
with the expected products were detected in the Mv1 extract (6a-c; Figures S3 and S4C). 
Isolation and structure elucidation of the major derivative 6b revealed that myxochromides C 
indeed represent novel lipopentapeptides (chapter 2.7.3). In addition to myxochromide C3 
(6b), two minor derivatives (6a and 6c) were detected and designated as myxochromides C2 
and C4 based on the corresponding MS2 spectra.         
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Myxochromides D – novel lipopentapeptides 
Based on the genome data, five strains were expected to produce another novel 
lipopentapeptide type designated as myxochromides D (Cy1, Hm1, Hm2, Hm3 and Se1; 
Table 1). As discussed in chapter 2.7.2.2, sequence analysis of the encoded putative 
myxochromide megasynthetase allowed for structure prediction of potential novel D-type 
biosynthesis products. Respective myxochromide derivatives with [M+H]+ masses and MS2 
spectra corresponding with the expected products were detected in extracts of the five 
analyzed producers (7a-d; Figures S3 and S4D). Isolation and structure elucidation of the 
major derivative 7a from strain Se1 revealed that myxochromides D indeed represent novel 
lipopentapeptides (chapter 2.7.4). Additionally to myxochromide D1 (7a), three other 
derivatives (7b-d) were detected and designated as myxochromides D2-4 based on the 
corresponding MS2 spectra. In contrast to strain Se1, strains Cy1 and Hm1-3 were shown to 
produce 7b and 7c as major myxochromide derivatives.     
Myxochromides S 
The previously described lipopentapeptides myxochromides S1, S2 and S3 (3a-c9; for MS2 
spectra see Figure S4E) were detected in extracts of Stigmatella aurantiaca strains Sa1-3 with 
3a as major derivative under the applied cultivation conditions (Figure S3). Myxochromides S 
and D feature the same amino acid composition (but different amino acid sequence) and can 
be distinguished due to different retention times and MS2 spectra.  
Myxochromides S-Abu and S-diAbu – novel lipopentapeptides from S-type producers 
Prior to this study, myxochromide producers were described to generate single myxochromide 
peptide cores (A-type, B-type or S-type7–9). Interestingly, our analysis of S-type producer 
strains revealed additional biosynthesis products (Figure S3), which according to the 
analytical data, seem to represent novel lipopentapeptides designated as myxochromides S-
Abu (4a-c; for MS2 spectra see Figure S4F) and myxochromides S-diAbu (5a-c; for MS2 
spectra see Figure S4G). A representative of each type (S2-Abu and S2-diAbu) was isolated 
from a previously described heterologous high-titer myxchromide S production strain (chapter 
2.7.5 and 2.7.6)15. Structure elucidation revealed that the novel pentapeptide cores differ from 
myxochromides S by replacement of one or two L-alanine (L-Ala) residues with L-α-
aminobutyric acid (L-Abu). This result correlates with the observation that production of 4 
and 5 can be increased when supplementing the production cultures with L-Abu (see below). 
Novel lipopeptides detected in A-,B-,C- and D-type producers after L-Abu feeding 
The production of additional Abu-containing myxochromides S-Abu and S-diAbu in S-type 
producer strains indicated that Ala-specific modules from the S-type assembly line can 
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alternatively incorporate Abu. To analyze whether similar variations can be observed for other 
(putative) myxochromide megasynthetase types as well, Abu feeding studies were performed 
with a representative producer strain for each myxochromide type: Mx1, M1, Mv1, Se1 and 
Sa1. The strains were routinely grown in duplicates under the same conditions as described 
above (XAD-16 was supplemented 6 h before cell harvest). One duplicate was supplemented 
with 4.2 mg L-α-aminobutyric acid three times per day for up to 7 days. Cell harvest, extract 
preparation and HPLC-MS-MS analysis was performed as described above. As illustrated in 
Figure S5, myxochromide production profiles from each of the analyzed strains clearly 
change when supplementing the cultures with L-Abu which indicates the production of novel 
Abu-containing myxochromides as already shown for Sa1 (myxochromides S-Abu and S-
diAbu). In case of A-, B and D-type producers, the detected novel derivatives (compounds 8, 
9, 10, 11, 13, 14) revealed mass shifts in [M+H]+ corresponding to one (+CH2, m/z +14) or 
two (+C2H4, m/z +28) additional methylene groups (Table S3). This points to the production 
of modified peptide cores, which contain either one or two Abu instead of Ala residues. In 
case of the C-type producer, only derivatives with mass shifts corresponding to one additional 
methylene group were detected (12; Figure S5). This was expected as the myxochromide C 
peptide core harbors only one Ala residue, which could be substituted with Abu (Table S3). 
Our data suggest that Ala-incorporating modules from all types of myxochromide 
megasynthetase can make use of L-Abu as alternative substrate. Feeding production cultures 
with L-Abu directed the biosynthesis towards novel derivatives (8-14) and further expanded 
the structural diversity of myxochromide peptide cores. 
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Figure S3. HPLC-MS analysis of myxochromide production in 15 myxobacterial producer strains (strain Mh1 
was not available). Extracted ion chromatograms (EICs) for ±0.02 m/z corresponding to the [M+H]+ ions of 
myxochromides are shown. A-E: Detection of myxochromides A in Mf1, Mx1, Mx2, Mx3 and Mx4; 
A2 ([M+H]+ = 834.47600), A3 ([M+H]+ = 846.47600) and A4 ([M+H]+ = 860.49165). F: Detection of 
myxochromides B in M1; B2 ([M+H]+ = 947.56007), B3 ([M+H]+ = 959.56007), B4 ([M+H]+ = 973.57572). 
G: Detection of myxochromides C in Mv1; C2 ([M+H]+ = 763.43889), C3 ([M+H]+ = 775.43889), C4 ([M+H]+ = 
789.45454). H-L: Detection of myxochromides D in Cy1, Hm1, Hm2, Hm3 and Se1; D1 ([M+H]+ = 723.40759), 
D2 ([M+H]+ = 737.42324), D3 ([M+H]+ = 749.42324), D4 ([M+H]+ = 763.43889). M-O: Detection of 
myxochromides S, S-Abu and S-diAbu in Sa1, Sa2 and Sa3; S1 ([M+H]+ = 723.40759), S2+S1-Abu ([M+H]+ = 
737.42324), S2-Abu+S1-diAbu ([M+H]+ = 751.43889), S3 ([M+H]+ = 749.42324), S3-Abu ([M+H]+ = 
763.43889). 
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Figure S4 (continued on next page) 
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Figure S4 (continued on next page) 
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Figure S4 (continued on next page) 
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Figure S4. Annotated FT-ICR MS2 spectra of different myxochromide derivatives (for m/z values see peak list 
table below). Full scan mass spectra were acquired in positive ESI mode in a range from 150-2500 m/z. A: 
Myxochromides A from an extract of strain Mx2. (I) MS2 of m/z 834.47647 identified as myxochromide A2. (II) 
MS2 of m/z 846.47327 identified as myxochromide A3. (III) MS2 of m/z 860.48891 identified as myxochromide 
A4. B: Myxochromides B from an extract of strain M1. (I) MS2 of m/z 947.55939 identified as myxochromide 
B2. (II) MS2 of m/z 959.55927 identified as myxochromide B3. (III) MS2 of m/z 973.57529 identified as 
myxochromide B4. C: Myxochromides C from an extract of strain Mv1. (I) MS2 of m/z 763.43784 identified as 
myxochromide C2. (II) MS2 of m/z 775.43855 identified as myxochromide C3. (III) MS2 of m/z 789.45341 
identified as myxochromide C4. D: Myxochromides D from extracts of strains Se1 and Hm2. (I) MS2 of m/z 
723.40758 identified as myxochromide D1 (Se1 extract). (II) MS2 of m/z 737.42373 identified as myxochromide 
D2 (Hm2 extract). (III) MS2 of m/z 749.42344 identified as myxochromide D3 (Hm2 extract). (IV) MS2 of m/z 
763.43957 identified as myxochromide D4 (Hm2 extract). E: Myxochromides S from an extract of strain Sa1. (I) 
MS2 of m/z 723.40774 identified as myxochromide S1. (II) MS2 of m/z 737.42319 identified as myxochromide 
S2. (III) MS2 of m/z 749.42391 identified as myxochromide S3. F: Myxochromides S-Abu from extracts of 
strains Sa1 and Sa2. (I) MS2 of m/z 737.42350 identified as myxochromide S1-Abu (Sa1 extract). (II) MS2 of m/z 
751.43762 from myxochromide S2-Abu (Sa2 extract). (III) MS2 of m/z 763.43973 identified as myxochromide 
S3-Abu (Sa1 extract). G: Myxochromides S-diAbu from an extract of strain Sa1 and authentic myxochromide S2-
diAbu reference substance. (I) MS2 of m/z 737.42350 identified as myxochromide S1-diAbu (Sa1 extract). (II) 
MS2 of m/z 751.43762 from myxochromide S2-diAbu (authentic reference). (III) MS2 of m/z 763.43973 
identified as myxochromide S3-diAbu (Sa1, L-α-aminobutyric acid feeding). 
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Table S2. MS2 fragments and retention times of different myxochromide derivatives. The m/z values correspond 
to the fragments, which are assigned in Figure S4. The characteristic threonine-polyketide fragments are 
highlighted in boldface.  
 
 
Peak no. - 
Myxochromide A2 
(12.79 min) 
Myxochromide A3 
(12.93 min) 
Myxochromide A4 
(13.57 min) 
1 - 239.14381 251.14349 265.15923 
2 - 258.14965 270.14935 284.16498 
3 - 336.19667 348.19623 362.21196 
4 - 354.20745 366.20673 380.22245 
5 - 520.31822 532.31681 546.33271 
6 - 688.40764 700.40549 714.42130 
7 - 756.43011 768.42712 782.44278 
8 - 816.46591 828.46263 842.47881 
9 - 834.47647 846.47327 860.48891 
Peak no. - 
Myxochromide B2 
(13.81 min) 
Myxochromide B3 
(13.95 min) 
Myxochromide B4 
(14.49 min) 
1 - 239.14373 251.14368 265.15948 
2 - 258.14956 270.14948 284.16525 
3 - 336.19659 348.19647 362.21227 
4 - 354.20719 366.20709 380.22293 
5 - 520.31746 532.31760 546.33374 
6 - 633.40192 645.40167 659.41719 
7 - 801.49081 813.49011 827.50707 
8 - 869.51339 881.51228 895.52855 
9 - 947.55939 959.55927 973.57529 
Peak no. - 
Myxochromide C2 
(12.72 min) 
Myxochromide C3 
(12.84 min) 
Myxochromide C4 
(13.49 min) 
1 - 239.14404 251.14419 265.15975 
2 - 258.14991 270.15003 284.16562 
3 - 336.19692 348.19699 362.21250 
4 - 354.20753 366.20768 380.22318 
5 - 389.22336 401.22370 415.23896 
6 - 407.23391 419.23411 433.24940 
7 - 492.32269 504.32307 518.33814 
8 - 520.31753 532.31795 546.33333 
9 - 685.39215 697.39174 711.40673 
10 - 745.42777 757.42799 771.44344 
11 - 763.43784 775.43855 789.45341 
Peak no. 
Myxochromide D1 
(11.83 min) 
Myxochromide D2 
(12.53 min) 
Myxochromide D3 
(12.69 min) 
Myxochromide D4 
(13.33 min) 
1 225.12799 239.14373 251.14371 265.15994 
2 244.13387 258.14958 270.14952 284.16579 
3 322.18091 336.19660 348.19653 362.21288 
4 340.19146 354.20718 366.20719 380.22360 
5 365.22306 379.23876 391.23872 405.25525 
6 393.21812 407.23388 419.23381 433.25008 
7 506.30200 520.31787 532.31761 546.33514 
8 549.34396 563.36006 575.35988 589.37602 
9 577.33916 591.35495 603.35488 617.37101 
10 645.36089 659.37692 671.37679 685.39284 
11 723.40758 737.42373 749.42344 763.43957 
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Peak no. 
Myxochromide S1 (12.17 
min) 
Myxochromide S2 (12.85 
min) 
Myxochromide S3 (12.99 
min) 
- 
1 225.12809 239.14411 251.14376 - 
2 244.13391 258.14997 270.14958 - 
3 322.18095 336.19704 348.19662 - 
4 407.27029 421.28618 433.28603 - 
5 435.26516 449.28960 461.28083 - 
6 478.30728 492.32320 504.32348 - 
7 506.30228 520.31808 532.31799 - 
8 549.34461 563.36014 575.36022 - 
9 577.33940 591.35497 603.35523 - 
10 645.36161 659.37674 671.37717 - 
11 723.40774 723.42319 749.42391 - 
Peak no. 
Myxochromide S1-Abu 
(12.43 min) 
Myxochromide S2-Abu 
(13.09 min) 
Myxochromide S3-Abu 
(13.22 min) 
- 
1 225.12800 239.14402 251.14376 - 
2 244.13387 258.14987 270.14960 - 
3 322.18092 336.19687 348.19668 - 
4 340.19148 354.20723 366.20726 - 
5 407.27016 421.28595 433.28579 - 
6 591.35482 605.36993 617.37078 - 
7 659.37678 673.39153 685.39273 - 
8 737.42350 751.43762 763.43973 - 
Peak no. 
Myxochromide S1-diAbu 
(12.70 min) 
Myxochromide S2-diAbu 
(13.37 min) 
Myxochromide S3-diAbu 
(13.48 min) 
- 
1 225.12844 239.14292 251.14285 - 
2 244.13429 258.14875 270.14861 - 
3 322.18135 336.19561 348.19567 - 
4 340.19179 354.20621 - - 
5 407.27042 421.28482 - - 
6 577.37548 591.39058 - - 
7 605.37051 619.38558 631.38563 - 
8 673.39260 687.40784 699.40533 - 
9 751.43863 765.45465 777.45432 - 
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Figure S5. HPLC-MS analysis of myxochromide production in selected producer strains after feeding of L-α-
aminobutyric acid (L-Abu) compared to standard cultivation experiments. The following strains were analyzed: 
Myxochromide A producer Mx1 (A/B), myxochromide B producer M1 (C/D), myxochromide C producer Mv1 
(E/F), myxochromide D producer Se1 (G/H) and myxochromide S/S-Abu/S-diAbu producer Sa1 (I/J). 
Extracted ion chromatograms (EICs) for ±0.02 m/z corresponding to the [M+H]+ ions of known myxochromides 
(compounds 1-7) and novel myxochromide derivatives detected after L-Abu feeding (compounds 8-14, labelled 
in red) are shown. For further details see Table S3.  
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Table S3. Myxochromide derivatives detected in feeding experiments with L-α-aminobutyric acid (L-Abu). The 
novel derivatives (compounds 8-14) are expected to harbor additional methylene groups in positions highlighted 
in red due to Abu instead of alanine incorporation.  
Strain Myxochromide Compound Formula [M+H]+ calc. Rt [min] Structures 
M
. 
x
a
n
th
u
s 
D
K
1
6
2
2
 
(M
x
1
) 
A2 1a C44H63N7O9 834,47600 12,80  
A3 1b C45H63N7O9 846,47600 12,93 
A4 1c C46H65N7O9 860,49165 13,58 
[A2 + CH2] 8a C45H65N7O9 848,49165 13,08 
[A3 + CH2] 8b C46H65N7O9 860,49165 13,20 
[A4 + CH2] 8c C47H67N7O9 874,50730 13,85 
[A2 + C2H4] 9a C46H67N7O9 862,50730 13,43 
[A3 + C2H4] 9b C47H67N7O9 874,50730 13,56 
[A4 + C2H4] 9c C48H69N7O9 888,52295 14,16 
M
yx
o
co
cc
u
s 
sp
. 
1
7
1
  
(M
1
) 
B2 2a C50H74N8O10 947,56007 13,82  
B3 2b C51H74N8O10 959,56007 13,92 
B4 2c C52H76N8O10 973,57572 14,50 
[B2 + CH2] 10a C51H76N8O10 961,57572 14,08 
[B3 + CH2] 10b C52H76N8O10 973,57572 14,17 
[B4 + CH2] 10c C53H78N8O10 987,59137 14,73 
[B2 + C2H4] 11a C52H78N8O10 975,59137 14,35 
[B3 + C2H4] 11b C53H78N8O10 987,59137 14,42 
[B4 + C2H4] 11c C54H80N8O10 1001,60702 14,99 
M
. 
vi
re
sc
en
s 
S
T
2
0
0
6
1
1
 (
M
v
1
) C3 6b C42H58N6O8 775,43889 12,86 
 
C4 6c C43H60N6O8 789,45454 13,50 
[C3 + CH2] 12b C43H60N6O8 789,45454 13,28 
[C4 + CH2] 12c C44H62N6O8 803,47019 13,90 
S
. 
er
ec
ta
 P
d
e7
7
  
(S
e1
) 
D1 7a C38H54N6O8 723,40759 11,83  
D2 7b C39H56N6O8 737,42324 12,54 
D3 7c C40H56N6O8 749,42324 12,68 
[D1 + CH2] 13a C39H56N6O8 737,42324 12,00 
[D2 + CH2] 13b C40H58N6O8 751,43889 12.71/12.91 
[D3 + CH2] 13c C41H58N6O8 763,43889 12.84/13.04 
[D1 + C2H4] 14a C40H58N6O8 751,43889 12,42 
[D2 + C2H4] 14b C41H60N6O8 765,45454 13,09 
[D3 + C2H4] 14c C42H60N6O8 777,45454 13,22 
S
. 
a
u
ra
n
ti
a
ca
 D
W
4
/3
-
1
  
(S
a
1
) 
S1 3a C38H54N6O8 723,40759 12,17  
S2 3b C39H56N6O8 737,42324 12,85 
S3 3c C40H56N6O8 749,42324 12,97 
E1 4a C39H56N6O8 737,42324 12,41 
E2 4b C40H58N6O8 751,43889 13,09 
E3 4c C41H58N6O8 763,43889 13,20 
F1 5a C40H58N6O8 751,43889 12,71 
F2 5b C41H60N6O8 765,45454 13,36 
F3 5c C42H60N6O8 777,45454 13,47 
 
 
 
 
 
Myxochromides A2-4 (1a-c) 
Myxochromides B2-4 (2a-c) 
Myxochromides C3-4 (6b-c) 
Myxochromides D1-3 (7a-c) 
Myxochromides S1-3 (3a-c; RA,B=H) 
Myxochromides E1-3 (4a-c; RA=CH3, RB=H) 
Myxochromides F1-3 (5a-c; RA,B=CH3) 
N
H
O
O
N R2-4
O
Me
O
HN
NH2
ON
H
O
O
HN
O
O
N
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2.7.3 Isolation and Structure Elucidation of Myxochromide C3 from M. virescens 
ST200611 
2.7.3.1 Cultivation of M. virescens ST200611 and Isolation of Myxochromide C3 
The putative myxochromide C producer strain Myxococcus virescens ST200611 (Mv1) was 
cultivated in 20 L (10x 2 L) CYS medium (casitone 0.25%, yeast extract 0.1%, CaCl2 × 2 
H2O 0.1%, starch 0.25%, HEPES 0.24%, vitamin B12 500 µg/L, pH adjusted to 7.0) including 
2% XAD-16 resin for 4 days at 30 °C and 180 rpm. Cells and XAD-16 amberlite adsorber 
resin were harvested by centrifugation at 10,500 rpm and 4 °C for 15 min and were five times 
extracted with 1 L of a mixture of methanol and acetone (1:1). The organic solvents were 
removed under reduced pressure and the residue was six times extracted with 200 mL of ethyl 
acetate. After removal of the solvent, the crude extract was dissolved in 15 mL of methanol 
for subsequent separation via size exclusion chromatography using Sephadex LH-20 and 
methanol as solvent. The collected fractions were concentrated and analyzed by HPLC-MS 
analysis for the presence of myxochromides C. Analysis was performed on a Dionex Ultimate 
3000 RSLC system coupled to a Bruker amaZon speed mass spectrometer using a Waters 
BEH C18, 50 × 2.1 mm, 1.7 µm dp column. At a flow rate of 0.6 mL/min, the following 
gradient was applied (A: deionized water + 0.1% formic acid, B: acetonitrile + 0.1% formic 
acid): 0-0.5 min 5% B, 0.5-9.5 min 5-95%, 9.5-10.5 min 95% B, 10.5-10.8 min 95-5% B, 
10.8-12.5 min 5% B. Full scan mass spectra were acquired in positive ESI mode ranging from 
200-2000 m/z. Sephadex fractions containing the target compound were combined, 
evaporated and dissolved in methanol for subsequent separation via reverse phase HPLC. A 
Dionex UltiMate 3000 system equipped with a Luna 5u C18(2) 100A column (250 × 10 mm, 
Phenomenex) was used. At constant flow rate (5.0 mL/min), the following multi-step gradient 
was applied (A: deionized water, B: acetonitrile): 0-5 min 10-45% B, 5-30 min 45-65% B, 30-
40 min 65-80% B, 40-41 min 80-10% B, 41-47 min 10% B. UV traces were recorded by a 
diode array detector (DAD) with specified wave lengths (210, 266 and 410 nm) with 
myxochromides showing good UV absorption at 410 nm. A total amount of 2.3 mg of pure 
myxochromide C3 (Rt = 27.7 min) was isolated.     
2.7.3.2 Structure Elucidation of Myxochromide C3 
Structure elucidation of myxochromide C3 was achieved using 1D and 2D NMR spectroscopy 
as well as HR-MS data. NMR spectra were acquired in CD3OD at a Bruker Ascend 700 or 
500 MHz spectrometer equipped with a 5 mm TXI cryoprobe. 1D 1H and 2D 1H−1H COSY, 
HSQC, HMBC and ROESY spectra were recorded using standard pulse programs and are 
illustrated in Figure S7. Carbon chemical shifts were extracted from 2D NMR data. NMR 
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spectroscopic data are listed in the Table S4. HR-ESI-MS data were obtained on a Bruker 
Maxis 4G mass spectrometer. Full scan mass spectra were acquired in a range from 150-2500 
m/z in a positive mode. HR-ESI-MS of myxochromide C3 gave a quasimolecular ion at m/z 
775.43921 [M+H]+consistent with a molecular formula C42H57N6O8 (775.43889, calculated 
for C42H58N6O8, Δm/z 0.413 ppm). The 1H NMR spectrum exhibited signals corresponding to 
five α-CH protons (δH 4.2-5.5), four CH3 groups (δH 0.9-1.3), three CH2 groups (δH 1.3-2.2) 
and one methine proton (δH 1.55) together with a N-Me group (δH 3.39, 3H, s). Moreover, a 
number of downfield signals belonging to the unsaturated polyketide side chain (δH 5.7-7.3) 
and a CH3 signal (δH 1.78, 3H, d) were observed. 2D NMR data revealed the presence of N-
Me-threonine, alanine, leucine, proline and glutamine residues and HMBC/ROESY data 
established the cyclic pentapeptide with the unsaturated polyketide side chain (Figure S6). 
The NMR data and core structure of myxochromide C3 were in accordance with the one of 
myxochromide A, which differs by its additional alanine residue.7 
For the assignment of the absolute configuration, Marfey’s method based on amino acid 
derivatization was applied.29 0.3 mg of pure myxochromide C3 was hydrolyzed with 37% HCl 
(0.2 mL) in a 1.5 mL glass vial for 3 days at 110°C. The hydrolysate was evaporated to 
dryness and dissolved in H2O (100 μL). A 50 μL aliquot was supplemented with 1N NaHCO3 
(20 μL) and 1% 1-fluoro-2,4-dinitrophenyl-5-L/D-leucinamide (L-FDLA or D-FDLA) 
solution in acetone (20 μL), and the mixtures were heated to 40 °C for 8 h at 700 rpm. After 
cooling down to room temperature, the solutions were neutralized with 2N HCl (20 μL), 
evaporated to dryness and the derivatized amino acids were dissolved in 300 μL acetonitrile. 
An amino acid standard mix (Sigma Aldrich) as well as N-Me-L-Threonine (Sigma Aldrich) 
were derivatized via the same procedure and all samples were analyzed on a Dionex Ultimate 
3000 RSLC system coupled to a Bruker Maxis 4G mass spectrometer. Separation was 
performed using a Waters BEH C18, 100 × 2.1 mm, 1.7 µm dp column. At a flow rate of 0.6 
mL/min, the following gradient was applied (A: deionized water + 0.1% formic acid, B: 
acetonitrile + 0.1% formic acid): 0 min 5% B, 0-1 min 5-10% B, 1-15 min 10-35% B, 15-22 
min 35-55% B, 22-25 min 55-80% B, 25-26 min 80% B, 26-26.5 min 80-5% B, 26.5-31 min 
5% B. Full scan mass spectra were acquired in a range from 100-1000 m/z. The 
chromatograms obtained from the HPLC-MS analysis are illustrated in Figure S8 and 
stereochemical assignments are illustrated in Table S5. 
Comparison of the retention times and m/z values of derivatized standard amino acids and the 
hydrolyzed lipopeptide revealed the presence of a D-configured alanine residue (C13) in 
myxochromide C3. The amino acids proline (C2), leucine (C7), N-Me-threonine (C16) and 
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glutamine (C20), which was converted to glutamic acid during hydrolysis, were found to be 
L-configured. Since the alanine activating module contains an epimerization domain, the 
detection of D-alanine was expected and was already observed for myxochromides A and 
B.7,8  
 
 
 
 
 
 
 
 
 
 
 
Figure S6. Structure of myxochromide C3 showing COSY (bold line), ROESY (dashed arrow) and key HMBC 
(plain arrow) correlations. 
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Table S4. NMR spectroscopic data of myxochromide C3. 
Moiety Position δCa δHb (J in Hz) HMBCc ROESYd, e 
L-Pro 1  174.6     
 2  63.3  4.31, dd (3.1, 9.1)  1, 3, 4, 5 7 
 3a  32.7  2.16, m  1, 4, 5  
 3b   2.43, m  1, 2, 4, 5  
 4  23.6  2.00, m  2, 3, 5  
 5a  47.9 3.52, m  2, 3, 4  
 5b   3.75, m  2, 3, 4  
L-Leu 6  174.2     
 7  49.6  4.68, dd (2.7, 11.4)  6, 8, 9, 12 2, 10, 11 
 8a  42.4  1.32, m 7  
 8b   1.61, m  6, 7  
 9  25.6  1.55, m  7, 8, 10, 11  
 10  23.7  0.93, d (6.2)  8, 9, 11  
 11 21.9 0.92, d (6.2) 10  
D-Ala 12  174.7     
 13 51.7 4.20, m 12, 14, 15  
 14 17.1 1.32, m 12, 13  
N-Me-L-Thr 15 170.9     
 16  61.3  5.50, d (2.9)  1', 15, 17, 24 2', 24 
 17  72.4  6.02, m  18, 19  
 18  16.6  1.19, d (6.7)  16, 17 24 
 24 35.0 3.39, s 1', 16 2', 18, 20 
L-Gln 19 171.4     
 20  55.0 4.40, dd (5.3, 6.9)  1, 19, 21, 22  
 21  29.0  2.09, m  20, 22, 23  
 22  31.6  2.22, t (7.8)  20, 21, 23  
 23  177.2     
Side chain 1' 171.2    
 2' 120.4  6.66, d (14.6)  1', 4' 16, 24 
 3' 145.1  7.34, dd (11.4, 14.6)  1', 2', 5'  
 4' 138.5  6.54, m  f  
 5' 142.0 6.72, m 3'  
 6'-14' f f f  
 15' 135.1 6.25, m f  
 16' 133.2 6.13, m 15', 18'  
 17' 131.2 5.76, m 15', 18'  
 18' 18.4 1.78, d (6.7) 15', 16', 17'  
a acquired at 175 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 700 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d proton showing ROESY correlations to indicated protons. 
e acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
f overlapped signals. 
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Figure S7 (continued on next page) 
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Figure S7 (continued on next page) 
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Figure S7 (continued on next page)  
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Figure S7 (continued on next page)  
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Figure S7.  NMR spectra of myxochromide C3.  
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Figure S8. Results of the analysis of the absolute configuration by advanced Marfey’s method.29 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. 
B: Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide C3 derivatized 
with D-FDLA reagent. D: Hydrolyzed myxochromide C3 derivatized with L-FDLA reagent. E: Standard solution 
of N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized with L-
FDLA. G: Same sample as in C analyzed for the N-Me-L-threonine D-FDLA derivative. H: Same sample as in 
D analyzed for the N-Me-L-threonine L-FDLA derivative. 
 
Table S5. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of the 
amino acids in myxochromide C3 (inverse correlation of retention times (tR) of D-configured Ala-FDLA 
derivatives from the peptide hydrolysate compared to L-configured Ala-FDLA standards are shown in bold). 
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.2 442.1617 14.2 442.1619 L 
Glu-L-FDLA 13.2 442.1619 13.2 442.1620 
Pro-D-FDLA 16.1 410.1711 16.1 410.1723 L 
Pro-L-FDLA 14.4 410.1720 14.4 410.1722 
Ala-D-FDLA 16.6 384.1554 14.1 384.1561 D 
Ala-L-FDLA 14.1 384.1561 16.6 384.1563 
Leu-D-FDLA 21.1 426.2027 21.1 426.2042 L 
Leu-L-FDLA 17.7 426.2038 17.7 426.2039 
N-Me-Thr-D-FDLA 14.3 428.1818 14.3 428.1822 L 
N-Me-Thr-L-FDLA 12.8 428.1831 12.8 428.1825 
85     Genomics-Guided Exploitation of Lipopeptide Diversity in Myxobacteria 
 
2.7.4 Isolation and Structure Elucidation of Myxochromide D1 from S. erecta Pde77 
2.7.4.1 Cultivation of S. erecta Pde77 and Isolation of Myxochromide D1 
The putative myxochromide D producer strain Stigmatella erecta Pde77 (Se1) was cultivated 
in 20 L (10x 2 L) VY/2 medium (Baker’s yeast 0.5%, CaCl2 × 2 H2O 0.05%, HEPES 0.11%, 
vitamin B12 500 µg/L, pH adjusted to 7.0) including 2% XAD-16 resin for 7 days at 30 °C 
and 180 rpm. Cells and XAD-16 were harvested by centrifugation at 8,000 rpm and 4 °C for 
15 min. Extraction and isolation of the target compound myxochromide D1 using size 
exclusion chromatography and semi-preparative HPLC was achieved as described for 
myxochromide C3 (see chapter 2.7.3.1). A total amount of 2.7 mg of pure myxochromide D1 
(Rt = 22.4 min) was isolated. 
2.7.4.2 Structure Elucidation of Myxochromide D1 
Structure elucidation of myxochromide D1 was achieved as described for myxochromide C3 
(see chapter 2.7.3.2). 1D 1H and 2D 1H-1H COSY, HSQC, HMBC and ROESY spectra are 
shown in Figure S10. Carbon chemical shifts were extracted from 2D NMR data. NMR 
spectroscopic data are listed in the Table S6. Myxochromide D1 showed quasimolecular ion at 
m/z 723.40748 [M+H]+ by HR-ESI-MS, which corresponds to the molecular formula 
C38H54N6O8 (723.40759, calculated for C38H55N6O8, Δm/z -0.152 ppm). Its 1H NMR spectrum 
closely resembled to that of myxochromide C3. In addition to the common structural parts, 
analysis of 2D NMR spectra corroborated the presence of two alanine residues, one of which 
substitutes the proline in myxochromide C3. Key HMBC correlations established the amino 
acid sequence and finalized its planar structure as depicted in Figure S9. Length of the 
polyene side chain was deduced based on the HR-MS data and molecular formula. For the 
assignment of the absolute configuration of myxochromide D1 the same procedure, hydrolysis 
and Marfey analysis of the obtained amino acids,29 was applied as described for 
myxochromide C3 in chapter 2.7.3.2. The chromatograms obtained from HPLC-MS analysis 
are illustrated in Figure S11 and stereochemical assignments are illustrated in Table S7. 
Comparison of the retention times and masses of derivatized standard amino acids and the 
hydrolyzed lipopeptide revealed that one of the two alanine residues (C2 and C11) from 
myxochromide D1 has D configuration. The second alanine residue as well as the amino acids 
leucine (C5), N-Me-threonine (C14) and glutamine (C18), which was converted to glutamic 
acid during hydrolysis, were found to be L-configured. According to the domain organization 
of the myxochromide D assembly line, which harbors an epimerization domain in module 2, 
the D-configured alanine was assigned to C11. This also correlates with the structures of 
myxochromides A, B and C (this study; see chapter 2.7.3.2)7,8.  
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Figure S9. Structure of myxochromide D1 showing COSY (bold line) and key HMBC (arrow) correlations. 
O
N
O
1
4
17
9
11
13
16
1'
2'
15'
22
O
HN
O
NH2
O
N
H
O
HN O
O
O
12
6a/b
8
3
19 21
16'
87     Genomics-Guided Exploitation of Lipopeptide Diversity in Myxobacteria 
 
Table S6. NMR spectroscopic data of myxochromide D1 (CD3OD). 
Moiety Position δCa δHb (J in Hz) HMBCc ROESYb, d, e 
L-Ala 1 173.0    
 2 50.8 4.27, q (6.8) 1, 3, 4  
 3 18.6 1.37, d (6.8) 1, 2  
L-Leu 4  174.7     
 5  54.4  4.16, dd (5.4, 10.0) 4, 6, 7, 10 8, 9 
 6a  40.7  1.64, m 7  
 6b  1.71, m   
 7  26.2  1.72, m 5, 6, 8, 9  
 8  21.4  0.92, d (6.3) 6, 7 5 
 9 23.2  0.98, d (6.3) 6, 7 5 
D-Ala 10  175.9     
 11 50.3 4.33, m 10, 12, 13 13 
 12 16.7 1.30, m 10, 11  
N-Me-L-Thr 13 170.0     
 14  59.5  5.44, d (2.0) 1', 13, 15, 22 2', 22 
 15  72.8  5.47, m  16, 17  
 16  17.2  1.15, d (5.4) 14, 15  
 22 35.2 3.07, s 1', 14 2', 14, 16, 18 
L-Gln 17 171.0     
 18  54.0 3.98, dd (5.3, 9.4) 1, 17, 19, 20  
 19a  26.3  2.22, m 18, 20, 21  
 19b  2.13, m 18, 20, 21  
 20a  32.2  2.26, m 18, 19, 21  
 20b  2.21, m 18, 19, 21  
 21  177.7     
Side chain 1' 170.7    
 2' 120.2 6.60, d (14.5) 1' 14, 22 
 3' 145.0 7.34, dd (11.4, 14.6) 1', 2', 5'  
 4' 138.6 6.53, m e  
 5' 141.9 6.71, m e  
 6'-12' e e e  
 13' 135.3 6.26, m e  
 14' 133.3 6.13, m 13', 16'  
 15' 131.4 5.77, m 13'  
 16' 18.4 1.79, d (6.3) 13', 14', 15'  
___________________________________________________________________________ 
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d proton showing ROESY correlations to indicated protons. 
e overlapped signals. 
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Figure S10 (continued on next page)  
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Figure S10 (continued on next page)  
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Figure S10 (continued on next page)  
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Figure S10 (continued on next page)  
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Figure S10.  NMR spectra of myxochromide D1.  
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Figure S11. Results of the analysis of the absolute configuration by advanced Marfey’s method.29 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA. B: Standard 
amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide D1 derivatized with D-FDLA 
reagent. D: Hydrolyzed myxochromide D1 derivatized with L-FDLA reagent. E: Standard solution of N-Me-L-
threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized with L-FDLA. G: 
Same sample as in C analyzed for the N-Me-L-threonine D-FDLA derivative. H: Same sample as in D analyzed 
for the N-Me-L-threonine L-FDLA derivative. 
Table S7. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of the 
amino acids in myxochromide D1 (inverse correlation of retention times (tR) of D-configured Ala-FDLA 
derivatives from the peptide hydrolysate compared to L-configured Ala-FDLA standards are shown in bold). 
 
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.2 442.1617 14.2 442.1618 L 
Glu-L-FDLA 13.2 442.1619 13.2 442.1622 
Ala-D-FDLA 16.6 384.1554 16.6 410.1723 L 
Ala-L-FDLA 14.1 384.1561 14.1 384.1563 
Ala-D-FDLA 16.6 384.1554 14.1 384.1561 D 
Ala-L-FDLA 14.1 384.1561 16.6 384.1565 
Leu-D-FDLA 21.1 426.2027 21.1 426.2042 L 
Leu-L-FDLA 17.7 426.2038 17.7 426.2038 
N-Me-Thr-D-FDLA 14.3 428.1818 14.3 428.1817 L 
N-Me-Thr-L-FDLA 12.8 428.1831 12.8 428.1838 
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2.7.5 Isolation and Structure Elucidation of Myxochromide S2-Abu from the 
Heterologous Expression Strain M. xanthus DK1622::pTpS-mchS 
2.7.5.1 Cultivation of M. xanthus DK1622::pTpS-mchS and Isolation of Myxochromide 
S2-Abu 
The myxochromide S overproducing mutant M. xanthus DK1622::pTpS-mchS  was cultivated 
in 9 L (6x 1.5 L) CTT medium amended with kanamycin (50 mg/L) including 2% XAD-16 
adsorber resin for 5 days at 30 °C and 180 rpm.15 Cell harvest, extraction and isolation of the 
target compound myxochromide S2-Abu using size exclusion chromatography was achieved 
as described for myxochromide C3 (see chapter 2.7.3.1). Semi-preparative HPLC was 
performed on a Dionex UltiMate 3000 system equipped with a Kinetex 5u Biphenyl 100Å 
column (250 × 10 mm, Phenomenex). At constant flow rate (5.0 mL/min), the following 
multi-step gradient was applied (A: deionized water, B: acetonitrile): 0-1 min 1% B, 1-8 min 
1-40% B, 8-52 min 40-57% B, 52-54 min 57-95% B, 54-57 min 95% B, 57-58 min 95-1% B, 
58-62 min 1% B. UV traces were recorded by a diode array detector (DAD) with specified 
wave lengths (210, 266 and 410 nm) with myxochromides showing good UV absorption at 
410 nm. A total amount of 5.3 mg of pure myxochromide S2-Abu (Rt = 37.1 min) was 
isolated. 
2.7.5.2 Structure Elucidation of Myxochromide S2-Abu 
Structure elucidation of myxochromide S2-Abu was achieved as described for myxochromide 
C3 (see chapter 2.7.3.2). 1D 1H and 2D 1H-1H COSY, HSQC, HMBC and ROESY spectra are 
shown in Figure S13. Carbon chemical shifts were extracted from 2D NMR data. NMR 
spectroscopic data are listed in Table S8. HR-ESI-MS of myxochromide S2-Abu gave a 
quasimolecular ion at m/z 751.43940 [M+H]+ ascribable to a molecular formula C40H58N6O8 
(751.43889, calculated for C40H59N6O8, Δm/z 0.679 ppm). The COSY spectrum supported by 
HSQC and HMBC data showed presence of spin systems corresponding to N-Me-threonine, 
glutamine, alanine and leucine residues as well as an unusual amino acid (α-aminobutyric 
acid, Abu) and an polyene side chain. Amino acid sequence was established by means of key 
HMBC correlations and final structure was elucidated as shown in Figure S12. For the 
assignment of the absolute configuration of myxochromide S2-Abu the same procedure, 
hydrolysis and Marfey analysis of the obtained amino acids,29 was applied as described for 
myxochromide C3 (see chapter 2.7.3.2). The chromatograms obtained from HPLC-MS 
analysis are illustrated in Figure S14 and stereochemical assignments are illustrated in Table 
S9. Comparison of the retention times and masses of derivatized standard amino acids and the 
hydrolyzed lipopeptide revealed that all amino acids of the myxochromide S2-Abu peptide 
core show L-configuration, while glutamine was converted to glutamic acid during hydrolysis. 
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This correlates with the major product, myxochromides S,9 as well as with myxochromide S2-
diABu produced by the same pathway (see chapter 2.7.6). Despite the presence of an 
epimerization domain in the second module of the assembly line, L-configured amino acids 
are incorporated into this position of the peptide core. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S12. Structure of myxochromide S2-Abu showing selected COSY (bold line) and key HMBC (arrow) 
correlations. 
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Table S8. NMR spectroscopic data of myxochromide S2-Abu (CD3OD). 
Moiety Position δCa δHb (J in Hz) HMBCc ROESYd 
L-Ala 1 173.2    
 2 53.1 3.77, q (7.4) 1, 3, 4  
 3 15.4 1.65, d (7.3) 1, 2  
L-Abu 4  173.3     
 5  58.2  3.52, dd (3.9, 10.7) 4, 6, 7, 8  
 6a  21.9  1.85, m 4, 5, 7  
 6b  2.03, m 5, 7  
 7  11.3  0.92, d (7.3) 5, 6, 8, 9  
L-Leu 8  176.2     
 9 54.3 4.07, m 8, 10, 11, 14  
 10a 40.8 1.47, m 8, 9, 13  
 10b  1.60, m 9, 13  
 11 25.6 1.75, m 10, 12, 13  
 12 22.2 0.97, d (6.6) 10, 11, 13  
 13 22.9 1.01, d (6.6) 10, 11, 12  
N-Me-L-Thr 14 171.4    
 15  59.6 5.56, d (4.2) 1', 14, 16, 23 2', 23 
 16  73.9 5.52, m  17, 18  
 17  16.5 1.25, d (6.3) 15, 16  
 23 35.1 3.26, s 1', 15 2', 15, 17, 19 
L-Gln 18 171.0     
 19  51.9 4.66, dd (3.6, 9.8) 1, 18, 20, 21  
 20a  27.8  1.92, m 18, 19, 21, 22  
 20b  2.31, m   
 21a 31.9  2.31, m 19, 20, 22  
 21b  2.25, m   
 22  178.2     
Side chain 1' 170.6    
 2' 119.8 6.58, d (14.6) 1' 23 
 3' 145.4 7.30, dd (11.3, 14.6) 1', 2', 5'  
 4' 138.6 6.52, m e  
 5' 142.0 6.69, dd (11.1, 14.6) e  
 6'-12' e e e  
 13' 135.5 6.26, m e  
 14' 131.0 6.12, m 13', 16'  
 15' 131.0 5.80, dt (6.7, 15.0) 13', 16', 17'  
 16' 26.7 2.14, m 17'  
 17' 13.7 1.02, t (7.5) 16'  
 
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d proton showing ROESY correlations to indicated protons. 
e overlapped signals. 
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Figure S13 (continued on next page)  
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Figure S13 (continued on next page)  
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Figure S13 (continued on next page)  
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Figure S13 (continued on next page)  
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Figure S13.  NMR spectra of myxochromide S2-Abu.  
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Figure S14. Results of the analysis of the absolute configuration by advanced Marfey’s method.29 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide S2-Abu derivatized 
with D-FDLA reagent. D: Hydrolyzed myxochromide S2-Abu derivatized with L-FDLA reagent. E: Standard 
solution of N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized 
with L-FDLA. G: Standard solution of L-aminobutyric acid derivatized with D-FDLA. H: Standard solution of 
L-aminobutyric acid derivatized with L-FDLA. I: Same sample as in C analyzed for the N-Me-L-threonine D-
FDLA derivative and for the L-aminobutyric acid D-FDLA derivative. J: Same sample as in D analyzed for the 
N-Me-L-threonine L-FDLA derivative and for the L-aminobutyric acid L-FDLA derivative. 
Table S9. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of the 
amino acids in myxochromide S2-Abu. 
 
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.2 442.1617 14.2 442.1615 L 
Glu-L-FDLA 13.2 442.1619 13.2 442.1615 
Abu-D-FDLA 18.2 398.1740 18.2 398.1730 L 
Abu-L-FDLA 15.2 398.1739 15.2 398.1725 
Ala-D-FDLA 16.6 384.1554 16.6 384.1568 L 
Ala-L-FDLA 14.1 384.1561 14.1 384.1568 
Leu-D-FDLA 21.1 426.2027 21.1 426.2040 L 
Leu-L-FDLA 17.7 426.2038 17.7 426.2038 
N-Me-Thr-D-FDLA 14.3 428.1818 14.3 428.1826 L 
N-Me-Thr-L-FDLA 12.8 428.1831 12.8 428.1828 
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2.7.6 Isolation and Structure Elucidation of Myxochromide S2-diAbu from the 
Heterologous Expression Strain M. xanthus DK1622::pTpS-mchS 
2.7.6.1 Cultivation of M. xanthus DK1622::pTpS-mchS and Isolation of Myxochromide 
S2-diAbu 
The myxochromide S overproducing mutant M. xanthus DK1622::pTpS-mchS was cultivated 
in 4.5 L (3x 1.5 L) CTT medium amended with kanamycin (50 mg/L) including 2% XAD-16 
adsorber resin for 4 days at 30 °C and 180 rpm.15 After 6, 12, 24, 30, 36, 48, 54, 60, 66 and 72 
h, 8.5 mg of L-α-aminobutyric acid were added to the cultures. Cell harvest and extraction of 
the target compound myxochromide S2-diAbu was performed as described for myxochromide 
C3 (see chapter 2.7.3.1) and isolation was achieved using semi-preparative HPLC as described 
for myxochromide S2-Abu (see chapter 2.7.5.1). A total amount of 6.4 mg of pure 
myxochromide S2-diAbu (Rt = 39.7 min) was isolated. 
2.7.6.2 Structure Elucidation of Myxochromide S2-diAbu 
Structure elucidation of myxochromide S2-diAbu  was achieved as described for 
myxochromide C3 (see chapter 2.7.3.2). 1D 1H and 2D 1H-1H COSY, HSQC, HMBC and 
ROESY spectra are shown in Figure S16. Carbon chemical shifts were extracted from 2D 
NMR data. NMR spectroscopic data are listed in Table S10. HR-ESI-MS of myxochromide 
S2-diAbu displayed a quasimolecular ion at m/z 765.45520 [M+H]+ which is 14 Da heavier 
than that of myxochromide S2-Abu consistent with a molecular formula C41H60N6O8 
(765.45454, calculated for C41H61N6O8, Δm/z 0.862 ppm). Analysis of 2D NMR data revealed 
the presence of two Abu spin systems, one of which was replacing the alanine residue in 
myxochromide S2-Abu. Consequently, its final structure was established as depicted in Figure 
S15.  
For the assignment of the absolute configuration of myxochromide S2-diAbu the same 
procedure, hydrolysis and Marfey analysis of the obtained amino acids,29 was applied as 
described for myxochromide C3 (see chapter 2.7.3.2). The chromatograms obtained from 
HPLC-MS analysis are illustrated in Figure S17 and stereochemical assignments are 
illustrated in Table S11. Comparison of the retention times and masses of derivatized amino 
acids and the hydrolyzed lipopeptide revealed that all amino acids of the myxochromide S2-
diAbu peptide core show L-configuration, while glutamine was converted to glutamic acid 
during hydrolysis. This correlates with the major product, myxochromides S,9 as well as with 
myxochromide S2-Abu produced by the same pathway. Despite the presence of an 
epimerization domain in the second module of the assembly line, L-configured amino acids 
are incorporated into this position of the peptide core. 
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Figure S15. Structure of myxochromide S2-diAbu showing selected COSY (bold line) and key HMBC (arrow) 
correlations. 
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Table S10. NMR spectroscopic data of myxochromide S2-diAbu (CD3OD). 
Moiety Position δCa δHb (J in Hz) HMBCc ROESYd 
L-Abu (1) 1 172.8    
 2 59.8 3.50, dd (4.3, 11.4) 1, 3, 4, 5  
 3a 22.3 2.12, m 1, 2, 4  
 3b  2.33, m 2, 4  
 4 11.5 0.96, t (7.5) 2, 3  
L-Abu (2) 5  173.3     
 6  58.0 3.56, dd (4.1, 10.7) 5, 7, 8, 9  
 7a  21.9  1.86, m 5, 6, 8  
 7b  2.03, m 6, 8  
 8  11.4  0.93, t (7.5) 6, 7  
L-Leu 9  176.2     
 10 54.3 4.08, dd (6.1, 8.4) 9, 11, 12, 15  
 11a 40.8 1.47, m 9, 10, 12, 13, 14  
 11b  1.61, m 9, 10, 12, 13, 14  
 12 25.6 1.75, m 10, 11, 13, 14  
 13 22.1 0.97, d (6.5) 11, 12  
 14 22.9 1.01, d (6.5) 11, 12  
N-Me-L-Thr 15 171.4    
 16  59.6 5.57, d (4.2) 1', 15, 17, 24 2', 24 
 17  73.8 5.53, m  18, 19  
 18  16.4 1.25, d (6.3) 16, 17  
 24 35.1 3.26, s 1', 16 2', 18 
L-Gln 19 171.1     
 20  51.8 4.67, dd (3.6, 9.8) 1, 19, 21, 22 21 
 21a  27.6  1.92, m 19, 20, 22, 23  
 21b  2.31, m 20, 22, 23  
 22a 32.0  2.25, m 21, 22  
 22b  2.30, m 21, 22  
 23  178.2     
Side chain 1' 170.7    
 2' 119.7 6.58, d (14.5) 1' 24 
 3' 145.4 7.30, dd (11.4, 14.5) 1', 2', 5'  
 4' 138.6 6.52, m e  
 5' 142.0 6.69, dd (11.2, 14.5) e  
 6'-12' e e e  
 13' 135.5 6.26, m e  
 14' 131.0 6.12, m 13', 16'  
 15' 131.0 5.80, dt (6.7, 15.0) 13', 16', 17'  
 16' 26.8 2.14, m 17'  
 17' 13.8 1.02, t (7.5) 16'  
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d proton showing ROESY correlations to indicated protons.             e overlapped signals. 
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Figure S16 (continued on next page)  
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Figure S16 (continued on next page 
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Figure S16 (continued on next page)  
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Figure S16 (continued on next page)  
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Figure S16.  NMR spectra of myxochromide S2-diAbu.  
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Figure S17. Results of the analysis of the absolute configuration by advanced Marfey’s method.29 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide S2-diAbu derivatized 
with D-FDLA reagent. D: Hydrolyzed myxochromide S2-diAbu derivatized with L-FDLA reagent. E: Standard 
solution of N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized 
with L-FDLA. G: Standard solution of L-aminobutyric acid derivatized with D-FDLA. H: Standard solution of 
L-aminobutyric acid derivatized with L-FDLA. I: Same sample as in C analyzed for the N-Me-L-threonine D-
FDLA derivative and for the L-aminobutyric acid D-FDLA derivative. J: Same sample as in D analyzed for the 
N-Me-L-threonine L-FDLA derivative and for the L-aminobutyric acid L-FDLA derivative. 
Table S11. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of 
the amino acids in myxochromide S2-diAbu. 
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.2 442.1617 14.2 442.1628 L 
Glu-L-FDLA 13.2 442.1619 13.2 442.1619 
Abu-D-FDLA 18.2 398.1740 18.2 398.1723 L 
Abu-L-FDLA 15.2 398.1739 15.2 398.1721 
Abu-D-FDLA 18.2 398.1740 18.2 398.1723 L 
Abu-L-FDLA 15.2 398.1739 15.2 398.1721 
Leu-D-FDLA 21.1 426.2027 21.1 426.2041 L 
Leu-L-FDLA 17.7 426.2038 17.7 426.2037 
N-Me-Thr-D-FDLA 14.3 428.1818 14.3 428.1822 L 
N-Me-Thr-L-FDLA 12.8 428.1831 12.8 428.1825 
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2.7.7 Detailed in silico Analysis of the 16 Analyzed mch Clusters 
2.7.7.1 Sequence Analysis of Catalytic Domains of the Encoded Megasynthetases 
The applied genome mining approach identified 16 (putative) mch clusters encoding seven 
different (sub)types of myxochromide megasynthetases (Figure 2), which could be correlated 
to distinct myxochromide production profiles (Figure S3). The detected myxochromide 
products differ in the number, type, sequence and configuration of the incorporated amino 
acids (Figure 1). In order to explain the observed structural diversity, catalytic domains of the 
involved NRPSs were analyzed in detail to evaluate in silico their substrate specificities 
and/or general activity. Protein sequence alignments of selected PCP, E and C domains were 
performed using the Geneious alignment tool integrated into Geneious software 
version 9.1.245; see Figure S18. In addition, A domain substrate specificities predicted with 
antiSMASH 3.013, as well as the corresponding 8Å signatures and Stachelhaus codes35,36, both 
retrieved with the NRPSpredictor2 analysis tool34, were compared for each set of orthologous 
A domains (Figure S19). In the following, the in silico analysis data are discussed in the light 
of observed structural differences.  
Lack of proline incorporation in myxochromides D and S (S-Abu/S-diAbu) 
Myxochromide D and myxochromide S megasynthetases generate lipopentapeptide products 
lacking the proline residue compared to myxochromides A, B and C. In case of the D-subtype 
2 megasynthetase this result can be explained by the absence of two essential catalytic 
domains (A4-PCP4) due to partial module deletion (see chapter 2.7.7.2). In contrast, the S-type 
and D-subtype 1 megasynthetases still harbor the complete C4-A4-PCP4 domain set. However, 
detailed sequence analysis of PCP4 domains revealed a mutated core motif lacking the highly 
conserved serine residue (Figure S18F). As expected and shown previously for PCP4 from the 
Sa1 S-type pathway,7 this mutation impairs posttranslational activation by 4-
phosphopantetheinyl transferases (PPTases)50. Therefore, PCP4 is not converted into its active 
holo form and not able to bind amino acid substrates or biosynthetic intermediates. 
Consequently, due to the PCP4 “loss of function mutation”, a unique NRPS module-skipping 
process takes place during myxochromides S and D biosynthesis.  
Only L-configured amino acids in myxochromides S (S-Abu/S-diAbu) 
All analyzed myxochromide megasynthetase types harbor an E domain in module 2, which 
correlates with the presence of a D-configured alanine in myxochromides A, B, C and D as 
verified for myxochromide A3 from Mx1,7 B3 from M1,8 C3 from Mv1 and D1 from Se1. 
However, lipopentapeptide products from S-type pathways seem to exclusively contain L-
configured amino acids as shown for myxochromides S1,9 S2-Abu and S2-diAbu from the Sa1 
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megasynthetase. More precisely, they contain a L-leucine residue in the second position of the 
assembled peptide cores, for which a D-configured amino acid would be predicted by 
sequence analysis. According to textbook biochemistry, after chain elongation with L-leucine 
the generated PCP2-bound dipeptidyl intermediate is expected to be epimerized by the action 
of E2 and only D-configured intermediates are expected to be processed by the downstream 
C3 domain. Such C domains, which are D-specific for the peptidyl donor and L-specific for 
the aminoacyl acceptor are described as so-called DCL domains.51 Interestingly, although C3 
domains from S-type megasynthetases feature the sequence motifs reported for DCL domains 
(Figure S18B;33) only L-configured ‘leucine intermediates’ (peptidyl donors) seem to be 
processed. Whether ‘D-leucine intermediates’ are actually provided by S-type MchB subunits 
remains uncertain. Sequence analysis revealed that PCP2 domains show the characteristic core 
motif of specialized PCPE domains (Figure S41A), which are required as partner for E 
domains to be active.32 Sequence comparison of the E2 domains from S-type pathways with 
(certainly functional) E2 domains from A-, B-, C- and D-type megasynthetases revealed a few 
deviations from the reported E domain core motifs (core E1-E7;31; see Figure S18C), which 
probably have no significant effect on activity.52 In case of E domains from Sa1 and Sa2 S-
type producer strains, these also include a mutation of one of the two key active site residues 
described from structural studies on the E domain of tyrocidine synthetase A (His743 and 
Glu882; 53: The glutamate from core motif E4, which is assumed to act as catalytic base 
during the epimerization process, is replaced with an aspartate, which still might fulfill the 
same function. In terms of codon usage adaptation, E domains of S-type producers (Sa1-3) are 
compared to surrounding functional domains not obviously lower adapted (Figure S25B), in 
contrast to the lower CAI values of the inactive ER* domain in mchA (Figure S25A). In 
summary, based on the present in silico data, we speculate that E domains from S-type 
megasynthetases are possibly still active, but might not exert their function on the more bulky 
leucine residue. Alternatively, the downstream C3 domain is not able to process D-configured 
‘leucine intermediates’ (peptidyl donors). This finding illustrates a limitation of sequence-
based structure prediction approaches, which would point to the epimerization and thus 
incorporation of a D-configured amino acid during myxochromide S (S-Abu/S-diAbu) 
biosynthesis.  
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Different amino acid sequence in myxochromide S and aminobutyric acid containing 
derivatives (myxochromides S-Abu/S-diAbu) 
Whereas myxochromides A, B, C and D all harbor D-Ala/L-Leu in the module 2/3 derived 
peptide core positions, myxochromides S consist of L-Leu/L-Ala indicating that substrate 
specificities of modules 2 and 3 have switched. Based on phylogenetic analysis, intragenic A 
domain swapping, e.g. as proposed for the mycosubtilin/iturin A operons,17 could be excluded 
as the molecular reason for this phenomenon (Figure S23A). In silico analysis of residues 
from the A domain substrate binding pocket (8Å signature and Stachelhaus code)35,36 clearly 
illustrate that A2/A3 from S-type pathways deviate from orthologous A domains of other 
myxochromide megasynthetases (Figure S19). Although no distinct substrate specificities 
could be predicted by the applied analysis tools, these point mutations (and probably 
additional mutations in the involved C domains) seem to cause the observed structural 
variation. Additionally identified myxochromide S-Abu and S-diAbu derivatives showed that 
modules 3 and 5 of the S-type megasynthases can also incorporate α-aminobutyric acid 
besides alanine. A similar substrate tolerance, which could not be predicted from the in silico 
specificity analysis, is assumed for A2/A5 from A- or D-type, A2/A6 from B-type and A2 from 
C-type pathways based on the detection of novel myxochromide derivatives in feeding 
experiments with α-aminobutyric acid (Figure S5/Table S3). Substrate specificities of 
threonine, proline and glutamine incorporating modules correlate well with the in silico 
predictions for all myxochromide pathways (Figure S19).  
Overall, the detailed sequence analysis of catalytic NRPS domains (C, A, PCP, E) 
demonstrated how point mutations during natural gene cluster evolution lead to structural 
diversity of the biosynthesis products.  
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Figure S18 (continued on next page) 
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Figure S18. Sequence alignments of selected NRPS condensation (C), epimeriation (E) and peptidyl carrier 
protein (PCP) domains from the 16 analyzed myxochromide megasynthetases. A/B: Two groups of homologous 
C domains according to Figure S23B are compared. The consensus sequences of the seven conserved core motifs 
(core C1-C7) described by Marahiel et al. are illustrated on top of the alignment.31 The lines indicate the 
extended core regions, which were analyzed by Rausch et al. to distinguish different C domain subtypes, 
whereas yellow bars indicate significant specificity determining positions between LCL, DCL and starter C domain 
subtypes (those marked with an asterisk represent the most significant positions)33. A: C domains from module 2 
harbor the described residues typical for LCL domains. B: C domains from modules 3 harbor the described 
residues typical for DCL domains (except in pos. 316 of C3 from Cy1, Hm1, Hm2, Hm3, Se1, Sa1, Sa2 and Sa3). 
C: Sequence alignment of the module 2 E domains. The consensus sequences of the seven conserved core motifs 
(core E1-E7) described by Marahiel et al. are illustrated on top of the alignment.31 Key active site residues 
described from structural analysis of the E domain of tyrocidine synthetase A (His743 and Glu882)53 located in 
core E2 and E4 are highlighted with yellow bars. D-F: Three groups of homologous PCP domains according to 
Figure S23C are compared. D: The characteristic [GGDSI] core motif described for PCP domains associated 
with epimerization (E) domains, so-called PCPE domains,32 can be detected in all PCP domains from modules 2. 
E: The characteristic [GGHSL] core motif described for PCP domains from ordinary NRPS elongation modules, 
so-called PCPC domains,32 can be detected in all PCP domains from modules 3 (and the M1_B_PCP4 homolog). 
F: PCP domains from modules 4 (module 5 for M1_B) can be subdivided into two groups: PCP domains from 
active modules incorporating proline during myxochromide A, B and C biosynthesis harbor an intact [GGHSL] 
core motif. PCP domains from inactive modules from myxochromide D and S megasynthetases show several 
mutations within the core motif (see red box) and lack the highly conserved Ser residue required for 
posttranslational activation (which was biochemically analyzed for Sa1_S_PCP4 in previous studies 7).  
 
  
E 
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Figure S19 (continued on next page) 
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From Pro-incorporating modules: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S19. Substrate specificity analysis of the 94 adenylation (A) domains from the 16 analyzed 
myxochromide megasynthetases. Six groups of homologous A domains according to Figure S23A are compared 
(A-F). The two sequence columns represent the 8Å signature (a set of 34 active site residues as defined by 
Rausch et al.35 and the Stachelhaus code (ten specificity-conferring residues defined by Stachelhaus et al.36, nine 
of which are part of the 8Å signature as labeled with asterisks). The 8Å signature/Stachelhaus code for each A 
domain was retrieved via the NRPSpredictor2 analysis tool.34 Predicted substrate specificities, shown in the four 
columns to the right, were retrieved from reports of the applied antiSMASH 3.0 gene cluster analysis.13 They 
include substrate predictions based on the NRPSPredictor2 method34 (1st column) / Stachelhaus code36 (2nd 
column) / method of Minowa et al.54 (3rd column) / consensus of the three approaches (4th column; “-“ indicates 
no consensus). In some cases, no single substrates but (only) classes/clusters of several amino acids were 
predicted by NRPSPredictor2 as indicated by (a-f): (a) Apolar, aliphatic (Gly, Ala, Val, Leu, Ile, Abu, Iva), (b) 
Aliphatic, branched hydrophobic (Val, Leu, Ile, Abu, Iva), (c) Hydrophobic aliphatic (Ala, Gly, Val, Leu, Ile, 
Abu, Iva Ser, Thr, Hpg, Dhpg, Cys, Pro, Pip), (d) Unpolar aromatic ring (Phe, Trp), (e) Tiny, hydrophilic, 
transition to aliphatic (Gly, Ala), (f) Aliphatic chain with H-bond donor (Asp, Asn, Glu, Gln, Aad).  
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2.7.7.2 Analysis of Recombination Sites 
Comparison of the domain organization of the different myxochromide megasynthetase  
(sub)types suggests that three different recombination events took place in the course of mch 
gene cluster diversification (Figure 2). Based on data from phylogenetic analysis of A-, C- 
and (P)CP domain regions (Figure S23), the three novel cluster types (B-type, C-type and D-
subtype 2) result from duplication or deletion of specific catalytic domain regions. To detect 
possible recombination sites, alignments with selected regions of mchC genes were performed 
using the Geneious alignment tool integrated into Geneious software version 9.1.245 (Figures 
S20-22). In the following, the in silico analysis data are discussed for each of the three novel 
megasynthetase types. 
Myxochromide B megasynthetase (‘module duplication’) 
Phylogenetic analysis revealed that the heptamodular myxochromide B megasynthetase 
contains a duplicate of A3, CP3 and C4 compared to other myxochromide assembly lines 
(Figure S23). This indicates that the B-type mch cluster evolved from an A-type cluster by 
duplication of the A3-CP3-C4 region. Sequence alignments point to a recombination site that is 
located at the 5’ end of the A3/A4 domain regions, more precisely and on protein level located 
between the first α-helix/β-sheet according to structural data of A domain regions from other 
NRPS systems (Figure S20).55,56 This result is in accordance with detected repeat regions in 
the B-type mch cluster dot plot (Figure S1), which additionally indicates mutational activities 
in the N-terminal C domain regions after the duplication event. Furthermore, the analysis of 
the local codon usage adaptation along the catalytic domains shows a highly similar pattern in 
the ‘duplicated’ A3-CP3-C4 assembly line region (with exception of the ultimate N-terminal 
A3 region; Figure S25C, line M1). The ‘duplicated module’ introduces a second L-leucine 
residue into the myxochromide B heptapeptide core.                   
Myxochromide C megasynthetase (‘module deletion’) 
Phylogenetic analysis revealed that the pentamodular myxochromide C megasynthetase lacks 
A5, CP5 and C6 compared to other myxochromide assembly lines (Figure S23). This indicates 
that the C-type mch cluster evolved from the A-type cluster by deletion of the A5-CP5-C6 
region. Sequence alignments point to a recombination site that is located at the 3’ end of the 
C5/C6 domain regions, more precisely and on protein level between the last β-sheet/α-helix 
according to structural data of C domain regions from other NRPS systems (Figure S21).55,57 
Deletion of the A5-CP5-C6 assembly line region (compared to the A-type megasynthetase) 
causes the lack of L-alanine in myxochromide C lipopentapeptide cores compared to 
myxochromides A. 
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Myxochromide D-subtype 2 megasynthetase (‘partial module deletion’) 
Phylogenetic analysis revealed that the myxochromide D-subtype 2 megasynthetase lacks A4 
and CP4 compared to other myxochromide assembly lines (Figure S23). This indicates that 
the D-subtype 2 mch cluster evolved from the D-subtype 1 cluster by deletion of the A4-CP4 
region. Sequence alignments point to a recombination site that is located around the C4-
A4/CP4-C5 (linker) regions (Figure S22).55,57 Deletion of the A4-CP4 causes the lack of L-
proline in the myxochromide D lipopentapeptide products compared to myxochromides A. 
Interestingly, we see also less codon usage adaptation in this inactive A4-CP4 region in all 
Cystobacterineae strains compared with the following  A5-CP5 or preceding A3-CP3 region 
(see Figure S25C). 
In summary, the three discussed recombination events (followed by additional mutational 
activities) established novel and in all cases functional myxochromide assembly lines 
directing the production of altered myxochromide peptide cores. The observed ‘natural’ 
assembly line diversification results from duplication/deletion of ‘A-CP(-C) units’ instead of 
dedicated ‘C-A-CP’ modules (for further discussion see chapter 2.7.7.4).  
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Figure S20. Module duplication resulting in a B-type NRPS assembly line. A: Illustration of the identified 
recombination site at regions encoding the A3/A4 N-termini of the A-type pathway. B: Translation 
alignment of the regions encoding the A3/A4 N-termini (first 147/144 nt, 49/48 aa) from A-type pathways 
from strains Mf1, Mx1, Mx2, Mx3 and Mx4 with the respective region of A3/A4/A5 from the B-type 
pathway from strain M1. The identified recombination site is indicated with a black line. C: Protein 
alignment of the regions analyzed in B with the respective regions from the surfactin synthetase subunit 
SrfA-C (PDB:2VSQ,28) and the gramicidin S synthetase subunit GrsA (PDB:1AMU,29). According to this 
comparison, the ‘fusion site’ after the module duplication event resulting in a B-type pathway is located 
between the first A domain α-helix and β-sheet. 
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Figure S21. Module deletion resulting in a C-type NRPS assembly line. A: Illustration of the identified 
recombination site at regions encoding the C5/C6 C-termini of the A-type pathway. B: Translation 
alignment of the regions encoding the C5/C6 C-termini (last 147 nt / 49 aa) from A-type pathways from 
strains Mf1, Mx1, Mx2, Mx3 and Mx4 with the respective region of C5 from C-type pathways from 
strains Mh1 and Mv1. The identified recombination site is indicated with a black line. C: Protein 
alignment of the regions analyzed in B with the respective regions of the tyrocidine synthetase subunit 
TycC (PDB:2JGP,30) and the surfactin synthetase subunit SrfA-C (PDB:2VSQ,28). According to this 
comparison, the ‘fusion site’ after the module deletion event resulting in C-type pathways is located 
between the last C domain β-sheet and α-helix. 
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Figure S22. Partial module deletion resulting in a D-type (subtype 2) NRPS assembly line. A: Illustration 
of the identified recombination site between the C4-A4 linker and the CP4-C5-linker/C5 N-terminus 
regions of the D-type (subtype 1) pathway. B: Translation alignment of the C4(C-term)/linker/ C5(N-term) 
region from the D-type (subtype 2) pathway from strain Cy1 with regions encoding the C4 C-term (last 48 
nt / 16 aa) plus part of the downstream C4-A4 linker (first 57 nt / 19 aa) and regions encoding part of the 
CP4/C5 linker (last 24 nt / 8 aa) plus C5 N-term (first 48 nt / 16 aa) from D-type (subtype 1) pathways from 
strains Hm1, Hm2 and Hm3. The identified recombination region is indicated with a black line. C: Two 
protein alignments (boxed in blue and red) of the regions analyzed in B (containing the entire C4-A4 and 
CP4-C5 linker sequences) with the respective regions from the surfactin synthetase subunit SrfA-C 
(PDB:2VSQ,28) and the tyrocidine synthetase subunit TycC (PDB:2JGP,30). According to this alignment 
the C4/C5 domain interface in the D-type (subtype 2) pathway consists of the first part of the C4-A4 linker 
region. 
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2.7.7.3 Phylogenetic Analysis 
Phylogenetic reconstructions were mainly performed on the basis of coding DNA sequences. 
The sequences were aligned using the GUIDANCE2Server38 applying the MAFFT algorithm 
with the codon option. Columns with a GUIDANCE score below 0.93 were removed from the 
alignments. Reconstructions were done by the distance-based neighbor-joining method using 
the modules “dnadist” and “neighbor” of the PHYLIP package37 and applying the F84 model 
of nucleotide substitution. The reliability of tree topologies was evaluated by means of the 
bootstrap method based on 1000 pseudo-replicates using the module “seqboot”. Majority 
consensus trees were calculated using the “consense” module. For the megasynthetase 
subunits (MchA, MchB and MchC), phylogenetic reconstructions were also performed based 
on amino acid sequences. The sequences were aligned using ClustalX,39 and manually edited 
to remove areas that could not be aligned with confidence. The phylogenetic reconstruction 
was conducted using the modules “protdist” and “neighbor” of the PHYLIP package applying 
the JTT model of amino acid substitution and a gamma distribution to represent among-site 
rate heterogeneity. Reliability of branching topologies was evaluated by the bootstrap method 
based on 1000 pseudo-replicates of the alignment. To reconstruct the phylogeny of the 
complete clusters, the nucleotide sequences of mchA, mchB and mchC were concatenated and 
aligned using the GUIDANCE2Server with the same settings described above. The neighbor-
joining tree was calculated based on the F84 model of nucleotide substitution and its reliablity 
tested by bootstrapping 1000 pseudo-replicates. For the reconstruction of the phylogeny of the 
myxobacterial producer strains, the nucleotide sequences of the 16S small ribosomal subunit 
rRNA genes were concatenated with the nucleotide sequences of 15 selected genes encoding 
highly conserved proteins, a subset of 24 genes previously suggested for use in bacterial 
taxonomy.58 The 15 genes were small ribosomal subunit proteins S3, S5, S7, S9, S10, S12 
and S19, large ribosomal subunit proteins L2, L4, L6, L11, L14 and L16, elongation factor 4 
and phenylalanine-tRNA ligase subunit alpha. The subset was selected on uniqueness and 
completeness of all 16 orthologs, sequence assembly without ambiguous or missing 
nucleotides and gap-free alignments of identical length. The sequences (supplemental 
Microsoft Excel file “Supplemental_file_16_gene_sets.xlsx”) were aligned using ClustalX. 
Phylogenetic reconstruction was conducted using the modules “dnadist” and “neighbor” and 
was based on the F84 model of nucleotide substitution. Tree reliability was again tested by the 
bootstrap method with 1000 pseudo-replicates. A comparison of strain and cluster 
phylogenies is illustrated and discussed in the main text (Figure 3). 
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Phylogeny of NRPS domains (A, C and PCP) 
The phylogenetic tree of adenylation (A) domains (see Figure S23A) shows a clear separation 
of the domains according to the module they belong to. The phylogenetic relationships within 
each main branch correspond to the strain phylogeny of the producers. Such a pattern is 
typical for orthologous genes, which share the same ancestor and were diversified by 
speciation or separation into strains. The only exceptions are sequences from Stigmatella 
erecta Pde77 (Se1), which have a tendency not to cluster together with the other Stigmatella 
strains Sa1, Sa2 and Sa3 but instead with the Hyalangium minutum strains Hm1, Hm2 and 
Hm3 and the unclassified strain Cy1. However, this phylogenetic pattern does not exclude the 
possibility of independent heterologous integration events by horizontal gene transfer (see 
chapter 2.7.7.4 and main text). The A domain phylogeny also revealed that the A domains of 
NRPS modules 2 and 3 from the S-type megasynthetases fall together on the same branch 
with the respective counterparts of the other megasynthetases (see the green and orange box 
in Figure S23A). Therefore, all A domains of the second NRPS module as well as all A 
domains of the third NRPS module appear to be orthologs and thus the change in substrate 
specificity of the A domains belonging to S-type megasynthetases is probably the result of 
mutations in the active center (see chapter 2.7.7.1). Furthermore, the A domain phylogeny 
shows that the heptamodular B-type megasynthetase harbors a ‘duplicate’ of A3 (A3/A4; see 
the orange box in Figure S23A). A similar observation was made in the phylogeny of peptidyl 
carrier protein (PCP) domains, which revealed an additional copy of PCP3 (PCP3/PCP4; see 
the orange box in Figure S23C). However, the evolutionary relationships are different in the 
case of condensation (C) domains. Here, the phylogeny revealed that the B-type 
megasynthetase contains a ‘duplicate’ of C4 (C4/C5; see the blue box in Figure S23B). These 
data suggest that the additional module from the heptamodular B-type assembly line 
originated from an ‘A3-PCP3-C4’ instead of a ‘C3-A3-PCP3’ duplication event. Corresponding 
recombination sites were identified (see chapter 2.7.7.2).  
Phylogeny of NRPS subunits (MchA, MchB and MchC) 
The phylogenies of the whole megasynthetase subunits MchA, MchB and MchC are shown in 
Figure S24. The tree topologies were the same for reconstructions based on nucleotide or 
amino acid sequences. For each type of subunit, the phylogenetic relationships follow the 
strain phylogenies. However, as in the case of single domain phylogenies, there is always one 
exception: The subunits from the Stigmatella erecta strain (Se1) mainly cluster together with 
Hyalangium minutum strains but not with the other Stigmatella sp. strains, which could be 
explained by a horizontal gene transfer of the mch cluster to the Se1 strain. 
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Figure S23. Phylogeny of NRPS domains from the 16 analyzed myxochromide megasynthetases based on DNA 
sequences. A: Adenylation (A) domains. B: Condensation (C) domains. C: Peptidyl carrier protein (PCP) 
domains. 
C 
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Figure S24. Phylogeny of subunits of the 16 analyzed NRPS megasynthetases based on DNA and protein 
sequences. A: PKS subunits mchA (DNA) and MchA (protein). B: NRPS subunits mchB (DNA) and MchB 
(protein). C: NRPS subunits mchC (DNA) and MchC (protein). 
C 
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2.7.7.4 CAI Analysis 
Adaptation of the specific synonymous codon usage of CDS to their corresponding genome’s 
codon usage of highly expressed (hxp) genes correlates with the expression level of the CDS, 
which is usually robustly measured by calculating the codon adaptation index (CAI).59 
Additionally, the codon usage of horizontally acquired gene clusters is likely to differ from 
the new host genome at the time of gene transfer. Consequently, the CAI value of such gene 
clusters is expected to be subsequently adjusted over evolutionary time scales. “Old” and 
conserved genes have therefore generally higher codon adaptation compared with newly 
acquired and “young” genes.23,60,61 However, mutational hotspots in rapidly evolving  genes, 
e.g. after a recent genome rearrangement or due to new evolutionary pressures, may initially 
change the codon adaptation to lower values due to higher pressure for selection of the 
encoded amino acid sequence. After this process yields mutational equilibrium, codon 
optimised genes may re-evolve again via silent mutations.62,63 We therefore analyzed global 
and local codon usage adaptation to gain additional insights into cluster evolution.   
Selection of hxp2 gene sets 
We previously selected a modified hxp gene set (hxp2) for the Myxococcales Mx1 
(Myxococcus xanthus DK1622), Sorangium cellulosum So ce56 and Chondromyces crocatus 
Cm c5,64 based on estimations of translation efficiency in E. coli and identification of 
functional orthologs and paralogs.65 We used the established hxp2 protein set of Mx1 to 
search with locally installed NCBI BLAST66 for respective homologous and paralogous 
protein sequences from all 16 strains investigated here. We manually reviewed the list, 
calculated intermediary CAI values, as described below, from the initial list members and 
removed paralogs having low codon adaptation manually, which may represent protein family 
members expressed alternatively during non-optimal growth conditions with changed codon 
usage or generally lowly expressed family members. The selected hxp2 gene sets are provided 
in the Microsoft Excel document “Supplemental_file_hxp2_gene_sets.xlsx”. For the 16 
strains, following numbers of hxp2 proteins were selected: Mx1 (353)64, Mx2 (346), Mx3 
(353), Mx4 (358), Mf1 (369), Mv1 (356), Mh1 (374), M1 (364), Sa1 (377), Sa2 (378), Sa3 
(367), Se1 (391), Cy1 (405), Hm1 (378), Hm2 (385), Hm3 (387). Within the header line of 
the provided FASTA files, the categories of functionally related highly-expressed protein 
subsets are annotated: hxp2 = A (ATP synthase and adenylate kinases), C (chaperones), D 
(DNA-related), E (export-related), F (fatty acid metabolism), G (glycolysis and basic 
carbohydrate metabolism), H (respiration), K (citrate cycle and related carboxylases), N 
(nitrogen metabolism), O (major outer membrane proteins), P (pentose phosphate cycle), R 
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(transcription), S (detoxification), T (translation). Additionally the CAI value calculated with 
the codon usage table of the respective strain-specific hxp2 sequences is indicated by the tag 
“cai_hxp2”. 
Calculation of codon adaptation index (CAI) values 
The codon usage tables for the selected set of hxp2 cds sequences were calculated by the 
EMBOSS program cusp41 after removing FASTA headers and sequence line breaks by a Perl 
pipeline program. The respective sequence-specific CAI was calculated by a Perl program as 
described by Sharp and Li.59 The CAI was calculated for the myxochromide cluster CDS 
sequences. A color scale blue-yellow-red (CAI 0.48 to 0.77) was used to illustrate the level of 
adaptation in codon usage (see Figure 3 and Table S12). The color scale and the respectively 
colored CDS symbols of Figure 3 and Table S12 were generated with R.67 
Local CAI values along the CDS of mchA, mchB and mchC were calculated for overlapping 
CDS regions of 101 codons using a Perl program. For each codon, the local CAI represents 
the CAI value of a window of 101 codons centered at the actual codon. At the start and the 
end of the CDS, the window size was reduced for the missing codons on the respective 5’- or 
3’-sides. The local CAI values were visualized as plotted color-shaded vertical lines along the 
three CDS for all 16 strains, where the codons were aligned to orthologous positions based on 
protein sequence alignments performed with ClustalX.39 The alignment was additionally 
corrected according to the identified recombination sites for deletions/insertions within the 
MchC protein sequences (see Figures S20-22). The color scale was constructed for the CAI 
range of 0.2 to 0.91 (710 steps) as follows: 0.2-0.4, black to blue (201 colors); 0.401-0.6, blue 
to yellow (200 colors), 0.601-0.8, yellow to red (200 colors), 0.801-0.910 red to dark-red (110 
colors). The respective Figures S25A (mchA), S25B (mchB) and S25C (mchC) were plotted 
using R.67  
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Table S12. Codon adaptation of the mch CDS of the myxochromide gene clusters to the hxp2 gene sets of their 
host genomes. The three disks represent the megasynthetase CDS mchA, mchB and mchC and are colored for 
their respective CAI value according to the displayed color scale. The disks were used accordingly in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cluster mchA mchB mchC mchD 
Mx1_A 0.690 0.684 0.618 0.748 
Mx2_A 0.673 0.684 0.610 0.772 
Mx3_A 0.685 0.682 0.614 0.729 
Mx4_A 0.713 0.714 0.643 0.804 
Mf1_A 0.746 0.738 0.672 0.799 
Mv1_C 0.760 0.746 0.631 0.777 
Mh1_C 0.719 0.702 0.632 0.825 
M1_B 0.714 0.677 0.570 0.767 
Sa1_S 0.566 0.586 0.597 0.606 
Sa2_S 0.531 0.517 0.535 0.608 
Sa3_S 0.584 0.579 0.568 0.618 
Se1_D 0.490 0.516 0.484 0.383 
Cy1_D 0.617 0.658 0.644 0.561 
Hm1_D 0.588 0.630 0.621 0.514 
Hm2_D 0.572 0.636 0.624 0.487 
Hm3_D 0.590 0.632 0.620 0.502 
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Figure S25: Local codon adaption index (CAI) values for a shifting window of 101 codons along the mchA 
(A), mchB (B) and mchC (C) CDS sequences of the 16 analyzed myxochromide pathways. Colors represent 
CAI values according to the shown color scale. 
C 
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Extended discussion of the CAI analysis 
The adaptation of codon usage generally follows sequence phylogeny (Figure 3) and is 
different for the six separate genomic mch cluster locations A-F (see Figure S2), which 
represent independent cluster integration events by horizontal gene transfer. As we have no 
contradicting data, we assume that the expression levels and biological function of the 
myxochromide gene clusters within their host strains are comparable. Therefore, our data 
suggest that the clusters with higher codon usage adaptation represent more ancient versions 
regarding genomic residence time compared with lower adaptation for more recently acquired 
clusters. A combination of horizontal gene transfer events and inheritance by strain 
divergence would agree with the general complex pattern of megasynthetase evolution 
observed throughout all kingdoms of life.21,68 
Cluster history in Myxococcaceae 
All Myxococcaceae gene clusters are located in the same genomic integration site (Locus A; 
Figure S2) and show higher levels of codon usage adaptation compared with the 
Cystobacteraceae strains, especially for the structurally conserved mchA and mchB CDS. The 
highest adaptation is found in the two clusters of types A and C of the Mf1 and Mv1 strains, 
respectively. Myxochromide clusters may therefore have been acquired initially by Mf1 in the 
past, as indicated by the highest codon usage, the most common and intact cluster structure 
and a 5’-UTR region in front of the mchA CDS without deletions of the upstream neighboring 
AraC transcription factor (gene 5 in Figure S2). Next, the C-type cluster of Mv1 may have 
evolved, as suggested by its close association to the Mf1 cluster in phylogeny, harboring also 
an intact AraC transcription factor and having an exceptionally high CAI value for mchA and 
mchB as well. The deletion in mchC found in Mv1 leads to a reduced CAI because of loss of 
the highly adapted A5-PCP5-C6 region. These two prototype-clusters were subsequently 
inherited by or distributed to other Myxococcaceae by more recent homologous 
recombination events. They therefore do not show the same level of codon adaptation as 
observed in the primordial cluster versions, which have resided in their genomes for the 
longest time periods. M1 acquired or evolved the B-type cluster presumably even more 
recently, where the module duplication in mchC triggered mutational events reducing codon 
usage adaptation of mchC (see Figure S25C, line M1). Additionally, the mchC CDS CAI 
value was reduced also by duplication of the exceptionally low adapted A3-PCP3-A4 region of 
M1, which also shows generally lower adaptation in all strains. With the exception of Mx4 all 
other cluster integration sites in Myxoccoccaceae lost the upstream AraC transcription factor 
gene by a deletion event, which may have occurred during a more recent homologous 
recombination event, corroborating the proposed sequence of events. 
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Cluster history in Cystobacteraceae 
In contrast to the Myxococcaceae strains, the Cystobacteraceae strains show 5 independent 
genomic integration sites (Figure S2, Locus B-F), which may correspond to 5 instances of 
horizontal gene transfer at different time points. Consequently, for all 5 types of integration 
sites, different levels of adaptations are found. These are generally much lower for the 
conserved mchA and mchB CDS (Figure S25A,B). If the interpretation of cluster CAI values 
as genomic residence time indicator is valid, the sequence of integration events was 1) 
introduction of the D-type cluster into Cy1 locus B, 2) followed by independent integration of 
D-type clusters in Hm1, Hm2 and Hm3 in locus C, 3) acquirement of S-type clusters by Sa1 
and Sa3 in locus E, 4) integration of S-type cluster in Sa2 in locus F and most recently 
transfer of the D-type cluster to Se1 to locus D. 
Inactive regions show lower CAI values 
Inactive domains may have released evolutionary pressure to optimize codon usage and may 
therefore show reduced CAI values. The inactive ER* domains in the MchA  proteins show 
reduced CAI throughout all 16 strains (Figure S25A). Additionally, the inactive A4-PCP4 
region in the MchC proteins within the Stigmatella strains Sa1, Sa2, Sa3 and Se1 show 
reduced CAI levels when compared to the neighboring A3-PCP3 and A5-PCP5 regions (Figure 
S25C). Similar observations are made for the Hyalangium strains, Hm1, Hm2 and Hm3, 
whereas in Cy1 this region was even deleted. Generally, codon usage adaptation in the 
regions of modules 3 and 4 (A3-PCP3-C4-A4-PCP4) of mchC is found at relatively low levels 
for all strains indicating these as presumably younger regions with ongoing mutational 
changes. This suggestion is corroborated by the structural changes observed in that region 
(duplication of the A3-PCP3-C4 region in M1, deletion of the A4-PCP4 region in Cy1, change 
of the specificity of A3 domain in S-type clusters).  
Duplication event in M1 strain 
The local CAI values along the mchC CDS of strain M1 (Figure S25C, line M1) show that the 
duplicated region A3-PCP3-C4 most likely originated from the M1 A4-PCP4-C5 region 
(orthologous to A3-PCP3-C4 in other strains), which is also suggested by domain phylogeny 
(as described above) and recombination site analysis (as described above). The local CAI 
value of the N-terminal regions of the duplicated A3 domain in M1, however, has 
substantially changed when compared with its template region. Additionally, several regions 
along the CDS show lower adaptation compared with all other Myxococcaceae strains. This 
finding could indicate ongoing adaptation to the new heptapeptide assembly regime due to co-
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evolutionary changes not only in the duplicated domains C4 and C5, but also at the N-termini 
of the subsequent domains A5, C6, C7 and A7. 
Relation to general megasynthetase cluster evolution 
The observations described above are in line with a recent discussion of megasynthetase gene 
clusters evolution throughout all kingdoms of life,68 which summarizes that gene clusters 
evolve by combined horizontal and vertical gene transfer and are formed by a series of gene 
duplications, insertions/deletions, recombinations, mutation and reshuffling events. These 
may follow common rules, specific for co-evolving sets of clusters or sub-clusters, which mix 
by recombination events and evolve independently.21 E.g., for myxochromide clusters the 
mchA-mchB CDS and the mchC CDS may constitute two such independently evolving sub-
clusters, where mchC may be formed by family specific recombination rules, e.g. 
recombinations occur in the three known cases always near the regions encoding C-A domain 
interfaces. As in the case of polyketide synthase encoding gene clusters in Streptomyces 
avermitilis,69 natural biorecombinatorics may be confined to regions that account for the 
structural diversity of the products, as it is the case here for mchC A-domain-driven 
recombinations. 
2.7.8 Fruiting Body Formation and Swarm Expansion Assays with M. xanthus DK1622 
and Myxochromide-Deficient as well as Overproducing Mutants 
In order to obtain first insights into a possible biological function of myxochromides for their 
natural producers, fruiting body assays and swarm expansion assays with the myxobacterial 
model strain M. xanthus DK1622 and mutants thereof were performed. In addition to M. 
xanthus DK1622 wild type (WT, characterized as myxochromide A producer)7, a 
myxochromide A-deficient mutant M. xanthus DK1622::pMch22a7, as well as two 
myxochromide overproducing mutants were analyzed: M. xanthus DK1622::pMch70a 
(Wenzel et al., unpublished) and M. xanthus DK1622::pTps-mchS.15 M. xanthus 
DK1622::pMch70a was generated by insertion of the constitutive Tn5 promoter upstream the 
myxochromide A biosynthetic gene cluster, which led to an about 10-fold increase of 
myxochromide A production compared to M. xanthus DK1622 WT. M. xanthus 
DK1622::pTpS-mchS was generated via transposon mediated integration of the Sa1 
myxochromide S biosynthetic gene cluster under control of the constitutive Tn5 promoter and 
produces myxochromides A at the same level as the wild type plus myxochromides S/S-
Abu/S-diAbu at about 50-fold higher production yields.  
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Fruiting body formation assays 
Comparative fruiting body assays were performed as follows: Routinely grown liquid cultures 
were washed twice with MC7 buffer (0.5 M Mops buffer, 50 mM CaCl2 ∙ 2 H2O, pH 7.0) and 
5∙109 cells were spotted onto ‘agar wells’ of a 24-well microtiter plate. Each well contained 
600 µl TPM agar (Tris-HCl [pH 8.0] 10 mM, K2HPO4/KH2PO4 buffer [pH 7.6] 1mM, MgSO4 
∙ 7 H2O 8 mM, pH adjusted to 7.6). Microscopic images were recorded after 6, 24, 48 and 72 
h incubation at 30 °C by using a Zeiss binocular microscope with 10× magnification (see 
Figure S26). In this assay, no significant difference in fruiting body development was 
observed between the M. xanthus WT and the myxochromide deficient mutant strain 
indicating that myxochromides are not essential for fruiting body formation. However, both 
myxochromide overproducers showed a clear deviation from the standard development 
process as formation of fruiting bodies was significantly delayed and the total number of 
fruiting bodies was severely reduced relative to the wild type strain. This phenotype seems to 
be more pronounced in M. xanthus DK1622::pTpS-mchS, which produces the highest 
amounts of myxochromides. High (and constitutive) myxochromide production therefore 
seems to have a negative impact on fruiting body formation. This finding correlates with a 
recent study on enhancer binding proteins, in which a mutant with altered secondary 
metabolite profile (increased myxochromide production, decreased DKxanthene and 
myxovirescin production) showed similar effects on fruiting body development (M. xanthus 
DK1622hsfA::kan)26. The observed negative effects on fruiting body formation due to 
myxochromide overproduction could e.g. be explained by myxochromide surfactant 
properties or myxochromide-mediated increased swarming activity and cell movement, which 
might hamper cell aggregation.70       
Swarm expansion assays 
Comparative swarm expansion assays were performed in triplicates on 1% CTT agar at 21 °C 
as described by Kaiser et al.,42 and were monitored for 2 weeks. The daily increase in swarm 
expansion and selected images are illustrated in Figure S27. In this assay, no significant 
difference in swarm expansion between the four analyzed strains was observed. After seven 
days slightly higher colony diameters were detected in myxochromide overproducing strains, 
but the myxochromide-deficient mutant also showed marginal higher swarm expansion 
compared to WT. Based on this assay there is no clear indication that myxochromides 
contribute to swarming motility as described e.g. for lipopeptides from Pseudomonas sp.  and 
B. subtilis.71,72  
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Figure S26. Microscopic images of fruiting body developement of different M. xanthus strains on TPM agar at 
6, 24, 48 and 72 h after inoculation. A: M. xanthus DK1622 wild type (WT). B: M. xanthus DK1622::pMch22a 
(myxochromide deficient). C: M. xanthus DK1622::pMch70a (~10-fold higher myxochromide production than 
WT). D: M. xanthus DK1622::pTpS-mchS (~50-fold higher myxochromide production than WT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S27. Photographic images of swarming colonies of different M. xanthus strains on 1 % CTT agar at 3, 9 
and 14 d after inoculation and daily increase in diameter of swarms. A: M. xanthus DK1622 wild type (WT). 
B: M. xanthus DK1622::pMch22a (myxochromide deficient). C: M. xanthus DK1622::pMch70a (~10-fold 
higher myxochromide production than WT. D: M. xanthus DK1622::pTpS-mchS (~50-fold higher 
myxochromide production than WT). 
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3 Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis 
3.1 Abstract 
The intriguing structural diversity of the myxochromide lipopeptide family originates from 
evolutionary diversification of the underlying myxochromide megasynthetases, making these 
pathways a promising model system to further increase the chemical diversity of lipopeptides 
in myxobacteria using biocombinatorial approaches. In this study, the redesign and assembly 
of artificial A-, B-, C-, D- and S-type myxochromide biosynthetic gene clusters (mch clusters) 
and hybrid combinations thereof based on synthetic gene fragments is described. A versatile 
assembly strategy was established which relies on type IIS restriction enzymes and allows for 
directed exchanges of gene segments coding for PKS/NRPS subunits, modules or even single 
domains. Heterologous expression of five artificial hybrid mch clusters in Myxococcus 
xanthus and secondary metabolite profile analysis of mutant strains revealed the production of 
engineered hybrid myxochromides, which were subsequently isolated and structurally 
characterized. Stereochemical analysis of hybrid myxochromides also contributed to the 
identification of the relevant determinant controlling the stereospecificity of the processed 
lipopeptide intermediates. Finally, mutated PCP domains based on the inactive module 4 of 
the native myxochromide S pathway were engineered in every module of the artificial A-type 
mch pathway to evaluate if ‘module-skipping’ scenarios can be induced at different positions 
of the assembly line. The presented work thus reflects the potential of synthetic DNA 
platforms not only for pathway assembly and engineering but also for the elucidation of 
biosynthetic mechanisms. 
 
3.2 Introduction 
The generation of novel secondary metabolite analogues via genetic alterations of the 
corresponding biosynthetic pathways continues to be a promising tool in natural products 
research to increase the chemical diversity of a certain compound class,1,2 as chemical 
synthesis remains rather challenging or even impossible due to the impressive structural 
complexity of most natural products. However, rational engineering of polyketide synthase 
(PKS),3 and nonribosomal peptide synthetase (NRPS) directed biosynthesis,4 is often limited 
by a lack of detailed structural information of the involved megasynthetases, e.g. including 
the flexible linker regions between individual assembly line subunits, modules and domains,5,6 
that are important for their functional and dynamical interplay within the large 
megasynthetase complexes. In addition, several experimental hurdles further impede the 
success of combinatorial biosynthesis approaches: (1) cultivation and genetic manipulation of 
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native producer strains is often laborious or in some cases not feasible at all, (2) fermentation 
yields in the native producers are too low, and (3) the large size of PKS/NRPS biosynthetic 
gene clusters, which can span from 10 to more than 100 kb,7 makes direct cloning from 
natural sources, rational engineering and subsequent implantation into suitable host genomes 
difficult. Taken this into account, it is not surprising that only a few examples have been 
extensively described demonstrating the efficient expression of rationally altered (and closely 
related) PKS/NRPS biosynthetic gene clusters and the production of the corresponding 
‘unnatural’ secondary metabolite derivatives,8–11 although the combinatorial reprogramming 
of PKS/NRPS systems already started more than 30 years ago.12 Recent advances in the field 
of synthetic biology have the potential to address these challenges to generate customized 
production platforms for complex natural products.13–16 However, gaining detailed knowledge 
about relevant factors for the redesign of biosynthetic gene clusters for improved expression 
of natural product assembly lines is highly desirable as current gene optimization strategies 
were not as successful as for standard genes. The BMBF funded project ‘SynBioDesign’ 
basically aimed at understanding the principles of redesigning artificial biosynthetic pathways 
for heterologous expression in a selected host organism based on synthetic DNA by 
combining and implementing comprehensive analyses on the genome, transcriptome, 
proteome and metabolome levels of various gene cluster variants in order to experimentally 
verify, understand and further improve the in silico sequence design. A critical step towards 
this ambitious task is the development of a flexible and efficient assembly strategy for 
complex biosynthetic gene clusters to generate numerous variants within a relatively short 
time frame. This would also allow any desired genetic modification of the gene clusters in 
order to use this platform to further expand the chemical diversity of the produced compound 
class by combinatorial approaches. To address these demands, we aimed at generating 
flexible synthetic DNA platforms based on the well-studied mch lipopeptide pathways, as 
they are encoded in one single operon comprising medium sized four-gene clusters (~ 30 kb). 
Furthermore, different myxochromides have been heterologously expressed at high yields and 
did not show any toxicity to their host. In addition, engineering of the precursor supply is not 
necessary as myxochromides contain only proteinogenic amino acids. Detailed sequence 
analyses of 16 PKS/NRPS mch clusters from various myxobacterial species producing this 
versatile class of lipopeptides revealed a high degree of sequence homology on the nucleotide 
and protein level.17 Moreover, studies on the strain and mch cluster phylogeny revealed the 
close evolutionary relationship between the different mch cluster types, which exhibit 
different product spectra, thereby qualifying these pathways as ideal model systems for 
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combinatorial studies in the ‘SynBioDesign’ project. Thus, we intended to further increase the 
structural diversity of the myxochromide lipopeptide family and to study the effects of 
artificial gene combinations on myxochromide biosynthesis by establishing flexible synthetic 
DNA platforms for the different mch cluster types (A-, B-, C-, D- and S-type).   
 
3.3 Results and Discussion 
3.3.1 Sequence Requirements for the Design of Artificial Myxochromide Pathways 
To assemble and functionally express an artificial mch pathway in a myxobacterial 
heterologous host, several key requirements for the sequence design need to be considered.  
 
 
 
 
 
 
 
 
 
 
Figure 1. Sequence requirements considered for the generation of synthetic mch expression platforms. A: Gene 
organization of the native myxochromide A biosynthetic gene cluster from M. xanthus DK1622. B: De novo 
redesign and DNA synthesis of 11 building blocks for pathway assembly. C: In vitro reconstitution of the 
artificial A-type pathway. D: Integration into the host genome and functional expression of the artificial A-type 
pathway. 
 
General sequence requirements encompass the demands on DNA synthesis (1). As the size of 
a biosynthetic gene cluster is far too large to be synthesized in one piece via standard gene 
synthesis approaches, it has to be subdivided into smaller DNA segments. Constructional 
sequence requirements consider the specific demands of the envisaged assembly strategy to 
construct the desired expression constructs (2). The assembly and downstream modification 
of entire mch cluster constructs particularly required the choice and engineering of unique 
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restriction sites (R-sites) between the defined synthetic DNA fragments and the elimination of 
appropriate R-sites along the whole mch cluster sequences as well as the introduction of a 
homology region for the specific integration of the artificial pathways into the genome of the 
heterologous host. Functional sequence requirements are defined by the host strain selected 
for heterologous expression and comprise the choice of suitable genetic elements to achieve 
gene expression such as promoter and terminator sequences as well as elements to ensure 
construct propagation and stability (3). An overview on the applied strategy is exemplified for 
the A-type mch pathway from M. xanthus DK1622 (Figure 1).18 
 
3.3.2 Functional Sequence Design for Heterologous Expression in M. xanthus 
According to the current state of research, Myxococcus xanthus seems to be the most 
promising heterologous host for the expression of myxobacterial natural product pathways 
and numerous studies have been previsouly reported, which support this assumption.19 Since 
the A- and S-type mch pathways were already known to be well expressed in M. xanthus 
DK1622,18,20 this myxobacterial strain was selected as a heterologous host for functional 
expression of the artificial mch cluster constructs. A myxochromide A-deficient mutant of M. 
xanthus DK1622 (M. xanthus DK1622 ΔmchA-tet, Wenzel et al., unpublished), in which the 
native A-type mch cluster was replaced by an (oxy-)tetracycline resistance cassette, was 
already available in the group as heterologous production strain. 
To deliver and functionally express the synthetic mch pathways in M. xanthus DK1622 
ΔmchA-tet, the expression vector pSynbio2 was designed and manufactured by DNA 
synthesis (Supporting Information Figure S2). The minimal vector backbone includes a p15A 
low-copy origin of replication to ensure stability of the large mch cluster constructs during 
propagation in E.coli, an antibiotic resistance gene (kanamycin, kanR) suitable for selection of 
M. xanthus DK1622 ΔmchA-tet transformants, an origin of transfer (oriT), to allow for 
conjugation as an alternative strategy to transformation via electroporation, and a multiple 
cloning site (MCS), which is composed of all the R-sites needed for pathway assembly and 
engineering (Supporting Information Table S2). In addition, unique R-sites were introduced 
between the genetic elements (PacI, PmeI, SwaI) to allow for the exchange or addition of 
vector backbone elements by conventional cloning techniques, e.g. to investigate other 
chromosomal integration sites. Integration of the artificial mch constructs into the former 
mchA locus in the genome of M. xanthus DK1622 ΔmchA-tet was intended via single 
crossover by using the downstream helicase gene rhlE as homologous region (which is part of 
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the 3’mchC-mchD-rhlE terminator fragments, see Section ‘Constructional Sequence Design 
of Artificial Myxochromide Pathways’). 
To achieve gene expression in M. xanthus, we decided to place all artificial mch pathways 
under the control of the native promoter from the A-type mch cluster from M. xanthus 
DK1622. Moreover, to ensure the transcriptional termination of artificial mch pathways 
originating from different myxobacterial species (B-type mch pathway from Myxococcus 
sp.,17 C-type mch pathway from Myxococcus virescens,17 D-type mch pathway from 
Stigmatella erecta,17 S-type mch pathway from Stigmatella aurantica,21) in M. xanthus, the 
3’mchC-mchD-rhlE terminator fragments were designed in a way that the terminator 
sequence (plus the rhlE gene) from the A-type mch cluster was integrated downstream of the 
mchD genes from the other mch pathways to generate hybrid terminator fragments, which is 
schematically illustrated in Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Design of hybrid terminator fragments for artificial A-, B-, C-, D- and S-type mch pathways. The 
individual 3’mchC-mchD-rhlE terminator fragments contain the native 3’mchC ends including the mchD gene of 
each mch cluster type, which are genetically fused to the downstream helicase gene (rhlE) including the 
terminator sequence from the A-type mch pathway (illustrated in gray) as a homologous region to allow for 
specific integration into the host genome and for functional termination of transcription in M. xanthus.  
 
 
3.3.3 Constructional Sequence Design of Artificial Myxochromide Pathways 
To address the generation of synthetic DNA platforms for the production of complex 
nonribosomal peptides, the development of a versatile assembly strategy for large and GC-
rich myxochromide gene clusters was required, which includes the possibility to (1) assemble 
numerous mch cluster variants fast and efficiently using a combination of conventional 
cloning techniques and modern DNA assembly strategies based on the use of type IIS 
restriction enzymes, (2) to allow for flexible interchanges of mch cluster segments on the 
domain, module and subunit level based on the generation of a mch gene library to generate 
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novel ‘unnatural’ peptide cores via combinatorial biosynthesis and (3) to allow for the 
interchangeability of genetic elements for vector backbone modifications. Initially, the A-type 
mch cluster from M. xanthus DK1622,18 was subjected to the sequence design process. As the 
size of a DNA fragment to be synthesized is still a limiting factor of DNA fabrication, the A-
type mch operon, which is approximately 30 kb in size, was rationally dissected into seven 
segments comprising the promoter-5’mchA (P5mchA) and 3’mchC-mchD-terminator-rhlE 
(T3mchC) regions, the three 5’/3’ end truncated biosynthesis genes mchA, mchB and mchC 
and the two intergenic linker regions 3’mchA-5’mchB (3A5B) and 3’mchB-5’mchC (3B5C) 
between the biosynthesis genes. The large mchC gene (13.4 kb) was subdivided into three 
fragments (MchC_A_AarI_fragABCE, MchC_A_AarI_fragD and MchC_A_AarI_fragF) for 
gene synthesis ranging in size from 6.2 to 9.4 kb. To meet the objectives described above, we 
aimed at establishing a three-step assembly strategy comprising the assembly of the truncated 
biosynthesis genes, the generation of a gene library for combinatorial approaches and the 
assembly of entire mch cluster constructs using a combination of conventional 
restriction/ligation cloning techniques and state-of-the-art assembly technologies. 
To allow for the future interchangeability of every desired PKS or NRPS domain, so-called 
splitter elements (SE) were designed and implemented into the interdomain linker regions 
within the truncated biosynthesis gene fragments mchA-C (except the linker between the PKS 
enoylreductase domain and the acyl carrier protein domains). The SEs basically consist of 
recognition sequences of a type IIS restriction enzyme (Figure 3). 
 
 
 
 
 
 
 
 
 
Figure 3. Structure and composition of splitter elements (SE) used for mch cluster engineering. The SE were 
placed between each PKS/NRPS domain fragment (except between the ER-ACP domain fragments, illustrated 
as dark gray boxes) and contain two recognition sites for a type IIS restriction enzyme (highlighted in red boxes), 
which hydrolyzes the DNA double strand outside of this recognition sequence, thereby generating 4 bp 5’ 
overhangs (shown in light gray). The introduced sequence in the middle (shown in red, R) represents the 
recognition site of a unique conventional type II restriction enzyme to allow for gene assemblies and fragment 
exchanges. A: SE based on the type IIS restriction enzyme AarI (32-34 bp in size). B: SE based on the type IIS 
restriction enzyme BsaI (26-28 bp in size). 
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These enzymes exhibit the special ability to hydrolyze the DNA double strand outside of their 
asymmetric recognition sequence,22 which enables the selection and design of unique 
overhangs between the domain fragments of each biosynthesis gene. This approach allows for 
the directed and seamless reassembly of the biosynthesis genes at the second stage of the 
assembly process. In the first instance, suitable fusion sites in the interdomain linkers along 
the A-type mch cluster were defined and introduced SEs were equipped with the recognition 
sequences of the type IIS restriction enzyme AarI.23 Moreover, an additional R-site for a 
unique ‘standard’ type II restriction enzyme between the AarI recognition sites was 
introduced for downstream domain or module exchanges and for the assembly of large 
biosynthesis genes (mchC) from smaller synthetic DNA fragments. Based on the domain 
organization of the mch biosynthesis genes, the mchA gene was equipped with 4 SEs, mchB 
with 6 and in mchC, 12 SEs were introduced with an overall size of 32-34 bp. After gene 
assembly using these conventional R-sites within the SEs, SEs need to be eliminated by a 
‘desplitting’ process, which basically describes the hydrolysis of the biosynthesis genes using 
AarI. The released SEs can easily be removed using PCR purification columns and the single 
domain fragments can be rejoined in a one-pot multi-fragment ligation exploiting the unique 4 
bp overhangs as compatible fusion sites. Following this approach led to the generation of a 
gene library containing fully ‘desplitted’ gene constructs. The last stage of the assembly 
process is the stitching of the three ‘desplitted’ biosynthesis gene fragments together with four 
additional fragments harboring the promoter, terminator and intergenic linker regions 
described above to assemble functional mch cluster constructs. In addition to the internal SEs 
between the domain encoding fragments, external SEs were implemented at the 5’ and 3’ ends 
of each synthetic cluster fragment in a way that the generated 4 bp overhangs are part of 
another unique R-sites, which were engineered within the coding sequence by silent mutations 
(BsiWI, MreI, MluI, NotI, SphI, AgeI) whenever possible (Supporting Information Table S5). 
This concept allows in parallel the assembly of entire mch cluster constructs from the seven 
building blocks either in a one-pot fashion or their conventional stitching as a backup strategy, 
if the one-pot assembly fails. In total, R-sites of a set of 25 enzymes used for gene assembly, 
domain/module engineering and pathway reconstitution were eliminated along the A-type 
mch cluster sequence, including R-sites for the exchange of vector backbone elements (PacI, 
PmeI, SwaI) on the designed pSynbio2 vector. 
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3.3.4 Construction and Heterologous Expression of a Synthetic A-type mch Cluster 
The de novo synthesis of the redesigned A-type mch cluster fragments based on the AarI 
design approach was accomplished by a gene synthesis company commissioned by our 
bioinformatics collaborator ATG:Biosynthetics GmbH. The synthesis of the genes mchA-C 
required high delivery times (~ 3-5 months) due to their large size and complexity (GC-rich 
sequences), whereas the significantly smaller promoter (P5mchA), terminator (T3mchC) and 
intergenic linker fragments (3A5B/3B5C) were delivered in reasonable time frames (several 
weeks). In the case of the large mchC gene, we received three individual DNA fragments, 
since synthesis of this gene in one piece was not successful. Thus, we followed the envisaged 
assembly strategy and first assembled the full-length mchC gene in two steps using the unique 
R-sites within the introduced SEs for the construction of pGH-MchC_A_AarI_fragABCEF 
and subsequent complementation with pGH-MchC_A_AarI_fragD to construct pGH-
MchC_A_AarI_SE. Since each synthetic fragment was delivered in the standard pGH vector 
backbone, the seven building blocks were subcloned into our cloning vector pSynbio1 that 
was subjected to the R-sites engineering and thus does not contain any recognition sequences 
of the restriction enzymes needed for ‘desplitting’ or pathway reconstitution/engineering, 
which is a prerequisite for the downstream stages of the assembly process. After mchC gene 
assembly and subcloning, the truncated biosynthesis genes mchA-C were successfully 
‘desplitted’ via hydrolysis with AarI followed by religation of the single domain fragments 
after removal the SEs. Although the ‘desplitting’ process of the biosynthesis gene fragments 
was initially successful, cloning efficiencies were insufficiently low in terms of establishing a 
fast and efficient assembly strategy. ‘Desplitting’ of the smaller mchA and mchB gene 
constructs already required some screening effort (one correct clone out of 24) and 
‘desplitting’ of the large mchC gene containing 12 SEs was difficult to achieve at all. In this 
case, up to 100 colonies needed to be tested to find a correct clone harboring a fully 
‘desplitted’ version of this gene construct. In addition, partially ‘desplitted’ mchC constructs 
were often observed, which still contained some SEs despite of the performed purification 
step using the PCR column. In some other cases, fully ‘desplitted’ but shortened mchC 
constructs were detected, in which several domain fragments were deleted. This can happen if 
three out of the four nucleotides making up the fusion sites are complementary to each other, 
so that they can anneal and subsequently be ligated.24 The type IIS restriction enzyme AarI 
additionally requires a synthetic oligonucleotide to gain full activity and thus seemed to be the 
bottleneck, although it was recently used in studies describing the similar Golden Gate 
assembly strategy.24,25 Constructs, which were thought to be fully ‘desplitted’ based on 
restriction analyses, were sequenced by employing Illumina sequencing technology in order 
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to guarantee a verified gene library. However, we continued with the third stage of the 
assembly strategy and tried to assemble the first artificial A-type mch pathway from the seven 
building blocks plus the expression vector pSynbio2 (which contains a MCS flanked by two 
SEs generating unique fusion sites to capture the promoter-5’mchA and 3’mchC-mchD-
terminator-rhlE fragments and thus acts as acceptor vector) via separate hydrolysis of each 
construct using AarI followed by a directed one-pot religation of the linearized synthetic 
fragments to form functional mch cluster constructs. Unfortunately, one-pot assemblies of 
artificial mch pathways failed, which is most likely due to the diverse size distribution of the 
synthetic fragments (150 bp up to 13.4 kb). The assembly of ~ 35 kb constructs from non-
standardized DNA fragments (in terms of fragment size) might thus be hard to achieve in a 
highly efficient and flexible way. In contrast, the similar Golden Gate Cloning platform for 
the assembly of large DNA constructs from modular building blocks, which relies on type IIS 
restriction enzymes and their special features, has recently become popular describing the 
custom-specific generation of Transcription Activator-Like Effector Nuclease (TALEN) 
libraries used for in vivo gene editing.26,27 In these and other studies, modules exhibiting 
similar sequence lengths in equimolar amounts were used for one-pot restriction/ligation 
assemblies and relatively small constructs were assembled (up to 10 kb). Taken this into 
account, fragment and final construct sizes might be the relevant factors limiting the success 
of this assembly strategy. Thus, the first artificial A-type mch pathway was stepwise 
constructed from the seven building blocks via conventional cloning using the engineered 
unique R-sites (Rx1, Rx6, Ry1, Ry8, Rz1, Rz14) plus the two R-sites flanking the multiple cloning 
site of the expression vector pSynbio2 (RL, RR), which revealed the intermediate constructs 
pSyn2-ca1, pSyn2-ca2, pSyn2-ca3, pSyn2-ca4, pSyn2-ca5, pSyn2-ca6 and the final 
expression construct pSynMch1 harboring the entire synthetic mchA cluster (Supporting 
Information Table S9). The expression construct was verified by a combination of restriction 
analyses and Illumina sequencing prior to transformation into M. xanthus DK1622. 
Integration of the artificial A-type mch pathway into the former locus of the corresponding 
native pathway in M. xanthus was analyzed by PCR (Supporting Information Figure S4) and 
genotypically verified mutant strains were cultivated for subsequent preparation of culture 
extracts. As controls, the wild type strain as well as the myxochromide A-deficient mutant M. 
xanthus DK1622 ΔmchA-tet were cultivated in parallel. Culture extracts were analyzed for 
myxochromide production by HPLC-MS and target masses for myxochromides A2, A3 and A4 
were detected in the extracts of the wild type strain as well as of the mutant strains harboring 
the artificial version of the A-type mch cluster (experimental data not shown). Myxochromide 
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production titers were comparable in both strains showing that the synthetic DNA platform is 
principally a robust and competitive system for further studies. However, the assembly 
strategy and thus the constructional sequence design needed to be modified to significantly 
improve the robustness and efficiency of the described procedure. 
 
3.3.5 Adaption of the Constructional Sequence Design to an Alternative Type IIS 
Restriction Enzyme 
To have an efficient assembly strategy in hand for which the presented concept still builds the 
basis, the constructional sequence design was adapted to the alternative type IIS restriction 
enzyme BsaI, which is also known from published DNA assembly protocols,24,25 and which 
does not require any additives to become active. However, the use of BsaI has some 
limitations regarding the strategic possibilities of the envisaged assembly strategy, e.g. the 
BsaI enzyme only skips one nucleotide until it hydrolyzes the DNA double strand compared 
to four nucleotides, which are skipped by AarI. Thus, it was not possible anymore to design 
the SE-derived 4 bp overhangs in a way that they are simultaneously part of the 
‘conventional’ R-site recognition sequences at the 5’/3’ ends of the synthetic DNA fragments, 
which allowed the construction of synthetic mch clusters via both one-pot and conventional 
assemblies. Thus, we only focused on the conventional construction of entire artificial mch 
constructs by using the unique R-sites at the 5’/3’ ends of each synthetic DNA fragment. 
Furthermore, and in addition to the A-type mch pathway, the strategy was extended to the B-, 
C-, D- and S-type mch clusters in order to generate a diversified gene library for 
combinatorial biosynthesis.  
First, we decided to redesign the whole A-type mch cluster based on the sequence 
requirements, which were determined by the adaption to the BsaI design plus a minimal set of 
cluster fragments from the other described mch pathways, which allows their rational 
recombination to assemble a maximum number of different mch cluster variants to produce 
novel myxochromides (Supporting Information Figure S3). Thus, the mchA gene from the A-
type pathway encoding the polyketide synthase that directs the biosynthesis of the 
polyunsaturated side chain, was subjected to the sequence design process and was 
subsequently used for the assembly of all mch pathways described in this study (plus the 
corresponding promoter-5’mchA and the 3’mchA-5’mchB intergenic linker fragment). Since 
the MchB subunits of the A-, B- and C-type mch pathways share a relatively high degree of 
sequence homology, originate from Myxococcus sp. and activate the same amino acids for 
incorporation into the growing peptide chain (in contrast to the MchB subunit from the S-type 
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mch pathway), the mchB gene from the A-type mch cluster was redesigned and used for the 
construction of artificial A-, B- and C-type mch clusters. To assemble an artificial D-type mch 
cluster, the corresponding mchB gene from Stigmatella sp. was redesigned and, in addition, 
the S-type mchB gene since the corresponding S-type MchB subunit exhibits a different 
amino acid specificity. Due to various recombination events and the resulting differences in 
the mchC genes of the mch clusters, we redesigned the mchC genes from all mch pathways 
(including the corresponding 3’mchB-5’mchC intergenic linker and terminator fragments). 
Sequence alignments of the selected mch genes were performed in order to find suitable 
positions for the BsaI-based SEs (or fusion sites respectively) between each domain encoding 
fragment. We intended to choose fusion sites, which were located at the same positions 
among the different mch genes to allow for directed exchanges of domains or modules 
originating from mch genes from different mch clusters. In some cases, it was not possible to 
detect identical 4 bp combinations in the interdomain linker regions among the different mch 
genes. Alternative fusion sites were then chosen, which were located either within the 
upstream or downstream domain based on revised domain annotations. However, overall 15 
out of 72 fusion sites needed to be modified by silent point mutations (except one fusion site 
mutation which affected the amino acid sequence of the corresponding protein) to be identical 
and located at the same positions among all mch genes (Supporting Information Table S4). In 
the B-type mch gene, three additional fusion sites were selected and appropriate SEs were 
introduced (15 instead of 12 as for the A-, D- and S-type mchC genes) due to the duplicated 
module described in Chapter 2. Analogously, the C-type mch gene was only equipped with 9 
SEs as a result of the module deletion. 
In analogy to the AarI-based design process, the mch genes were truncated at their 5’ and 3’ 
ends and were further subdivided into smaller DNA fragments due to their large size (overall 
11 synthetic cluster fragments for the A-, D- and S-type pathways; 10 cluster fragments for 
the C-type pathway and 12 cluster fragments for the B-type pathway). The unique R-sites at 
the 5’ and 3’ ends, which were previously defined, were introduced at the same positions as 
described for the AarI design. Since the one-pot assembly of entire mch cluster constructs did 
not work efficiently using AarI most likely due to the diverse size distribution of the synthetic 
cluster fragments, we decided to assemble the expression constructs via conventional cloning 
methods using these unique R-sites. Thus, only the truncated mch gene fragments were 
equipped with external SEs at their 5’/3’ ends to allow for the religation of the gene fragments 
into the pSynbio1 cloning vector after the ‘desplitting’ process. 
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Figure 4. Assembly strategy for the generation of artificial mch clusters. The assembly process involves overall 
three steps starting with the construction of the biosynthesis genes from smaller synthetic DNA fragments. 
‘Desplitting’ of the biosynthesis genes using type IIS restriction enzymes followed by directed religation of the 
single domain fragments results in the generation of a gene library consisting of splitter-free gene constructs. To 
reconstitute the entire mch clusters, seven synthetic building blocks comprising the gene constructs from the 
gene library as well as four additional cluster fragments harboring the promoter, intergenic linker and terminator 
sequences are stepwise cloned into the expression vector pSynbio2 using the unique R-sites at the 5’ and 3’ ends 
of each synthetic cluster fragment (RL, Rx1, Rx6, Ry1, Ry8, Rz1, Rz14, RR). 
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In addition, R-sites engineering was performed for the selected mch cluster fragments to 
eliminate perturbing R-sites. The whole assembly strategy starting from gene assemblies over 
‘desplitting’ of mch gene constructs to the reconstitution of artificial mch clusters for 
heterologous expression is exemplified for the A-type mch cluster in Figure 4 (for a detailed 
overview on the designed mch cluster fragments see Supporting Information Figure S3). 
In addition to the mch cluster fragments, the cloning (pSynbio1_AarI) and expression vectors 
(pSynbio2_AarI) also needed to be modified to meet the constructional sequence 
requirements of the BsaI design. To eliminate a BsaI R-site in the ampicillin resistance gene 
in pSynbio1, a small synthetic analogous fragment was designed, in which this R-site was 
removed by silent point mutation and which can be easily exchanged by restriction/ligation 
cloning (Supporting Information Table S7). In pSynbio2, a modified MCS equipped with 
flanking BsaI R-sites instead of AarI sites was designed and exchanged using unique R-sites 
on the original vector backbone (Supporting Information Table S7). 
 
3.3.6 In vitro Reconstitution of Artificial Hybrid mch Clusters 
Despite the modification and expansion of the described constructional sequence design, the 
basic assembly strategy remained unaffected as we still intended to construct the mch 
pathways via the established three-step approach starting with the assembly of the split 
biosynthesis genes using the unique R-sites within the SEs followed by subcloning of these 
fragments into the cloning vector pSynbio1, which revealed the following constructs: pSyn1-
MchA_A_SE, pSyn1-MchB_A_SE, pSyn1-MchB_D_SE, pSyn1-MchB_S_SE, pSyn1-
MchC_A_SE, pSyn1-MchC_B_SE, pSyn1-MchC_C_SE, pSyn1-MchC_D_SE and pSyn1-
MchC_S_SE. At the second stage, hydrolysis of these constructs with BsaI and subsequent 
religation of domain fragments gave the fully ‘desplitted’ genes providing a versatile gene 
library for the combinatorial reprogramming of myxochromide assembly lines. Compared to 
the ‘desplitting’ procedure using AarI, ‘desplitting’ reactions with the BsaI type IIS restriction 
enzyme appeared to be much more efficient. The ‘desplitted’ versions of the smaller mchA 
(pSyn1-MchA_A) and mchB (pSyn1-MchB_A, pSyn1-MchB_D and pSyn1-MchB_S) gene 
constructs were easily obtained without putting significant effort in the screening of correct 
clones (cloning efficiencies were ~ 50-70%). However, cloning efficiencies dropped 
noticeably together with the number of SEs or construct size, respectively. ‘Desplitting’ of the 
largest mchC gene construct (pSyn1-MchC_B_SE) was not successful, although ‘desplitting’ 
reactions were optimized in terms of enzyme and substrate concentrations, incubation time 
and temperature needed for the efficient religation to form the fully ‘desplitted’ construct. 
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Thus, we designed four modified mchC gene fragments from the B-type mch pathway 
(MchC_B_fragA_woSE, MchC_B_fragB_woSE, MchC_B_fragC_woSE and 
MchC_B_fragD_woSE), in which the SEs were completely removed (except one BsaI site 
plus the pre-defined unique R-site at the 5’/3’ ends of each fragment for gene assembly as a 
kind of partial SE) in order to reduce the complexity of the ‘desplitting’ reaction. The mchC 
gene was constructed from the modified gene fragments via conventional cloning methods 
using the unique R-sites, thereby generating SEs at the ligation sites. Removal of the resulting 
three SEs via hydrolysis using BsaI efficiently worked, thereby revealing pSyn1-MchC_B, 
which underpins the assumption that the efficiency of the ‘desplitting’ process is mainly 
limited by the number of SEs. ‘Desplitting’ of the mchC gene constructs from the A-, C-, D- 
and S-type mch pathways harboring 10 to 12 SEs was still possible and revealed pSyn1-
MchC_A, pSyn1-MchC_C, pSyn1-MchC_D and pSyn1-MchC_S, even though the cloning 
efficiencies were lowered compared to mchA/mchB construct ‘desplittings’ (Supporting 
Information Table S8). A number of 12 SEs thus seems to be the benchmark in the described 
experimental set-up, for which reasonable cloning efficiencies can be realized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of the five artificial hybrid mch clusters generated by rational recombination 
of the seven synthetic building blocks. The illustrated pathways are assumed to direct the biosynthesis of the 
naturally occurring myxochromides A, B, C, D and S. The color code illustrates the origin of the single 
redesigned mch cluster fragments: synthetic building blocks from the A-type mch pathway are shown in dark 
gray, from the B-type mch cluster in blue, from the C-type mch cluster in red, from the D-type pathway in green 
and from the S-type pathway in orange. Black lines indicate the positions of unique R-sites for the conventional 
assembly of the mch cluster constructs from the synthetic building blocks. 
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On the basis of the generated mch gene library, we first intended to create synthetic DNA 
platforms for the production of the native myxochromide scaffolds, which serve as a starting 
point for combinatorial engineering to increase the chemical diversity of myxochromides. By 
rationally recombining the seven synthetic building blocks including the different mch genes 
from the gene library, five hybrid mch pathways were constructed via conventional cloning, 
which were assumed to be responsible for the production of the native A-, B-, C-, D- and S-
type myxochromides (Figure 5, work by Dr. Fu Yan, unpublished).  
Heterologous expression of the artificial mch pathways in M. xanthus followed by genotypic 
verification of selected mutant strains and HPLC-MS analysis of culture extracts revealed that 
all pathways were correctly integrated into the host chromosome and were functionally 
expressed. The corresponding A-, B-, C-, D- and S-type myxochromides were detected in 
culture extracts of the mutant strains (data not shown; work by Dr. Fu Yan, unpublished). 
We then intended to go one step further to generate entirely new myxochromide peptide 
cores, which have not (yet) been found in Nature, by exchanging the MchB/MchC subunits, 
which might change the amino acid order in the produced lipopeptide compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of the five artificial hybrid mch clusters generated by rational swaps of the 
mch genes from the gene library. The illustrated pathways are assumed to direct the biosynthesis of novel hybrid 
myxochromide cores (AS-, SA-, SB-, SC- and SD-type). The color code illustrates the origin of the single 
redesigned mch cluster fragments: synthetic building blocks from the A-type mch pathway are shown in dark 
gray, from the B-type mch cluster in blue, from the C-type mch cluster in red, from the D-type pathway in green 
and from the S-type pathway in orange. Black lines indicate the positions of unique R-sites for the conventional 
assembly of the mch cluster constructs from the synthetic building blocks. 
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Using the gene library consisting of the ‘desplitted’ biosynthetic mch genes, five different 
mch gene combinations can be deduced, which in conjunction with the available promoter-
5’mchA (P5mchA), intergenic linker 3’mchA-5’mchB (3A5B), 3’mchB-5’mchC (3B5C) and 
3’mchC-mchD-terminator-rhlE (T3mchC) fragments might encode biosynthetic machineries 
producing novel myxochromide cores (Figure 6). Alternative gene combinations would 
inevitably lead to mch pathways, which are assumed to be responsible for the production of 
the native myxochromide scaffolds. 
Since we intended to focus on the engineering of the NRPS (MchB/MchC) subunits to switch 
amino acid positions in the peptide core, the PKS (MchA) encoding mchAA gene from the A-
type mch pathway was consistently used as a standard building block for the assembly of the 
mentioned hybrid mch clusters together with the P5mchAA promoter fragment and the 
3AA5BA intergenic linker fragment, which derived from the A-type mch cluster as well. We 
decided to use the 3AA5BA linker fragment from the A-type mch cluster to ensure native 
docking interactions at the corresponding PKS/NRPS interface in the megasynthetase 
complex rather than using hybrid linker fragments which combine the 3’ end of the mchAA 
and the 5’ end of the mchBS fragment. 
Similar considerations were made for the integration of the 3mchA-5mchB (3B5C) linker 
fragments. We intended to maintain the native docking regions between mchBA/mchBS and the 
different mchC gene fragments and thus used the individual linker fragments harboring the 
3’mchB and 5’mchC ends originating from the different mch cluster types (3BA5CA, 3BB5CB, 
3BC5CC and 3BD5CD). If one NRPS encoding gene (mchB/mchC) derived from the A-type 
mch pathway, the corresponding A-type intergenic linker fragment (3BA5CA) was used 
(Figure 6). Based on the established gene library, the different hybrid mch clusters (Figure 6) 
were constructed stepwise in four to seven cloning steps using the unique R-sites at the 5’/3’ 
ends of the synthetic mch cluster fragments, thereby yielding the final expression constructs, 
which harbor the artificial AS- (pSynMch8), SA- (pSynMch9), SB- (pSynMch11), SC- 
(pSynMch10) and SD-type (pSynMch12) hybrid mch clusters (Supporting Information Table 
S9). 
All expression constructs were fully sequenced by employing Illumina sequencing 
technology. In some cases, frameshift mutations were detected in common parts of the 
expression constructs, which needed to be repaired prior to heterologous expression 
(Supporting Information Table S9). 
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3.3.7 Heterologous Expression of Artificial Hybrid mch Clusters in M. xanthus and 
Production Analysis of Mutant Strains 
To heterologously produce the assumed novel hybrid myxochromides in M. xanthus DK1622, 
the expression constructs pSynMch8 (AS-type), pSynMch9 (SA-type), pSynMch10 (SC-
type), pSynMch11 (SB-type) and pSynMch12 (SD-type) harboring the artificial hybrid mch 
clusters were subsequently transformed into the heterologous host strain M. xanthus DK1622 
ΔmchA-tet lacking the native A-type mch cluster. Integration into the host genome via single 
crossover was achieved using the rhlE gene, which is part of the terminator fragments 
(3’mchC-mchD-terminator-rhlE) and originated from the native A-type mch pathway as a 
homologous region (see Chapter 3.3.2). Correct integration into the former locus of the A-
type mch cluster was analyzed by PCR using two sets of primers at the 5’ and 3’ ends of the 
synthetic mch clusters generating mutant-specific PCR products (Supporting Information 
Figure S4) and selected mutant strains harboring the hybrid mch clusters were grown in 
duplicates in 50 mL CTT medium (casitone 1%, Tris-HCl [pH 8.0] 10 mM, K2HPO4/KH2PO4 
buffer [pH 7.6] 1 mM, MgSO4 × 7 H2O 8 mM, pH adjusted to 7.6) at 30°C and analyzed for 
myxochromide production via HPLC-MS (Figure 7). To relatively compare hybrid 
myxochromide production titers with the native production levels of myxochromide A in M. 
xanthus DK1622, the wild type strain was analyzed as well. The myxochromide A-deficient 
mutant strain M. xanthus DK1622 ΔmchA-tet served as a negative control. Production of 
novel lipopeptide cores (Figure 8) was successfully demonstrated and is summarized below: 
  
Myxochromides AS – novel engineered lipopentapeptides 
Myxochromide derivatives with [M+H]+ masses corresponding to the expected hybrid 
myxochromides AS2, AS3 and AS4 (1a-c, Figures 7/8) were detected in extracts of M. xanthus 
DK1622 ΔmchA-tet::pSynMch8. The most prominent derivative was 1a under the applied 
cultivation conditions, whereas derivatives 1b and 1c were produced in lower yields but at 
similar levels compared to each other (Figure 7). 
Myxochromides SA – novel engineered lipohexapeptides 
Myxochromide derivatives with [M+H]+ masses corresponding to the expected novel hybrid 
lipohexapeptides myxochromides SA2, SA3 and SA4 (2a-c, Figures 7/8) were detected in 
extracts of M. xanthus DK1622 ΔmchA-tet::pSynMch9. Compound 2b was found to be the 
major derivative under the applied cultivation conditions, whereas derivatives 2a and 2c were 
produced in significantly lower amounts (Figure 7). 
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Myxochromides SB – novel engineered lipoheptapeptides 
Myxochromide derivatives with [M+H]+ masses corresponding to the assumed hybrid 
lipoheptapeptides myxochromides SB2, SB3 and SB4 (3a-c, Figures 7/8) were detected in 
extracts of M. xanthus DK1622 ΔmchA-tet::pSynMch11. The major derivative was 3c under 
the applied cultivation conditions followed by 3b and 3a, which were produced in 
significantly lower amounts (Figure 7). 
Myxochromides SC – novel engineered lipopentapeptides 
Myxochromide derivatives with [M+H]+ masses corresponding to the expected novel 
lipopentapeptides myxochromides SC2, SC3 and SC4 (4a-c, Figures 7/8) were detected in 
extracts of M. xanthus DK1622 ΔmchA-tet::pSynMch10. The production profile was found to 
be highly similar to that of the myxochromide SB producing mutant strain (Figure 7). 
Compound 4c was identified as most prominent derivative under the applied cultivation 
conditions, whereas derivatives 4a and 4b were produced as minor products. 
Myxochromides SD – novel engineered lipopentapeptides 
Myxochromide derivatives with [M+H]+ masses corresponding to the expected hybrid 
myxochromides SD2, SD3 and SD4 (5a-c, Figures 7/8) were detected in extracts of M. xanthus 
DK1622 ΔmchA-tet::pSynMch12. In comparison to the other hybrid myxochromides, 
production of 5a-c was found to be significantly lower, and was also observed for several 
independent clones.  The major derivative was 5b under the applied cultivation conditions and 
was roughly produced at similar levels as some minor compounds in the other extracts. 
Derivatives 5a and 5c were produced in even lower yields (Figure 7). 
 
The successful heterologous expression in M. xanthus demonstrated the functionality of the 
artificially recombined hybrid mch clusters, which were constructed based on synthetic DNA. 
NRPS subunits from different mch pathways, which were rationally recombined in a non-
native way, were obviously able to successfully interact with each other. In addition, non-
native biosynthetic intermediates, which are not biosynthesized by the native mch 
biosynthetic machineries, were transferred to and processed by the downstream domains of 
the hybrid mch pathways, thereby providing fully functional synthetic DNA platforms for the 
production of entirely novel myxochromide lipopeptide cores. 
When comparing the production titers of the synthetic hybrid mch clusters in the heterologous 
mutant strains with the native myxochromide A production in M. xanthus DK1622, it turned 
out that the corresponding hybrid myxochromides AS2-4, SA2-4, SB2-4 and SC2-4 were 
produced at different production levels in this initial cultivation experiment (Figure 7/Table1). 
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Figure 7. HPLC-MS analysis of hybrid myxochromide production in  myxobacterial mutant strains. Extracted 
ion chromatograms (EICs) for ±0.02 m/z corresponding to the [M+H]+ ions of myxochromides are shown. A: 
Detection of myxochromides A in M. xanthus DK1622 wild type; A2 ([M+H]+ = 834.47655), A3 ([M+H]+ = 
846.47655) and A4 ([M+H]+ = 860.49220). B: No myxochromide production in M. xanthus DK1622 ΔmchA-tet. 
C: Detection of myxochromides AS in M. xanthus DK1622 ΔmchA-tet::pSynMch8; AS2 ([M+H]+ = 695.37684), 
AS3 ([M+H]+ = 707.37684), AS4 ([M+H]+ = 721.39249). D: Detection of myxochromides SA in M. xanthus 
DK1622 ΔmchA-tet::pSynMch9; SA2 ([M+H]+ =876.52350), SA3 ([M+H]+ = 888.52350), SA4 ([M+H]+ = 
902.53915). E: Detection of myxochromides SB in M. xanthus DK1622 ΔmchA-tet::pSynMch11; SB2 ([M+H]+ 
= 989.60757), SB3 ([M+H]+ = 1001.60757), SB4 ([M+H]+ = 1015.62322). F: Detection of myxochromides SC in 
M. xanthus DK1622 ΔmchA-tet::pSynMch10; SC2 ([M+H]+ = 805.48639), SC3 ([M+H]+ = 817.48639), SC4 
([M+H]+ = 831.50204). G: Detection of myxochromides SD in M. xanthus DK1622 ΔmchA-tet::pSynMch12; 
SD2 ([M+H]+ = 779.47074), SD3 ([M+H]+ = 791.47074), SD4 ([M+H]+ = 805.48639). 
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Table 1: Chromatographic data of detected mxochromide derivatives. 
  
Compound Rt [min] Peak area Intensity 
Myxochromide A2 12.8 68958 25765 
Myxochromide A3 12.9 1009846 319991 
Myxochromide A4 13.6 128337 42760 
Myxochromide AS2 11.9 5448946 1659018 
Myxochromide AS3 12.1 3684638 997237 
Myxochromide AS4 12.7 3746519 925440 
Myxochromide SA2 14.0 34121 13702 
Myxochromide SA3 14.1 450801 153900 
Myxochromide SA4 14.7 59352 23614 
Myxochromide SB2 14.8 49470 17853 
Myxochromide SB3 14.9 178012 56136 
Myxochromide SB4 15.5 639513 206972 
Myxochromide SC2 14.1 69915 31898 
Myxochromide SC3 14.2 137546 50067 
Myxochromide SC4 14.8 551340 186612 
Myxochromide SD2 13.9 n.d.a) 3252 
Myxochromide SD3 14.0 138982 46565 
Myxochromide SD4 14.6 n.d. a) 11506 
a) not determined; signal-to-noise ratio too low 
 
Whilst myxochromides SA2-4, SB2-4 and SC2-4 were produced at approximately 50-70% 
relative to the production of myxochromides A2-4 in the wild type strain, the hybrid 
myxochromides AS2-4 were produced at significantly higher titers (increased production by a 
factor of 10 relative to myxochromide A2-4 production). Consequently, these hybrid mch 
pathways might be efficiently expressed in the host strain since the A-type mch pathway from 
M. xanthus DK1622 is a prominent example for a well-expressed myxobacterial PKS/NRPS 
gene cluster showing relatively high production yields. However, production of the SD-type 
myxochromide family was found to be significantly reduced (<12% relative to myxochromide 
A production levels). Analysis of the codon usage in the D-type mchC gene in correlation to 
the host genome’s codon usage suggested that the D-type mchC gene might be suitably 
expressed in M. xanthus DK1622, although codon usage of this gene is slightly lower adapted 
to the host genome compared to the S-type mchC gene, which was shown to be efficiently 
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expressed as part of the AS-type hybrid mch cluster (data on codon usage analysis not 
shown). This assumption is supported by the fact that the production titer of the synthetic D-
type mch cluster is in the same range as observed for the native A-type mch cluster as well as 
for the synthetic SA-, SB- and SC-type mch clusters described above (production profile not 
shown). Thus, we speculate that the chimeric MchBSD protein consisting of the MchBS 
subunit linked to the C-terminus of the MchBD subunit could potentially somehow influence 
proper protein-protein interactions between the NRPS subunits, thereby affecting the 
efficiency of the SD-type hybrid mch pathway. However, it cannot be excluded that the D-
type MchC subunit is not able to efficiently process the non-native biosynthetic intermediate, 
which is supplied by the upstream MchB subunit or that the D-type mchC gene is not properly 
expressed for other reasons. Interestingly, analysis of the hybrid myxochromide production 
profiles also revealed that the different hybrid mch pathways show significant differences in 
the preference for the polyunsaturated side chain generated by the PKS subunit, although the 
PKS encoding mchA gene from the A-type mch pathway was specifically used for all hybrid 
mch pathways, thereby providing identical pairs of interaction partners (mchAA/mchBA or 
mchAA/mchBS). In addition, the preference for a specific polyketide side chain varies not only 
between the different mutant strains but sometimes also within the same mutant strain when 
changing the culture conditions (e.g. the culture volume as observed for some hybrids when 
upscaling the production for compound isolation). For those reasons, it is not possible to draw 
rational conclusions from this initial cultivation experiment regarding the biosynthetic 
mechanisms which determine the preference for the polyene side chains. To ultimately prove 
the existence of the five novel hybrid myxochromide cores, isolation and structure elucidation 
was carried out for one prioritized derivative of each myxochromide type (Figure 8). 
 
3.3.8 Isolation and Structure Elucidation of Hybrid Myxochromides 
Since the production profiles of the hybrid myxochromides significantly changed in some 
cases regarding the major derivatives as well as the production yields, the native promoter 
was exchanged for the strong constitutive Tn5 promoter, which was recently established in M. 
xanthus,20 in the SA-, SB- and SD-type mch pathways to improve production titers and to 
simplify the isolation of the corresponding hybrid myxochromides. To structurally 
characterize the novel hybrid myxochromides in detail, one representative of each hybrid 
myxochromide type was isolated from the corresponding heterologous production mutant 
strains and their planar structures were solved by NMR spectroscopy. The structure 
elucidation process indeed confirmed five novel lipopeptide scaffolds belonging to the 
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myxochromide family (Figure 8). The underlying hybrid mch biosynthetic machineries are 
obviously capable of directing the biosynthesis of the engineered myxochromides. The 
number and order of the amino acids of the generated peptide cores unambiguously conform 
to the expected and artificially engineered hybrid structures. In comparison to the naturally 
occurring myxochromide lipopeptide cores, single amino acids of the peptide backbones were 
successfully switched at several positions (modules 2/3), thereby creating entirely new 
scaffolds based on the rational recombination of the synthetic mch biosynthetic genes from 
the established gene library. Elucidation of the absolute configuration of the characterized 
hybrid myxochromides also revealed the reason for the incorpation of only L-configured 
amino acids by the native S-type assembly line despite the presence of an epimerization (E) 
domain in module 2, which led to the incorporation of D-configured alanine in case of A-, B-, 
C- and D-type mch pathways.17,21 Whereas the presence of D-alanine in myxochromides A,18 
B,28 C and D correlates with the presence of the epimerase domain in module 2 (E2) of the 
underlying mch biosynthetic machineries, the amino acids in myxochromides S are invariably 
L-configured, although the leucine residue, which is incorporated by module 2, is predicted to 
be D-configured as well. In theory, several assumptions can be made to explain this 
observation: (1) the E2 domains are somehow inactive in the native S-type mch pathways, 
although mutations which were detected might not be critical for exhibiting catalytic 
activity,17,29,30 (2) the E2 domains of the mch pathways are evolutionary adapted to act on 
alanine and the more bulky leucine substrate cannot be converted by the E2 domain due to its 
increased steric hindrance or (3) the downstream condensation domains of modules 3 (C3) in 
the S-type mch pathways, which were predicted to be D-specific for the peptidyl donor and L-
specific for the aminoacyl acceptor (DCL domain),31 are actually L-specific condensation 
domains for both donor and acceptor (LCL domain) and are not able to further process D-
configured peptidyl intermediates.17 
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Figure 8. Chemical structures of novel hybrid myxochromides. Structurally characterized myxochromide 
derivatives are highlighted in bold. Minor derivatives, which were not characterized in detail, were postulated 
based on HPLC-MS analysis. The corresponding assembly lines are shown in Figure 9. 
 
These hypotheses were verified by determination of the absolute configuration of the five 
hybrid myxochromides using Marfey’s method,32 exploiting the non-native combinations of 
A-type E2 domains with S-type C3 domains and vice versa (plus combinations of S-type E2 
domains with B-, C- and D-type C3 domains). In myxochromide AS4, all amino acids were 
found to be L-configured including the alanine residue, which is incorporated by module 2. In 
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contrast, 1:1 ratios of D-leucine/L-leucine were detected in hydrolysates of myxochromides 
SA3, SC4 and SD3, whereas 1:2 ratios of D-leucine/L-leucine were found in the hydrolysate of 
myxochromide SB4 (Supporting Information Chapter 3.4.8). According to the biosynthetic 
logic of the underlying hybrid mch pathways (Figure 9), the detected D-configured leucine 
residues in myxochromides SA3, SB4, SC4 and SD3 must originate from epimerization by the 
obviously active E2 domains of the corresponding modules 2. Consequently, these results 
exclude the hypotheses that the E2 domains of the native S-type mch pathways are inactivated 
by mutations or that the E2 domains cannot exert their catalytic function on the more bulky 
leucine substrate. In fact, the sequence-based models for predicting the specificities of NRPS 
condensation domains (DCL/LCL) seems to be not accurate enough to reliably predict the 
preferences of condensation domains for D- or L-configured peptide intermediates, as the C3 
domains of the S-type mch pathways were obvisously predicted as DCL domains by mistake. 
In conclusion, the E2 domains of all mch pathways are indeed active and are not specific for 
alanine alone. The C3 domains of the downstream modules are the key determinants of the 
observed stereochemistry in both native and hybrid myxochromides, thereby fulfilling their 
role as gatekeepers in the mch megasynthetases. 
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of hybrid myxochromide assembly lines. The coloring of the PKS and NRPS 
subunits corresponds to the biosynthesis products shown in Figure 8. Catalytic domain abbreviations: KS, 
ketosynthase; AT, acyltransferase; DH, dehydratase; ER, enoylreductase; KR, ketoreductase; CP, acyl carrier 
protein (in MchA) or peptidyl carrier protein (in MchB/C); C, condensation domain; A, adenylation domain; 
MT, methyltransferase; E, epimerization domain; TE, thioesterase. Domains marked with an asterisk are 
supposed to be inactive. The corresponding myxochromide structures are shown in Figure 8. 
173     Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis 
 
3.3.9 PCP Inactivation Experiments to Induce Module-Skipping Events 
To further exploit the tool box given by the established highly flexible assembly strategy, we 
intended to not only recombine mch genes from the different mch pathways but also to 
exchange selected catalytic domains using the unique R-sites within the SEs. We initially 
focused on the NRPS encoding mchC genes from the A-type mch pathway as well as from the 
S-type mch cluster and targeted the ‘module-skipping’ process, which was recently described 
to occur in myxochromide S biosynthesis.21 Based on sequence alignments, it is assumed that 
the observed ‘module-skipping’ process is the result of a mutation (Ser  Pro) in the PCP 
core motif of module 4, which leads to the loss of the catalytically active serine residue, 
thereby inactivating the PCP domain, which cannot be post-translationally modified.33–35 In 
addition, several other mutations were detected in the core motif (GGHSL  GGNPS) in 
comparison with the PCP core motif, which corresponds to the described core motif sequence 
of PCP domains.36 We therefore aimed at answering the question whether it is possible to 
induce ‘module-skipping’ in the A-type mch pathway by mutating PCP domain core motifs in 
a similar way as detected in the S-type mch cluster. By applying this approach to module 4 of 
the A-type mch cluster, a D-type mch pathway might emerge in terms of the activated amino 
acids, which would be incorporated by the corresponding assembly line and can be used to 
mimic evolutionary diversification by turning one mch pathway into another. The opposite 
strategy, the reactivation of module 4 in the S-type mch cluster by using artificial PCP 
domains harboring an active serine residue, would potentially result in an entirely new mch 
pathway responsible for the production of a novel myxochromide scaffold. To achieve this, 
two PCP4 encoding fragments from the A-type pathway were designed, which harbor either 
the same core motif as the S-type PCP4 domain (Figure 10A) or which harbor a Ser  Ala 
mutation as an alternative (Figure 10A). The latter mutation was recently described to 
inactivate or to reduce the flexible motion of PCP domains of NRPS megasynthetases in 
activity-related and structural studies.37,38 In addition, a synthetic PCP4 encoding fragment 
based on the S-type mch pathway was designed in a way that the core motif from the A-type 
mch cluster was reconstituted by applying several mutations and which was assumed to 
restore the activity of the corresponding S-type PCP4 domain (Figure 10B). Mutations were 
rationally introduced at certain positions within the core motif to meet the constructional 
sequence requirements for the gene cluster assemblies, which basically means that the 
generation of R-sites used for pathway assembly and engineering by the exchange of single 
nucleotides needs to be avoided. The synthetic fragments were flanked with SEs, which allow 
the exchange of the PCP domain fragments based on the mch genes from the gene library 
using the unique R-sites and the directed religation of the domain fragments after the 
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‘desplitting’ process by exploiting the unique fusion sites. To further expand the scope of this 
approach, appropriate mutated PCP domain fragments were designed for the other modules of 
the synthetic A-type mch cluster (CP1, CP2, CP3, CP5, CP6) as well. In those cases, only one 
version harboring the described Ser  Ala mutation was designed. By following this strategy, 
we aimed at inducing ‘module-skipping’ at different positions of the synthetic A-type mch 
cluster to verify the hypothesis that ‘module-skipping’ can potentially be induced by point 
mutations, thereby further increasing the chemical diversity of myxochromides. 
 
 
Figure 10. Design of synthetic DNA fragments encoding mutated PCP domains (illustrated as dark gray boxes). 
The core motifs of the artificial PCP domains are particularly highlighted. DNA fragments are flanked with SEs 
harboring unique R-sites for the exchange of domain fragments in the mch genes from the gene library (Rz6/Rz7). 
R-sites are highlighted in red, unique overhangs (fusion sites) in light grey and mutated nucleotides in green 
(referred to the native nucleotide sequences of the corresponding original PCP domains). A: Synthetic PCP4 
domain fragments from the A-type mch pathway harboring either a Ser  Ala mutation (CP4_A_inact1) or the 
S-type derived amino acid mutations (CP4_A_inact2) in the core motif. For comparison, the original PCP4 
domain fragment from the synthetic A-type mch pathway is also shown. B: Synthetic PCP4 domain fragment 
from the S-type mch pathway harboring mutations to reconstitute the core motif observed in the native A-type 
PCP4 domain. For comparison, the original PCP4 domain fragment from the synthetic S-type mch pathway is 
shown. 
The respective modified mch gene constructs were constructed following a three-step cloning 
approach, which is exemplarily shown for a PCP4 exchange in the mchC gene (Figure 11). 
The mutated PCP domain fragments described above were cloned into the artificial mchB 
(pSyn1-MchB_A_SE) and mchC (pSyn1-MchC_A_SE or pSyn1-MchC_S_SE) gene 
constructs harboring the SEs, followed by ‘desplitting’ of these constructs and subsequent 
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religation of the domain fragments, which resulted in the generation of fully ‘desplitted’ 
constructs complementing the mch gene library. Integration of the modified mch biosynthesis 
genes harboring the described mutations into a synthetic A-type mch cluster, which is under 
the control of the strong, constitutive Tn5 promoter (pSynMch13, constructed by Dr. Fu Yan, 
unpublished) was achieved using the unique R-sites at the 5’ and 3’ ends of the generated 
constructs (Ry1/Ry8 for mchB gene constructs and Rz1/Rz14 for mchC gene constructs).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Strategy to generate synthetic mch gene constructs harboring mutated PCP domains. Synthetic PCP 
domain encoding fragments harboring mutations in the core motif (illustrated as dark grey boxes and marked 
with an asterisk) were cloned into the mch gene constructs from the gene library using the unique R-sites within 
the SEs. ‘Desplitting’ of these constructs using BsaI results in splitter-free mch gene constructs, which can be 
cloned into the mch expression constructs by conventional cloning using the unique R-sites at the 5’ and 3’ ends 
(Rz1/Rz14). 
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A list of the generated mch gene constructs as well as entire expression constructs describing 
their construction is given in Tables S6 and S7 (Supporting Information). Results from the 
Sanger sequencing of the PCP domain encoding regions revealed that the original PCP2 
domain fragment harboring the active GGHSL core motif was still integrated in the pSyn1-
MchB_A_CP2inact1_SE construct. Furthermore, Illumina sequencing results of the entire 
expression constructs indicated a 1 bp deletion in constructs pSynMch20 (harboring the 
MchC_A_CP4inact1 fragment) and pSynMch21 (harboring the MchC_A_CP4inact2 
fragment) causing a frameshift mutation and a 1.2 kb domain fragment duplication in the 
pSynMch22 construct (harboring the MchC_A_CP5inact1 fragment). In the latter case, 
duplication of the C5 condensation domain happened most likely during the ‘desplitting’ 
procedure due to incorrect ligations of non-complementary overhangs. The 1 bp deletion in 
constructs pSynMch20 and pSynMch22 was most likely acquired during the last assembly 
step. The affected expression constructs were thus not considered for heterologous expression 
experiments. After sequence verification, the remaining expression constructs harboring 
inactive PCP domains in modules 1 (pSynMch17), 3 (pSynMch19) and 6 (pSynMch23) of the 
synthetic A-type mch pathway and the reactivated PCP4 domain in module 4 (pSynMch24) of 
the synthetic S-type mch cluster were transformed into the heterologous host M. xanthus 
DK1622 ΔmchA-tet for subsequent heterologous expression of the modified mch cluster 
constructs. Several clones were routinely cultivated and prepared extracts were analyzed for 
the expected myxochromides by HPLC-MS (data not shown). The respective myxochromides 
lacking either N-Me-L-threonine (incorporated by module 1), L-leucine (incorporated by 
module 2) or L-glutamine (incorporated by module 6) compared to the original 
lipohexapaptides myxochromides A were not detected in culture extracts of the mutant 
strains. In these cases, the addressed modules are located at the N-termini (module 1 in MchB 
and module 3 in MchC) as well as at the C-termini (module 6 in MchC) of the NRPS 
subunits, which represent the interfaces between the individual proteins making up the entire 
assembly lines (MchA/MchB and MchB/MchC) or the termination points of the biosynthesis 
respectively (MchC). One can assume that the transfer of biosynthetic intermediates across 
PKS/NRPS subunits (from the PKS (MchA) subunit to module 1 of the first NRPS (MchB) 
subunit and from module 2 of the first NRPS to module 3 of the second NRPS (MchC)) is 
more critical than substrate shuttling between ‘internal’ modules, which are part of one 
distinct subunit. However, mutated PCP domains, which were introduced in the A-type mch 
pathway, only harbor a few mutations exclusively in the core motif, whereas the surrounding 
interdomain linker regions remained unchanged. Thus, direct domain-domain interactions, 
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intermodule communication or even interactions between the Mch subunits might not be 
directly affected when mediated by significant conformational changes. In fact, details on the 
‘module-skipping’ mechanism, e.g. from structural studies, is unfortunately not available thus 
far and the MchC subunit of the S-type mch pathway is currently, to the best of our 
knowledge, the only reported example for a NRPS, for which module-skipping was 
described.18 It is very likely that the biosynthetic intermediate in the native S-type mch 
pathway is transferred from the module 3 PCP domain to the PCP domain of module 5, 
thereby skipping the entire fourth module, as proposed recently.21 This would suggest that the 
PCP3 domain must directly interact with the C5 domain, which represents a noncognate 
domain-domain interaction that needs to be evolutionary arranged. This would have strong 
implications for the engineered hybrid assembly lines, which is discussed below: 
 
Skipping of module 1 in the synthetic A-type mch pathway 
In case the first module in the MchB subunit responsible for the incorporation of N-Me-L-
threonine is skipped, the ACP domain from the PKS subunit must directly interact with the 
donor site of the C2 domain from module 2, which represents a noncognate interaction. 
Sequence analysis of the C domains from mch pathways revealed that all orthologue C2 
domains fall into the class of LCL domains (see Chapter 2), which significantly differ from so-
called starter C domains,31 which initiate NRPS biosynthesis. It can be assumed that the 
interaction of the ACP domain with the downstream starter C1 domain is highly specific and 
the noncognate ACP-C2 interaction is thus not facilitated in the engineered PKS/NRPS 
assembly line, which would explain abolishment of myxochromide production. The crucial 
role of tightly synchronized interactions between an ACP domain and a downstream starter C 
domain and the high specificity of the C domain for the incoming acyl intermediate from in 
trans acting PKS machineries has been recently described in the biosynthesis of the 
lipopeptide antibiotic CDA.39 Furthermore, in the myxochromide A lipohexapeptide core, the 
N-Me-L-threonine moiety is connected over its side chain hydroxyl group with the carboxyl 
group of the L-glutamine residue to form the cyclic depsipeptide structure.18 From a 
(bio)chemical point of view, it is rather unlikely that the TE domain of the termination 
module responsible for the cyclization reaction is able to cyclize the linear lipopeptide without 
the N-Me-L-threonine moiety in a similar manner, which could potentially affect proper 
termination of the biosynthesis. It is more likely that the linear peptide intermediate is 
hydrolyzed and thus cleaved off the assembly line (spontaneous hydrolysis or catalyzed by the 
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TE domain), which may reduce the production yield significantly. Unfortunately, such linear 
biosynthetic intermediates were not detected in culture extracts. 
 
Skipping of module 3 in the synthetic A-type mch pathway 
Similarly, skipping of module 3 in the MchC subunit would result in a noncognate interaction 
between the PCP2 domain and the donor site of the downstream C4 domain. According to the 
phylogenetic C domain sequence analysis (see Chapter 2),31 the C4 domain was predicted to 
be a LCL domain, whereas the E domain of module 2 provides a racemic mixture of the 
biosynthetic intermediate N-Me-L-Thr-(D/L)-Ala. Consequently, the C4 (LCL) domain might 
choose the L-configured intermediate, but is most likely not able to further process non-native 
dipeptide intermediate. Furthermore, it is not clear how the transfer of biosynthetic building 
blocks is mechanistically realized across individual NRPS subunits communicating via 
specific com-domains,40 which may additionally be problematic if the first module at the N-
terminus is skipped. As already mentioned above, proper termination of the biosynthesis via 
cyclization of the mature peptide could be impaired as the TE domain is possibly not able 
exert its function on the non-native intermediate. This might lead to hydrolysis of the 
biosynthetic intermediate, but linear peptide precursors were not detected in culture extracts. 
 
Skipping of module 6 in the synthetic A-type mch pathway 
The termination module of the A-type mch pathway harbors a thioesterase (TE) domain, 
which catalyzes the cyclization of the linear lipopeptide, thereby releasing the final product 
from the assembly line. It was shown that extensive domain-domain interactions between PCP 
and TE domains are crucial for the proper synchronization of this final step of the NRP 
biosynthesis.41–43 Recent structural studies on the surfactin termination module suggested that 
tremendous conformational rearrangements are necessary to guide the PCP-bound peptide 
intermediate to the adjacent TE domain due to long distances between these domains.38 In the 
case of the inactive module 6 in the engineered A-type mch pathway, it is assumed that the 
PCP5 domain, which is even more spatially separated from the downstream TE6 domain, is 
not able to interact with the TE6 acceptor site making the engineered assembly line unable to 
produce the expected lipopentapeptide core. If the noncognate PCP5-TE6 interaction is not 
functional in the engineered assembly line, the linear lipopentapeptide would most likely be 
hydrolyzed from the NRPS. However, linear biosynthetic intermediates were not found in 
culture extracts. In addition, the important role of native PCP-TE interactions is underpinned 
by the module deletion event, which was observed in the native C-type mch pathway (see 
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Chapter 2).17 The A5-PCP5-C6 unit was deleted in the course of pathway diversification rather 
than the C5-A5-PCP5 module, thereby conserving the cognate PCP6-TE6 and native PCP4-C5 
interaction.  
 
Reactivation of module 4 in the synthetic S-type mch pathway 
Surprisingly, the installation of a synthetic S-type PCP4 domain harboring the restored 
GGHSL core motif in the synthetic S-type mch pathway did not lead to the production of a 
novel lipohexapeptide core. In addition, module 4 is obviously not skipped in this engineered 
pathway as myxochromide S biosynthesis products were not detected as well. This 
unexpected result only allows highly speculative conclusions about the functionality of the 
underlying assembly line due to the lack of mechanistic and structural insights. A vague 
hypothesis could be that the native S-type mch assembly line undergoes significant structural 
changes or domain rearrangements to allow the lipopeptide intermediate to get transferred 
from module 3 to module 5, thereby skipping module 4. The Ser  Pro mutation may play an 
important role in stabilizing this conformation in conjunction with additional mutations in the 
interdomain and intermodule linkers around module 4. To re-verify the reactivation of this 
module, new mutant strains should be obtained and analyzed to exclude unexpected 
phenotypic characteristics, which could also be responsible for this observation. 
 
Overall, induction of module skipping by applying point mutations to PCP domains does not 
seem to be a tool that can be generally used in NRPS engineering. Several key factors might 
play a role in the ‘module-skipping’ process observed in myxochromide S biosynthesis,21 
including e.g. mutational changes in the surrounding linker regions of the PCP4 domain and/or 
a specific function of the proline residue in the PCP4 core motif. As codon usage analysis 
indicated that the region around modules 3 and 4 (A3-PCP3-C4-A4-PCP4) is particularly less 
adapted (see Chapter 2) and thus a hotspot for mutational activity,17 it is likely that structural 
changes of the encoded native S-type mch assembly line took place in this region, thereby 
enabling the megasynthetase to skip an entire module. However, as neither linear biosynthetic 
intermediates nor complete myxochromide derivatives were detected in extracts of the 
heterologous mutants, it has to be further analyzed whether ‘module-skipping’ indeed takes 
place in the engineered mch clusters. 
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3.3.10 Significance 
In conclusion, the establishment of synthetic DNA platforms based on a dedicated gene 
library enables an unprecedented high degree of flexibility towards the engineering of 
artificial biosynthetic gene clusters. By following the predefined constructional and functional 
sequence requirements, it is possible to design and exchange any gene cluster fragment of 
interest ranging from domains, modules and entire subunits to other functional building 
blocks for specific engineering efforts based on the described innovative DNA assembly 
strategy including the ‘desplitting’ approach. In conjunction with the detailed sequence 
analysis of evolutionary related pathways, the established platforms allow for the 
recombination of PKS/NRPS subunits to generate non-native hybrid pathways on a rational 
basis for subsequent functional expression and hybrid compound production in a selected 
heterologous host strain. This approach led to the identification of five novel ‘unnatural’ 
myxochromide peptide scaffolds, thereby further increasing the structural diversity of this 
compound class. Moreover, chemical characterization of novel hybrid metabolites can 
provide deep insights into the biosynthetic mechanisms and allows straightforward 
experimental verification of biosynthetic hypotheses based on in silico predictions. Here, the 
role of the condensation domain as a gatekeeper for stereospecific processing of biosynthetic 
intermediates has been successfully illuminated and gave rational explanations for the 
observed stereochemistry also in the native lipopeptide cores, which could not deduced from 
in silico analyses of the native mch pathways. In this study, we demonstrated how synthetic 
biology approaches essentially contribute to the rational engineering and elucidation of 
microbial natural product biosynthesis pathways. Our strategy can generally be applied to any 
desired biosynthetic gene cluster in order to alter product structures or to improve production 
yields on a broad scale, which might also be of interest for the development of natural product 
derived drugs with improved pharmacological properties driven by structure-activity 
relationship studies. It also sets the stage for future initiatives aiming at understanding the 
general principles of the sequence modulation process for the design of improved complex 
biosynthetic gene clusters. 
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3.3.11 Experimental Procedures 
3.3.11.1 Sequence Analysis and Design 
The mch clusters from strains Myxococcus xanthus DK1622 (A-type), Myxococcus sp. 171 
(B-type), Myxococcus virescens ST200611 (C-type), Stigmatella erecta Pde77 (D-type) and 
Stigmatella aurantiaca DW4/3-1 (S-type) were extensively analyzed in silico to meet the 
demands for the construction of a gene library as well as entire gene cluster constructs and for 
engineering of artificial mch pathways. To ensure the directed assembly of mch cluster 
constructs by conventional restriction/ligation cloning, six restriction enzyme sites were 
engineered within the coding sequence at the 5’ and 3’ ends of the biosynthesis genes mchA, 
mchB and mchC by point mutations (Supporting Information Table S5). A set of 19 restriction 
enzymes were further selected for the ‘desplitting’ procedure as well as for pathway 
engineering to allow for module and domain swaps, and the corresponding recognition 
sequences were eliminated along the whole gene cluster sequences by silent mutations as well 
(Supporting Information Table S2). Comparative sequence analysis of the mch clusters listed 
in Table S1 was carried out by using the Geneious alignment tool integrated into Geneious 
software version 9.1.2,44 to identify suitable positions for the SEs. Based on these sequence 
alignments, 4 bp fusion sites were selected and designed to be unique within all mch genes 
and between each domain fragment to enable the Golden Gate-based generation of a mch 
gene library using the type IIS restriction enzyme BsaI. SE sequences harboring the pre-
defined recognition sequences of conventional type II enzymes are summarized in Table S3 
(Supporting Information). 
 
3.3.11.2 De Novo Gene Synthesis of Artificial Gene Cluster Fragments and Synthetic 
Vectors 
The artificial gene cluster fragments needed for the assembly of entire synthetic mch 
pathways were designed as described in chapter 3.3.3 and were generated via DNA synthesis 
(ATG Biosynthetics GmbH, Merzhausen). The > 30 kb mch pathways were split into seven 
synthetic building blocks. Additionally, biosynthesis genes (6 up to 16 kb) were subdivided 
into two to four fragments (2.1-5.9 kb). In addition to the mchA-C gene fragments, artificial 
sequences were synthesized, which contain the promoter (native promotor from A-type 
pathway and synthetic Tn5 promoter), intergenic linkers (3mchA-5mchB and 3mchB-5mchC) 
as well as terminator (including the mchD gene and the downstream helicase gene rhlE) 
sequences. Since the domain organization of the MchA subunits appears to be basically 
identical in mch pathways, only the mchA gene of the A-type mch cluster was synthesized and 
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used for the assembly of all artificial mch cluster constructs described in this study. 
Furthermore, the MchB subunits from the A-, B-, C- and D-type assembly lines are identical 
in terms of domain arrangement and amino acid substrate selection (but different from the S-
type MchB). Thus, a synthetic version of the A-type mchB gene was also used for the 
construction of B-, C- and D-type pathways. Due to various recombination events and the 
resulting differences in the mchC genes of the mch clusters, synthetic mchC fragments from 
all mch pathways (including the corresponding terminator fragments) were designed. The 
fragments generated by DNA synthesis were additionally flanked by unique R-sites to allow 
for the subcloning of individual fragments or assembled genes into the cloning vector 
pSynbio1. The vector backbones pSynbio1 and pSynbio2 were provided as circularized 
vectors by the gene synthesis company. The synthetic constructs used in this study are listed 
in Table S4 (Supporting Information). The constructs were delivered in a standard cloning 
vector (pGH or pUC57) harboring an ampicillin resistance gene. Genetic features of the 
cloning and expression vectors are illustrated in Figures S1-S2 (Supporting Information). 
 
3.3.11.3 Microbial Strains and Culture Conditions 
Escherichia coli strains (HS996 or DH10β) were routinely grown in LB medium (1% 
tryptone, 0.5% yeast extract, 0.5% NaCl) at 30 or 37°C overnight. For myxochromide 
production analysis, Myxococcus xanthus DK1622 wildtype strain,21 the myxochromide A-
deficient mutant strain M. xanthus DK1622 ΔmchA-tet (Wenzel et al., unpublished) and its 
heterologous expression mutants (harboring artificial mch clusters) were routinely grown in 
300 mL shaking flasks on a 50 mL scale in CTT medium (casitone 1%, Tris-HCl [pH 8.0] 10 
mM, K2HPO4/KH2PO4 buffer [pH 7.6] 1 mM, MgSO4 × 7 H2O 8 mM, pH adjusted to 7.6) at 
30°C and 180 rpm for 4-5 days. For the isolation of hybrid myxochromides, fermentations on 
a 1 L scale were performed under the same conditions in 5L shaking flasks.  Cultures were 
amended with antibiotics if necessary in the following final concentrations: ampicillin 100 
µg/mL, kanamycin 50 µg/mL, oxytetracycline 10 µg/mL. 
 
3.3.11.4 DNA Isolation, Processing and Analysis 
Enzymes used in this study were purchased from Fermentas. Oligonucleotides used in 
polymerase chain reactions (PCR) were obtained from Sigma. DNA was extracted and 
purified from E. coli strains by using a standard alkaline lysis protocol,45 or by using the 
GeneJET Plasmid Miniprep Kit from Thermo Fisher Scientific. For standard cloning 
procedures, plasmid DNA, which was hydrolyzed for subsequent ligation into an acceptor 
183     Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis 
 
vector, was separated by agarose gel electrophoresis and cleaved DNA fragments were 
purified from the agarose gel by using the peqGOLD Gel Extraction Kit from PeqLab. 
Acceptor DNA was further dephosphorylated using the shrimp alkaline phosphatase from 
Fermentas. Ligations were carried out using the T4 ligase from Fermentas. Ligations were 
routinely dialyzed using MF-nitrocellulose membranes (0.025 µm) from Merck Millipore 
prior to transformation via electroporation in either E. coli or M. xanthus host strains. 
‘Desplitting’ reactions were purified by applying the QIAquick PCR Purification Kit from 
Qiagen with a cut-off of 100 bp in order to remove the released SEs. PCRs were performed 
using the PCR machine Mastercycler pro from Eppendorf. All methods were performed 
according to the manufacturers or to standard protocols.45 For details regarding the cloning 
vectors, constructed plasmids, expression constructs and applied PCR conditions see 
Supporting Information. 
 
3.3.11.5 Heterologous Expression of Artificial mch Pathways in M. xanthus  
The mch expression constructs were transformed into M. xanthus DK1622 ΔmchA-tet 
(Wenzel et al., unpublished) via electroporation using established standard protocols.20 
Mutants resistant to kanamycin were selected and further analyzed for correct integration of 
the mch pathways into the former mchA gene cluster locus in M. xanthus DK1622 ΔmchA-tet 
via single crossover. To isolate chromosomal DNA, cells from a CTT agar plate were re-
suspended in 100 µL water and heated at 100°C for 10 min. 1 µL of this mixture was used as 
template for PCR. Detailed information on applied PCR conditions and used oligonucleotides 
is given in the Supporting Information (Figure S4, Tables S10 and S11). 
 
3.3.11.6 Myxochromide Production Analysis 
Myxochromide production analysis in the heterologous production strains was carried out on 
a 50 mL scale under routine cultivation conditions. Cells and Amberlite XAD-16 adsorber 
resin were harvested by centrifugation at 8,000 rpm and 4 °C for 10 min and subsequently 
extracted twice with 50 mL of a mixture of methanol and acetone (1:1). The extracts were 
evaporated to dryness, dissolved in methanol and subjected to HPLC-MS analysis using a 
Dionex Ultimate 3000 RSLC system coupled to a Bruker maXis 4G TOF mass spectrometer. 
Separation was performed using a Waters BEH C18, 100 × 2.1 mm, 1.7 µm dp column. At a 
flow rate of 0.6 mL/min, the following gradient was applied (A: deionized water + 0.1% 
formic acid, B: acetonitrile + 0.1% formic acid): 0-0.5 min 5% B, 0.5-18.5 min 5-95% B, 
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18.5-20.5 min 95% B. Full scan mass spectra were acquired in positive ESI mode in a range 
from 150-2500 m/z. 
 
3.3.11.7 Isolation and Structure Elucidation of Engineered Hybrid Myxochromides 
Selected representatives of the engineered hybrid myxochromides (AS-type, SA-type, SB-
type, SC-type, and SD type) were isolated from culture extracts of the heterologous 
production strains via semi-preparative reversed-phase HPLC. The planar structures were 
elucidated based on 1D (1H) and 2D (1H−1H COSY, HSQC, HMBC, and ROESY) NMR 
spectroscopy as well as HR-ESI-MS data. The absolute configuration of the amino acid 
residues was determined by HPLC-MS analysis of the L- and D-FDLA (1-fluoro-2,4- 
dinitrophenyl-5-L-/D-leucinamide) derivatives of the acid hydrolysate of myxochromides in 
comparison with corresponding derivatives of L-configured amino acid standards (Marfey’s 
method).32 The following myxochromide derivatives were purified and structurally 
characterized: 
 
Myxochromide AS4 (1c). A total of 4.5 mg of 1c was isolated from a 18 L culture (18x 1L) of 
Myxococcus xanthus DK1622 ΔmchA-tet::pSynMch8. The molecular formula was established 
to be C38H52N6O8 (m/z 721.39373 [M + H]+). NMR spectra and selected correlations are 
illustrated in Supporting Information Figures S5 and S6, and HPLC-MS analysis of L- and D-
FDLA derivatives from the 1c hydrolysate is shown in Supporting Information Figure S7. For 
details, see Supporting Information. 
Myxochromide SA3 (2b). A total of 7.2 mg of 2b was isolated from a 9 L culture (9x 1L) of 
Myxococcus xanthus DK1622 ΔmchA-tet::pSynMch14. The molecular formula was 
established to be C48H69N7O9 (m/z 888.52409 [M + H]+). NMR spectra and selected 
correlations are illustrated in Supporting Information Figures S8 and S9, and HPLC-MS 
analysis of L- and D-FDLA derivatives from the 2b hydrolysate is shown in Supporting 
Information Figure S10. For details, see Supporting Information. 
Myxochromide SB4 (3c). A total of 7.5 mg of 3c was isolated from a 9 L culture (9x 1L) of 
Myxococcus xanthus DK1622 ΔmchA-tet::pSynMch15. The molecular formula was 
established to be C54H80N8O10 (m/z 1015.62390 [M + H]+). NMR spectra and selected 
correlations are illustrated in Supporting Information Figures S11 and S12, and HPLC-MS 
analysis of L- and D-FDLA derivatives from the 3c hydrolysate is shown in Supporting 
Information Figure S13. For details, see Supporting Information. 
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Myxochromide SC4 (4c). A total of 0.5 mg of 4c was isolated from a 18 L culture (18x 1L) of 
Myxococcus xanthus DK1622 ΔmchA-tet::pSynMch11. The molecular formula was 
established to be C46H66N6O8 (m/z 831.50222 [M + H]+). NMR spectra and selected 
correlations are illustrated in Supporting Information Figures S14 and S15, and HPLC-MS 
analysis of L- and D-FDLA derivatives from the 4c hydrolysate is shown in Supporting 
Information Figure S16. For details, see Supporting Information. 
Myxochromide SD3 (5b). A total of 0.7 mg of 5b was isolated from a 9 L culture (9x 1L) of 
Myxococcus xanthus DK1622 ΔmchA-tet::pSynMch16. The molecular formula was 
established to be C44H64N6O8 (m/z 791.47051 [M + H]+). NMR spectra and selected 
correlations are illustrated in Supporting Information Figures S17 and S18, and HPLC-MS 
analysis of L- and D-FDLA derivatives from the 5b hydrolysate is shown in Supporting 
Information Figure S19. For details, see Supporting Information. 
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3.4 Supporting Information 
3.4.1 Constructional Sequence Design of mch Clusters 
Synthetic DNA platforms for the production of novel myxochromide peptide scaffolds were 
created based on the native mch pathways, which were characterized in detail in Chapter 2.17 
The artificial mch cluster sequences were adapted to the highly flexible assembly strategy 
based on type IIS restriction enzymes developed in this work. Native mch clusters, which 
were subjected to the constructional sequence design process, are shown in Table S1.  
Table S1: Overview on myxochromide biosynthetic gene clusters (mch clusters) which were subjected to the 
gene design process in this study. 
 
Producer strain Strain abbrev. Cluster 
GenBank  
Accession[a] 
Myxococcus xanthus DK1622 Mx1 A-type [b] KX622595 
Myxococcus sp. 171 [c] M1 B-type [d] KX622591 
Myxococcus virescens ST200611 Mv1 C-type [e] KX622594 
Stigmatella erecta Pde77 Se1 D-subtype 1 [f] KX622602 
Stigmatella aurantiaca DW4/3-1 Sa1 S-type [g] KX622599 
    
[a] Annotated cluster files were additionally deposited in the MiBIG database. [b] Characterized in previous 
study.18 [c] Unclassified strain belonging to the genus Myxococcus. [d] Characterized in Chapter 2.17 [e] 
Characterized in Chapter 2.17 [f] Characterized in Chapter 2.17 [g] Characterized in previous study.21 
 
To allow for the interchangeability of modules or even single domains, splitter elements (SE) 
were introduced between each domain of the biosynthesis genes mchA-C. The SE are 
composed of type IIS R-sites (AarI/BsaI) at both sites and harbor an additional spacer 
sequence in-between, which displays the recognition sequence of a type II restriction enzyme 
suitable for domain and module swaps or for the introduction of additional cluster fragments. 
The 4 bp overhangs, which are generated by hydrolysis with AarI/BsaI, are selected and 
designed to be unique between each domain fragment along the whole cluster sequence, and 
can thus be used as unique fusion sites to allow for a directed reassembly of the biosynthesis 
genes. Selected type II restriction enzymes are listed in Table S2. Sequences of designed SE 
are shown in Table S3. Locations of the unique fusion sites are summarized in Table S4. 
Locations of unique R-sites, which were engineered in the coding sequence (CDS) at the 5’ 
and 3’ ends of each mch gene fragment, are shown in Table S5. 
 
 
187     Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis 
 
Table S2: Restriction enzyme sites used for pathway assembly and engineering. To allow for the assembly and 
interchangeability of mch cluster parts, the recognition sequences of 6 type II restriction enzymes were 
introduced into the coding sequence of mch genes (highlighted in red) and recognition sequences of another 19 
restriction enzymes were eliminated from the CDS sequences. 
 
Restriction enzyme Recognition sequence Function 
AarI 
CACCTGC 
GTGGACG 
RIIS 
AflII (BspTI) 
CTTAAG 
GAATTC 
Rx5, Ry6, Rz7 
AgeI 
ACCGGT 
TGGCCA 
Rz14 
AseI (VspI) 
ATTAAT 
TAATTA 
Rz9 
AsiSI (SfaAI) 
GCGATCGC 
CGCTAGCG 
Rx3, Ry3, Rz3 
AvrII (XmaJI) 
CCTAGG 
GGATCC 
Ry7, Rz11 
BamHI 
GGATCC 
CCTAGG 
Rz10 
BsaI 
GGTCTC 
CCAGAG 
RIIS 
BsiWI 
CGTACG 
GCATGC 
Rx1 
DraI 
TTTAAA 
AAATTT 
Destruction of cloning 
vector backbone 
EcoRI 
GAATTC 
CTTAAG 
Rz4 
HindIII 
AAGCTT 
TTCGAA 
Rz12 
KpnI 
GGTACC 
CCATGG 
RL 
MfeI (MunI) 
CAATTG 
GTTAAC 
Rz6 
MluI 
ACGCGT 
TGCGCA 
Ry1, Rz15 
MreI 
CGCCGGCG 
GCGGCCGC 
Rx6, Rz17 
NdeI 
CATATG 
GTATAC 
Rx4, Ry2, Rz5 
NheI 
GCTAGC 
CGATCG 
Rz13 
NotI 
GCGGCCGC 
CGCCGGCG 
Ry8, Rz16 
PacI 
TTAATTAA 
AATTAATT 
Vector backbone 
modification 
PmeI (MssI) 
GTTTAAAC 
CAAATTTG 
Vector backbone 
modification 
PvuI 
CGATCG 
GCTAGC 
RR 
SpeI (BcuI) 
ACTAGT 
TGATCA 
Rx2, Ry5, Rz2 
SphI 
GCATGC 
CGTACG 
Rz1 
SwaI (SmiI) 
ATTTAAAT 
TAAATTTA 
Vector backbone 
modification 
XbaI 
TCTAGA 
AGATCT 
Rx6, Ry4, Rz8 
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Table S3. Artificial splitter element (SE) sequences of mch genes derived from A-, B-, C-, D- and S-type mch 
clusters based on the BsaI design. SEs were introduced between each domain fragment of the mch genes (except 
between the KR and ACP domain of mchA). For the mchA gene, only the PKS CDS sequence from the A-type 
producer strain (Mx1) was subjected to the sequence design. For the mchB gene, only the NRPS CDS sequences 
from the A-, D- and S-type producer strains (Mx1, Se1, Sa1) were subjected to the sequence design. Unique 
fusion sites are highlighted in light gray, the BsaI recognition sequence in red, and the unique R-sites within the 
SEs in black. The spacer nucleotide which is skipped by the type IIS restriction enzyme is shown in dark grey. 
 
Linker region Splitter element sequence (including fusion sites) 
 
Function 
mchA (A-type) 
N-Term NA-GGTCTCCGCAA-KS BsiWI 
KS-AT KS-CACCTGAGACCACTAGTGGTCTCCCACC-AT SpeI 
AT-DH AT-GGCAGGAGACCGCGATCGCGGTCTCTGGCA-DH AsiSI 
DH-ER DH-ACGGAGAGACCCATATGGGTCTCGACGG-ER NdeI 
ER-KR/ACP ER-CGTTCGAGACCCTTAAGGGTCTCTCGTT-KR/ACP AflII 
C-Term KR/ACP-ATCGCGAGACC-CA MreI 
mchB (A-, D- and S-type) 
N-Term NB-GGTCTCCTTCG-C1 MluI 
C1-A1 C1-GCGCCGAGACCCATATGGGTCTCCGCGC-A1 NdeI 
A1-CP1 A1-CGCGGGAGACCGCGATCGCGGTCTCTCGCG-CP1 AsiSI 
CP1-C2 CP1-AGCGAGAGACCTCTAGAGGTCTCGAGCG-C2 XbaI 
C2-A2 C2-CAGCCGAGACCACTAGTGGTCTCGCAGC-A2 SpeI 
A2-CP2 A2-GAAGTGAGACCCTTAAGGGTCTCCGAAG-CP2 AflII 
CP2-E2 CP2-GCAGGGAGACCCCTAGGGGTCTCTGCAG-E2 AvrII 
C-Term E2-TCCCCGAGACC-CB NotI 
mchC (A-, D- and S-type) 
N-Term NC-GGTCTCTAGCA–C3 SphI 
C3-A3 C3-GAGCCGAGACCACTAGTGGTCTCGGAGC-A3 SpeI 
A3-CP3 A3-GGAGCGAGACCGCGATCGCGGTCTCGGGAG-CP3 AsiSI 
CP3-C4 CP3-GGACTGAGACCGAATTCGGTCTCCGGAC-C4 EcoRI 
C4-A4 C4-ACACCGAGACCCATATGGGTCTCTACAC-A4 NdeI 
A4-CP4 A4-CCGCAGAGACCCAATTGGGTCTCTCCGC-CP4 MfeI 
CP4-C5 CP4-CGAGCGAGACCCTTAAGGGTCTCTCGAG-C5 AflII 
C5-A5 C5-CGGACGAGACCTCTAGAGGTCTCTCGGA-A5 XbaI 
A5-CP5 A5-TGGAGGAGACCATTAATGGTCTCATGGA-CP5 AseI 
CP5-C6 CP5-CGCCAGAGACCGGATCCGGTCTCACGCC-C6 BamHI 
C6-A6 C6-CGACCGAGACCCCTAGGGGTCTCACGAC-A6 AvrII 
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A6-CP6 A6-GCGATGAGACCAAGCTTGGTCTCCGCGA-CP6 HindIII 
CP6-TE CP6-CGCTGGAGACCGCTAGCGGTCTCTCGCT-TE NheI 
C-Term TE-GCTCCGAGACC-CC AgeI 
mchC (B-type) 
N-Term NC-GGTCTCTAGCA–C3 SphI 
C3-A3 C3-GAGCCGAGACCACTAGTGGTCTCGGAGC-A3 SpeI 
A3-CP3 A3-GGAGCGAGACCGCGATCGCGGTCTCGGGAG-CP3 AsiSI 
CP3-C4 CP3-GGACTGAGACCGAATTCGGTCTCCGGAC-C4 EcoRI 
C4-A4 C4-ACCTCGAGACCACGCGTGGTCTCGACCT-A4 MluI 
A4-CP4 A4-TCGCCGAGACCGCGGCCGCGGTCTCGTCGC-CP4 NotI 
CP4-C5 CP4-TCTCCGAGACCCGCCGGCGGGTCTCGTCTC-C5 MreI 
C5-A5 C5-ACACCGAGACCCATATGGGTCTCTACAC-A5 NdeI 
A5-CP5 A5-CCGCAGAGACCCAATTGGGTCTCTCCGC-CP5 MfeI 
CP5-C6 CP5-CGAGCGAGACCCTTAAGGGTCTCTCGAG-C6 AflII 
C6-A6 C6-CGGACGAGACCTCTAGAGGTCTCTCGGA-A6 XbaI 
A6-CP6 A6-TGGAGGAGACCATTAATGGTCTCATGGA-CP6 AseI 
CP6-C7 CP6-CGCCAGAGACCGGATCCGGTCTCACGCC-C7 BamHI 
C7-A7 C7-CGACCGAGACCCCTAGGGGTCTCACGAC-A7 AvrII 
A7-CP7 A7-GCGATGAGACCAAGCTTGGTCTCCGCGA-CP7 HindIII 
CP7-TE CP7-CGCTGGAGACCGCTAGCGGTCTCTCGCT-TE NheI 
C-Term TE-GCTCCGAGACC-CC AgeI 
mchC (C-type) 
N-Term NC-GGTCTCTAGCA–C3 SphI 
C3-A3 C3-GAGCCGAGACCACTAGTGGTCTCGGAGC-A3 SpeI 
A3-CP3 A3-GGAGCGAGACCGCGATCGCGGTCTCGGGAG-CP3 AsiSI 
CP3-C4 CP3-GGACTGAGACCGAATTCGGTCTCCGGAC-C4 EcoRI 
C4-A4 C4-ACACCGAGACCCATATGGGTCTCTACAC-A4 NdeI 
A4-CP4 A4-CCGCAGAGACCCAATTGGGTCTCTCCGC-T4 MfeI 
CP4-C5 CP4-CGAGCGAGACCCTTAAGGGTCTCTCGAG-C5 AflII 
C5-A6 C5-CGGACGAGACCTCTAGAGGTCTCTCGGA-A6 XbaI 
A6-CP6 A6-GCGATGAGACCAAGCTTGGTCTCCGCGA-CP6 HindIII 
CP6-TE CP6-CGCTGGAGACCGCTAGCGGTCTCTCGCT-C6 NheI 
C-Term TE-GCTCCGAGACC-CC AgeI 
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Table S4. Locations of selected/designed unique fusion sites between the domains of mch genes derived from A-
, B-, C-, D- and S-type mch clusters based on the BsaI design. Locations are referring to the individual mch 
genes retrieved from the GenBank mch cluster entries. Unique fusion sites were designed between each domain 
fragment of the mch genes (except between the KR and CP domain of mchA). For the mchA gene, only the PKS 
CDS sequence from the A-type producer strain (Mx1) was subjected to the sequence design. For the mchB gene, 
only the NRPS CDS sequences from the A-, D- and S-type producer strains (Mx1, Se1, Sa1) were subjected to 
the sequence design. Unique fusion sites are highlighted in gray. Mutated nucleotides/amino acids are shown in 
italics. 
 
Linker Fusion site 
Location 
(within gene) 
Relevant Codons 
Amino 
acids 
mchA (A-type)[1] 
N-Term R5A GCAA 191 – 194  GGC AAG ACG G K T 
KS-AT Rx2 CACC 1498 – 1501  GAG CAC CGG E H R 
AT-DH Rx3 GGCA 2645 – 2648  TGG CAG CGT W Q R 
DH-ER Rx4 ACGG 4295 – 4298  CTC GAC GGC L D G 
ER-
KR/ACP 
Rx5 CGTT 5186 – 5189  CTG ACG TTC L T F 
C-Term R3A ATCG 6361 – 6364  GAA ATC GAG E I E 
mchB (A-type)[1] 
N-Term R5B TTCG 232 – 235  TTC GGA ATG F G L 
C1-A1 Ry2 GCGC 1304 – 1307  CGG GGC GCC R G A 
A1-CP1 Ry3 CGCG 4282 – 4285  CGG CGC GCC R R A 
CP1-C2 Ry4 AGCG 4604 – 4607  ATG GAG CGC M E R 
C2-A2 Ry5 CAGC 5826 – 5829  TTC AGC GCG F S A 
A2-CP2 Ry6 GAAG 7437 - 7440 AAG AAG CTT K K L 
CP2-E2 Ry7 GCAG 7739 – 7742  GGC AGC GCG G S A 
C-Term R3B TCCC 9080 – 9083  GAC TTC CCG D F P 
mchB (D-type)[2] 
N-Term R5B TTCG 232 – 235  TTC GAG ATA F E I 
C1-A1 Ry2 GCGC 1304 – 1307  CGC GGC GCG R G A 
A1-CP1 Ry3 CGCG 4312 – 4315  CGG CGC GCC 
(CGG CGA GCC) 
R R A 
(R R A) 
CP1-C2 Ry4 AGCG 4634 – 4637  ATG GAG CGG M E R 
C2-A2 Ry5 CAGC 5856 – 5859  TAC AGC GCG Y S A 
A2-CP2 Ry6 GAAG 7467 – 7470  AAG AAG CTG K K L 
CP2-E2 Ry7 GCAG 7769 – 7772  ACG GGC AGT 
(ACG GGG AGT) 
T G S 
(T G S) 
C-Term R3B TCCC 9107 – 9110  GAC TTC CCA D F P 
mchB (S-type)[3] 
N-Term R5B TTCG 232 – 235  TTC GAG ATG F E M 
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C1-A1 Ry2 GCGC 1304 – 1307  CGC GGC GCG R G A 
A1-CP1 Ry3 CGCG 4312 – 4315  CGG CGC GCG R R A 
CP1-C2 Ry4 AGCG 4634 – 4637  ATG GAG CGG M E R 
C2-A2 Ry5 CAGC 5856 – 5859  TAC AGC GCG Y S A 
A2-CP2 Ry6 GAAG 7467 – 7470  AAG AAG CTC K K L 
CP2-E2 Ry7 GCAG 7769 – 7772  ACG GGC AGC T G S 
C-Term R3B TCCC 9107 – 9110 GAT TTC CCA D F P 
mchC (A-type)[1] 
N-Term R5C AGCA 50 – 53  CAG CAC GGC Q H G 
C3-A3 Rz2 GAGC 1240 – 1243  GCG GAG CGC A E R 
A3-CP3 Rz3 GGAG 2853 – 2856  CTG GAG GCC L E A 
CP3-C4 Rz4 GGAC 3147 – 3150  GGG GAC ACG 
(GGA GAC ACG) 
G D T 
(G D T) 
C4-A4 Rz5 ACAC 4325 – 4328  GAC ACG GAC D T D 
A4-CP4 Rz6 CCGC 5960 – 5963  CCC GCC CCC P A P 
CP4-C5 Rz7 CGAG 6270 – 6273  CCC GAG GGC P E G 
C5-A5 Rz8 CGGA 7469 – 7472  ACG GAC CTC T D L 
A5-CP5 Rz9 TGGA 9083 – 9086  GTG GAC AAG V D K 
CP5-C6 Rz10 CGCC 9400 – 9403  GTC CGC CTG 
(GTC CGA CTG) 
V R L 
(V R L) 
C6-A6 Rz11 CGAC 10605 – 10608  CGC GAC CTC R D L 
A6-CP6 Rz12 GCGA 12235 – 12238  AGC GCG ATG S A M 
CP6-TE Rz13 CGCT 12527 – 12530  CCG CTC ACC P L T 
C-Term R3C GCTC 13227 – 13230  GCG GCG CTC A A L 
mchC (B-type)[4] 
N-Term R5C AGCA 50 – 53  CAG CAC GGC Q H G 
C3-A3 Rz2 GAGC 1240 – 1243  GCG GAG CGC A E R 
A3-CP3 Rz3 GGAG 2853 – 2856  CTG GAG GCC L E A 
CP3-C4 Rz4 GGAC 3147 – 3150  GGG GAC ACG 
(GGA GAC ACG) 
G D T 
(G D T) 
C4-A4 Rz15 ACCT 4414 – 4417  CAA ACC TCC Q T S 
A4-CP4 Rz16 TCGC 5971 – 5974  GAG TCG CAG E S Q 
CP4-C5 Rz17 TCTC 6239 – 6242  ATC TCT CGC I S R 
C5-A5 Rz5 ACAC 7439 – 7442  GAC ACC GAC D T D 
A5-CP5 Rz6 CCGC 9074 – 9077  CCC GCG CCG P A P 
CP5-C6 Rz7 CGAG 9381 – 9384  CCC GAG GGC 
(CCC GAA GGC) 
P E G 
(P E G) 
C6-A6 Rz8 CGGA 10580 – 10583  ACG GAC CTC T D L 
A6-CP6 Rz9 TGGA 12194 – 12197  GTG GAC AAG V D K 
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CP6-C7 Rz10 CGCC 12511 – 12514  GTC CGC CTG 
(GTC CGG TTG) 
V R L 
(V R L) 
C7-A7 Rz11 CGAC 13716 – 13719  GTC GAC CTC V D L 
A7-CP7 Rz12 GCGA 15346 – 15349  GGT GCG ATG G A M 
CP7-TE Rz13 CGCT 15638 – 15641  CCG CTG ACC P L T 
C-Term R3C GCTC 16335 - 16338 CCG GCG CTC P A L 
 mchC (C-type)[5]  
N-Term R5C AGCA 50 – 53  CAG CAC GGC Q H G 
C3-A3 Rz2 GAGC 1240 – 1243  GCC GAG CGC A E R 
A3-CP3 Rz3 GGAG 2853 – 2856  CAG GAG ACG Q E T 
CP3-C4 Rz4 GGAC 3147 – 3150  GAG GAC ACG E D T 
C4-A4 Rz5 ACAC 4325 – 4328  GAC ACC GAC D T D 
A4-CP4 Rz6 CCGC 5960 – 5963  CCC GCG CCT P A P 
CP4-C5 Rz7 CGAG 6270 – 6273  CCC GAG GGC 
(CCG GAG GGC) 
P E G 
(P E G) 
C5-A6 Rz8 CGGA 7469 – 7472  ACG GAC CTC T D L 
A6-CP6 Rz12 GCGA 9100 – 9103  GGC GCG ATG 
(GGC GCG CTG) 
G A M 
(G A L) 
CP6-TE Rz13 CGCT 9392 – 9395  CCG CTG ACG P L T 
C-Term R3C GCTC 10098 - 10101 CCG GAG CTC P E L 
mchC (D-type)[2] 
N-Term R5C AGCA 50 – 53  CAG CAC GGC Q H G 
C3-A3 Rz2 GAGC 1240 – 1243  GCC GAG CGG A E R 
A3-CP3 Rz3 GGAG 2880 – 2883  ACG GAG CAC 
(ACA GAG CAC) 
T E H 
(T E H) 
CP3-C4 Rz4 GGAC 3156 – 3159  GGG GAC GGG 
(GGT GAC GGG) 
G D G 
(G D G) 
C4-A4 Rz5 ACAC 4334 – 4337  AAC ACC GAC N T D 
A4-CP4 Rz6 CCGC 5969 – 5972  CCC GCG CCT P A P 
CP4-C5 Rz7 CGAG 6276 – 6279  CCC GAG AGC 
(CCG GAG AGC) 
P E S 
(P E S) 
C5-A5 Rz8 CGGA 7475 – 7478  ACG GAC CTC T D L 
A5-CP5 Rz9 TGGA 9089 – 9092  GTG GAC AAG V D K 
CP5-C6 Rz10 CGCC 9406 – 9409  GTG CGC CTG 
(GTG CGG CTG) 
V R L 
(V R L) 
C6-A6 Rz11 CGAC 10611 – 10614  CTC GAC CTG L D L 
A6-CP6 Rz12 GCGA 12241 – 12244  GGG GCG ATG 
(GGG ACG ATG) 
G T M 
(G A M) 
CP6-TE Rz13 CGCT 12533 – 12536  CCG CTC ACG 
(CCT CTC ACG) 
P L T 
(P L T) 
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C-Term R3C GCTC 13239 – 13242  CCT GAG CTC 
(CCT GAG CTT) 
P E L 
(P E L) 
mchC (S-type)[3] 
N-Term R5C AGCA 50 – 53 CAG CAC GGC Q H G 
C3-A3 Rz2 GAGC 1240 – 1243  GTC GAG CAG V E Q 
A3-CP3 Rz3 GGAG 2862 – 2865  AAG GAG TTG K E L 
CP3-C4 Rz4 GGAC 3156 – 3159  GGG GAC GTC G D V 
C4-A4 Rz5 ACAC 4337 – 4340  AAC ACC GAC N T D 
A4-CP4 Rz6 CCGC 5972 – 5975  CCC GCG CCC P A P 
CP4-C5 Rz7 CGAG 6279 – 6282  CCC GAG AGC 
(CCG GAG AGC) 
P E S 
(P E S) 
C5-A5 Rz8 CGGA 7478 – 7481  ACG GAC CTC T D L 
A5-CP5 Rz9 TGGA 9092 – 9095  GTG GAC AAG V D K 
CP5-C6 Rz10 CGCC 9409 – 9412  GTG CGC CTG 
(GTG CGG CTG) 
V R L 
(V R L) 
C6-A6 Rz11 CGAC 10614 – 10617  CTC GAC CTG L D L 
A6-CP6 Rz12 GCGA 12244 – 12247  GCC GCG ATG A A M 
CP6-TE Rz13 CGCT 12536 – 12539  CCG CTC ACG P L T 
C-Term R3C GCTC 13242 – 13245  CCA GAG CTC P E L 
[1] Location of fusion sites based on mch cluster retrieved from GeneBank entry KX622595. [2] Location of 
fusion sites based on mch cluster retrieved from GeneBank entry KX622602. [3] Location of fusion sites based 
on mch cluster retrieved from GeneBank entry KX622599. [4] Location of fusion sites based on mch cluster 
retrieved from GeneBank entry KX622591. [5] Location of fusion sites based on mch cluster retrieved from 
GeneBank entry KX622594. 
 
Table S5. Locations of the unique R-sites at the 5’ and 3’ ends of the mch biosynthesis gene fragments. R-sites 
engineering was performed within the CDS sequences of the mch gene fragments to allow for conventional 
stitching of the artitifical mch clusters by applying point mutations. Locations are referring to the individual mch 
genes retrieved from the GenBank mch cluster entries. Unique R-sites (Rx1, Rx6, Ry1, Ry8, Rz1, Rz14) are 
highlighted in gray. Mutated nucleotides/amino acids are shown in italics. 
 
Terminus Gene R-sites 
Location 
(within gene) 
Relevant Codons 
Amino 
acids 
A-type mch cluster[1] 
N-Term mchA Rx1 197 – 202  ACG TAC GTG T Y V 
C-Term mchA Rx6 6326 – 6333  GCG CCG GCG 
(GCG CCC GCG) 
A P A 
(A P A) 
N-Term mchB Ry1 254 – 259  CAC GCG TCC H A S 
C-Term mchB Ry8 9052 – 9059  GCG GCC GCG 
(GCC GCG GCG) 
A A A 
(A A A) 
N-Term mchC Rz1 56 – 61  GGC ATG CTC G M L 
C-Term mchC Rz14 13202 – 13207  GAC CGG TGT 
(GAC CGC AGT) 
D R C 
(D R S) 
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B-type mch cluster[2] 
N-Term mchC Rz1 56 – 61  GGC ATG CTC G M L 
C-Term mchC Rz14 16310 – 16315  GAC CGG TGC 
(GAC CGT GGC) 
D R C 
(D R G) 
C-type mch cluster[3] 
N-Term mchC Rz1 56 – 61  GGC ATG CTC G M L 
C-Term mchC Rz14 10073 – 10078  GAC CGG TGC 
(GAC CGG AGC) 
D R C 
(D R S) 
D-type mch cluster[4] 
N-Term mchB Ry1 254 – 259  CAC GCG TGC 
(CAC CCG AGC) 
H A C 
(H P S) 
C-Term mchB Ry8 9079 – 9086  GCG GCC GCG 
(GCC GCG ACG) 
A A A 
(A A T) 
N-Term mchC Rz1 56 – 61  GGC ATG CTC G M L 
C-Term mchC Rz14 13214 – 13219  GAC CGG TAT 
(GAC AGG GAT) 
D R Y 
(D R D) 
S-type mch cluster[5] 
N-Term mchB Ry1 254 – 259  CAC GCG TGC 
(CAC CCG AGC) 
H A C 
(H P S) 
C-Term mchB Ry8 9079 – 9086  GCG GCC GCA 
(GCA GCC GCA) 
A A A 
(A A A) 
N-Term mchC Rz1 56 – 61  GGC ATG CTG G M L 
C-Term mchC Rz14 13217 – 13222  GAC CGG TAC 
(GAC AGG GAC) 
D R Y 
(D R D) 
[1] Location of R-sites based on mch cluster retrieved from GeneBank entry KX622595. [2] Location of R-sites 
based on mch cluster retrieved from GeneBank entry KX622591. [3] Location of R-sites based on mch cluster 
retrieved from GeneBank entry KX622594. [4] Location of R-sites based on mch cluster retrieved from 
GeneBank entry KX622602. [5] Location of R-sites based on mch cluster retrieved from GeneBank entry 
KX622599. 
 
 
3.4.2 Design of the Cloning Vector pSynbio1 and the Expression Vector pSynbio2 
For the assembly of large biosynthesis gene fragments and for ‘desplitting’ processes, the 
cloning vector pSynbio1, which is a derivative of the pGH vector, was designed and 
manufactured by DNA synthesis. The high-copy vector backbone pSynbio1 is composed of a 
minimal set of genetic elements needed for the amplification and selection in E. coli. These 
include the oriV origin of vegetative replication from the broad-range RK2 plasmid,46 the trfA 
gene, whose gene product binds to and activates oriV, which leads to unidirectional 
replication,47–49 and an ampicillin resistance gene (ampR). To meet the constructional 
requirements, the recognition sequences needed for cloning and assembly of the expression 
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constructs (Table S2) were calculated out of the vector sequence. Recognition sequences of 
the type II enzymes KpnI and PmeI were introduced into the vector backbone to allow for the 
subcloning of synthetic fragments. The genetic map of pSynbio1 is illustrated in Figure S1. 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Genetic map of the cloning vector pSynbio1. 
 
The expression vector pSynbio2 was designed and manufactured by DNA synthesis for the 
functional expression of artificial mch clusters in the heterologous host M. xanthus DK1622 
(see Section ‘Functional Sequence Design for Heterologous Expression’). The genetic map of 
the pSynbio2 vector showing the unique R-sites for modification of the vector backbone is 
illustrated in Figure S2. Information on the different genetic element are given in Chapter 
3.3.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Genetic map of the expression vector pSynbio2. 
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3.4.3 Generation of mch Cluster Fragments via DNA Synthesis 
Artificial mch cluster fragments, which were designed and synthesized in this study, are 
shown in Table S6. Cluster fragments were delivered either in the pGH vector (pUC 
derivative) or in the pUC57 vector backbone harboring an ampicillin resistance gene. 
 
Table S6. Artificial DNA fragments from mch gene clusters generated via DNA synthesis.  
 
Construct Name Description 
(Location in GenBank file) 
Size 
[bp] 
Flanking R-sites 
A-type mch cluster fragments from M. xanthus DK1622[1] 
pGH-P-5mchA_Ab Promotor fragment 
(6607-7208 nt) 
3539 KpnI-BsiWI/PmeI 
pGH-3mchA-5mchB_Ab Linker fragment 
(13332-13720 nt) 
3326 KpnI/MreI-MluI/PmeI 
pGH-3mchB-5mchC_Ab Linker fragment 
(22513-22701nt) 
3126 KpnI/NotI-SphI/PmeI 
pGH-T-3mchC_Ab Terminator fragment 
(35867-38440 nt) 
5547 KpnI/AgeI-PvuI/PmeI 
pGH-MchA_A_fragA mchA gene fragment 
(7197-11354 nt) 
7116 KpnI/BsiWI-NdeI/PmeI 
pGH-MchA_A_fragA_dcm mchA gene fragment 
(7197-8507 nt) 
4260 KpnI/BsiWI-SpeI 
pGH-MchA_A_fragB mchA gene fragment 
(11301-13394 nt) 
5063 KpnI/NdeI-MreI/PmeI 
pGH-MchB_A_fragA mchB gene fragment 
(13693-19364 nt) 
8628 KpnI/MluI-SpeI/PmeI 
pGH-MchB_A_fragA_dcm mchB gene fragment 
(13693-14768 nt) 
4026 KpnI/MluI-NdeI 
pGH-MchB_A_fragB mchB gene fragment  
(19287-22592 nt) 
6275 KpnI/SpeI-NotI/PmeI 
pGH-MchC_A_fragA mchC gene fragment 
(22690-27042 nt) 
7295 KpnI/SphI-NdeI/PmeI 
pGH-MchC_A_fragA_dcm mchC gene fragment 
(22690-23883 nt) 
4138 KpnI/SphI-SpeI 
pGH-MchC_A_fragB mchC gene fragment 
(26965-31798 nt) 
7797 KpnI/NdeI-AseI/PmeI 
pGH-MchC_A_fragC mchC gene fragment 
(31723-35966 nt) 
7207 KpnI/AseI-AgeI/PmeI 
pGH-MchC_A_fragC_dcm mchC gene fragment 
(31723-32043 nt) 
3264 AseI-BamHI 
pUC57-CP1_A_inact1 Carrier protein fragment 
(17743-18068 nt) 
3078 KpnI/AsiSI-XbaI/PmeI 
pUC57-CP2_A_inact1 Carrier protein fragment 
(20898-21203 nt) 
3056 KpnI/AflII-AvrII/PmeI 
pUC57-CP3_A_inact1 Carrier protein fragment 
(25494-25787 nt) 
3050 KpnI/AsiSI-EcoRI/PmeI 
pGH-CP4_A_inact1 Carrier protein fragment 
(28601-28914 nt) 
3079 KpnI/MfeI-AflII/PmeI 
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pGH-CP4_A_inact2 Carrier protein fragment 
(28601-28914 nt) 
3079 KpnI/MfeI-AflII/PmeI 
pUC57-CP5_A_inact1 Carrier protein fragment 
(31724-32042 nt) 
3071 KpnI/AseI-BamHI/PmeI 
pUC57-CP6_A_inact1 Carrier protein fragment 
(34876-35171 nt) 
3046 KpnI/HindIII-NheI/PmeI 
B-type mch cluster fragments from Myxococcus sp. 171[4] 
pGH-3mchB-5mchC_Bb Linker fragment 
(22380-22568 nt) 
3126 KpnI/NotI-SphI/PmeI 
pGH-T-3mchC_Bb Terminator fragment 
(38817-39474 nt) [7] 
5547 KpnI/AgeI-PvuI/PmeI 
pGH-MchC_B_fragA mchC gene fragment 
(22557-26924 nt) 
7406 KpnI/SphI-MluI/PmeI 
pGH-MchC_B_fragB mchC gene fragment 
(26921-31584 nt) 
7709 KpnI/MluI-MfeI/PmeI 
pGH-MchC_B_fragC mchC gene fragment 
(31581-34704 nt) 
6141 KpnI/MfeI-AseI/PmeI 
pGH-MchC_B_fragD mchC gene fragment 
(34701-38845 nt) 
7210 KpnI/AseI-AgeI/PmeI 
pGH-MchC_B_fragA_woSE mchC gene fragment 
(22557-26924 nt) 
7332 KpnI/SphI-MluI/PmeI 
pGH-MchC_B_fragB_woSE mchC gene fragment 
(26921-31584 nt) 
7633 KpnI/MluI-MfeI/PmeI 
pGH-MchC_B_fragC_woSE mchC gene fragment 
(31581-34704 nt) 
6093 KpnI/MfeI-AseI/PmeI 
pGH-MchC_B_fragD_woSE mchC gene fragment 
(34701-38845 nt) 
7114 KpnI/AseI-AgeI/PmeI 
C-type mch cluster fragments from M. virescens ST200611[5] 
pGH-3mchB-5mchC_Cb Linker fragment 
(23091-23279 nt) 
3126 KpnI/NotI-SphI/PmeI 
pGH-T-3mchC_Cb Terminator fragment 
(33291-33948 nt) [7] 
5525 KpnI/AgeI-PvuI/PmeI 
pGH-MchC_C_fragA mchC gene fragment 
(23268-27546 nt) 
7311 KpnI/SphI-NdeI/PmeI 
pGH-MchC_C_fragA_dcm mchC gene fragment 
(23268-24461 nt) 
4142 KpnI/SphI-SpeI 
pGH-MchC_C_fragB mchC gene fragment 
(27543-33319 nt) 
8860 KpnI/NdeI-AgeI/PmeI 
D-type mch cluster fragments from S. erecta Pde77[2] 
pGH-3mchB-5mchC_Db Linker fragment 
(21027-21217 nt) 
3568 KpnI/NotI-SphI/PmeI 
pGH-T-3mchC_Db Terminator fragment 
(34370-35036 nt) [7] 
5550 KpnI/AgeI-PvuI/PmeI 
pGH-MchB_D_fragA mchB gene fragment 
(12179-17807 nt) 
8660 KpnI/MluI-SpeI/PmeI 
pGH-MchB_D_fragB mchB gene fragment 
(17804-21058 nt) 
6226 KpnI/SpeI-NotI/PmeI 
pGH-MchC_D_fragA mchC gene fragment 
(21206-25493 nt) 
7319 KpnI/SphI-NdeI/PmeI 
pGH-MchC_D_fragB mchC gene fragment 7793 KpnI/NdeI-VspI/PmeI 
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(25490-30248 nt) 
pGH-MchC_D_fragC mchC gene fragment 
(30245-34398 nt) 
7213 KpnI/VspI-AgeI/PmeI 
S-type mch cluster fragments from S. aurantiaca DW4/3-1[3] 
pGH-3mchB-5mchC_Sb Linker fragment 
(22680-22869 nt) 
3127 KpnI/NotI-SphI/PmeI 
pGH-T-3mchC_Sb Terminator fragment 
(36025-36701 nt) [7] 
5544 KpnI/AgeI-PvuI/PmeI 
pGH-MchB_S_fragA mchB gene fragment 
(13833-19460 nt) 
8650 KpnI/MluI-SpeI/PmeI 
pGH-MchB_S_fragA_dcm mchB gene fragment 
(13833-14908 nt) 
4020 KpnI-NdeI 
pGH-MchB_S_fragB mchB gene fragment 
(19457-22711 nt) 
6272 KpnI/SpeI/NotI/PmeI 
pGH-MchC_S_fragA mchC gene fragment 
(22858-27148 nt) 
7329 KpnI/SphI/NdeI/PmeI 
pGH-MchC_S_fragA_dcm mchC gene fragment 
(22858-24051 nt) 
4138 KpnI/SpeI 
pGH-MchC_S_fragB mchC gene fragment 
(27145-31903 nt) 
7800 KpnI/NdeI/VspI/PmeI 
pGH-MchC_S_fragC mchC gene fragment 
(31900-36053 nt) 
7211 KpnI/VspI/AgeI/PmeI 
pGH-MchC_S_fragC_dcm mchC gene fragment 
(31900-32220 nt) 
3264 AseI/BamHI 
pGH-CP4_S_react Carrier protein fragment 
(28780-29090 nt) 
3076 KpnI/MfeI-AflII/PmeI 
A-type mch cluster fragments from M. xanthus DK1622[6] 
pGH-P-5mchA_A_AarI Promotor fragment 
(6603-7206 nt) 
4003 KpnI-BsiWI/PmeI 
pGH-3mchA-5mchB_A_AarI Linker fragment 
(13335-13718 nt) 
3783 KpnI/MreI-MluI/PmeI 
pGH-3mchA-5mchB_A_AarI Linker fragment 
(22517-22699 nt) 
3582 KpnI/NotI-SphI/PmeI 
pGH-T-3mchC_A_AarI Terminator fragment 
(35842-38443 nt) 
6001 KpnI/AgeI-PvuI/PmeI 
pGH-MchA_A_AarI_SE mchA gene fragment 
(7203-13468 nt) 
9665 KpnI/BsiWI-MreI/PmeI 
pGH-MchB_A_AarI_SE mchB gene fragment 
(13715-22746 nt) 
12431 KpnI/MluI-NotI/PmeI 
pGH-
MchC_A_AarI_fragABCE 
mchC gene fragment 
(22696-26974 nt, ABC) 
(+ 30110-32063 nt, E) 
9404 KpnI/SphI-BamHI/MluI 
pGH-MchC_A_AarI_fragD mchC gene fragment 
(26971-30113 nt) 
6186 NdeI-XbaI 
pGH-MchC_A_AarI_fragF mchC gene fragment 
(32060-35845 nt) 
6863 BamHI-MluI 
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Cloning vectors, expression vectors, and genetic elements 
pSynbio1_AarI Cloning vector 3383 - 
pSynbio2_AarI Expression vector 2700 - 
pGH-Amp_Synbio1mut ampR gene fragment 3587 PstI-MscI 
pGH-MCS_Synbio2 Multiple cloning site 3415 SwaI-HindIII 
pUC57-PTn5-5mchA_Ab Tn5 promoter fragment 3086 KpnI-BsiWI/PmeI 
[1] BsaI design based on mch cluster retrieved from GeneBank entry KX622595. [2] BsaI design based on mch 
cluster retrieved from GeneBank entry KX622602. [3] BsaI design based on mch cluster retrieved from 
GeneBank entry KX622599. [4] BsaI design based on mch cluster retrieved from GeneBank entry KX622591. 
[5] BsaI design based on mch cluster retrieved from GeneBank entry KX622594. [6] AarI design based on mch 
cluster retrieved from GeneBank entry KX622595. [7] Location is referring to the 3’mchC-mchD region (without 
terminator-rhlE region). 
 
3.4.4 Construction of Modified Cloning and Expression Vectors 
To adapt the original cloning (pSynbio1_AarI) and expression (pSynbio2_AarI) vectors to the 
BsaI design, modified synthetic DNA fragments were designed, in which either a BsaI R-site 
was eliminated by applying a point mutation (Amp_Synbio1mut) or the MCS was equipped 
with BsaI sites. The synthetic fragments were cloned into the original vector backbones and 
revealed pSynbio1 and pSynbio2 (Table S7). 
Table S7: Cloning and expression vectors generated in this study. 
Plasmid Construction 
pSynbio1 
666 bp PstI/MscI Amp_Synbio1mut fragment from pGH- 
Amp_Synbio1mut ligated into pSynbio1_AarI hydrolyzed 
with PstI/MscI to generate pSynbio1 
pSynbio2 
495 bp SwaI/HindIII MCS_Synbio2 fragment from pGH-
MCS_Synbio2 ligated into pSynbio2_AarI hydrolyzed with 
SwaI/HindIII to generate pSynbio2 
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Figure S3. Design of mch cluster fragments from the different mch pathways. To generate artificial hybrid mch pathways for the production of 
naturally occurring and entirely new myxochromide cores, a minimal set of mch cluster fragments were designed and generated via DNA synthesis. 
The promoter fragment from the A-type mch cluster (P5mchAA) as well as the A-type mchAA gene and mchAA/mchBA intergenic linker fragment 
(3AA5BA) were used for the construction of all hybrid mch pathways described in this study. Large biosynthetic genes were subdivided into two 
(mchBA, mchBS, mchBD, mchCC), three (mchCA, mchCD, mchCS) or even four (mchCB) individual gene fragments. 
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3.4.5 Assembly of Artificial mch Biosynthesis Genes and Generation of a Gene Library 
The large artificial biosynthesis genes mchA-C from the different mch clusters were 
assembled using traditional restriction/ligation techniques (Figure 4).45 To release the SEs 
between the domain fragments, the gene constructs were hydrolyzed with BsaI. Directed 
religation of the single domain fragments resulted in fully desplitted mch gene constructs. The 
plasmids, which were constructed in this study to form functional mch genes, are shown in 
Table S8. 
 
Table S8: Constructs for mch gene library generated in this study. 
 
Plasmid Construction 
A-type mch gene constructs[2] 
pSyn1-MchA_A_SE 
(1) 2122 bp NdeI/PmeI MchA_A_fragB fragment from pGH-
MchA_A_fragB ligated into pGH-MchA_A_fragA 
hydrolyzed with NdeI/PmeI to generate pGH-
MchA_A_fragAB 
(2) 6302 bp KpnI/PmeI MchA_A_fragAB fragment from pGH-
MchA_A_fragAB ligated into pSynbio1 hydrolyzed with 
KpnI/PmeI to generate pSyn1-MchA_A_SE_pre 
(3) 1336 bp KpnI/SpeI MchA_A_fragA_dcm fragment from 
pGH-MchA_A_fragA_dcm ligated into pSyn1-
MchA_A_SE_pre to generate pSyn1-MchA_A_SE 
pSyn1-MchA_A 
Hydrolysis of pSyn1-MchA_A_SE by BsaI followed by 
religation to remove SE[1] 
pSyn1-MchB_A_SE 
(1) 3335 bp SpeI/PmeI MchB_A_fragB fragment from pGH-
MchB_A_fragB ligated into pGH-MchB_A_fragA 
hydrolyzed with SpeI/PmeI to generate pGH-
MchB_A_fragAB 
(2) 9028 bp KpnI/PmeI MchB_A_fragAB fragment from pGH-
MchB_A_fragAB ligated into pSynbio1 hydrolyzed with 
KpnI/PmeI to generate pSyn1-MchB_A_SE_pre 
(3) 1100 bp KpnI/NdeI MchB_A_fragA_dcm fragment from 
pGH-MchB_A_fragA_dcm ligated into pSyn1-
MchB_A_SE_pre to generate pSyn1-MchB_A_SE 
pSyn1-MchB_A Hydrolysis of pSyn1-MchB_A_SE by BsaI followed by 
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religation to remove SE[1] 
pSyn1-MchC_A_SE 
(1) 4862 bp NdeI/PmeI MchC_A_fragB fragment from pGH-
MchC_A_fragB ligated into pGH-MchC_A_fragA 
hydrolyzed with NdeI/PmeI to generate pGH-
MchC_A_fragAB 
(2) 9237 bp KpnI/PmeI MchC_A_fragAB fragment from pGH-
MchC_A_fragAB ligated into pSynbio1 hydrolyzed with 
KpnI/PmeI to generate pSyn1-MchC_A_fragAB 
(3) 4272 bp AseI/PmeI MchC_A_fragC fragment from pGH-
MchC_A_fragC ligated into pSyn1-MchC_A_fragAB 
digested with AseI/PmeI to generate pSyn1-MchC_A_SE_pre 
(4) 1219 bp KpnI/SpeI MchC_A_fragA_dcm fragment from 
pGH-MchC_A_fragA_dcm ligated into pSyn1-
MchC_A_SE_pre to generate pSyn1-MchC_A_SE_pre2 
(5) 344 bp AseI/BamHI MchC_A_fragC_dcm fragment from 
pGH-MchC_A_fragC_dcm ligated into pSyn1-
MchC_A_SE_pre2 to generate pSyn1-MchC_A_SE 
pSyn1-MchC_A 
Hydrolysis of pSyn1-MchC_A_SE by BsaI followed by 
religation to remove SE[1] 
pSyn1-
MchB_A_CP1inact1_SE
350 bp AsiSI/XbaI MchB_A_CP1inact1 fragment from 
pUC57-MchB_A_CP1inact1 ligated into pSyn1-
MchB_A_SE to generate pSyn1-MchB_A_CP1inact1_SE 
pSyn1-
MchB_A_CP1inact1 
Hydrolysis of pSyn1-MchB_A_CP1inact1_SE by BsaI 
followed by religation to remove SE[1] 
pSyn1-
MchB_A_CP2inact1_SE
330 bp AflII/AvrII MchB_A_CP2inact1 fragment from 
pUC57-MchB_A_CP2inact1 ligated into pSyn1-
MchB_A_SE to generate pSyn1-MchB_A_CP2inact1_SE 
pSyn1-
MchB_A_CP2inact1 
Hydrolysis of pSyn1-MchB_A_CP2inact1_SE by BsaI 
followed by religation to remove SE[1] 
pSyn1-
MchC_A_CP3inact1_SE
322 bp AsiSI/EcoRI MchC_A_CP3inact1 fragment from 
pUC57-MchC_A_CP3inact1 ligated into pSyn1-
MchC_A_SE to generate pSyn1-MchC_A_CP3inact1_SE 
pSyn1-
MchC_A_CP3inact1 
Hydrolysis of pSyn1-MchC_A_CP3inact1_SE by BsaI 
followed by religation to remove SE[1] 
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pSyn1-
MchC_A_CP4inact1_SE
338 bp MfeI/AflII MchC_A_CP4inact1 fragment from 
pUC57-MchC_A_CP4inact1 ligated into pSyn1-
MchC_A_SE to generate pSyn1-MchC_A_CP4inact1_SE 
pSyn1-
MchC_A_CP4inact1 
Hydrolysis of pSyn1-MchC_A_CP4inact1_SE by BsaI 
followed by religation to remove SE[1] 
pSyn1-
MchC_A_CP4inact2_SE
338 bp MfeI/AflII MchC_A_CP4inact2 fragment from 
pUC57-MchC_A_CP4inact2 ligated into pSyn1-
MchC_A_SE to generate pSyn1-MchC_A_CP4inact2_SE 
pSyn1-
MchC_A_CP4inact2 
Hydrolysis of pSyn1-MchC_A_CP4inact2_SE by BsaI 
followed by religation to remove SE[1] 
pSyn1-
MchC_A_CP5inact1_SE
344 bp AseI/BamHI MchC_A_CP5inact1 fragment from 
pUC57-MchC_A_CP5inact1 ligated into pSyn1-
MchC_A_SE to generate pSyn1-MchC_A_CP5inact1_SE 
pSyn1-
MchC_A_CP5inact1 
Hydrolysis of pSyn1-MchC_A_CP5inact1_SE by BsaI 
followed by religation to remove SE[1] 
pSyn1-
MchC_A_CP6inact1_SE
320 bp HindIII/NheI MchC_A_CP6inact1 fragment from 
pUC57-MchC_A_CP6inact1 ligated into pSyn1-
MchC_A_SE to generate pSyn1-MchC_A_CP6inact1_SE 
pSyn1-
MchC_A_CP6inact1 
Hydrolysis of pSyn1-MchC_A_CP6inact1_SE by BsaI 
followed by religation to remove SE[1] 
B-type mch gene constructs 
pSyn1-MchC_B_SE 
(1) 2954 bp KpnI/MluI MchC_B_fragA fragment from pGH-
MchC_B_fragA_woSE and 2947 bp MluI/PmeI 
MchC_B_fragB fragment from pGH-MchC_B_fragB_woSE 
ligated into pSynbio1 hydrolyzed with KpnI/PmeI to generate 
pSyn1-MchC_B_fragAB 
(2) 4854 bp KpnI/AseI MchC_B_fragC fragment from pGH-
MchC_B_fragC_woSE and 4269 AseI/PmeI MchC_B_fragD 
fragment from pGH-MchC_B_fragD_woSE ligated into 
pSynbio1 hydrolyzed with KpnI/PmeI to generate pSyn1-
MchC_B_fragCD 
(3) 7318 bp MunI/PmeI MchC_B_fragA fragment from pSyn1-
MchC_B_fragCD ligated into pSyn1-MchC_B_fragAB 
hydrolyzed with MunI/PmeI to generate pSyn1-
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MchC_B_SE_pre 
(4) 3193 bp MunI/AseI MchC_B_fragC fragment from pGH-
MchC_B_fragC ligated into pSyn1-MchC_B_SE_pre to 
generate pSyn1-MchC_B_SE 
pSyn1-MchC_B 
Hydrolysis of pSyn1-MchC_B_SE by BsaI followed by 
religation to remove SE[1] 
C-type mch gene constructs 
pSyn1-MchC_C_SE 
(1) 5923 bp NdeI/PmeI MchC_C_fragB fragment from pGH-
MchC_C_fragB ligated into pGH-MchC_C_fragA 
hydrolyzed with NdeI/PmeI to generate pGH-MchC_C_SE 
(2) 10296 bp KpnI/PmeI MchC_C_SE fragment from pGH-
MchC_C_SE ligated into pSynbio1 hydrolyzed with 
KpnI/PmeI to generate pSyn1-MchC_C_SE_pre 
(3) 1211 bp KpnI/SpeI MchC_C_fragA_dcm fragment from 
pGH-MchC_C_fragA_dcm ligated into pSyn1-
MchC_C_SE_pre hydrolyzed with KpnI/PmeI to generate 
pSyn1-MchC_C_SE 
pSyn1-MchC_C 
Hydrolysis of pSyn1-MchC_C_SE by BsaI followed by 
religation to remove SE[1] 
D-type mch gene constructs 
pSyn1-MchB_D_SE 
5719 bp KpnI/SpeI MchB_D_fragA fragment from pGH-
pMchB_D_fragA and 3332 bp SpeI/PmeI MchB_D_fragB 
fragment from pGH-pMchB_D_fragB ligated into pSynbio1 
hydrolyzed with KpnI/PmeI to generate pSyn1-MchB_D_SE 
pSyn1-MchB_D 
Hydrolysis of pSyn1-MchB_D_SE by BsaI followed by 
religation to remove SE[1] 
pSyn1-MchC_D_SE 
(1) 4386 bp KpnI/NdeI MchC_D_fragA fragment from pGH-
MchC_D_fragA and 4859 bp NdeI/PmeI MchC_D_fragB 
fragment from pGH-MchC_D_fragB ligated into pSynbio1 
hydrolyzed with KpnI/PmeI to generate pSyn1-
MchC_D_fragAB 
(2) 4278 bp AseI/PmeI MchC_D_fragC fragment from pGH-
pMchC_D_fragC ligated into pSyn1-MchB_D_fragAB 
hydrolyzed with AseI/PmeI to generate pSyn1-MchC_D_SE 
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pSyn1-MchC_D 
Hydrolysis of pSyn1-MchC_D_SE by BsaI followed by 
religation to remove SE[1] 
S-type mch gene constructs 
pSyn1-MchB_S_SE 
(1) 3328 bp SpeI/PmeI MchB_S_fragB fragment from pGH-
MchB_S_fragB ligated into pGH-pMchB_S_fragA 
hydrolyzed with SpeI/PmeI to generate pGH-
MchB_S_fragAB 
(2) 9051 bp KpnI/PmeI MchB_S_fragAB fragment from pGH-
MchB_S_fragAB ligated into pSynbio1 hydrolyzed with 
KpnI/PmeI to generate pSyn1-MchB_S_SE_pre 
(3) 1100 bp KpnI/NdeI MchB_S_fragA_dcm fragment from 
pGH-MchB_S_fragA_dcm ligated into pSyn1-
MchB_S_SE_pre to generate pSyn1-MchB_S_SE 
pSyn1-MchB_S 
Hydrolysis of pSyn1-MchB_S_SE by BsaI followed by 
religation to remove SE[1] 
pSyn1-MchC_S_SE 
(1) 4857 bp NdeI/PmeI MchC_S_fragB fragment from pGH-
MchC_S_fragB ligated into pGH-MchC_S_fragA hydrolyzed 
with NdeI/PmeI to generate pGH-MchC_S_fragAB 
(2) 9234 bp KpnI/PmeI MchC_S_fragAB fragment from pGH-
MchC_S_fragAB ligated into pSynbio1 hydrolyzed with 
KpnI/PmeI to generate pSyn1-MchC_S_fragAB 
(3) 4276 bp AseI/PmeI MchC_S_fragC fragment from pGH-
MchC_S_fragC ligated into pSyn1-MchC_S_fragAB 
hydrolyzed with AseI/PmeI to generate pSyn1-
MchC_S_SE_pre 
(4) 1219 bp KpnI/SpeI MchC_S_fragA_dcm fragment from 
pGH-MchC_S_fragA_dcm ligated into pSyn1-
MchC_S_SE_pre to generate pSyn1-MchC_S_SE_pre2 
(5) 344 bp AseI/BamHI MchC_S_fragC_dcm fragment from 
pGH-MchC_S_fragC_dcm ligated into pSyn1-
MchC_S_SE_pre2 to generate pSyn1-MchC_S_SE 
pSyn1-MchC_S 
Hydrolysis of pSyn1-MchC_S_SE by BsaI followed by 
religation to remove SE[1] 
pSyn1- 335 bp MfeI/AflII MchC_S_CP4react fragment from pUC57-
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MchC_S_CP4react_SE MchC_S_CP4act ligated into pSyn1-MchC_S_SE to generate 
pSyn1-MchC_S_CP4react_SE 
pSyn1-
MchC_S_CP4react 
Hydrolysis of pSyn1-MchC_S_CP4react_SE by BsaI 
followed by religation to remove SE[1] 
A-type mch gene constructs[3] 
pSyn1-
MchA_A_AarI_SE 
6303 bp KpnI/PmeI MchA_A_AarI_SE fragment from pGH-
MchA_A_AarI_SE ligated into pSynbio1_AarI hydrolyzed 
with KpnI/PmeI to generate pSyn1-MchA_A_AarI_SE 
pSyn1-MchA_A_AarI 
Hydrolysis of pSyn1-MchA_A_AarI_SE by AarI followed by 
religation to remove SE[1] 
pSyn1-
MchB_A_AarI_SE 
9069 bp KpnI/PmeI MchB_A_AarI_SE fragment from pGH-
MchB_A_AarI_SE ligated into pSynbio1_AarI hydrolyzed 
with KpnI/PmeI to generate pSyn1-MchB_A_AarI_SE 
pSyn1-MchB_A_AarI 
Hydrolysis of pSyn1-MchB_A_AarI_SE by AarI followed by 
religation to remove SE[1] 
pSyn1-
MchC_A_AarI_SE 
(1) 3944 bp BamHI/MluI MchC_A_AarI_fragF fragment from 
pGH-MchC_A_AarI_fragF ligated into pGH-
MchC_A_AarI_fragABCE hydrolyzed with BamHI/MluI to 
generate pGH-MchC_A_AarI_fragABCEF 
(2) 3256 bp NdeI/XbaI MchC_A_AarI_fragD fragment from 
pGH-MchC_A_AarI_fragD ligated into pGH-
MchC_A_AarI_fragABCEF hydrolyzed with NdeI/XbaI to 
generate pGH-MchC_A_AarI_SE 
(3) 13637 bp KpnI/PmeI MchC_A_AarI_SE fragment from 
pGH-MchC_A_AarI_SE ligated into pSynbio1_AarI 
hydrolyzed with KpnI/PmeI to generate pSyn1-
MchC_A_AarI_SE 
pSyn1-MchC_A_AarI 
Hydrolysis of pSyn1-MchC_A_AarI_SE by AarI followed by 
religation to remove SE[1] 
pSyn1-P-
5mchA_A_AarI 
641 bp KpnI/PmeI P-5mchA_A_AarI fragment from pGH- P-
5mchA_A_AarI ligated into pSynbio1_AarI hydrolyzed with 
KpnI/PmeI to generate pSyn1-P-5mchA_A_AarI 
pSyn1-3mchA-
5mchB_A_AarI 
421 bp KpnI/PmeI 3mchA-5mchB_A_AarI fragment from 
pGH-3mchA-5mchB_A_AarI ligated into pSynbio1_AarI 
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hydrolyzed with KpnI/PmeI to generate pSyn1-3mchA-
5mchB_A_AarI 
pSyn1-3mchB-
5mchC_A_AarI 
220 bp KpnI/PmeI 3mchB-5mchC_A_AarI fragment from 
pGH-3mchB-5mchC_A_AarI ligated into pSynbio1_AarI 
hydrolyzed with KpnI/PmeI to generate pSyn1-3mchB-
5mchC_A_AarI 
pSyn1-T-
3mchC_A_AarI 
2639 bp KpnI/PmeI T-3mchC_A_AarI fragment from pGH-
T-3mchC_A_AarI ligated into pSynbio1_AarI hydrolyzed 
with KpnI/PmeI to generate pSyn1-T-3mchC_A_AarI 
[1] SE = splitter elements. [2] Based on BsaI design. [3] Based on AarI design. 
 
3.4.6 In Vitro Reconstitution of Artificial mch Clusters 
Artificial mch cluster constructs were constructed using traditional restriction/ligation cloning 
techniques (Figure 4).45 Constructed mch clusters encompass hybrid gene clusters for the 
production of novel myxochromides as well as artificial A-type mch clusters harboring 
inactivated PCP domains in modules 1-6. In addition, an artificial S-type mch cluster was 
constructed, which harbors a reactivated PCP domain in module 4. Construction of the 
mentioned mch clusters is described in Table S9. 
 
Table S9: Constructs for mch cluster assemblies generated in this study. 
 
Plasmid Construction 
pSynMch1 
(1) 621 bp KpnI/BsiWI P5mchAA fragment from pSyn1-P-5mchA_A_AarI 
ligated into pSynbio2 hydrolyzed with KpnI/BsiWI to generate pSyn2-
ca1 
(2) 6134 bp BsiWI/MreI mchAA fragment from pSyn1-MchA_A_AarI 
ligated into pSyn2-ca1 hydrolyzed with BsiWI/MreI to generate pSyn2-
ca2 
(3) 386 bp MreI/MluI 3AA5BA fragment from pSyn1-3mchA-
5mchB_A_AarI ligated into pSyn2-ca2 hydrolyzed with MreI/MluI to 
generate pSyn2-ca3 
(4) 8803 bp MluI/NotI mchBA fragment from pSyn1-MchB_A_AarI ligated 
into pSyn2-ca3 hydrolyzed with MluI/NotI to generate pSyn2-ca4 
(5) 186 bp NotI/SphI 3BA5CA fragment from pSyn1-3mchB-5mchC_A_AarI 
ligated into pSyn2-ca4 hydrolyzed with NotI/SphI to generate pSyn2-ca5 
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(6) 13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A_AarI ligated 
into pSyn2-ca5 hydrolyzed with SphI/AgeI to generate pSyn2-ca6 
(7) 2616 bp AgeI/PvuI T3mchCA fragment from pSyn1-T-3mchC_A_AarI 
ligated into pSyn2-ca6 hydrolyzed with AgeI/PvuI to generate 
pSynMch1 
pSynMch2 
(1) 606 bp KpnI/BsiWI P5mchAA fragment from pGH-P-5mchA_Ab ligated 
into pSynbio2 hydrolyzed with KpnI/BsiWI to generate pSyn2-ca7 
(2) 6134 bp BsiWI/MreI mchAA fragment from pSyn1-MchA_A ligated into 
pSyn2-ca7 hydrolyzed with BsiWI/MreI to generate pSyn2-ca8 
(3) 386 bp MreI/MluI 3AA5BA fragment from pGH-3mchA-5mchB_Ab 
ligated into pSyn2-ca8 hydrolyzed with MreI/MluI to generate pSyn2-
ca9 
(4) 8803 bp MluI/NotI mchBA fragment from pSyn1-MchB_A ligated into 
pSyn2-ca9 hydrolyzed with MluI/NotI to generate pSyn2-ca10 
(5) 186 bp NotI/SphI 3BA5CA fragment from pGH-3mchB-5mchC_Ab 
ligated into pSyn2-ca10 hydrolyzed with NotI/SphI to generate pSyn2-
ca11 
(6) 13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A ligated into 
pSyn2-ca11 hydrolyzed with SphI/AgeI to generate pSyn2-ca12 
(7) 2601 bp AgeI/PvuI T3mchCA fragment from pGH-T-3mchC_Ab ligated 
into pSyn2-ca12 hydrolyzed with AgeI/PvuI to generate pSynMch2_pre 
(8) 15917 bp KpnI/NotI P5mchAA-mchAA-3AA5BA-mchBA fragment from 
pSyn2-ca10 ligated into pSynMch2_pre hydrolyzed with KpnI/NotI to 
generate pSynMch2 
pSynMch3 
(1) 186 bp NotI/SphI 3BB5CB fragment from pGH-3mchB-5mchC_Bb 
ligated into pSynbio2 hydrolyzed with NotI/SphI to generate pSyn2-ca13 
(2) 2601 bp AgeI/PvuI T3mchCB fragment from pGH-T-3mchC_Bb ligated 
into pSyn2-ca13 hydrolyzed with AgeI/PvuI to generate pSyn2-ca14 
(3) 16250 bp SphI/AgeI mchCB fragment from pSyn1-MchC_B ligated into 
pSyn2-ca14 hydrolyzed with SphI/AgeI to generate pSyn2-ca15 
(4) 15909 bp KpnI/NotI P5mchAA-mchAA-3AA5BA-mchBB fragment from 
pSynMch2 ligated into pSyn2-ca15 hydrolyzed with KpnI/NotI to 
generate pSynMch3 
pSynMch4 (1) 186 bp NotI/SphI 3BC5CC fragment from pGH-3mchB-5mchC_Cb 
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ligated into pSyn2-ca10 hydrolyzed with NotI/SphI to generate pSyn2-
ca16 
(2) 10013 bp SphI/AgeI mchCC fragment from pSyn1-MchC_C ligated into 
pSyn2-ca16 hydrolyzed with SphI/AgeI to generate pSyn2-ca17 
(3) 2601 bp AgeI/PvuI T3mchCC fragment from pGH-T-3mchC_Cb ligated 
into pSyn2-ca17 hydrolyzed with SphI/AgeI to generate pSynMch4 
pSynMch5 
(1) 205 bp NotI/SphI 3BD5CD fragment from pGH-3mchB-5mchC_Db 
ligated into pSynbio2 hydrolyzed with NotI/SphI to generate pSyn2-ca18 
(2) 2610 bp AgeI/PvuI T3mchCD fragment from pGH-T-3mchC_Db ligated 
into pSyn2-ca18 hydrolyzed with AgeI/PvuI to generate pSyn2-ca19 
(3) 13154 bp SphI/AgeI mchCD fragment from pSyn1-MchC_D ligated into 
pSyn2-ca19 hydrolyzed with SphI/AgeI to generate pSyn2-ca20 
(4) 8826 bp MluI/NotI mchBD fragment from pSyn1-MchB_D ligated into 
pSyn2-ca20 hydrolyzed with MluI/NotI to generate pSyn2-ca21 
(5) 7110 bp KpnI/MluI P5mchAA-mchAA-3AA5BA from pSynMch2 ligated 
into pSyn2-ca21 hydrolyzed with KpnI/MluI to generate pSynMch5 
pSynMch6 
(1) 8830 bp MluI/NotI mchBS fragment from pSyn1-MchB_S ligated into 
pSyn2-ca9 hydrolyzed with MluI/NotI to generate pSyn2-ca22 
(2) 187 bp NotI/SphI 3BS5CS fragment from pGH-3mchB-5mchC_Sb 
ligated into pSyn2-ca22 hydrolyzed with NotI/SphI to generate pSyn2-
ca23 
(3) 13157 bp SphI/AgeI mchCS fragment from pSyn1-MchC_S ligated into 
pSyn2-ca23 hydrolyzed with SphI/AgeI to generate pSyn2-ca24 
(4) 2620 bp AgeI/PvuI T3mchCS fragment from pGH-T-3mchC_Sb ligated 
into pSyn2-ca24 hydrolyzed with SphI/AgeI to generate pSynMch6 
pSynMch8 
(1) 13165 bp SphI/AgeI mchCS fragment from pSyn1-MchC_S ligated into 
pSyn2-ca11 hydrolyzed with SphI/AgeI to generate pSyn2-ca31 
(2) 2620 bp AgeI/PvuI T3mchCS fragment from pGH-T-3mchC_Sb ligated 
into pSyn2-ca31 hydrolyzed with AgeI/PvuI to generate pSynMch8_pre 
(3) 15917 bp KpnI/NotI P5mchAA-mchAA-3AA5BA-mchBA fragment from 
pSyn2-ca10 ligated into pSynMch8_pre hydrolyzed with KpnI/NotI to 
generate pSynMch8 
pSynMch9 
(1) 186 bp NotI/SphI 3BA5CA fragment from pGH-3mchB-5mchC_Ab into 
pSyn2-ca22 hydrolyzed with NotI/SphI to generate pSyn2-ca32 
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(2) 13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A ligated into 
pSyn2-ca32 hydrolyzed with SphI/AgeI to generate pSyn2-ca33 
(3) 2608 bp AgeI/PvuI T3mchCA fragment from pGH-T-3mchC_Ab ligated 
into pSyn2-ca33 hydrolyzed with AgeI/PvuI to generate pSynMch9_pre 
(4) 15944 bp KpnI/NotI P5mchAA-mchAA-3AA5BA-mchBS fragment from 
pSyn2-ca22 ligated into pSynMch9_pre hydrolyzed with KpnI/NotI to 
generate pSynMch9 
pSynMch10 
(1) 186 bp NotI/SphI 3BC5CC fragment from pGH-3mchB-5mchC_Cb into 
pSyn2-ca22 hydrolyzed with NotI/SphI to generate pSyn2-ca34 
(2) 10021 bp SphI/AgeI mchCC fragment from pSyn1-MchC_C ligated into 
pSyn2-ca34 hydrolyzed with SphI/AgeI to generate pSyn2-ca35 
(3) 2601 bp AgeI/PvuI T3mchCC fragment from pGH-T-3mchC_Cb ligated 
into pSyn2-ca35 hydrolyzed with AgeI/PvuI to generate pSynMch10_pre 
(4) 15944 bp KpnI/NotI P5mchAA-mchAA-3AA5BA-mchBS fragment from 
pSyn2-ca22 ligated into pSynMch10_pre hydrolyzed with KpnI/NotI to 
generate pSynMch10 
pSynMch11 
19037 bp NotI/PvuI 3BB5CB-mchCB-T3mchCB fragment from pSyn2-
ca15 ligated into pSynMch10 hydrolyzed with NotI/PvuI to generate 
pSynMch11 
pSynMch12 
15952 bp NotI/PvuI 3BD5CD-mchCD-T3mchCD fragment from pSyn2-
ca20 ligated into pSynMch10 hydrolyzed with NotI/PvuI to generate 
pSynMch12 
pSynMch13 
(1) The native promoter of A-type mch cluster on pSynMch2 was replaced 
with cmR-ccdB cassette by Red/ET recombination to generate 
pSynMch2-cmccdB 
(2) The cmR-ccdB cassette on pSynMch2-cmccdB was substituted with 
overexpression promoter Ptn5 by Red/ET recombination 
pSynMch14 
8830 bp MluI/NotI mchBS fragment from pSyn1-MchB_S ligated into 
pSynMch13 hydrolyzed with NotI/PvuI to generate pSynMch14 
pSynMch15 
21643 bp KpnI/NotI 3BB5CB-mchCB-T3mchCB fragment from pSyn2-
ca15 ligated into pSynMch14 hydrolyzed with KpnI/NotI to generate 
pSynMch15 
pSynMch16 
18558 bp KpnI/NotI 3BD5CD-mchCD-T3mchCD fragment from pSyn2-
ca20 ligated into pSynMch14 hydrolyzed with KpnI/NotI to generate 
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pSynMch16 
pSynMch17 
8803 bp MluI/NotI mchBA fragment from pSyn1-MchB_A_CP1inact1 
ligated into pSynMch13 hydrolyzed with MluI/NotI to generate 
pSynMch17 
pSynMch19 
13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A_CP3inact1 
ligated into pSynMch13 hydrolyzed with MluI/NotI to generate 
pSynMch19 
pSynMch20 
13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A_CP4inact1 
ligated into pSynMch13 hydrolyzed with MluI/NotI to generate 
pSynMch20 
pSynMch21 
13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A_CP4inact2 
ligated into pSynMch13 hydrolyzed with MluI/NotI to generate 
pSynMch21 
pSynMch22 
13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A_CP5inact1 
ligated into pSynMch13 hydrolyzed with MluI/NotI to generate 
pSynMch22 
pSynMch23 
13150 bp SphI/AgeI mchCA fragment from pSyn1-MchC_A_CP6inact1 
ligated into pSynMch13 hydrolyzed with MluI/NotI to generate 
pSynMch23 
pSynMch24 
13165 bp SphI/AgeI mchCS fragment from pSyn1-MchC_S_CP4react 
ligated into pSynMch6 hydrolyzed with MluI/NotI to generate 
pSynMch24 
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3.4.7 Transfer and Heterologous Expression of Artificial mch Clusters in Myxococcus 
xanthus 
To heterologously express the artificial mch gene clusters in the myxochromide-deficient 
mutant DK1622 ΔmchA-tet (Wenzel et al., unpublished), the expression constructs 
(pSynMch1-6, pSynMch8-12) were transformed by electroporation into the heterologous host 
strain using established standard procedures. Integration of the artificial mch clusters into the 
former mchA locus in the host chromosome was achieved via homologous recombination 
(single crossover) using the helicase gene rhlE as homologous region. The resulting genotype 
of the mutant strains as well as the genotype of the heterologous host are exemplified for the 
myxochromide AS production strain M. xanthus DK1622 ΔmchA-tet::pSynMch8 and 
illustrated in Figure S4. Oligonucleotides used for genotypic verification of the resulting 
mutant strains and PCR conditions are listed in Tables S10 and S11. 
 
 
 
Figure S4. Specific integration of artificial mch clusters into the former myxochromide A gene cluster locus of 
M. xanthus DK1622 ΔmchA-tet. (A) Genotype representation of the myxochromide A-deficient mutant M. 
xanthus DK1622 ΔmchA-tet. Integration of mch cluster constructs was achieved via single crossover using the 
helicase gene rhlE, which is part of the synthetic terminator fragments, as homologous region. (B) Genotype 
representation of mutant strains harboring artificial mch clusters. Mutant strains were verified by PCR; binding 
sites of oligonucleotides for amplification of specific diagnostic markers are shown in green. 
 
 
 
 
 
Helicase gene rhlEtetR box
Helicase gene rhlEtetR box
Artificial mch cluster
Artificial mch cluster
A
B
mch5_1
mch5_2
mch3_1
mch3_2
T
TP
P
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Table S10: Oligonucleotides used for PCR amplification of specific markers to verify integration of artificial 
mch clusters into the host chromosome of M. xanthus DK1622 ΔmchA-tet. 
 
Oligonucleotide  Sequence    
mch5_1 
 
mch5_2 
CGGAGAACTGTGAATGCGC 
 
GTTTCATTTGATGCTCGATG 
                 
 
mch3_1 
 
mch3_2 
 
CGCCGGACGCATGACTCAC 
 
AGAGGCACTCCAGGCCTCTTA 
                 
 
Oligonucleotide pairs Amplicon size 
Present in 
heterologous host 
Present in 
production strain 
mch5_1 / mch5_2 1572 bp               -  + 
mch3_1 / mch3_2 1563 bp               - + 
 
Table S11: Protocol for polymerase chain reaction used to amplify specific markers to verify integration of 
artificial mch clusters into the host chromosome of M. xanthus DK1622 ΔmchA-tet. 
 
PCR step  Temperature [°C] Time [min] Cycles   
Initialization           95       5                 
Denaturation           95     0.5                 
Annealing           58     0.5    30   
Extension           72     1.5    
Final extension           72     10    
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3.4.8 Structure Elucidation of Novel Hybrid Myxochromides 
3.4.8.1 Cultivation of Heterologous Production Strains and Isolation of Myxochromides 
The heterologous producer strains M. xanthus DK1622 ΔmchA-tet::pSynMch8 
(Myxochromides AS) and DK1622 ΔmchA-tet::pSynMch11 (Myxochromides SC) were 
cultivated in 18 L (18x 1 L) and the producer strains DK1622 ΔmchA-tet::pSynMch14 
(Myxochromides SA), DK1622 ΔmchA-tet::pSynMch15 (Myxochromides SB) and DK1622 
ΔmchA-tet::pSynMch16 (Myxochromides SD) were cultivated in 9L (10x 1 L) CTT medium 
(casitone 1%, Tris-HCl [pH 8.0] 10 mM, K2HPO4/KH2PO4 buffer [pH 7.6] 1 mM, MgSO4 × 7 
H2O 8 mM, pH adjusted to 7.6) including 2% XAD-16 resin for 5-6 days at 30 °C and 180 
rpm. 
For the isolation of myxochromides AS, SA and SC, cells and XAD-16 Amberlite adsorber 
resin were harvested by centrifugation at 10,500 rpm and 4 °C for 15 min and were five times 
extracted with 1 L of a mixture of methanol and acetone (1:1). The organic solvents were 
removed under reduced pressure and the residues were five times extracted with 200 mL of 
ethyl acetate. After removal of the solvent, the crude extracts were dissolved in up to 10 mL 
of methanol for subsequent separation via reverse phase HPLC. A Dionex UltiMate 3000 
system equipped with a Luna 5u C18(2) 100A column (250 × 10 mm, Phenomenex) was 
used. At constant flow rate (5.0 mL/min), the following multi-step gradient was applied for 
isolation of myxochromides AS4 and SC4 (A: deionized water, B: acetonitrile): 0-5 min 10-
45% B, 5-30 min 45-65% B, 30-40 min 65-80% B, 40-41 min 80-10% B, 41-47 min 10% B. 
Myxochromide SC4 was further purified by applying the following modified gradient (A: 
deionized water, B: acetonitrile): 0-5 min 10% B, 5-50 min 10-95% B, 50-55 min 95% B, 55-
56 min 95-10% B, 56-60 min 10%B. For separation of myxochromide SA, the following 
modified gradient was applied (A: deionized water, B: acetonitrile): 0-4 min 5% B, 4-8 min 5-
65%, 8-41 min 65-95% B, 41-43 min 95% B, 43-45 min 95-5% B, 45-51 min 5% B). 
For the isolation of myxochromides SB and SD, cells and XAD adsorber resin were placed in 
a glass column over glass wool and a sand layer. Myxochromides were extracted by pouring 
600 mL n-hexane, 900 mL dichloromethane, 600 mL ethyl acetate, 600 mL acetone and 
600 mL methanol through the packed column. The fractions were concentrated and analyzed 
for target myxochromides via HPLC-MS. Separation was performed on a Dionex UltiMate 
3000 system using a Waters BEH C18 (100 × 2.1 mm, 1.7 µm) column. At a flow rate of 0.6 
mL/min, the following gradient was applied (A: deionized water + 0.1% formic acid, B: 
acetonitrile + 0.1% formic acid): 0-0.5 min 5% B, 0.5-18.5 min 5-95% B, 18.5-20.5 min 95% 
B. Full scan mass spectra were acquired in positive ESI mode in a range from 200-2000 m/z. 
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After removal of the solvent, myxochromides were dissolved in 3 mL of methanol for further 
separation via reverse phase HPLC. Myxochromides SB were purified on a Dionex Ultimate 
3000 system equipped with an EclipseC8 column (250 x 10 mm, 4 µm) at constant flowrate 
(5 mL/min) by applying the following gradient (A: deionized water, B: acetonitrile): 0-2 min 
5 % B, 2-10 min 5-65 % B, 10-30 min 65-70 % B, 30-31 min 70-95% B, 31-34 min 95 % B, 
34-35 min 95-5 % B, 35-38 min 5 % B. Myxochromides SD were purified on a Dionex 
Ultimate 3000 system equipped with a Jupiter column (250 x 10 mm, 4 µm) at constant 
flowrate (5 mL/min) by applying the following modified gradient (A: deionized water, B: 
acetonitrile): 0-2 min 5 % B, 2-10 min 5-66 % B, 10-30 min 66-68 % B, 30-31 min 68-95% 
B, 31-34 min 95 % B, 34-35 min 95-5 % B, 35-38 min 5 % B. 
UV traces were recorded by a diode array detector (DAD) with specified wave lengths (210, 
300 and 410 nm) with myxochromides showing good UV absorption at 410 nm. Retention 
times (Rt) and yields of the isolated compounds are shown in Table S12. 
 
 
Table S12: Retention times and total amounts of hybrid myxochromides isolated in this study.  
 
Mutant strain Isolated compound Rt [min] Yield [mg] 
DK1622 ΔmchA-tet::pSynMch8 Myxochromide AS4 27.6 4.5 
DK1622 ΔmchA-tet::pSynMch14 Myxochromide SA3 18.9 7.2 
DK1622 ΔmchA-tet::pSynMch15 Myxochromide SB4 23.0 7.5 
DK1622 ΔmchA-tet::pSynMch11 Myxochromide SC4 39.2 0.5 
DK1622 ΔmchA-tet::pSynMch16 Myxochromide SD3 19.6 0.7 
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3.4.8.2 Structure Elucidation of Hybrid Myxochromides 
Structure elucidation of myxochromide AS4, myxochromide SA3, myxochromide SB4, 
myxochromide SC4 and myxochromide SD3 was achieved using 1D and 2D NMR 
spectroscopy as well as HR-MS data. NMR spectra were acquired in CD3OD at a Bruker 
Ascend 700 or 500 MHz spectrometer equipped with a 5 mm TXI cryoprobe. 1D 1H and 2D 
1H−1H COSY, HSQC, HMBC (and if necessary) ROESY spectra were recorded using 
standard pulse programs and are illustrated in Figures S5, S8, S11, S14 and S17. Carbon 
chemical shifts were extracted from 2D NMR data. NMR spectroscopic data are listed in the 
Tables S14, S16, S18, S20 and S22. HR-ESI-MS data were obtained on a Bruker Maxis 4G 
mass spectrometer. Full scan mass spectra were acquired in a range from 150-2500 m/z in a 
positive mode. HR-ESI-MS data of hybrid myxochromides is shown in Table S13. 
 
Table S13: HR-ESI-MS data of isolated hybrid myxochromides. 
  
Compound Formula [M+H]+ calc. [M+H]+ exp. Δm/z [ppm] 
Myxochromide AS4 C38H52N6O8 721.39194 721.39373 2.48 
Myxochromide SA3 C48H69N7O9 888.52295 888.52409 1.28 
Myxochromide SB4 C54H80N8O10 1015.62267 1015.62390 1.21 
Myxochromide SC4 C46H66N6O8 831.50149 831.50222 0.88 
Myxochromide SD3 C44H64N6O8 791.47019 791.47051 0.40 
 
For the assignment of the absolute configuration, Marfey’s method based on amino acid 
derivatization was applied.32 0.1-0.3 mg of pure compound was hydrolyzed with 37% HCl 
(0.2 mL) in a 1.5 mL glass vial for 3 days at 110°C. The hydrolysate was evaporated to 
dryness and dissolved in H2O (100 μL). A 50 μL aliquot was supplemented with 1N NaHCO3 
(20 μL) and 1% 1-fluoro-2,4-dinitrophenyl-5-L/D-leucinamide (L-FDLA or D-FDLA) 
solution in acetone (20 μL), and the mixtures were heated to 40 °C for 8 h at 700 rpm. After 
cooling down to room temperature, the solutions were neutralized with 2N HCl (20 μL), 
evaporated to dryness and the derivatized amino acids were dissolved in 300 μL acetonitrile. 
An amino acid standard mix (Sigma Aldrich) as well as N-Me-L-Threonine (Sigma Aldrich) 
were derivatized via the same procedure and all samples were analyzed on a Dionex Ultimate 
3000 RSLC system coupled to a Bruker Maxis 4G mass spectrometer. Separation was 
performed using a Waters BEH C18, 100 × 2.1 mm, 1.7 µm dp column. At a flow rate of 0.6 
mL/min, the following gradient was applied (A: deionized water + 0.1% formic acid, B: 
acetonitrile + 0.1% formic acid): 0 min 5% B, 0-1 min 5-10% B, 1-15 min 10-35% B, 15-22 
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min 35-55% B, 22-25 min 55-80% B, 25-26 min 80% B, 26-26.5 min 80-5% B, 26.5-31 min 
5% B. Full scan mass spectra were acquired in a range from 100-1000 m/z. 
 
Structure of myxochromide AS4 
Structure elucidation of myxochromide AS4 was achieved using 1D 1H and 2D 1H-1H COSY, 
HSQC and HMBC spectra (Figure S6). Carbon chemical shifts were extracted from 2D NMR 
data. NMR spectroscopic data are listed in Table S14. The 1H NMR spectrum exhibited 
signals corresponding to five α-CH protons (δH 3.8-5.6), four CH3 groups (δH 1.3-1.7) and two 
CH2 groups (δH 2.0-2.3) together with a N-Me group (δH 3.29, 3H, s). Moreover, a number of 
downfield signals belonging to the unsaturated polyketide side chain (δH 5.8-7.3) and a CH3 
signal (δH 1.04, 3H, t) were observed. 2D NMR data revealed the presence N-Me-threonine, 
glutamine, alanine and a polyene side chain. Amino acid sequence was established by means 
of key HMBC correlations and final structure was elucidated as shown in Figure S5. For the 
assignment of the absolute configuration of myxochromide AS4, hydrolysis and Marfey 
analysis of the obtained amino acids,32 was applied as described above. The chromatograms 
obtained from HPLC-MS analysis are illustrated in Figure S7 and stereochemical assignments 
are illustrated in Table S15. Comparison of the retention times and masses of derivatized 
standard amino acids and the hydrolyzed lipopeptide revealed that all amino acids of the 
myxochromide AS4 peptide core show L-configuration, while glutamine was converted to 
glutamic acid during hydrolysis. This correlates with the assumption that in the underlying 
hybrid pathway, the condensation domain of module 3 specifically processes the L-configured 
aminoacyl donor (LCL domain), although the presence of an epimerization domain in module 
2 of the assembly line points to the incorporation of D-Ala into this position of the peptide 
core (see Chapter 3.3.8). 
 
 
 
Figure S5. Structure of myxochromide AS4 showing selected COSY (bold line) and key HMBC (arrow) 
correlations. 
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Table S14. NMR spectroscopic data of myxochromide AS4. 
Moiety Position δCa δHb (J in Hz) HMBCc 
L-Ala (1) 1 173.2   
 2 53.0 3.77, q (7.3) 1, 3, 4 
 3 15.3 1.65, d (7.3 ) 1, 2 
L-Ala (2) 4  173.7   
 5  51.6 3.82, q (7.0) 4, 6,7 
 6  14.9 1.39, d (7.0) 4, 5 
L-Ala (3) 7  176.6   
 8 51.1 4.03, q (7.3) 7, 9,10 
 9 16.1 1.32, m 7, 8 
N-Me-L-Thr 10 171.1   
 11  59.5 5.55, d (4.2) 1',10, 12, 19 
 12  74.0 5.46, m 13, 14 
 13  16.5 1.26, d (6.5) 11, 12 
 19 35.0 3.27, s 1', 11 
L-Gln 14 170.9   
 15  51.9 4.67, dd (3.2, 9.6) 1, 14, 16, 17 
 16a  27.8 1.93, m 15, 17, 18 
 16b  2.04, m  
 17a 31.9 2.26, m 14, 16 
 17b  2.32, m  
 18  178.2   
Side chain 1' 170.6   
 2' 119.7 6.57, d (14.6) 1' 
 3' 145.2 7.29, dd (11.4, 14.6) 1', 2', 5' 
 4' 138.4 6.52, m  
 5' 141.8 6.69, m  
 6'-14' d d  
 15' 135.1 6.24, m  
 16' 130.9 6.12, m 15', 18' 
 17' 138.1 5.79, m 15', 18', 19' 
 18' 26.7 2.14, m 16', 17', 19' 
 19' 13.7 1.02, t (7.2) 18' 
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d overlapped signals. 
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Figure S6 (continued on next page) 
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Figure S6 (continued on next page) 
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Figure S6 (continued on next page) 
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Figure S6.  NMR spectra of myxochromide AS4. 
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Figure S7. Results of the analysis of the absolute configuration by advanced Marfey’s method.32 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide AS4 derivatized with 
D-FDLA reagent. D: Hydrolyzed myxochromide AS4 derivatized with L-FDLA reagent. E: Standard solution of 
N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized with L-
FDLA. G: Same sample as in C analyzed for the N-Me-L-threonine D-FDLA derivative. H: Same sample as in 
D analyzed for the N-Me-L-threonine L-FDLA derivative. 
 
Table S15. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of 
the amino acids in myxochromide AS4. 
 
12 14 16 18 20 22 Rt [min]
L-AlaL-Glu
L-Glu L-Ala
N-Me-L-Thr
N-Me-L-Thr
A
B
C
D
E
F
G
H
Standard amino acid mix
D-FDLA derivatives
Standard amino acid mix
L-FDLA derivatives
Hydrolyzed myxochromide AS4
D-FDLA derivatives
Hydrolyzed myxochromide AS4
L-FDLA derivatives
N-Me-L-Thr standard
D-FDLA derivatives
N-Me-L-Thr standard
L-FDLA derivatives
Hydrolyzed myxochromide AS4
N-Me-Thr-D-FDLA derivative
Hydrolyzed myxochromide AS4
N-Me-Thr-L-FDLA derivative
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration Rt [min] m/z [M+H]+ Rt [min] m/z [M+H]+ 
Glu-D-FDLA 14.3 442.1578 14.3 442.1563 L 
Glu-L-FDLA 13.3 442.1579 13.3 442.1574 
Ala-D-FDLA 16.7 384.1520 16.7 384.1517 L 
Ala-L-FDLA 14.3 384.1524 14.3 384.1518 
Ala-D-FDLA 16.7 384.1520 16.7 384.1517 L 
Ala-L-FDLA 14.3 384.1524 14.3 384.1518 
Ala-D-FDLA 16.7 384.1520 16.7 384.1517 L 
Ala-L-FDLA 14.3 384.1524 14.3 384.1518 
N-Me-Thr-D-FDLA 14.4 428.1782 14.3 428.1774 L 
N-Me-Thr-L-FDLA 12.9 428.1786 12.8 428.1776 
Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis     224 
 
Structure of myxochromide SA3 
Structure elucidation of myxochromide SA3 was achieved using 1D 1H and 2D 1H-1H COSY, 
HSQC and HMBC spectra (Figure S9). Carbon chemical shifts were extracted from 2D NMR 
data. NMR spectroscopic data are listed in Table S16. The COSY spectrum supported by 
HSQC and HMBC data showed presence of spin systems corresponding to N-Me-threonine, 
glutamine, alanine, proline and leucine residues as well as a polyene side chain. Amino acid 
sequence was established by means of key HMBC correlations and final structure was 
elucidated as shown in Figure S8. For the assignment of the absolute configuration of 
myxochromide SA3, Marfey analysis of the obtained amino acids,32 was applied as described 
above. The chromatograms obtained from HPLC-MS analysis are illustrated in Figure S10 
and stereochemical assignments are illustrated in Table S17. Comparison of the retention 
times and m/z values of derivatized standard amino acids and the hydrolyzed lipopeptide 
revealed the presence of a D-configured leucine residue (C16) in myxochromide SA3. The 
amino acids alanine (C2), proline (C5), another leucine (C10), N-Me-threonine (C22) and 
glutamine (C26), which was converted to glutamic acid during hydrolysis, were found to be 
L-configured. These findings demonstrate that the epimerization domain of module 2 in the 
underlying hybrid assembly line is not specific for alanine, but also extert its function on the 
more bulky leucine residue. The downstream condensation domain from module 3 originating 
from the A-type mch pathway is obviously a DCL-type domain, thereby processing the D-
configured dipeptide intermediate. 
 
 
 
Figure S8. Structure of myxochromide SA3 showing selected COSY (bold line) and key HMBC (arrow) 
correlations. 
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Table S16: NMR spectroscopic data of myxochromide SA3. 
Moiety Position δCa δHb (J in Hz) HMBCc 
L-Ala 1 172.9   
 2 52.1 3.84, q (7.3) 1, 3, 4 
 3 15.8 1.56, d (7.3) 1, 2 
L-Pro 4  174.3   
 5  63.5 4.00, dd (9.6, 6.9) 4, 6, 9 
 6a  29.8 1.89, m 5, 7 
 6b  2.24, m 5, 7 
 7a 26.4 2.02, m 6, 8 
 7b  2.16, m 6, 8 
 8a 47.8 3.55, m 7 
 8b  3.74, m 7 
L-Leu 9  172.0   
 10 52.1 4.40, m 9, 11, 12, 15 
 11a 38.0 1.51, m 10 
 11b  1.56, m 10 
 12 25.8 1.53, m 10, 11, 13, 14 
 13 23.4 0.98, d (6.9) 11, 12, 14 
 14 23.4 0.98, d (6.9) 13 
D-Leu 15 174.8   
 16 51.7 4.78, t (7.5) 15, 18, 21 
 17a 40.4 1.49, m 18, 19, 20 
 17b  1.57, m 18, 19, 20 
 18 25.9 1.52, m  
 19 22.6 0.94, m 20 
 20 22.6 0.94, m 19 
N-Me-L-Thr 21 169.0   
 22  60.7 5.57, d (3.3) 1', 21, 23 
 23  72.2 5.73, m 24, 25 
 24  16.3 1.09, d (6.6) 21, 22 
 30 35.2 3.21, s 1', 22 
L-Gln 25 171.5   
 26  54.0 4.51, dd (8.4, 8.1) 1, 25, 27, 28 
 27a  28.8 1.80, m 29 
 27b  2.34, m 29 
 28a 32.1 2.23, m 29 
 28b  2.32, m 29 
 29  177.2   
Side chain 1' 170.9   
 2' 120.0 6.60, d (14.7) 1' 
 3' 144.8 7.35, dd (14.7, 11.5) 1' 
 4' 131.3 6.49, m  
 5'-15' d d d 
 16' 133.1 6.14, m  
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 17' 131.1 5.75, m 18' 
 18' 18.2 1.78, d (6.6) 17' 
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d overlapped signals. 
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Figure S9 (continued on next page) 
 
1 H
-N
M
R
 s
pe
ct
ru
m
 o
f 
m
yx
oc
hr
om
id
e 
S
A
3 
in
 C
D
3O
D
 (
50
0 
M
H
z)
 
Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis     228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S9 (continued on next page) 
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Figure S9 (continued on next page) 
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Figure S9. NMR spectra of myxochromide SA3. 
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Figure S10. Results of the analysis of the absolute configuration by advanced Marfey’s method.32 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide SA3 derivatized with 
D-FDLA reagent. D: Hydrolyzed myxochromide SA3 derivatized with L-FDLA reagent. E: Same sample as in C 
analyzed for the L-glutamic acid D-FDLA derivative. F: Same sample as in D analyzed for the L-glutamic acid 
L-FDLA derivative. G: Standard solution of N-Me-L-threonine derivatized with D-FDLA. H: Standard solution 
of N-Me-L-threonine derivatized with L-FDLA. I: Same sample as in C analyzed for the N-Me-L-threonine D-
FDLA derivative. J: Same sample as in D analyzed for the N-Me-L-threonine L-FDLA. 
 
Table S17. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of 
the amino acids in myxochromide SA3. 
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.3 442.1578 14.3 442.1576 L 
Glu-L-FDLA 13.3 442.1579 13.3 442.1570 
Ala-D-FDLA 16.7 384.1520 16.7 384.1515 L 
Ala-L-FDLA 14.3 384.1524 14.3 384.1511 
Pro-D-FDLA 16.2 410.1675 16.2 410.1676 L 
Pro-L-FDLA 14.5 410.1675 14.5 410.1673 
Leu-D-FDLA 21.1 426.1989 21.1 426.1993 L 
Leu-L-FDLA 17.8 426.1988 17.8 426.1986 
Leu-D-FDLA 21.1 426.1989 17.8 426.1993 D 
Leu-L-FDLA 17.8 426.1988 21.1 426.1982 
N-Me-Thr-D-FDLA 14.4 428.1782 14.4 428.1786 L 
N-Me-Thr-L-FDLA 12.9 428.1786 12.9 428.1785 
L-Glu L-AlaL-Pro L-Leu(L-Ile)
L-Leu(L-Ile)L-Glu L-Ala L-Pro
A
B
C
D
E
F
Standard amino acid mix
D-FDLA derivatives
Standard amino acid mix
L-FDLA derivatives
Hydrolyzed myxochromide SA3
D-FDLA derivatives
Hydrolyzed myxochromide SA3
L-FDLA derivatives
Hydrolyzed myxochromide SA3
Glu-D-FDLA derivative
Hydrolyzed myxochromide SA3
Glu-L-FDLA derivative
N-Me-L-Thr
N-Me-L-Thr
G
H
I
J
12 14 16 18 20 22 Rt [min]
N-Me-L-Thr standard
D-FDLA derivatives
N-Me-L-Thr standard
L-FDLA derivatives
Hydrolyzed myxochromide SA3
N-Me-Thr-D-FDLA derivative
Hydrolyzed myxochromide SA3
N-Me-Thr-L-FDLA derivative
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Structure of myxochromide SB4 
Structure elucidation of myxochromide SB4 was achieved using 1H and 2D 1H-1H COSY, 
HSQC, HMBC and ROESY spectra (Figure S12). Carbon chemical shifts were extracted from 
2D NMR data. NMR spectroscopic data are listed in the Table S18. The 1H NMR spectrum 
closely resembled to that of myxochromide SA3. In addition to the common structural parts, 
analysis of 2D NMR spectra corroborated the presence of an additional leucine residue 
compared to myxochromide SA3. Key HMBC correlations established the amino acid 
sequence and finalized its planar structure as depicted in Figure S11. Length of the polyene 
side chain was deduced based on the HR-MS data and molecular formula. For the assignment 
of the absolute configuration of myxochromide SB4, hydrolysis and Marfey analysis of the 
obtained amino acids,32 was applied as described above. The chromatograms obtained from 
HPLC-MS analysis are illustrated in Figure S13 and stereochemical assignments are 
illustrated in Table S19. Comparison of the retention times and masses of derivatized standard 
amino acids and the hydrolyzed lipopeptide revealed that one of the three leucine residues 
(C10, C16 and C22) from myxochromide SA3 has D configuration. The remaining leucine 
residues as well as the amino acids alanine (C2), proline (C5), N-Me-threonine (C28) and 
glutamine (C32), which was converted to glutamic acid during hydrolysis, were found to be 
L-configured. According to the domain organization of the underlying hybrid assembly line, 
which harbors an epimerization domain in module 2, the D-configured leucine was assigned 
to C22. This also correlates with the structure of myxochromide SA3 and identifies the 
condensation domain of module 3 originating from the B-type mch pathway as a DCL domain. 
 
 
Figure S11. Structure of myxochromide SB4 showing selected COSY (bold line), ROESY (dashed arrow) and 
key HMBC (arrow) correlations. 
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Table S18. NMR spectroscopic data of myxochromide SB4. 
Moiety Position δCa δHb (J in Hz) HMBCc ROESYd, e 
L-Ala 1 174.5    
 2 50.3 4.26 m 1,3  
 3 15.5 1.42 d (7.4) 1,2  
L-Pro 4  174.0    
 5  63.6 4.11 m 4, 6a/b,7a/b 10 
 6a  30.5 1.90 m 4,5,7a/b  
 6b 30.5 2.35 m 4, 5,7a/b  
 7a 25.9 2.05 m 5,6a/b,8a/b  
 7b 25.9 2.13 m 5,6a/b,8a/b  
 8a 48.3 3.68 m 6a/b,7a/b 10 
 8b 48.3 3.85 m 6a/b,7a/b,9 10 
L-Leu 9  174.0    
 10 49.6 4.95 dd (f) 9,11,12,15 8a/b, 5 
 11a 41.3 1.51 m 10,12  
 11b 41.3 1.64 m 10,12  
 12 25.8 1.65 m 13,14  
 13 21.2 0.99 m 11,12,14  
 14 23.5 0.95 m 11,12,13  
L-Leu 15 174.4    
 16 54.5 4.27 m 15,17a/b,18,21  
 17a 41.8 1.65 m 19,20  
 17b 41.8 1.76 m 19,20  
 18 25.9 1.74 m   
 19 21.1 0.91 d (6.1) 17a/b  
 20 23.1 1.01 m 17a/b  
D-Leu 21 174.1    
 22 52.6 4.68 m 21,23a/b,24  
 23a 44.3 1.59 m 22,24,25,26  
 23b 44.3 1.44 m 22,24,25,26  
 24 25.7 1.52 m   
 25 22.8 0.94 m 23a/b,24,25  
 26 22.8  0.94 m 23a/b,24,25  
N-Me-L-Thr 27 168.6    
 28  61.0 5.57 d (3.5) 1´,27,29,36  
 29  71.0 5.83 m 30,31  
 30  16.2 1.09 d (6.6) 27,28,29  
 36 35.5 3.23 s  1´,28  
L-Gln 31 170.7    
 32  55.4 4.12 m 31,33,34  
 33a  28.5 1.92 m 32,34,35  
 33b 28.5 2.16 m 32,34,35  
 34a 31.9 2.29 m 32,33a/b,35  
 34b 31.9 2.53 m 32,33a/b,35  
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 35 177.4    
Side chain 1' 170.8    
 2' 120.0 6.69 d (14.9) 1´,3´  
 3' 145.0 7.36 dd (14.5,11.2) 1´,2´,4´  
 4' 138.4 6.55 m 5´  
 5' 141.6 6.72 m 3´,4´  
 6´-14´ f f   
 15' 135.1 6.24 m 17´  
 16' 130.9 6.12 dd (9.8,15.0) 17´  
 17' 138.1 5.79 m 15´,18´,16´  
 18' 26.5 2.14 m 16´,17´,  
 19´ 13.6 1.02 t (7.4) 18´,17´  
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d proton showing ROESY correlations to indicated protons. 
e acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
f overlapped signals. 
g correlation obtained from HMBC spectra in (CD3)2SO (data not shown). 
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Figure S12 (continued on next page) 
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Figure S12 (continued on next page) 
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Figure S12 (continued on next page) 
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Figure S12 (continued on next page) 
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Figure S12.  NMR spectra of myxochromide SB4. 
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Figure S13. Results of the analysis of the absolute configuration by advanced Marfey’s method.32 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide SB4 derivatized with 
D-FDLA reagent. D: Hydrolyzed myxochromide SB4 derivatized with L-FDLA reagent. E: Standard solution of 
N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized with L-
FDLA. G: Same sample as in C analyzed for the N-Me-L-threonine D-FDLA derivative. H: Same sample as in 
D analyzed for the N-Me-L-threonine L-FDLA derivative. 
Table S19. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of 
the amino acids in myxochromide SB4. 
 
A
B
C
D
E
F
G
H
Standard amino acid mix
D-FDLA derivatives
Standard amino acid mix
L-FDLA derivatives
Hydrolyzed myxochromide SB4
D-FDLA derivatives
Hydrolyzed myxochromide SB4
L-FDLA derivatives
N-Me-L-Thr standard
D-FDLA derivatives
N-Me-L-Thr standard
L-FDLA derivatives
Hydrolyzed myxochromide SB4
N-Me-Thr-D-FDLA derivative
Hydrolyzed myxochromide SB4
N-Me-Thr-L-FDLA derivative
L-Leu(L-Ile)
L-Leu(L-Ile)
L-AlaL-ProL-Glu
L-ProL-AlaL-Glu
N-Me-L-Thr
N-Me-L-Thr
12 14 16 18 20 22 Rt [min]
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.3 442.1578 14.3 442.1572 L 
Glu-L-FDLA 13.3 442.1579 13.3 442.1582 
Ala-D-FDLA 16.7 384.1520 16.7 384.1513 L 
Ala-L-FDLA 14.3 384.1524 14.3 384.1525 
Pro-D-FDLA 16.2 410.1675 16.2 410.1672 L 
Pro-L-FDLA 14.5 410.1675 14.5 410.1676 
Leu-D-FDLA 21.1 426.1989 21.1 426.1986 L 
Leu-L-FDLA 17.8 426.1988 17.8 426.1985 
Leu-D-FDLA 21.1 426.1989 21.1 426.1986 L 
Leu-L-FDLA 17.8 426.1988 17.8 426.1985 
Leu-D-FDLA 21.1 426.1989 17.8 426.1991 D 
Leu-L-FDLA 17.8 426.1988 21.1 426.1988 
N-Me-Thr-D-FDLA 14.4 428.1782 14.4 428.1775 L 
N-Me-Thr-L-FDLA 12.9 428.1786 12.9 428.1779 
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Structure of myxochromide SC4 
Structure elucidation of myxochromide SC4 was achieved using 1D 1H and 2D 1H-1H COSY, 
HSQC, HMBC and ROESY spectra (Figure S15). Carbon chemical shifts were extracted from 
2D NMR data. NMR spectroscopic data are listed in Table S20. The COSY spectrum 
supported by HSQC and HMBC data showed presence of spin systems corresponding to N-
Me-threonine, glutamine, proline and leucine residues as well as a polyene side chain. Amino 
acid sequence was established by means of key HMBC correlations and final structure was 
elucidated as shown in Figure S14. For the assignment of the absolute configuration of 
myxochromide SC4, hydrolysis and Marfey analysis of the obtained amino acids,32 was 
applied as described above.32 The chromatograms obtained from HPLC-MS analysis are 
illustrated in Figure S16 and stereochemical assignments are illustrated in Table S21. 
Comparison of the retention times and masses of derivatized standard amino acids and the 
hydrolyzed lipopeptide revealed that one of the two leucine residues (C7 and C13) from 
myxochromide SC4 is D-configured. The second leucine residue as well as the amino acids 
proline (C2), N-Me-threonine (C19) and glutamine (C23), which was converted to glutamic 
acid during hydrolysis, were found to be L-configured. According to the domain organization 
of the underlying hybrid assembly line, which harbors an epimerization domain in module 2, 
the D-configured leucine was assigned to C13. This also correlates with the structures of 
myxochromide SA3 myxochromide SB4 and and identifies the condensation domain of 
module 3 originating from the C-type mch pathway as a DCL domain. 
 
 
 
Figure S14. Structure of myxochromide SC4 showing selected COSY (bold line), ROESY (dashed arrow) and 
key HMBC (arrow) correlations. 
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Table S20. NMR spectroscopic data of myxochromide SC4. 
Moiety Position δCa δHb (J in Hz) HMBCc ROESYd,e,g 
L-Pro 1 174.2    
 2 63.0 4.34, m 1, 3, 7 7 
 3a 32.6 2.18, m 4  
 3b  2.42, m 4  
 4 23.4 2.00, m   
 5a 47.7 3.59, m   
 5b  3.74, m   
L-Leu 6  173.9 f    
 7  49.7 4.66, m 6, 8, 9 2 
 8a  42.5 1.55, m   
 8b  1.62, m   
 9 25.6 1.53, m   
 10 23.3 0.93, m 8, 9  
 11 23.3 0.93, m 8, 9  
D-Leu 12  173.9 f    
 13 54.4 4.26, m 12, 14,15,18  
 14a 40.8 1.39, m 12, 15  
 14b  1.75, m 12, 15  
 15 25.6 1.53, m   
 16 21.5 0.91, m 15  
 17 21.5 0.91, m 15  
N-Me-L-Thr 18 170.8    
 19  61.6 5.41, m 18  
 20  72.1 5.97, m   
 21  16.8 1.24, d (6.5) 19, 20  
 27 34.8 3.40, m 1', 19  
L-Gln 22 171.1    
 23  54.4 4.42, m 1, 24, 25  
 24a  28.8 2.03, m 26  
 24b  2.11, m 26  
 25a 31.7 2.22, m 26  
 25b  2.22, m 26  
 26  176.9    
Side chain 1' 170.8    
 2' 119.8 6.65, d (14.8)   
 3' 144.9 7.34, dd (14.8,11.7 )   
 4' 141.8 6.54, m   
 5'-14' f f   
 15' 134.9 6.27, m   
 16' 130.7 6.12, dd (15.0, 10.0 )   
 17' 138.1 5.79, dt (15.0, 6.7) 15'  
 18' 26.6 2.14, m 17', 19'  
 19' 13.6 1.02, t (7.4) 18'  
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a acquired at 175 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 700 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d proton showing ROESY correlations to indicated protons. 
e acquired at 700 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
f overlapped signals. 
gonly relevant correlations listed 
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Figure S15 (continued on next page) 
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Figure S15 (continued on next page) 
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Figure S15 (continued on next page) 
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Figure S15 (continued on next page) 
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Figure S15.  NMR spectra of myxochromide SC4. 
R
O
E
S
Y
 s
pe
ct
ru
m
 o
f 
m
yx
oc
hr
om
id
e 
S
C
4 
in
 C
D
3
249     Synthetic Biotechnology to Engineer Myxobacterial Lipopeptide Biosynthesis 
 
 
 
Figure S16. Results of the analysis of the absolute configuration by advanced Marfey’s method.32 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide SC4 derivatized with 
D-FDLA reagent. D: Hydrolyzed myxochromide SC4 derivatized with L-FDLA reagent. E: Standard solution of 
N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized with L-
FDLA. G: Same sample as in C analyzed for the N-Me-L-threonine D-FDLA derivative. H: Same sample as in 
D analyzed for the N-Me-L-threonine L-FDLA derivative 
. 
 
Table S21. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of 
the amino acids in myxochromide SC4. 
 
 
12 14 16 18 20 22 Rt [min]
A
B
C
D
E
F
G
H
Standard amino acid mix
D-FDLA derivatives
Standard amino acid mix
L-FDLA derivatives
Hydrolyzed myxochromide SC4
D-FDLA derivatives
Hydrolyzed myxochromide SC4
L-FDLA derivatives
N-Me-L-Thr standard
D-FDLA derivatives
N-Me-L-Thr standard
L-FDLA derivatives
Hydrolyzed myxochromide SC4
N-Me-Thr-D-FDLA derivative
Hydrolyzed myxochromide SC4
N-Me-Thr-L-FDLA derivative
L-Leu(L-Ile)
L-Leu(L-Ile)
L-ProL-Glu
L-ProL-Glu
N-Me-L-Thr
N-Me-L-Thr
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.3 442.1578 14.3 442.1572 L 
Glu-L-FDLA 13.3 442.1579 13.3 442.1572 
Pro-D-FDLA 16.2 410.1675 16.2 410.1679 L 
Pro-L-FDLA 14.5 410.1675 14.5 410.1668 
Leu-D-FDLA 21.1 426.1989 21.1 426.1990 L 
Leu-L-FDLA 17.8 426.1988 17.8 426.1982 
Leu-D-FDLA 21.1 426.1989 17.8 426.1981 D 
Leu-L-FDLA 17.8 426.1988 21.1 426.1980 
N-Me-Thr-D-FDLA 14.4 428.1782 14.4 428.1780 L 
N-Me-Thr-L-FDLA 12.9 428.1786 12.9 428.1777 
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Structure of myxochromide SD3 
Structure elucidation of myxochromide SD3 was achieved using 1D 1H and 2D 1H-1H COSY, 
HSQC and HMBC spectra (Figure S18). Carbon chemical shifts were extracted from 2D 
NMR data. NMR spectroscopic data are listed in Table S22. The COSY spectrum supported 
by HSQC and HMBC data revealed the presence of N-Me-threonine, glutamine, alanine and 
leucine residues as well as and a polyene side chain. Amino acid sequence was established by 
means of key HMBC correlations and final structure was elucidated as shown in Figure S17. 
For the assignment of the absolute configuration of myxochromide SD3, hydrolysis and 
Marfey analysis of the obtained amino acids,32 was applied as described above. The 
chromatograms obtained from HPLC-MS analysis are illustrated in Figure S19 and 
stereochemical assignments are illustrated in Table S23. Comparison of the retention times 
and masses of derivatized standard amino acids and the hydrolyzed lipopeptide revealed that 
one of the two leucine residues (C5 and C11) from myxochromide SD3 is D-configured. The 
second leucine residue as well as the amino acids alanine (C2), N-Me-threonine (C17) and 
glutamine (C21), which was converted to glutamic acid during hydrolysis, were found to be 
L-configured. This is in accordance with the absolute configurations observed in 
myxochromides SA3, SB4 and SC4. According to the domain organization of the underlying 
hybrid assembly line, which harbors an epimerization domain in module 2, the D-configured 
leucine was assigned to C11. This also correlates with the structures of myxochromide SA3 
myxochromide SB4 and and identifies the condensation domain of module 3 originating from 
the D-type mch pathway as a DCL domain.  
 
 
 
 
 
 
 
 
 
Figure S17. Structure of myxochromide SD3 showing selected COSY (bold line) and key HMBC (arrow) 
correlations. 
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Table S22. NMR spectroscopic data of myxochromide SD3. 
Moiety Position δCa δHb (J in Hz) HMBCc 
L-Ala 1 172.7   
 2 50.6 4.21 m 1,3,4 
 3 18.7 1.37 d (6.7) 1,3 
L-Leu 4  174.7   
 5  54.2 4.19 m 4,6a/b,7, 10e 
 6a  40.6 1.58 m  
 6b  1.65 m  
 7 25.9 1.71 m  
 8 23.2 0.99 d (6.3) 6,7,9 
 9 21.1 0.91 d (6.5) 6,7,8 
D-Leu 10  175.2   
 11 53.1 4.39 m 10,12,13,16 
 12a 40.6 1.49 m 11 
 12b 40.6 1.60 m 11 
 13 25.7 1.56 m  
 14 22.6 0.92 m 12,13,15 
 15 22.6 0.92 m 12,13,14 
N-Me-L-Thr 16 169.8   
 17  59.5 5.43 m 16,18 
 18  72.4 5.52 m 19,20 
 19  17.2 1.15 d (6.9) 18,20 
 25 35.1 3.02 s 1´,17 
L-Gln 20 170.9   
 21  53.9 3.95 m 1,20,22a/b,23a/b 
 22a  26.3 2.13 m 20,21,23a/b,24 
 22b 26.3 2.25 m 20,21,23a/b,24 
 23a 32.1 2.16 m 24 
 23b 32.1 2.27 m 24 
 24  177.7   
Side chain 1' 170.6   
 2' 120.1 6.59 m 1´,4´ 
 3' 144.9 7.35 m 1´ 
 4' 131.5 6.53 m  
 5´-15' dd dd  
 16' 133.1 6.15 m  
 17' 131.1 5.75 m   
 18' 18.3 1.78 d (7.1) 17´,16´ 
a acquired at 125 MHz and assigned from 2D NMR spectra, referenced to solvent signal CD3OD at δ 49.15 ppm. 
b acquired at 500 MHz, referenced to solvent signal CD3OD at δ 3.31 ppm. 
c proton showing HMBC correlations to indicated carbons. 
d overlapped signals. 
eHMBC acquired with 2k F1 resolution 
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Figure S18 (continued on next page) 
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Figure S18 (continued on next page) 
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Figure S18 (continued on next page) 
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Figure S18.  NMR spectra of myxochromide SD3. 
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Figure S19. Results of the analysis of the absolute configuration by advanced Marfey’s method.32 Extracted ion 
chromatograms (EIC) for ±0.05 m/z corresponding to the [M+H]+ ions of derivatized amino acids, which are 
present in the peptide scaffold, are shown. A: Standard amino acid mix derivatized with D-FDLA reagent. B: 
Standard amino acid mix derivatized with L-FDLA reagent. C: Hydrolyzed myxochromide SD3 derivatized with 
D-FDLA reagent. D: Hydrolyzed myxochromide SD3 derivatized with L-FDLA reagent. E: Standard solution of 
N-Me-L-threonine derivatized with D-FDLA. F: Standard solution of N-Me-L-threonine derivatized with L-
FDLA. G: Same sample as in C analyzed for the N-Me-L-threonine D-FDLA derivative. H: Same sample as in 
D analyzed for the N-Me-L-threonine L-FDLA derivative. 
 
Table S23. Analytical data of detected amino acid derivatives and assignment of the absolute configuration of 
the amino acids in myxochromide SD3. 
 
 
12 14 16 18 20 22 Rt [min]
A
B
C
D
E
F
G
H
Standard amino acid mix
D-FDLA derivatives
Standard amino acid mix
L-FDLA derivatives
Hydrolyzed myxochromide SD3
D-FDLA derivatives
Hydrolyzed myxochromide SD3
L-FDLA derivatives
N-Me-L-Thr standard
D-FDLA derivatives
N-Me-L-Thr standard
L-FDLA derivatives
Hydrolyzed myxochromide SD3
N-Me-Thr-D-FDLA derivative
Hydrolyzed myxochromide SD3
N-Me-Thr-L-FDLA derivative
N-Me-L-Thr
N-Me-L-Thr
L-Glu
L-Glu
L-Ala
L-Ala L-Leu(L-Ile)
L-Leu(L-Ile)
aa-FDLA 
derivative 
L-aa standards Peptide hydrolysate Assigned 
configuration tR [min] m/z [M+H]+ tR [min] m/z [M+H]+ 
Glu-D-FDLA 14.3 442.1578 14.3 442.1575 L 
Glu-L-FDLA 13.3 442.1579 13.3 442.1564 
Ala-D-FDLA 16.7 384.1520 16.7 384.1512 L 
Ala-L-FDLA 14.3 384.1524 14.3 384.1519 
Leu-D-FDLA 21.1 426.1989 21.1 426.1986 L 
Leu-L-FDLA 17.8 426.1988 17.8 426.1986 
Leu-D-FDLA 21.1 426.1989 17.8 426.1982 D 
Leu-L-FDLA 17.8 426.1988 21.1 426.1984 
N-Me-Thr-D-FDLA 14.4 428.1782 14.4 428.1773 L 
N-Me-Thr-L-FDLA 12.9 428.1786 12.9 428.1784 
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4 Discussion & Outlook 
4.1 General Scope of the Present Work 
The present studies described in this thesis deal with various aspects of myxobacterial natural 
product research ranging from secondary metabolite pathway identification, evolution and 
diversification to synthetic biology approaches in order to heterologously express artificial 
biosynthetic gene clusters based on synthetic DNA. 
It could be demonstrated how genome-mining on a large scale can contribute to the in-depth 
analysis of the distribution and evolution of PKS/NRPS-derived lipopeptide pathways leading 
to numerous diversified gene cluster types responsible for the production of structurally 
different lipopeptide core structures. Furthermore, the observed structural differences could be 
rationalized on the basis of detailed comparative in silico sequence analyses, which 
additionally provided valuable insights into the evolutionary scenarios that might have led to 
the emergence of different but closely related lipopeptide pathways in various strains covering 
different genera of myxobacteria. 
In addition, synthetic DNA platforms for the heterologous expression of myxobacterial 
lipopeptide pathways based on a dedicated gene library consisting of different lipopeptide 
biosynthetic genes from the identified lipopeptide gene clusters were established exhibiting a 
broad applicability. They provide the basis for the rational engineering of the underlying 
megasynthetases to produce hybrid lipopeptides, which do not occur naturally, thereby further 
increasing the structural diversity of this compound class. In the course of this study, a highly 
flexible assembly strategy for the construction of large artificial expression constructs 
harboring the synthetic gene clusters was established allowing the directed modification of the 
artificial pathways. Moreover, it was demonstrated that the established synthetic DNA 
platforms can also be used for the investigation of biosynthetic mechanisms and to evaluate in 
silico predictions regarding substrate specificities. Finally, synthetic biology approaches were 
used to mimic the observed mechanisms of pathway diversification, exemplarily 
demonstrated for the previously described ‘module-skipping’ process. 
 
4.2 Bacterial Secondary Metabolite Pathways – Evolution and Diversification 
Bacterial biosynthetic gene clusters are ideal genetic elements used as model systems to study 
gene evolution. The major prerequisite for comprehensive studies on pathway evolution and 
diversification is the availability of a robust genome database that can be screened for related 
natural product pathways using genome-mining tools.1 As the costs for whole genome 
sequencing dramatically dropped over the past decades, it is now possible to decipher and 
Discussion & Outlook     260 
 
analyze bacterial genome sequences in a high-throughput manner using steadily improved 
state-of-the-art next generation sequencing platforms,2 thereby revealing an outstanding 
degree of natural product pathway diversification and their widespread distribution and 
frequency among different bacterial taxa. This particularly accounts for the tendency of 
bacterial biosynthetic gene clusters to get transferred to other host microbes via horizontal 
gene transfer,3–5 thereby providing the possibility to further evolve in a different genomic 
context. In addition, microbial biosynthetic gene clusters evolve in relatively short time 
frames compared to genes from higher organisms, which results from shorter replication times 
of their host strains.6 
Among the prokaryotic genomes sequenced so far, myxobacterial genomes still represent a 
minor fraction in common sequence repositories. However, the number of myxobacterial 
genomes exploded over the past years as a result of still reducing sequencing costs and the 
isolation of hundreds of novel strains. With the increasing number of available genome 
sequences, comprehensive studies on the evolutionary relationships of interesting 
myxobacterial natural product pathways, particularly polyketide synthase (PKS) and 
nonribosomal peptide synthetase (NRPS) pathways, just begin to contribute to the still limited 
knowledge that currently exists on the evolution of microbial biosynthetic gene clusters.7–11 
Moreover, the structural diversity of the produced natural products can be directly assessed 
and rationally explained on a genetic basis as biosynthetic gene clusters provide a clear link 
between genotype (biosynthetic gene cluster) and phenotype (natural product(s)). Common 
mechanisms by which biosynthetic gene clusters diverge into new pathway types such as 
point mutations, rearrangements, replacements, insertions, and deletions are generally known 
and have been previously described for very few examples based on phylogenetic data.10,12 
However, these reports rarely gave detailed insights into how these evolutionary processes 
explicitly change the pathways on the sequence level, thereby lacking practical implications 
for biotechnological applications. 
Studying natural products pathway evolution is not just a fascinating aspect for theoretical 
biologists as it has tremendous implications for the modification of existing pathways and, 
more ambitiously, for the tailor-made recreation of entirely new pathways from the scratch. 
Understanding the ‘evolutionary rules’ that direct natural pathway diversification would 
ultimately contribute to the realization of this long-term goal, thereby improving the chances 
to synthesize novel products with useful biological functions.13 
In the following, the emergence of numerous myxobacterial lipopeptide pathways through 
diversification via various recombination events, such as module duplication and (partial) 
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module deletion, as well as via point mutations is discussed from an evolutionary point of 
view providing valuable information for the future engineering of NRPS megasynthetases. 
 
4.2.1 Recombination Events Lead to Myxochromide Pathway Diversification 
Screening of the available 122 myxobacterial genome sequences revealed 14 putative 
myxochromide gene clusters (mch clusters) in addition to the previously described A-type 
mch cluster from M. xanthus DK1622 and S-type mch cluster from S. aurantiaca DW4/3-
1.14,15 Among those, four additional A-type and two S-type mch clusters were identified as 
well as the putative mch cluster from Myxococcus sp. 171, which was recently demonstrated 
to be a myxochromide B producer,16 was completely deciphered for the first time by a 
combination of genome sequencing and screening of a cosmid library of this strain, which 
was constructed during this thesis. The remaining 7 mch clusters represent three entirely new 
mch pathways, designated C-type, D-subtype 1 and D-subtype 2 mch clusters, which were 
predicted to encode the megasynthetases responsible for the biosynthesis of novel 
myxochromide cores using bioinformatics tools. In silico prediction of the expected 
lipopeptide products based on the acquired sequence data in conjunction with results from 
previous studies on myxochromide A and S biosynthesis suggested the production of novel 
lipopentapeptides, accordingly designated myxochromides C and D, which was 
experimentally verified with success. Sequence analysis of the identified B-type, C-type and 
D-type mch clusters revealed striking differences regarding the corresponding assembly line 
organizations, which resulted from homologous recombination events.17 
The lipopeptide myxochromide B3 has been previously detected and structurally characterized 
in a secondary metabolomics approach. Myxochromide B3 harbors an additional leucine 
residue adjacent to the leucine residue present in myxochromides A. Whether this additional 
leucine residue in myxochromide B3 is introduced as a result of a module duplication event or 
an iteratively acting leucine-specific NRPS module was not clear.16 The underlying 
biosynthetic pathway was not identified as the genome sequence of the producer strain 
Myxococcus sp. 171 was not available at that time. In this thesis, the biosynthetic pathway 
responsible for the biosynthesis of myxochromides B was completely established and indeed 
revealed a duplicated module in the MchC NRPS subunit, which was acquired via 
homologous recombination.17 Phylogenetic analysis revealed that the heptamodular 
myxochromide B megasynthetase contains a duplicate of the catalytic domains A3, CP3 and 
C4 compared to other myxochromide assembly lines. Additionally, phylogenetic studies in 
conjunction with the analysis of local codon usage adaption along the catalytic domains 
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supports the hypothesis that the B-type mch cluster evolved from an ancestral A-type cluster 
by duplication of the A3-CP3-C4 region. Intriguingly, detailed sequence analysis shed light on 
the exact recombination sites, which are located in the regions encoding the N-termini of A 
domains of module 3 and 4 of the MchC subunit near the regions encoding C-A domain 
interfaces. Consequently, an ‘A-T-C’ unit was duplicated instead of a dedicated C-A-T 
module.17 
Since the distinct C, A and T domains, which make up an entire functional module, are 
usually highly homologous and thus share high sequence similarities, recombination events 
are assumed to take place regularly in the course of pathway evolution. In light of these 
results, homologous recombination in NRPS pathways might be a common strategy by which 
Nature employs pathway diversification. The first phylogenetic studies on selected PKS and 
NRPS systems revealed significant rates of homologous recombination and gene 
duplication.18–21 In particular, duplication events are assumed to play an essential role in the 
overall genesis of NRPS biosynthetic pathways. In many cases, individual ‘A-T-C’ units from 
a certain NRPS subunit group together as a monophyletic clade indicating that NRPSs could 
hypothetically arise from tandem duplication of a single ancestral module.11 A fascinating 
example that supports this hypothesis is the family of related ferrichrome synthetases from 
various fungal species ranging from fission yeast, filamentous ascomycetes and 
basidiomycetes. Phylogenetic analysis of the ferrichrome NRPSs suggested that these 
biosynthetic machineries derive from an ancestral gene encoding a hexamodular NRPS, 
which eventually evolved independently via additional recombination events and that the 
hexamodular NRPS is most likely created by tandem duplication of ‘A-T-C’ units.11 A similar 
scenario seen in ferrichrome synthetases is described for the 49 kb gene encoding the yet 
uncharacterized NRPS Plu2670 from Photorhabdus luminescens from which module 
encoding regions group into five clades exhibiting high sequence similarity of > 85%.22 The 
same conclusion is drawn from phylogenetic analyses of the multimodular PKS responsible 
for the production of mycolactone in Mycobacterium ulcerans. This PKS machinery consists 
of the three individual subunits MLSA1, MLSA2 and MLSB and modules of these subunits 
also group into monophyletic clades with sequence identity of > 98% suggesting the role of 
an ancestral gene for the generation of this large biosynthetic complex via intragenic module 
duplication.23 A recent phylogenetic study on the evolution of polyketide structural diversity 
in the genus Streptomyces by Jenke-Kodama et al. also underpins the role of module 
duplications in natural product pathway evolution. They showed that locations of the 
corresponding recombination sites are not restricted to interdomain linkers, but can be also 
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located in homologous stretches of the corresponding domains.19 Nevertheless, recombination 
sites may be confined to regions that account for the structural diversity of the produced 
compounds. Although the duplication of ‘A-T-C’ units in NRPS megasynthetases seems to be 
quite common in the ‘de novo’ generation of NRPS pathways, an intragenic module 
duplication event in an already ‘established’ functional bacterial NRPS assembly line was 
never described before in such detail. Thus, the observed module duplication event leading to 
the myxochromide B pathway builds the basis for developing concepts for NRPS pathway 
diversification via intragenic module duplication and for the rational modification of the 
underlying pathways via engineered module duplications. It might be possible to engineer 
artificial C-A interdomain linker sequences at different positions of a gene cluster in a way 
that they contain the corresponding regions (N-termini of Ax/Ax+1 domain interfaces, x = 
module number) of the C-A domain interface as observed in the B-type mch cluster, thereby 
facilitating functional coupling of noncognate modules. 
In addition to recombination-based duplication of biosynthetic gene cluster regions, deletions 
of domain or module encoding regions were also detected in a few bacterial pathways.24–26 
Recent studies on the evolutionary roots and genetic distribution of cyanobacterial toxin 
pathways revealed that many toxin producer strains acquired the corresponding pathways 
responsible for the production of several hepatotoxins via horizontal gene transfer, mostly 
mediated by transposases associated with these pathways. This automatically led to the 
emergence of non-toxic strains, in which large portions (up to 90%) of the underlying 
pathways were deleted leading to the inability to produce these toxins through inactivation of 
the gene clusters.7 In analogy to the duplication events discussed above, deletion of defined 
parts of a biosynthetic gene cluster, like functional modules, might result from the highly 
homologous nucleotide sequences the distinct catalytic NRPS domains share. One of the most 
popular and very few examples, for which NRPS gene cluster evolution was demonstrated on 
a broad scale, are these cyanobacterial toxins, particularly the pathways responsible for the 
biosynthesis of the microcystins from Microcystis spp. and related compounds.7 It was 
specifically shown that a recombination-based deletion event that even comprises two NRPS 
modules across the microcystin synthetase subunits McyA and McyB, led to the emergence of 
the closely related and functional nodularin biosynthetic pathway occurring in Nodularia 
spumigena.24 Consequently, the cyclic nodularin peptide core exhibits a reduced ring size, 
thereby lacking the two amino acid residues, which would have been introduced in the core 
structure by the two modules present in the microcystin assembly line (Figure 1). In this case, 
the recombination sites were found to be located within the C domains of module 2 of McyA 
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and module 4 of McyB, regions that exhibit a high degree of sequence homology. 
Phylogenetic analysis involving the biosynthetic genes as well as selected genes associated 
with characterized microcystin and nodularin pathways revealed that the nodularin 
biosynthetic gene cluster might indeed originate from the microcystin pathway that might be 
the ancient ancestor from which the known related cyanobacterial toxin pathways have been 
evolved.24 
Additionally, module deletion also seems to play a role in the diversification of bacterial 
multimodular PKS pathways. The pathways responsible for the production of the polyketides 
spinosyn and butenyl-spinoysn in different Saccharopolyspora spp. also differ in the presence 
or absence of a module containing the catalytic domains KS-AT-DH-KR-ACP. Regarding the 
present enzymatic functions, this module might be responsible for this unique addition of the 
butenyl moiety. The authors stated that the butenyl-spinoysn pathway might be the common 
ancestor from which the spinoysn pathway may have evolved, although they did not give any 
additional details on phylogenetic studies and the exact recombination sites.26 
In the myxochromide C assembly line, module deletion occurred during pathway evolution 
leading to the loss of an ‘A-T-C’ unit between modules 5 and 6 (A5-T5-C6), thereby 
generating a recombined and functional C5-A6-T6-TE termination module. Similar to the 
module duplication process observed in myxochromide B biosynthesis, the recombination 
sites are located near regions encoding C-A domain interfaces, more precisely at the C-
termini of the corresponding C5/C6 domains. Phylogenetic studies show overall congruence 
between strain and gene cluster phylogeny, which suggests that the C-type mch cluster also 
evolved from the ancestral A-type cluster by deletion of the A5-CP5-C6 region.17 
Partial module deletion of an ‘A4-CP4’ unit was observed in the myxochromide D subtype 2 
assembly line leading to the production of a pentapeptide core lacking the proline residue, 
which was ‘encoded’ by the corresponding deleted region of module 4. Interestingly, the 
resulting assembly line harbors a C4/C5 interface after the deletion event, which does 
obviously not interfere with its functionality. The recombination sites were found to be 
located within the C4-A4 and CP4-C5 interdomain linkers, respectively, thereby conserving 
only parts of the original C4-A4 domain interface in the naturally occurring hybrid assembly 
line (Figure 1). Analysis of the local codon usage in all mch clusters revealed less codon 
usage adaptation in this inactive A4-CP4 region in all Cystobacterineae strains compared with 
the following A5-CP5 or preceding A3-CP3 region, which suggests that this region might be a 
kind of hotspot for assembly line modifications. 
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Figure 1. Module duplication events in M. virescens ST200611 and N. spumigena NSOR10. Emergence of the 
myxochromide C and nodularin (PKS)/NRPS assembly lines, which evolved from their ancestors myxochromide 
A and microcystin synthetase, respectively, resulted in structural diversification of the produced natural product 
families. R1/R2, variable amino acid residues; Racyl, acyl side chains. A: Multiple module deletion in nodularin 
biosynthesis. B: Module deletion in myxochromide C biosynthesis. 
 
This is further underpinned by additional mutational activities around the recombination sites, 
which possibly point to ongoing diversification of the resulting mch pathway.17 In light of the 
results obtained from the module deletion event in the myxochromide C pathway, in which a 
complete ‘A-T-C’ unit was deleted, the deletion of an ‘A-T’ unit could possibly indicate an 
evolutionary transition state, from which the remaining C domain region may be deleted in a 
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following second recombination event. Single domain deletions were also recently described 
for microcystin pathways, in which the N-methyltransferase (NMT) domain of the McyA 
subunit was removed yielding functional NRPS assembly lines capable of producing non-
methylated microcystins.27 
In the context of NRPS assembly line enzymology, the observed recombination sites in the 
mch clusters near regions encoding C-A domain interfaces or within C-A linker regions can 
be interpreted on the basis of the general role of interdomain and intermodule linkers in NRPS  
megasynthetases. These linkers are assumed to function in the communication between 
catalytic domains within and between adjacent modules by direct interaction with the 
interconnected domains. Several studies on the rational engineering of NRPS systems 
impressively showed that most targeted module and domain exchanges, in which the native 
interdomain/intermodule linkers are not maintained, lead to non-functional hybrid pathways, 
thereby highlighting the general importance of these linker regions.28–30 In addition, a recent 
crystal structure of an entire C-A-T-TE termination module from the surfactin NRPS 
megasynthetase published by Tanovic et al.,31 revealed that the C-A interdomain linker 
seemed to have a particularly important function by serving as a structurally rigid platform 
that remains invariant during chain elongation. This rigidity arises from extensive interactions 
of the linker region with both C and A domains of this module. In contrast, the linker regions 
between the other catalytic domains (A-PCP and PCP-TE) are much shorter, thereby making 
fewer interactions with the connected domains, which is attributed to their high flexibility to 
allow for the required movements of the rotating PCP and TE domains during catalysis.32 In 
the present cases, in which module duplication (B-type mch cluster) and deletion (C-type and 
D-type mch clusters) arise from recombination sites around these regions, the C-A domain 
interfaces remain largely conserved, which might be an evolutionary strategy in order to 
maintain the native linker architecture and to increase the chances to yield a functional 
evolved pathway in the course of gene cluster diversification. However, structural details on 
the underlying NRPS enzymatic machineries are still limited and even less knowledge is 
available on the dynamical interplay between modules and domains within the 
megasynthetase complexes. In addition, there are only very few examples investigating 
biosynthetic pathway evolution, which are based on a sufficiently high number of gene cluster 
sequences, thereby hampering the generalization of the obtained results. Whether the C-A 
linker regions generally play a protruding role as dedicated recombination spots in NRPS 
pathway diversification remains uncertain and awaits comparable analyses of other natural 
product pathway families. It is more likely that biosynthetic pathways diversify by following 
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specific recombination rules restricted to a family of secondary metabolites as suggested by a 
recent study on megasynthetase evolution.12 
 
4.2.2 ‘Module-Skipping’ Lead to Myxochromide Pathway Diversification 
Another strategy in secondary metabolite pathway diversification is ‘module-skipping’, a 
process that was already demonstrated to happen in some PKS systems.33–36 This known 
deviation from textbook biosynthetic logic eventually results in the formation of polyketides 
lacking an extender unit. ‘Module-skipping’ in NRPS assembly lines is much rarer. In fact, 
only one ‘non-linear’ NRPS system has been described so far.14 Although the myxochromide 
S pathway from S. aurantica DW4/3-1 represents a hexamodular assembly line, the proline 
activating module is skipped during biosynthesis leading to the production of a 
lipopentapeptide core lacking the proline residue. In the reported case, it could be concluded 
that ‘inactivation’ of this module arises from point mutations in the GGHSL core motif of the 
corresponding PCP, in which the conserved serine residue that is required for posttranslational 
activation of the PCP was replaced by a proline, among additional mutations (GGHSL  
GGNPS).14 However, as additional examples for ‘module-skipping’ in other NRPS 
megasynthetases did not appear, it was not clear whether this process represented a random 
event leading to a functional variant of the ancestral pathway by chance, or it is a mutation-
driven diversification path. As the genome-mining approach used during this thesis enabled 
the identification of numerous additional myxochromide biosynthetic gene clusters, it was 
possible to successfully assess the rational basis of this process by comparative sequence 
analyses.17 In addition to the myxochromide S pathway from S. aurantica DW4/3-1, S-type 
mch clusters were also found in several other S. aurantica strains, which exhibit the reported 
serine to proline ‘loss of function’ mutation in the same (proline incorporating) module 
suggesting that ‘module-skipping’ leads to structural diversity in a programmed manner. 
Interestingly, the same mutation was also detected in PCP domains of the orthologous 
modules in the identified D-type mch clusters from distant Hyalangium sp. as well as from 
closely related Stigmatella erecta Pde77 and results in ‘module-skipping’ as well. As these 
gene cluster variants independently evolved and were maintained in the course of pathway 
diversification, these results indicate that ‘module-skipping’ indeed directly contributes to the 
expansion of myxochromide structural diversity.17 Since this kind of mutation-induced 
diversification mechanism was not found in completely different NRPS systems from other 
bacteria so far, it can be assumed that it may reflect a family-specific mechanism in the 
evolutionary history of myxochromide pathways. However, Wenzel et al. hypothesized that 
Discussion & Outlook     268 
 
changing the serine residue from PCPs via site-directed mutagenesis might serve as a tool to 
induce ‘module-skipping’ at other positions in the mch clusters or possibly also in other 
NRPS systems in order to further expand structural diversity.14 In case of the S-type mch 
pathways, they assumed that restoration of the conserved serine residue in the PCP core motif 
might possibly reactivate the affected module leading to incorporation of the corresponding 
proline residue in the peptide core.14 These hypotheses were specifically addressed in this 
thesis using synthetic biology approaches and are further discussed in the last section of the 
discussion. 
 
4.2.3 Concluding Remarks 
As the cost of high-throughput DNA sequencing continues to decrease, more and more 
microbial genomes and metagenomes will be publically available for the identification of 
PKS/NRPS-derived secondary metabolite pathways and their corresponding natural products 
via genome-mining. However, comprehensive in silico screening specific for functionally 
similar or closely related families of biosynthetic gene clusters might accelerate the 
translation of DNA sequences into biotechnological applications rather than searching for a 
certain secondary metabolite that is linked to its corresponding pathway. In light of the 
diverse mechanisms by which biosynthetic gene clusters extensively undergo pathway 
evolution and diversification in bacteria,10,12,13 one can assume that to most ancient gene 
clusters several related pathway variants might exist, leading to the production of structurally 
different molecules even among different bacterial genera. This especially accounts for the 
unique biological functions the produced secondary metabolite derivatives have in their 
natural environment as a result of constant selective pressure that is on the underlying 
pathways.37 Biosynthetic gene clusters spread laterally via horizontal gene transfer resulting 
in novel microbial strains that are capable of producing the corresponding compounds, 
thereby subjecting the natural product pathways to further evolutionary pressure in a different 
genomic context.38 By implementation of sophisticated sequence analysis methods based on 
phylogenies on the domain, module, subunit and gene cluster level as well as on local codon 
usage and adaption in conjunction with the modern analytical techniques to the general 
genome-mining workflow, the importance of genome-mining is no longer restricted to the 
discovery of novel natural products. It also provides a broad picture regarding the 
interrelationships and distribution of biosynthetic gene clusters, which evolved independently 
from each other. The present work provides a guideline how these approaches can be 
combined in order to understand the rules of natural evolution, which might have a direct 
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impact on the rational engineering of PKS/NRPS systems. The recombination sites, which 
have been detected in different mch clusters around the C-A interdomain linkers, can now be 
taken into account when engineering module duplications and deletions at other positions, e.g. 
in the A-type mch cluster to generate novel hybrid assembly lines based on protein sequence 
alignments. However, interdomain linker-driven recombinations may be a family-specific 
recombination rule and may not be applicable to other NRPS assembly lines. Since there are 
not that many related bacterial NRPS pathways published, which were characterized on such 
a broad basis, special emphasis should be on the identification and analysis of already known 
as well as completely novel pathway families to reevaluate the observed recombination events 
regarding their general implications for NRPS pathway diversification. Eventually, the 
present genome-mining approach builds the basis for the identification and detailed analysis 
of related natural product families to assess their evolutionary relationships and based on that, 
to deduce common rules for pathway evolution in order to significantly improve future 
engineering efforts and to make new products via synthetic biology approaches. 
 
4.3 Synthetic Expression Platforms to Produce Myxobacterial Natural Products 
Significant advances in the field of DNA synthesis have recently led to new biotechnological 
applications, which were largely proven to be difficult to perform on native DNA. One 
important example with respect to natural product research is the transfer and functional 
expression of secondary metabolite pathways in heterologous hosts. As heterologous 
expression of biosynthetic gene clusters is per se a challenging task encompassing numerous 
requirements to be considered, synthetic biology approaches are expected to significantly 
contribute to address the challenges a natural product researcher is confronted with. In the 
present thesis, synthetic expression platforms have been established allowing the heterologous 
expression of myxochromide pathways based on synthetic DNA in a myxobacterial host 
strain. The presented strategy is characterized by a high flexibility and broad applicability 
towards pathway engineering and has been further exploited to produce ‘unnatural’ 
myxochromide cores via combinatorial biosynthesis and to study basic biosynthetic processes 
in myxochromide pathways. The work described here demonstrates the power of synthetic 
biology approaches for natural product research and builds the basis for far-reaching and 
systematic investigations on the general DNA sequence design to optimize production yields 
and to provide simplified, ready-to-use cell factories for the production of novel molecules. 
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4.3.1 Heterologous Expression of Myxobacterial Biosynthetic Gene Clusters 
Myxobacteria have been recognized as proficient producers of bioactive natural products, 
which predominantly derive from PKS and NRPS pathways and a significant number of 
promising lead compounds recently entered clinic trails.39 The high relevance of 
myxobacteria as a rich source of potential drug leads is however faced with several drawbacks 
as most myxobacteria are slow growing and difficult to cultivate or even uncultivable under 
standard laboratory conditions. In addition, the number of genetic tools for the manipulation 
of the native producer strains is quite limited compared e.g. to the intensively studied 
streptomycetes. Thus, the development of genetic tools to transfer and efficiently express 
interesting myxobacterial pathways in alternative hosts, which are easy to handle and 
manipulate (e.g. streptomycetes, pseudomonads, bacilli and Escherichia coli) was one of the 
main achievements in the myxobacterial field over the past two decades and many approaches 
for the heterologous expression of PKS/NRPS biosynthetic pathways have been 
established.40,41 These include the direct transfer of relatively small gene clusters mobilized in 
cosmids or BACs into related hosts, pathway modification and expression in unrelated 
bacteria and the co-expression of several gene cluster containing vector systems. The latter 
approach is referred to as multiplasmid approach, which was particularly used for huge 
biosynthetic gene clusters in the past considering the fact that only a small number of methods 
existed at that time for the construction of large DNA constructs on one physical entity such 
as the Red/ET approach.42,43 Direct transfer and expression of cosmids or BAC-derived 
constructs harboring the biosynthetic pathways requires suitable vector systems such as 
replicative plasmids. Unfortunately, replicative plasmids for any myxobacterial species are 
still not available leaving integration into the chromosome via homologous recombination, 
transposition or phage-derived systems the only reliable way to transfer foreign genes into a 
myxobacterial heterologous host.40,41 Most of the strategies are restricted to small biosynthetic 
gene clusters and are characterized by significant time-consuming cloning efforts, especially 
if heterologous expression focuses on large biosynthetic pathways. Recent advances in 
recombinant DNA technologies and assembly strategies led to the addition of valuable 
cloning methods either based on homologous recombination,44–46 or restriction/ligation 
procedures.47,48 The methods generally allow the assembly of sizable gene cluster constructs 
and are applicable to high-throughput set-ups. 
However, the assembly and heterologous expression of natural product biosynthetic pathways 
is not as simple and straightforward as it seems. Efficient expression of target biosynthetic 
pathways in a surrogate host requires in depth knowledge on several factors that influence 
functionality of the heterologous system such as the ability of the surrogate host to 
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posttranslationally activate the PKS and NRPS megasynthetases, the time-coordinated supply 
of biosynthetic precursors in sufficient amounts, the functionality of regulatory elements and 
native promoters, the stability of the transcribed mRNA, and the self-resistance of the host 
strain to the expressed secondary metabolites.40,41 Moreover, it should be pointed out that 
expression of huge biosynthetic pathways is a strong metabolic burden for the producer strain 
considering the complexity of these biosynthetic machineries. Technically, the selected 
heterologous host should exhibit excellent growth characteristics (short doubling times, high 
cell density) and a plethora of experimental tools to genetically modify the host strain should 
exist.40,41 Over the past decades, it was recognized that the efficient heterologous expression 
of PKS/NRPS biosynthetic pathways is often beneficial when transferring the pathways into 
closely related host organisms, e.g. from one myxobacterial species into another, which is 
attributed to a similar codon usage of the target pathway and the genome of the host strain.49 
However, many of the mentioned factors remain largely unknown, so it is not surprising that 
many efforts to heterologously express biosynthetic pathways often yield insufficient amounts 
of the target compounds or even fail completely.  
In summary, many new technological innovations in the fields of DNA cloning and 
engineering contributed to the increasing impact of heterologous expression platforms in 
natural products research over the past decades.40,41 However, as only a limited set of suitable, 
well-characterized heterologous hosts are available today and most of the described classical 
methods still require laborious procedures relying on the mobilization of the genetic blueprint 
responsible for the biosynthesis of a certain secondary metabolite, it is highly desirable to 
develop alternative approaches for heterologous expression (e.g. synthetic biology), which 
address and overcome the discussed limitations. 
Synthetic biology approaches are assumed to have an unprecedented impact on classical 
biology in general, but in particular on natural products research. This emerging discipline 
aims at the de novo recreation of biological systems using defined modular parts that can be 
arbitrarily recombined to yield artificial systems exhibiting novel unnatural features. Due to 
the per se modular architecture of PKS/NRPS systems, this concept might revolutionize our 
view on the rational reprogramming of hybrid megasynthetases producing any desired 
molecule.50 In the context of PKS/NRPS derived biosynthetic pathways, synthetic biology 
currently largely focusses on the application of DNA synthesis which by now came of age.51 
Today, large biosynthetic genes and even complete gene clusters can be designed and 
synthesized de novo, thereby allowing the addition and/or elimination of restriction sites 
without changing the encoded protein sequence as well as the modulation of the codon usage 
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bias. Implementation of ‘standardized’ regulatory elements and synthetic promoter sequences 
known to function in an optimized host supports heterologous expression of biosynthetic 
pathways based on synthetic DNA beyond the native regulatory networks.40,50 Today, only a 
limited number of microbial PKS/NRPS biosynthetic pathways have been ‘refactored’ to 
activate orphan gene clusters, to engineer the pathways for the production of natural product 
analogs and to study the effects of codon optimization.52–56 Interestingly, the latter approach 
does not necessarily lead to improvement of the production yields and even lower product 
amounts are often detected compared to the production titers seen in the native producers. A 
synthetic version of the PKS/NRPS hybrid epothilone pathway from Sorangium cellulosum, 
which was subjected to codon optimization for heterologous expression in the related host M. 
xanthus, merely yielded approximately 0.1 mg/L epothilones A-D, whereas epothilones A and 
B are produced at 20 and 10 mg/L, respectively, in the native producer S. cellulosum So 
ce90.55 However, in some cases codon adaption remains the only way to achieve functional 
expression in a phylogenetically distant host strain at all. Gemperlein et al. demonstrated the 
successful heterologous expression of a synthetic myxobacterial gene cluster encoding for a 
polyunsaturated fatty acid (PUFA) synthase from Aetherobacter fasciculatus in Pseudomonas 
putida. Formal codon optimization was applied to the synthetic PUFA gene cluster, thereby 
changing the gene cluster sequence significantly compared to the native sequence. Besides 
further strain improvement, the synthetic expression system provided at least slightly 
optimized production yields of the PUFA docosahexaenoic acid (DHA).56 
However, considering the fact that synthetic biology principles just begin to be applied to 
natural product biosynthetic pathways, the number of synthetic gene clusters reported in the 
literature is conceivably limited and it is still uncharted how to optimize a gene (cluster) 
sequence in an optimal way. More systematic studies, which include data acquired from 
interdisciplinary fields, need to be carried out to gain deeper insights into the numerous 
factors that contribute to the formation of a certain natural product. 
Thus, the SynBioDesign project presented in the introduction of this thesis aimed at a 
systematic view on the design of synthetic expression platforms for the production of 
myxobacterial secondary metabolites by implementing qualitative and quantitative data 
obtained from transcriptomics, proteomics and metabolomics approaches in conjunction with 
high-throughput DNA synthesis and assembly techniques. The development and application 
of a fast and efficient cloning strategy for large biosynthetic gene cluster constructs would 
provide the opportunity to synthesize, assemble and heterologously express many artificial 
versions of a target gene cluster in parallel, e.g. in terms of gene compositions to generate 
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hybrid gene clusters in order to produce novel compounds or in terms of testing different 
codon optimization protocols to improve production yields. Consequently, integration of the 
acquired analytical datasets might provide guidelines on how to optimally design functional 
and improved gene cluster sequences for heterologous expression, which could then be 
subsequently analyzed in a following round of DNA synthesis, assembly, expression and data 
analysis (Figure 2). 
 
 
 
Figure 2. General high-throughput workflow for the continuous optimization of synthetic DNA platforms for the 
heterologous expression of biosynthetic gene clusters. Iterative cycles of DNA sequence design, assembly and 
heterologous expression as well as integration of the acquired analytical data might facilitate the identification of 
critical factors relevant for the productivity of the encoded assembly lines.  
 
In this thesis, we specifically focused on the redesign of myxochromide biosynthetic 
pathways, on the development of a flexible and efficient DNA assembly strategy and on the 
establishment of synthetic DNA platforms for the heterologous expression and engineering of 
the Mch PKS/NRPS megasynthetases to produce novel myxochromide derivatives via 
Discussion & Outlook     274 
 
combinatorial biosynthesis in a suitable host organism. The choice of the host strain was one 
of the major issues to address as several microbes have been previously described as useful 
heterologous producers of myxobacterial secondary metabolites.40,41 One of the most 
promising host strains is certainly M. xanthus DK1622, which was already proven to 
functionally express foreign myxobacterial gene clusters such as PUFA pathways from 
Sorangium cellulosum and Aetherobacter sp.,57 the epothilone and disorazol machineries from 
S. cellulosum,55,58 the tubulysin pathway from Cystobacter sp.,59 as well as the myxochromide 
S assembly line from S. aurantiaca,60 (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structures and origin of selected myxobacterial secondary metabolites, which have been 
heterologously expressed in M. xanthus DK1622. A: Eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) from S. cellulosum and Aetherobacter sp. B: Disorazol A2 from S. cellulosum. C: Epothilone B from S. 
cellulosum.. D: Myxochromide S1 produced by S. aurantiaca. E: Tubulysin A from Cystobacter sp. 
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In addition, keeping in mind that the transfer of biosynthetic pathways into closely related 
host strains might be favorable and that the host strain must be able to functionally express 
PKS/NRPS pathways, M. xanthus has several advantages over different microbes, even 
compared to other myxobacterial strains as potential heterologous hosts. M. xanthus is 
characterized by higher growth rates and genetic manipulation is much more convenient 
compared to e.g. Sorangium species as several genetic tools have been established.61,62 
Especially the fact that a foreign myxochromide pathway was already heterologously 
expressed in M. xanthus without exhibiting toxic activities made this strain the ideal 
expression host. In contrast, cloning, assembly and engineering of large synthetic DNA 
constructs harboring the artificial myxochromide biosynthetic gene clusters was accomplished 
in E. coli and final expression constructs were transferred into M. xanthus DK1622 via 
electroporation. Taken into account that there are no replicative plasmids available for 
myxobacteria, the expression plasmids were equipped with genetic elements allowing for the 
homologous integration of the artificial pathways into the host chromosome. 
In the course of this thesis, the establishment of synthetic DNA platforms for the functional 
heterologous expression of synthetic mch clusters in M. xanthus was initially demonstrated 
with success on the basis of five artificially generated pathway versions, which were shown to 
produce the naturally occurring myxochromides A, B, C, D and S. In all cases, production 
levels were comparable to those observed for the native A-type mch pathway in the natural 
producer strain (work by Dr. Fu Yan, unpublished). Thus, M. xanthus seems to be the ideal 
host for heterologous expression of different myxochromide families. However, upscaling of 
fermentation processes using M. xanthus as a production host has been proven difficult, which 
might be problematic when applying our strategy from model pathways to pharmaceutically 
interesting myxobacterial pathways.63 As an alternative, other expression hosts could also be 
used, which are able to express and activate PKS/NRPS pathways, to sufficiently supply the 
precursors needed for the biosynthesis of PKs and NRPs and which show similar codon 
preferences. P. putida would be such an alternative, since it additionally exhibits even better 
growth characteristics, is genetically well established and has been shown to be a versatile 
host strain.64 Furthermore, previous studies demonstrated significant improvement of the 
production yields of myxochromides S in P. putida, when the native S-type mch pathway 
from S. aurantiaca was heterologously expressed.65 As mentioned earlier in this section, fast 
and efficient DNA assembly technologies are required to truly enable us to deduce common 
rules for the optimal DNA sequence design for improved heterologous expression by 
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analyzing numerous gene cluster variants in parallel, which can be rapidly assembled. This 
issue is discussed in the following section. 
 
4.3.2 Establishment of an Innovative Assembly Strategy for Synthetic Gene Clusters 
Besides the improvement of heterologous expression in general, synthetic biology has the 
potential to essentially contribute to the rational reprogramming and optimization of 
biosynthetic assembly lines.50,66,67 One major drawback of conventional engineering efforts is 
certainly the fact that with the standard cloning methods only a limited number of gene 
clusters could be assembled in parallel and in reasonable time frames. With focus on 
PKS/NRPS engineering, fast and efficient DNA assembly strategies for the construction of 
artificial biosynthetic gene clusters from smaller fragments, which can be rapidly provided by 
DNA synthesis, are now beginning to be applied to circumvent laborious library constructions 
followed by screening and stepwise assembly of target gene clusters via conventional cloning 
techniques.44,46–48,68 DNA synthesis in conjunction with recent advances in recombinant DNA 
technology allow us to create new entire artificial gene clusters much faster, thereby enabling 
the high-throughput assembly of numerous gene cluster versions to be tested and optimized 
for their functionality. In general, modern DNA assembly techniques include homology-based 
methods such as Gibson isothermal assembly, the related sequence- and ligation-independent 
cloning (SLIC) and transformation-associated recombination (TAR). Especially the TAR-
based assembly methods have been previously used to assemble entire NRPS (and PKS) gene 
clusters or to capture gene clusters from (environmental) genomic DNA.45 Whilst the Gibson 
assembly represents an in vitro tool making use of different enzymes required for the 
recombination of overlapping DNA fragments, TAR cloning is based on an in vivo 
recombination system in Saccharomyces cerevisiae. The major advantage of such homology-
based approaches is that these methods are largely sequence-independent. However, high 
sequence homology of DNA fragments to be assembled or the occurrence of repetitive 
sequence elements (as it is the case for NRPS domains/modules) may lead to mispairing of 
the DNA fragments during the assembly process.66,67 Over the past few years, targeted 
genome editing techniques in vivo such as transcription activator-like effector nuclease 
(TALEN) and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 
systems have been implemented into the genetic toolbox of streptomycetes to delete entire 
NRPS pathways.69,70 Especially the CRISPR-Cas technique is assumed to become an 
indespensible tool in order to modify or optimize biosynthetic gene clusters on the genome 
scale with unprecedented simplicity, accuracy and efficiency, thereby also allowing the 
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targeting of multiple engineering sites at once.71 However, the CRISPR-Cas9 technique needs 
has not been established for myxobacteria so far. To complement the toolbox, in vitro 
restriction/ligation-based assembly techniques have been developed such as ligase cycling 
reaction (LCR) and Golden Gate cloning.47,48 The latter technique relies on type IIS restriction 
enzymes, which hydrolyze the DNA double strand outside of their recognition sequence, 
thereby providing sequence-specific overhangs used for directed ligation. This method has 
been widely used for the assembly of TALEN libraries.72,73 Whilst in vitro assembly of large 
gene constructs usually takes several hours, in vivo methods may require several days to 
reconstitute entire NRPS pathways. On the other hand, using in vivo DNA assembly is usually 
much more efficient in terms of reconstituting large gene constructs. 
In light of the recent progress in recombinant DNA technology, we were motivated to 
establish a fast and efficient DNA assembly strategy for the generation of synthetic DNA 
platforms to provide a generic platform technology for both sequence optimization to improve 
production yields and pathway engineering to produce novel analogues. The choice of a 
suitable assembly strategy for the generation of entire gene cluster constructs was a critical 
issue that needed to be addressed. In this thesis, we considered the Golden Gate cloning 
method for the generation of a gene library, which built the basis for combinatorial 
experiments. Gene fragments encoding for parts of the biosynthesis genes of the different mch 
pathways (A-, B-, C-, D- and S-type) were designed and subjected to restriction sites (R-site) 
engineering to introduce unique R-sites at specific positions for pathway assembly and to 
remove the corresponding recognition sequences at other positions along the whole gene 
cluster sequences. In addition, we established for the first time so-called splitter elements (SE) 
harboring R-sites for a type IIS restriction enzyme exploiting their special feature of cutting 
outside of their recognition sequence as well as unique R-sites for defined conventional 
restriction enzymes between each and every catalytic domain encoding fragment of the mch 
biosynthetic genes. By defining unique 4 bp overhangs generated via type IIS mediated 
hydrolysis, a directed assembly of the single DNA fragments was accomplished to assemble 
the full-length biosynthetic genes, which make up the mch gene library, thereby eliminating 
the SE sequences (‘desplitting’ procedure). The R-sites located within the splitter elements 
allow the straightforward replacement of either catalytic domains or modules and engineered 
R-sites within the coding sequence at the 5’ and 3’ ends of each gene cluster fragment can be 
used to exchange the PKS/NRPS subunits, intergenic linker fragments as well as promoter 
and terminator fragments. Furthermore, SEs at the 5’/3’ ends of each synthetic gene cluster 
fragment were introduced and initially designed in a way that the resulting 4 bp overhangs 
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(after DNA hydrolysis) are part of the ‘conventional’ R-site recognition sequences. This 
strategy should allow not only the type IIS-mediated assembly of the biosynthesis genes but 
also the assembly of entire gene cluster constructs in a one-pot fashion, thereby making this 
method amenable to high-throughput cloning procedures. Neither the Golding Gate assembly 
nor this special SE-based strategy has ever been applied to biosynthetic genes and thus 
represents the first example how the established assembly method can be used for the 
generation of a gene library in conjunction with the innovative splitter technology for further 
engineering of the completely assembled pathways. 
In our first attempt to construct a synthetic A-type mch pathway from M. xanthus DK1622 
using the modified Golden Gate-based splitter strategy, we used the type IIS restriction 
enzyme AarI, which was previously reported to be used in conventional Golden Gate cloning 
protocols.74 However, it turned out that cloning efficiencies observed in the ‘desplitting’ of 
biosynthetic genes using this enzyme were extremely low and sometimes led to incompletely 
‘desplitted’ gene constructs or to shortened constructs lacking one or more domain encoding 
fragments, which is a result of ‘false ligations’ of non-complementary overhangs, which was 
also reported in some former studies, which described the Golden Gate approach.75 This can 
happen if three out of the four nucleotides making up the fusion sites are complementary to 
each other, so that they can anneal and subsequently be ligated. Overall, the relatively high 
number of SEs or domain fragments to be religated, respectively, strongly influences the 
success of the ‘desplitting’ approach and significantly decreases cloning efficiencies. 
However, successful ‘desplitting’ of the synthetic gene constructs was achieved using AarI. 
Unfortunately, one-pot assemblies of an artificial version of the A-type mch pathway was not 
met with success, which is most likely due to the diverse size distribution of the synthetic 
fragments (150 bp up to 13.4 kb). The assembly of ~ 35 kb constructs from non-standardized 
DNA fragments (in terms of fragment size) might thus be hard to achieve in a highly efficient 
and flexible way. In contrast, in the aforementioned TALEN library constructions, modules 
exhibiting similar sequence lengths in equimolar amounts were used for one-pot 
restriction/ligation assemblies and relatively small constructs were assembled (up to 10 kb). 
Taken this into account, fragment and final construct sizes might be the relevant factors 
limiting the success of this assembly strategy. However, the synthetic A-type mch cluster was 
successfully assembled by conventional means using the unique R-sites located at the 5’/3’ 
ends and was subsequently heterologously expressed in M. xanthus yielding comparable 
amounts of myxochromides A to those observed with the native A-type mch gene cluster. 
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This work demonstrated the general applicability and functionality of the presented synthetic 
DNA platform and built a promising basis for further improvement. 
To further optimize the ‘desplitting’ procedure, the DNA sequence design was completely 
adapted to the alternative type IIS restriction enzyme BsaI and was extended to all available 
mch cluster types. Unfortunately, the BsaI enzyme only skips one nucleotide until it 
hydrolyzes the DNA double strand compared to four nucleotides, which are skipped by AarI. 
Thus, it was not possible anymore to design the SE-derived 4 bp overhangs in a way that they 
are part of the ‘conventional’ R-site recognition sequences at the 5’/3’ ends of the synthetic 
DNA fragments. Alternatively, the unique R-sites at the 5’/3’ ends needed to be engineered at 
other positions, which would be elaborating or even not possible without changing the protein 
sequence of the biosynthetic genes. In light of the results obtained from the AarI-based one-
pot assemblies and due to the fact that the described limitations are also true for the BsaI 
design, we placed the outer SEs only at the 5’/3’ ends of the biosynthetic genes and in spatial 
separation (7-10 nucleotides) to the unique R-sites, which were engineered within the coding 
sequence at the same positions as done in the AarI design. Consequently, our assembly 
strategy can still be used for the generation of a gene library and for the engineering of the 
biosynthetic genes, but the assembly of entire synthetic gene cluster constructs can only be 
accomplished via stepwise stitching of the synthetic building blocks using the unique R-sites 
at the 5’/3’ ends. 
Changing the sequence/splitter design from AarI to BsaI in fact resulted in significantly 
improved cloning efficiencies, especially when applied to the smaller biosynthetic gene 
constructs. However, ‘desplitting’ of the large mchC-based containing gene constructs 
remained difficult to achieve and laborious screenings for correct clones harboring fully 
‘desplitted’ and correctly religated gene constructs needed to be carried out. However, a gene 
library consisting of different mchA, mchB and mchC gene constructs was successfully 
generated by using the BsaI-based splitter technology and subsequently used for 
combinatorial biosynthesis. In light of these results, it might be favorable to combine the 
innovative splitter technology (with a maximum number of SEs of 10 per gene construct) for 
the generation of dedicated gene libraries with homology-based assembly strategies such as 
TAR or Gibson assembly, which have already been proven to be suitable assembly strategies 
for the construction of large biosynthetic pathways exceeding the size of 60 kb.45,76 The 
synthetic gene fragments could be equipped with flanking homology arms the 5’/3’ ends for a 
directed assembly of the gene cluster constructs and could be directly provided by gene 
synthesis without performing any additional PCR steps (Figure 4). The assembly vector could 
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be designed to contain genetic elements, which are functional in E. coli, S. cerevisiae and e.g. 
M. xanthus to ensure construct assembly, propagation and functional heterologous expression 
in a myxobacterial host. In doing so, it might be possible to establish a highly efficient generic 
synthetic DNA platform based on the presented flexible splitter technology allowing the rapid 
assembly of numerous gene cluster variants to be tested in parallel. In addition to our gene 
library, other libraries containing e.g. intergenic linkers, inducible synthetic promoters and 
terminators, can also be included to further increase the scope of this versatile strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Possible future assembly strategy for the rapid construction of gene libraries and entire artificial 
biosynthetic pathways. Combination of Golden Gate based ‘desplitting’ for library construction and homology-
based assembly strategies such as TAR cloning. 
 
Our work demonstrates the general applicability of the developed expression platforms and 
sets the stage for further sequence optimization using high-throughput techniques. Moreover, 
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it gives rise to the rational engineering of artificial hybrid mch pathways to produce entirely 
new myxochromides via combinatorial approaches, which is discussed in the following 
section. 
 
4.3.3 Synthetic Biotechnology to Engineer Novel Nonribosomal Peptides 
Revealing and understanding the structure-activity relationships of different derivatives of a 
natural product family is one of the key steps towards the development of natural product 
derived drugs. Due to the inherent structural complexity of most secondary metabolites, their 
total synthesis or modification by chemical means is often limited or even impossible to 
achieve. Thus, genetic engineering of the underlying biosynthetic pathways was anticipated to 
allow alterations of the product structures yielding libraries of structurally diverse natural 
products, which can be subsequently screened for improved biological activity. The modular 
architecture of NRPS biosynthetic machineries together with their exceptional biosynthetic 
logic render them predestinated for such approaches, which address the alteration of single 
functional groups, the regiochemistry or the NRP backbone scaffold itself. In the past, early 
developments mainly included approaches to alter the nature of the incorporated precursor 
molecules such as precursor directed biosynthesis (PDB) and mutasynthesis. These methods 
both aim at the incorporation of novel unnatural building blocks by feeding these precursors 
to the culture broth, in which the respective producer strain is grown.77,78 Additionally, in the 
mutasynthesis approach, the genes encoding for enzymes that produce a natural precursor are 
deleted or inactivated, which enables exclusive production of the engineered compounds. 
Besides the engineering of the precursor molecules, the structural diversity of NRPs can be 
further increased via direct modification of the side chains of the peptide core. The utilization 
of exogenous tailoring enzymes such as halogenases, oxidases, glycosyltransferases, acylases 
or sulfatases from foreign NRPS pathways has been previously demonstrated to be a useful 
tool in the modification of the NRP scaffold, largely based on complementation mutants, in 
which the tailoring enzyme encoding genes were introduced.66 Almost 30 years ago, the era of 
combinatorial biosynthesis began to strongly influence the field of pathway engineering and, 
more ambitiously, aimed at generating entirely new pathways by ‘mixing and matching’ the 
domains, modules or subunits of existing NRPS assembly lines.79 Unlike the engineering of 
precursor supply and tailoring enzymes, this approach directly address the modification of the 
enzymatic assembly line. In the past, combinatorial biosynthesis included a significant 
number of different strategies ranging from gene fusions, inactivations and replacements to 
domain, subunit and module swaps. However, only a small number of NRPSs has been 
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reported to be subjected to combinatorial biosynthesis approaches and there is even only one 
example for which it was extensively performed on a broad scale. Engineering of the closely 
related NRPS pathways responsible for the production of the lipopeptides daptomycin, the 
calcium-dependent antibiotics (CDA) and the compound A54145 using the aforementioned 
strategies led to the formation of more than 120 different derivatives and some of these 
‘unnatural’ lipopeptides even exhibited improved pharmacological properties.80,81 However, 
most of the combinatorial experiments were carried out by chance and did not have any 
rational basis, which often led to the generation of nonfunctional assembly lines. It should be 
pointed out that the slow progress made is essentially a result of our currently very limited 
understanding of the dynamical inter- and intramolecular interactions of the megasynthetases 
as well as of the functional interplay of the single modules and catalytic domains within the 
biosynthetic complex. Recent structural studies on higher-order architechtures in NRPSs 
suggest that a well-defined, rigid ‘pearls on a string’ organization of the megasynthetases does 
not exist. In fact, the structural data shows an unexpected high degree of conformational 
variability between single NRPS modules, thereby proposing significant interactions between 
catalytic domains within a module (e.g. C-A domain interctions) but limited interactions 
between domains of adjacent modules of the assembly line.82 However, the overall 
organization of NRPS machineries is probably not totally unstructured, as transient 
interactions between individual modules might exist and potentially contribute to the 
functionality of the assembly line. This may also explain that even slight changes to the 
modular assembly line may affect proper protein-protein interactions and/or protein folding, 
thereby negatively influencing its functional integrity. In addition, the described approaches 
strongly rely on the defined substrate specificities of the biosynthetic enzymes, thereby 
restricting further structural diversification. A more rational approach for changing the NRP 
backbones is the engineering of the adenylation (A) domain specificities by exploiting their 
specificity-conferring code. Several examples have been described, for which a few mutations 
covering the amino acid residues that confer A domain specificity were sufficient to change 
the preference for a different amino acid precursor.83,84 However, and despite of the advances 
that have been made over the past decades, the promise of combinatorial biosynthesis to 
generate novel assembly lines for the production of any desired natural product at will is far 
from being realized. This can be partly attributed to technical reasons, e.g. most of the 
classical genetic tools including mobilization of the target gene clusters via library 
construction and screening as well as classical tools for the downstream engineering of the 
underlying NRPS systems are time-consuming and low-throughput. 
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With the established synthetic DNA platforms in hand, which circumvent the described 
limitations in an elegant way, ‘unnatural’ hybrid myxochromide assembly lines were created 
based on the mch gene library that was generated in the first step of the assembly process. By 
rationally recombining the NRPS subunits MchB and MchC from the different mch pathways, 
it was possible to generate five hybrid megasynthetases, which were successfully shown to 
heterologously produce five novel myxochromide families with altered structures of the 
peptide cores compared to the structures of the naturally occurring myxochromides (Chapter 
3, Figure 8). Isolation and structure elucidation of the novel lipopeptides unambiguously 
demonstrated the functionality of the artificially recombined hybrid mch clusters. The non-
cognate NRPS subunits from different mch pathways were obviously able to successfully 
interact with each other. In addition, non-native biosynthetic intermediates, which are not 
biosynthesized by the native mch biosynthetic machineries, were transferred to and processed 
by the downstream domains of the hybrid mch pathways, thereby providing fully functional 
synthetic DNA platforms for the production of entirely novel myxochromide lipopeptide 
cores. The successful heterologous production of the expected hybrid myxochromides 
confirms that our constructional sequence design generally works in terms of creating novel 
functional assembly lines. In light of the important role intergenic linker regions are supposed 
to play, as they contain the communication-mediating (COM) domains at the C-termini of 
donor proteins and at the N-termini of recipient proteins facilitating proper interaction 
between NRPS subunits,85 our constructional sequence design conserves the native linker 
regions, thereby eliminating the risk of disruption of assembly line integrity. 
Subunit swaps in NRPS systems have been previously reported only for the closely related 
lipopeptide pathways responsible for the production of daptomycin, CDA and A54145. The 
daptomycin megasynthetase consists of the three NRPS subunits DptA, DptBC and DptD, 
which catalyze the formation of the 13- amino acid lipopeptide. In this study, the dptD gene 
was deleted and the heterologous cdaPS3 and lptD genes from CDA and A54145 biosynthesis 
were complemented in trans leading to the production of novel lipopeptides.86 In light of 
these results, our work describes the first functional hybrid NRPS system, in which subunit 
exchanges have been successfully engineered within an intact assembly line. 
Beyond the subunit-level NRPS engineering, we tried to apply the lessons learned from mch 
pathway evolution using the established synthetic DNA platforms. The unique ‘module-
skipping’ process, which was observed in myxochromide S and D biosynthesis, is assumed to 
be the result of the mutation of the conserved serine by a proline residue in the PCP4 core 
motif.17 By using synthetic DNA fragments encoding mutated PCP regions, we tried to induce 
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‘module-skipping’ at every position of the synthetic A-type mch cluster as well as to 
reactivate module 4 of the S-type mch cluster. Unfortunately, several expression constructs 
harbored frameshift mutations, so that only four heterologous mutants could be analyzed for 
production of the expected lipopeptides (mutants harboring inactive modules 1, 3 or 6 of the 
A-type mch pathway plus reactivated module 4 of the S-type mch pathway). Induction of 
‘module-skipping’ by applying point mutations to PCP domains does not seem to be a tool 
that can be generally used in NRPS engineering, as none of these engineered assembly lines 
was shown to produce the expected lipopeptide cores lacking the corresponding amino acid, 
which would normally be incorporated by the skipped module. These findings indicate that 
the functionality of the engineered myxochromide assembly lines might somehow be 
impaired. In the case of the envisioned induction of ‘module-skipping’ at modules 1 and 3 in 
the A-type mch pathway, the observed results can be explained by the fact that adenylation 
(A) domains are not the only specificity determinants in NRPS assembly lines. Moreover, the 
condensation (C) domains serve as gatekeepers and exhibit distinct substrate specificities, 
especially at their acceptor sites. Consequently, unnatural biosynthetic intermediates are not 
properly recognized and processed leading to the premature release of these intermediates 
from the assembly line. Skipping of module 6 likely yields a nonfunctional assembly line due 
to the spatial separation between the upstream module and the terminal TE domain, which 
might impair correct termination of the NRP biosynthesis. However, as no linear biosynthetic 
intermediates could be identified in the culture extracts, more mutants should be obtained and 
analyzed to investigate whether ‘module-skipping’ may be induced via directed mutations in 
the PCP core motifs. If the induction of ‘module-skipping’ by applying point mutations 
indeed reflect total abolishment of hybrid myxochromide production, additional factors might 
be involved in the naturally occurring skipping processes including e.g. mutational changes in 
the surrounding linker regions of the PCP4 domain and/or a specific function of the proline 
residue in the PCP4 core motif. 
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Figure 5. Cloning strategy for the engineering of module duplications and deletions. A: Based on protein 
sequence alignments, hybrid A domains can be designed, in which the N-terminus of an A domain is replaced by 
the N-terminus of the downstream A domain. B: Based on protein sequence alignments, hybrid C domains can 
be designed, in which the C-terminus of a C domain is replaced by the C-terminus of the downstream C domain. 
RS = restriction site. 
 
4.3.4 Concluding Remarks 
Although significant progress has been made in engineering NRPS assembly lines, a true 
understanding of the rules for the rational reprogramming of NRPS systems to produce novel 
peptides is still missing. Synthetic biology is expected to essentially boost rational 
engineering efforts by providing ever decreasing costs for DNA synthesis, excellent DNA 
assembly strategies and well established heterologous hosts.50,66,67 The established methods 
and future developments will allow for the rapid construction and heterologous expression of 
numerous gene cluster variants, which provides the opportunity to test these variants in 
parallel, e.g. for improved production or for the generation of novel analogues. In this context, 
it might be highly desirable to establish libraries by making use of modern DNA assembly 
techniques. Our developed ‘desplitting’ approach provides an ideal starting point for the 
generation of gene libraries consisting of various genes encoding NRPS megasynthetases 
from different pathways. In combination with a more efficient assembly strategy for entire 
A 
B 
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gene cluster constructs, e.g. based on TAR cloning, our assembly strategy including the 
constructional sequence design can generally be applied to any desired biosynthetic gene 
cluster in order to alter product structures or to improve production yields on a broad scale. 
This might also be of interest for the development of natural product derived drugs with 
improved pharmacological properties driven by structure-activity relationship studies. In 
addition, as our synthetic DNA platforms can be exploited in manifold ways due to their 
remarkable flexibility towards domain and module exchanges, the processes leading to 
pathway diversification can now be mimicked to gain insights into the rules that govern 
NRPS evolution. These insights could potentially fuel the rational engineering of other NRPS 
systems, and await future exploitation. The established ‘desplitting’ procedure also enables 
far-reaching macroevolution approaches by e.g. parallel one-pot ‘desplitting’ and religation of 
several different genes harboring the identical set of splitter elements with compatible fusion 
sites between the different fragments that encode the catalytic domains. In this way, the 
generation of huge gene libraries consisting of numerous hybrid genes is no longer utopic 
regarding time constraints, but opens the door for high-throughput combinatorial biosynthesis 
followed by the analysis of countless unnatural domain, module and subunit combinations. 
Such applications certainly require sophisticated analytical set-ups as well as the management 
of the increasing appearance of samples obtained from high-throughput heterologous 
expression systems, e.g. in 96 well plates. As more and more NRPS pathways are being 
identified and analyzed, libraries of characterized linkers, which facilitate interdomain, 
intermodule or intersubunit communication, will be identified and could potentially one day 
open the door for the envisioned ‘plug-and-play’ approach. This approach aims at fusing 
standardized parts, e.g. modules from different NRPS pathways, to build entirely new 
assembly lines exhibiting novel unnatural features. Moreover, having high-throughput 
assembly and directed evolution methods available, the development of suitable heterologous 
hosts need to keep pace with this progress as well. One promising approach will be the 
development of minimal ‘chassis’, in which the majority of genes that are not essential for the 
host strain’s survival (e.g. all secondary metabolite gene clusters) are deleted. The present 
work sets the stage for future initiatives aiming at the understanding of general principles of 
the sequence modulation process for the design of complex biosynthetic gene clusters for 
improved heterologous expression and for the tailor-made engineering of novel natural 
products. 
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